<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> NOVAVAX INC (Form: 10-K, Received: 02/29/2016 08:14:26) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_LIQUIDITY_CAPITAL **FIS_CASH_FLOW **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW_2 **FIS_NOTES_TO_FINANCIAL_STATEMENT FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_10_3 FIS_EXHIBIT_21 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_23_2 **FIS_EXPERTS_CONSENT_2 FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="159">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="V431853_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	UNITED
	STATES SECURITIES AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Form 10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.8IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.6IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
</TD>
<TD STYLE="WIDTH: 0.6IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	x
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR
	15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.8IN; TEXT-ALIGN: LEFT">
<B>
	For the fiscal year ended December
	31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	OR
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
</TD>
<TD STYLE="WIDTH: 0.6IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	TRANSITION REPORT PURSUANT TO SECTION
	13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.8IN; TEXT-ALIGN: LEFT">
<B>
	For the transition period from
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Commission File No. 0-26770
</B>
</P>
<P STYLE="FONT: 24PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Exact name of Registrant as specified in
	its charter)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 30%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 40%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	20 Firstfield Road,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Gaithersburg, Maryland 20878
</B>
</P>
</TD>
<TD STYLE="WIDTH: 30%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	22-2816046
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;(State of incorporation)
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;(Address of principal executive offices)
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;(I.R.S. Employer Identification No.)
</I>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Registrant&rsquo;s telephone number,
	including area code: (240) 268-2000
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered pursuant to Section
	12(b) of the Act:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Title of each class
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Name of each exchange on which registered
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Common Stock, Par Value $0.01 per share
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The NASDAQ Global Select Market
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered pursuant to Section
	12(g) of the Act: Not Applicable
<BR>
<BR>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No &nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
	Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),
	and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter)
	during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).
	Yes&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.2IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
	contained, to the best of the Registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
	in Part III of this Form 10-K or any amendment to this Form 10-K.
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.2IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.2IN">
	Indicate by check mark
	whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
	See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
	in Rule 12b-2 of the Exchange Act. (Check one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 98%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 21%; PADDING-RIGHT: 5.4PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Large accelerated filer
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	x
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 16%; PADDING-RIGHT: 5.4PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accelerated filer&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 38%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Non-accelerated filer
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Do not check if a smaller reporting company)
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 25%; PADDING-RIGHT: 5.4PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Smaller reporting company
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.2IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	The aggregate market
	value of the voting and non-voting common equity held by non-affiliates of the Registrant (based on the last reported sale price
	of Registrants common stock on June 30, 2015 on the NASDAQ Global Select Market) was approximately $2,949,700,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	As of February 24,
	2016, there were 270,305,396 shares of the Registrant&rsquo;s common stock outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	Documents incorporated
	by reference: Portions of the Registrant&rsquo;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal
	year ended December 31, 2015 in connection with the Registrant&rsquo;s 2015 Annual Meeting of Stockholders are incorporated by
	reference into Part III of this Annual Report on Form 10-K to the extent indicated herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.2IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	TABLE OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 11%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 79%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 10%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B STYLE="TEXT-DECORATION: NONE">
<A HREF="#V431853_10K_HTM_A_001">
	PART I
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 1.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_002">
	BUSINESS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 1A.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_003">
	RISK FACTORS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	17
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 1B.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_004">
	UNRESOLVED STAFF COMMENTS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	35
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 2.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_005">
	PROPERTIES
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	35
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 3.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_006">
	LEGAL PROCEEDINGS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	36
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 4.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_007">
	MINE SAFETY DISCLOSURES
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	36
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_008">
	PART II
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 5.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_009">
	MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	37
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 6.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_010">
	SELECTED FINANCIAL DATA
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	39
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 7.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_011">
	MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	40
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 7A.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_024">
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	56
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 8.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_012">
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	57
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 9.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_013">
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	57
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 9A.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_014">
	CONTROLS AND PROCEDURES
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	57
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 9B.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_015">
	OTHER INFORMATION
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	58
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_016">
	PART III
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 10.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_017">
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	58
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 11.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_018">
	EXECUTIVE COMPENSATION
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	58
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 12.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_019">
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	58
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 13.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_020">
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	59
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 14.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_021">
	PRINCIPAL ACCOUNTING FEES AND SERVICES
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	59
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_022">
	PART IV
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item 15.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V431853_10K_HTM_A_023">
	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</A>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	59
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	CERTAIN DEFINITIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All references in this Annual Report on
	Form 10-K to &ldquo;Novavax,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to
	Novavax, Inc. and its consolidated subsidiary, Novavax AB (unless the context otherwise indicates).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE REGARDING TRADEMARKS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novavax&trade;, Resolve&trade;,
	Prepare&trade;, Matrix-M&trade; and Matrix&trade; are trademarks of Novavax. Any other trademarks referred to in this Annual
	Report on Form 10-K are the property of their owners. All rights reserved. We do not intend our use or display of other
	companies&rsquo; trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any
	relationship with any of these companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	FORWARD-LOOKING INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This Annual Report on Form 10-K contains
	forward-looking statements that involve risks and uncertainties. In some cases, forward-looking statements are identified by words
	such as &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo;
	&ldquo;expect&rdquo; and similar expressions. All forward-looking statements are based on information available to us at this time
	and speak only as of the date of this Annual Report on Form 10-K. We assume no obligation to update any of these statements. Actual
	results could differ materially from those projected in these forward-looking statements as a result of many factors, including
	those identified in the sections titled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
	Condition and Results of Operations&rdquo;. We urge you to review and consider the various disclosures made by us in this report,
	and those detailed from time to time in our other filings with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), that
	identify risks and factors that may affect our future results. Given these risks and uncertainties, readers are cautioned not to
	place undue reliance on such forward-looking statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V431853_10K_HTM_A_001">
</A>
	PART I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.7IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -50.35PT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_002">
</A>
	Item
	1.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	BUSINESS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recent Events
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In February 2016, Novavax
	completed the issuance of $325 million of 3.75% Convertible Senior Notes due in 2023, resulting in net proceeds of approximately
	$315 million, after deducting initial purchasers&rsquo; discounts and commissions, and approximately $314 million after deducting
	offering expenses. We used approximately $38 million of the net proceeds to pay the costs of a capped call transaction, which will
	function to reduce dilution from issuance of additional shares upon conversion of the notes between the note conversion price
	of $6.81 and the cap price of $9.73 per share. The resulting final net proceeds to the company were approximately $276 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our cash, cash equivalents
	and marketable securities on December 31, 2015 of approximately $231 million, as adjusted to give effect to the final net proceeds
	of the Convertible Senior Note offering of approximately $276 million, before giving effect to the anticipated use of the final
	net proceeds, would result in an as adjusted cash, cash equivalents and marketable securities balance of approximately $507 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Novavax, Inc., together
	with its wholly-owned Swedish subsidiary, Novavax AB, is a clinical-stage vaccine company focused on the discovery, development
	and commercialization of recombinant nanoparticle vaccines and adjuvants. Using innovative proprietary recombinant nanoparticle
	vaccine platform technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease
	threats.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We were incorporated
	in 1987 under the laws of the State of Delaware. Our principal executive offices are located at 20 Firstfield Road, Gaithersburg,
	Maryland, 20878, and our telephone number is (240) 268-2000. Our common stock is listed on the Nasdaq Global Select Market under
	the symbol &ldquo;NVAX.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our vaccine candidates
	are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.
	Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory
	syncytial virus (&ldquo;RSV&rdquo;), seasonal influenza, pandemic influenza, and Ebola virus (&ldquo;EBOV&rdquo;). We have
	additional preclinical stage programs for a variety of infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are also developing
	proprietary technology for the production of immune stimulating saponin-based adjuvants, through Novavax AB. Our lead adjuvant,
	Matrix-M&trade;, has been successfully tested in a Phase 1/2 clinical trial for our pandemic influenza H7N9 vaccine candidate and
	in a Phase 1 clinical trial for our EBOV vaccine candidate. Genocea Biosciences, Inc. has licensed rights to our Matrix technology
	and is now conducting Phase 2 clinical trials with its herpes simplex 2 vaccine candidate using Matrix-M.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Clinical Product Pipeline
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our clinical product
	pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
	Our nanoparticle technology platform targets antigens with conserved epitopes essential for viral function. Unlike traditional
	vaccines that &lsquo;mimic&rsquo; viruses and elicit the naturally occurring immune responses to them, our nanoparticles are engineered
	to elicit differentiated immune responses, which may be more efficacious than naturally-occurring immunity. We believe our vaccine
	technology can be applied broadly to a wide variety of human infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A current summary of
	our significant research and development programs and status of related products in development follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Program
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Development Stage
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Funding Collaborator
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Respiratory Syncytial Virus (RSV)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 45PT; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;
<B>
	Older Adults
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 45PT; TEXT-INDENT: -0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;
<B>
	Infants via Maternal Immunization
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	BMGF*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 45PT; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;
<B>
	Pediatric
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Influenza
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 45PT; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;
<B>
	Seasonal Quadrivalent
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	HHS BARDA
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 45PT; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;
<B>
	Pandemic H7N9
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	HHS BARDA
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Combination (Influenza/RSV)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Preclinical
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Ebola Virus (EBOV)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	*As detailed herein, our funding and development
	arrangement with PATH expired in April 2015; we entered into a grant agreement with the Bill and Melinda Gates Foundation (BMGF)
	in September 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Respiratory Syncytial Virus (RSV)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are developing
	our respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (&ldquo;RSV F Vaccine&rdquo;) for three
	susceptible target populations: older adults (60 years of age and older), infants via maternal immunization and children six
	months to five years of age (&ldquo;pediatrics&rdquo;). We estimate RSV F Vaccine peak revenue potential of six to eight
	billion dollars worldwide. Currently, there is no approved RSV vaccine available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Repeat infections and
	lifelong susceptibility to RSV are common; we estimate the current global cost burden of RSV in excess of $88 billion. Despite
	decades of effort to develop an RSV vaccine, there are currently no licensed vaccines. Although the monoclonal antibody palivizumab
	(Synagis&reg;) is effective in pre-term infants, it is not indicated for use in other populations. Novavax made a breakthrough
	in developing a vaccine that targets the fusion protein, or F-protein, of the RSV virus. The F-protein contains a highly conserved
	amino acid sequence called antigenic site II, which we believe is an ideal vaccine target. Palivizumab, which also targets antigenic
	site II, has demonstrated protection in five randomized clinical trials. We genetically engineered a novel F-protein antigen and
	enhanced its immunogenicity by exposing antigenic site II. Novavax&rsquo; RSV F Vaccine assembles into a recombinant protein nanoparticle
	optimized for F-protein antigen presentation. The RSV F Vaccine elicits palivizumab-competing antibodies at levels that we expect
	to confer protection. The Novavax RSV F Vaccine is the first RSV vaccine to demonstrate efficacy in a clinical trial, and Novavax
	is positioned to bring the first RSV vaccine to market to combat the 64 million RSV infections that occur each year.
<SUP>
	1,2
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	RSV Older Adults Program
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY">
<I>
	Burden of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Adults
	60 years of age and older are at increased risk for RSV disease due to age related declines in their immune systems. In this population,
	RSV is an important respiratory virus, distinct from influenza viruses, that is responsible for serious lower respiratory tract
	disease and may lead to hospitalization or even death. Additionally, RSV infection can lead to exacerbation of underlying co-morbidities
	such as chronic obstructive pulmonary disease, asthma and congestive heart failure. RSV infection occurs as a recurrent and predictable
	annual epidemic throughout the world. In the U.S. alone, the incidence rate is 2.5 million infections per year, and RSV is increasingly
	recognized as a significant cause of morbidity and mortality in the population of 64 million older adults.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	3
</SUP>
</FONT>
<SUP>
	,4
</SUP>
</FONT>
	Based on our analysis of published literature applied to 2014 population estimates in the U.S., the disease causes
	207,000 hospitalizations and 16,000 deaths among adults older than 65. Annually, we estimate that there are approximately 900,000
	medical interventions directly caused by RSV disease across all populations in the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	1
</SUP>
	Nair, H.
<I>
	et al.
</I>
	, (2010)
	Lancet. 375:1545 - 1555
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	2
</SUP>
	WHO Acute Respiratory Infections
	September 2009 Update: http://apps.who.int/vaccine_research/diseases/ari/en/index2.html
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	3
</SUP>
	Falsey, A.R.
<I>
	et al.
</I>
	(2005)
	NEJM. 352:1749&ndash;59 extrapolated to 2015 census population
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	4
</SUP>
	Falsey, A.R.
<I>
	et al.
</I>
	(1995)
	JID
<I>
	.
</I>
	172 :389-94
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
<SUP>
	&nbsp;
</SUP>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY">
<I>
	Clinical Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In August 2015, we
	announced positive top-line data from a Phase 2 clinical trial of our RSV F Vaccine in 1,600 older adults. The clinical trial was
	designed to prospectively examine the incidence of all symptomatic respiratory illnesses associated with RSV infection, in community-living
	older adults who were treated with placebo. The trial also evaluated safety and immunogenicity of our RSV F Vaccine compared to
	placebo. Finally, the trial estimated the efficacy of our RSV F Vaccine in reducing the incidence of respiratory illness due to
	RSV. The trial was the first to demonstrate efficacy of an active RSV immunization in any clinical trial population. In the per
	protocol population, the clinical trial showed statistically significant vaccine efficacy in prevention of all symptomatic RSV
	disease (41%) and, in an
<I>
	ad hoc
</I>
	analysis, showed a decrease in RSV disease with symptoms of lower respiratory tract infection
	(45%) in older adults. The clinical trial established an attack rate for symptomatic RSV disease of 4.9% in older adults, 95% of
	which included lower respiratory track symptoms. Efficacy against more severe RSV illness, defined by the presence of multiple
	lower respiratory tract symptoms associated with difficulty breathing, was 64% in ad hoc analyses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We initiated a pivotal
	Phase 3 clinical trial, known as Resolve&trade;, of our RSV F Vaccine in older adults in November 2015, and in December 2015 we
	completed enrollment of 11,850 older adult subjects at 60 sites in the U.S. The primary objective of the clinical trial is the
	prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple lower respiratory
	tract symptoms. We expect to provide top-line data from this clinical trial in the third quarter of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In October
	2015, we completed enrollment of 1,330 older adults in our Phase 2 rollover clinical trial of our RSV F Vaccine in the older
	adults who had participated in the recently concluded prior Phase 2 clinical trial. This trial is designed to evaluate safety
	and immunogenicity in response to immunization with the RSV F Vaccine during a second RSV season, and we expect to
	provide top-line data from this trial in the second half of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	RSV Infants via
	Maternal Immunization Program
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	RSV is the most common
	cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and
	young children worldwide.
<SUP>
	5
</SUP>
	In the U.S., RSV is the leading cause of hospitalization of infants, and globally, is second
	only to malaria as a cause of death in children under one year of age.
<SUP>
	6,7
</SUP>
	Despite the induction of post-infection immunity,
	repeat infection and lifelong susceptibility to RSV is common.
<SUP>
	8,9
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September 2015,
	we announced positive top-line data from a Phase 2 clinical trial of our RSV F Vaccine in 50 healthy pregnant women and their infants.
	This clinical trial evaluated the safety and immunogenicity of our RSV F Vaccine in pregnant women in their third trimester, and
	assessed the transplacental transfer of maternal antibodies induced by the vaccine. The trial also examined the impact of maternal
	immunization on infant safety during the first year of life and RSV-specific antibody levels through the infants&rsquo; first six
	months of life. Immunized women demonstrated a geometric mean 14-fold rise in anti-F IgG, 29-fold rise in palivizumab-competing
	antibodies and a 2.7 and 2.1-fold rise in microneutralization titers against RSV/A and RSV/B respectively. In contrast, women who
	received placebo demonstrated no significant change in antibody levels. The infants&rsquo; antibody levels at delivery averaged
	90-100% of the mothers&rsquo; levels, indicating efficient transplacental transfer of antibodies from mother to infant. The estimated
	half-lives of infant PCA, anti-F IgG, RSV/A and RSV/B microneutralizing antibodies, based on data through day 60, were 41, 30,
	36 and 34 days, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	5
</SUP>
	Nair, H.,
<I>
	et al.
</I>
	, (2010)
	Lancet. 375:1545 - 1555
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	6
</SUP>
	Hall, C.B.
<I>
	et al.
</I>
	(2013)
	Pediatrics; 132(2):E341-348
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	7
</SUP>
	Oxford Vaccine Group: http://www.ovg.ox.ac.uk/rsv
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	8
</SUP>
	Glezen, W.P.
<I>
	et al.
</I>
	(1986)
	Am J Dis Child; 140:543-546
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	9
</SUP>
	Glenn, G.M.
<I>
	et al.
</I>
	(2016)
	JID; 213(3):411-12
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We announced the initiation
	of a global pivotal Phase 3 clinical trial, known as Prepare&trade;, of the RSV F Vaccine in 5,000 to 8,255 healthy pregnant women
	in December 2015. The primary objective of the Prepare trial is to determine the efficacy of maternal immunization with the RSV
	F Vaccine against symptomatic RSV lower respiratory tract infection with hypoxemia in infants through the first 90 days of life.
	This Phase 3 trial utilizes a group sequential design and is expected to take between two and four years to complete. This trial
	is supported by a grant (the &ldquo;Grant&rdquo;) of up to $89.1 million from the Bill &amp; Melinda Gates Foundation (&ldquo;BMGF&rdquo;).
	The Grant will support development activities, product licensing efforts and WHO prequalification of our RSV F Vaccine. We concurrently
	entered into a Global Access Commitments Agreement (&ldquo;GACA&rdquo;) with BMGF as a part of the grant agreement (the &ldquo;Grant
	Agreement&rdquo;). Under the terms of the GACA, we agreed to make the RSV F Vaccine available and accessible at affordable pricing
	to people in certain low and middle income countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In November 2014, the
	U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (&ldquo;FDA&rdquo;) granted Fast Track designation
	to our RSV F Vaccine for protection of infants via maternal immunization. Fast Track designation is intended for products that
	treat serious or life-threatening diseases or conditions, and that demonstrate the potential to address unmet medical needs for
	such diseases or conditions. The program is designed to facilitate development and expedite review of drugs to treat serious and
	life-threatening conditions so that an approved product can reach the market expeditiously.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	RSV Pediatric
	Program
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There are
	currently approximately 18 million children in the U.S. between six months and five years of age.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	10
</SUP>
</FONT>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Based
	on our analysis of published literature applied to 2014 population estimates, we estimate
</FONT>
	nearly 9.8 million RSV
	infections annually. In the U.S., RSV is responsible for approximately 57,000 hospitalizations of children under five years
	of age annually, the vast majority of which occur in infants less than one year old, and especially those under six months of
	age.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	11
</SUP>
</FONT>
<SUP>
	,12,
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
	,14,
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	15
</FONT>
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September 2015,
	we announced positive top-line data from a Phase 1 clinical trial of our RSV F Vaccine in healthy children between two and six
	years of age. This clinical trial evaluated the safety and immunogenicity of our RSV F Vaccine, with one or two doses, with or
	without aluminum phosphate adjuvant. Trial enrollment was concluded with a smaller than planned cohort so that dosing could be
	completed ahead of the 2014-15 RSV season. The vaccine was well-tolerated and serum samples collected from a subset of 18 immunized
	children in the per-protocol population demonstrated that the RSV F Vaccine was highly immunogenic at all formulations and regimens.
	There were greater than 10-fold increases in both anti-F IgG and PCA antibody titers in the adjuvanted group and greater than 6-fold
	increases in anti-F IgG and PCA antibody titers in the unadjuvanted group. We are assessing the data from this clinical trial and
	evaluating the next steps in the development of our RSV F Vaccine for pediatrics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Influenza
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Influenza is a world-wide
	infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness
	occurs not only in susceptible populations such as pediatrics and older adults, but also in the general population when unique
	strains of influenza arise, for which most humans have not developed protective antibodies. We are developing vaccine candidates
	for both seasonal and pandemic influenza. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S.,
	Japan, France, Germany, Italy, Spain and UK), show potential growth from approximately $3.2 billion in the 2012/13 season to $5.3
	billion by the 2021/2022 season.
<SUP>
	16
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	10
</SUP>
	U.S. Census. www.census.go/population/international/data/idb/informationGateway.php
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	11
</SUP>
	Stockman, L.J.
<I>
	et al.
</I>
	(2012) Pediatr Infect Dis J. 31:5-9
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	12
</SUP>
	CDC update May 5, 2015. http://www.cdc.gov/rsv/research/us-surveillance.html
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	13
</SUP>
	Boyce, T.G.
<I>
	et al
</I>
	. (2000)
	J Pediatr. 137:865-870
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	14
</SUP>
	Hall, C.B.
<I>
	et al.
</I>
	(2009)
	NEJM. 360(6):588-98
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	15
</SUP>
	Hall, C.B.
<I>
	et al.
</I>
	(2013)
	Pediatrics. 132(2):E341-8
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	16
</SUP>
	Influenza Vaccines Forecasts.
	Datamonitor (2013)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Traditional vaccine
	manufacturing methods utilize live influenza virus to infect eggs in order to produce trivalent seasonal influenza vaccine candidates.
	Our recombinant nanoparticle technology does not utilize either a live influenza virus or eggs, but rather a recombinant
	baculovirus and insect cells which allows for the product to be potentially rapidly manufactured and quickly adapted to changing
	influenza strains. We are developing a quadrivalent seasonal influenza vaccine candidate, which we expect to elicit broader protection
	from circulating influenza strains; we are also exploring the development of novel influenza nanoparticle vaccine candidates. There
	are currently four quadrivalent seasonal influenza vaccines licensed in the U.S., although additional quadrivalent seasonal influenza
	vaccines are expected to be licensed over the next several years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Quadrivalent
	Seasonal Influenza Vaccine
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Advisory Committee
	for Immunization Practices of the CDC recommends that all persons aged six months and older be vaccinated annually against seasonal
	influenza. Influenza is a major burden on public health worldwide; an estimated one million deaths each year are attributed to
	influenza.
<SUP>
	17
</SUP>
	It is further estimated that, each year, influenza attacks 5%-10% of adults and 20%-30% of children, causing
	significant levels of illness, hospitalization and death
<FONT STYLE="COLOR: #333838">
	.
<SUP>
	18
</SUP>
</FONT>
	Recombinant seasonal
	influenza vaccines, like the candidate we are developing, have important advantages: once licensed for commercial sale, large
	quantities of vaccines can be potentially manufactured quickly and in a cost-effective manner, without the use of either the live
	influenza virus or eggs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In July 2015, we reported
	positive data from our Phase 2 clinical trial of our quadrivalent seasonal influenza virus-like particle (&ldquo;VLP&rdquo;) vaccine
	candidate in 400 healthy adults that we initiated in November 2014. These data show that our quadrivalent seasonal influenza VLP
	vaccine candidate is well-tolerated, and can induce influenza antibody responses that met the immunogenicity targets. These results
	demonstrate the potential for our seasonal quadrivalent influenza VLP vaccine candidate to meet the FDA criteria for accelerated
	approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We were awarded a contract
	by the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (&ldquo;HHS BARDA&rdquo;)
	in 2011 to fund the development of both our quadrivalent seasonal influenza and pandemic influenza vaccine candidates. This is
	a cost-plus-fixed-fee contract, which reimburses us for allowable direct contract costs incurred, allowable indirect costs, plus
	a fixed-fee, earned in the ongoing clinical development and product scale-up of our vaccine candidates. We announced that HHS BARDA
	had exercised and initiated a two-year option to our contract in September 2014. The option not only extended the contract until
	September 2016, but also added scope to support our development activities leading up to planned Phase 3 clinical studies and $70
	million of funding on top of the remainder of the $97 million base period funding. In June 2015, the contract was amended to increase
	the funding by $7.7 million to allow for the recovery of additional costs under the contract relating to the settlement of indirect
	rates for fiscal years 2011 and 2012. This additional amount was received and recorded as revenue in the second quarter of 2015.
	During 2015, we recognized revenue of $33.3 million and have recognized approximately $112 million in revenue since the inception
	of the contract. In recent meetings with HHS BARDA, we have been discussing the next steps in both our seasonal influenza VLP vaccine
	program and our pandemic influenza VLP vaccine program, as well as some of the delays associated with our development of both vaccine
	candidates. We expect to continue discussions with HHS BARDA during 2016 and to present plans for continued clinical and product
	development, although there can be no guarantee that the HHS BARDA contract will not be terminated early or will be extended beyond
	September 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	17
</SUP>
	Resolution of the World Health
	Assembly. (2003) WHA56.19
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	18
</SUP>
	WHO position paper (2012) Weekly
	Epidemiol Record;87(47):461&ndash;76
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	Pandemic H7N9 Influenza
	Vaccine
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Prevention of the potential
	devastation of a human influenza pandemic remains a key priority with both governmental health authorities and influenza vaccine
	manufacturers. In the U.S. alone, the 2009 H1N1 influenza pandemic led to the production of approximately 126 million doses of
	monovalent (single strain) vaccine. Public health awareness and government preparedness for the next potential influenza pandemic
	are driving development of vaccines that can be manufactured quickly against a potentially threatening influenza strain. Industry
	and health experts have focused attention on developing a monovalent influenza vaccine against either the H5N1 strain or the H7N9
	strain as potential key defenses against future pandemic disease threats.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have developed and
	delivered compelling safety and immunogenicity data on two pandemic vaccine candidates, H5N1 and H7N9. In September 2014, we announced
	positive results from a Phase 1/2 clinical trial of our pandemic H7N9 influenza VLP vaccine candidate adjuvanted with Matrix-M
	in 610 healthy adults. The Phase 1/2 clinical trial was designed as a dose-ranging, randomized, observer-blinded, placebo-controlled
	clinical trial, to determine the contribution of Matrix-M to potential antigen dose sparing regimens. Our H7N9 influenza vaccine
	candidate, with and without Matrix-M, was highly immunogenic and well tolerated. Matrix-M adjuvanted formulations demonstrated
	immunogenicity and dose-sparing benefits relative to unadjuvanted antigen. Hemagglutination-inhibiting antibody titers were comparable
	to those reported in prior studies and the vaccine elicited significant anti-neuraminidase antibodies. In October 2014, the FDA
	granted Fast Track designation to our pandemic H7N9 influenza vaccine candidate with Matrix-M.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our pandemic influenza
	vaccine program is supported by our HHS BARDA contract. Like our seasonal influenza vaccine program, we expect to continue discussions
	with HHS BARDA during 2016 and to present plans for continued clinical and product development of our pandemic influenza vaccine
	candidate, although there can be no guarantee that the HHS BARDA contract will not be terminated early or will be extended beyond
	September 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Combination Respiratory (Influenza and
	RSV)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Given the ongoing development
	of our seasonal influenza vaccine candidate and our RSV F Vaccine, we see an important opportunity to develop a combination respiratory
	vaccine candidate. Early preclinical development efforts have given us confidence that such a combination vaccine is viable, and
	in animal models, provides acceptable immunogenicity. We expect to initiate a Phase 1 clinical trial of a combination respiratory
	vaccine in the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Ebola Virus (EBOV)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	EBOV, formerly
	known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. Multiple strains of EBOV have been identified,
	the most recent of which, the Makona EBOV strain, is associated with a case fatality rate of between 50% and
	90%.
<SUP>
	19
</SUP>
	There are currently no licensed treatments proven to neutralize the virus, but a range of blood,
	immunological and drug therapies are under development. It should be noted, however, that recent vaccine approaches target
	either a previous strain of the virus or were initially developed to be delivered by genetic vectors. In contrast, our EBOV
	glycoprotein vaccine candidate (&ldquo;Ebola GP Vaccine&rdquo;) was developed using the Makona EBOV strain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In July 2015, we announced
	data from our Phase 1 clinical trial of our Ebola GP Vaccine in ascending doses, with and without our Matrix-M adjuvant, in 230
	healthy adults. Participants received either one or two intramuscular injections ranging from 6.5&micro;g to 50&micro;g of antigen,
	with or without adjuvant, or placebo. Immunogenicity was assessed at multiple time points, including days 28 and 35. These Phase
	1 data demonstrated that our Ebola GP Vaccine is highly immunogenic, well-tolerated and, in conjunction with our proprietary Matrix-M
	adjuvant, resulted in significant antigen dose-sparing. Although the adjuvanted Ebola GP Vaccine was highly immunogenic at all
	dose levels, the adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000
	ELISA units, representing a 500 to 750-fold rise over baseline at day 35. In 2015, we also announced successful data from two separate
	non-human primate challenge studies of our Ebola GP Vaccine in which, in both cases, the challenge was lethal for the control animal,
	whereas 100% of the immunized animals were protected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	19
</SUP>
	WHO.
</FONT>
<U>
	http://www.who.int/mediacentre/factsheets/fs103/en/
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	CPLB Programs (India)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our joint venture with
	Cadila Pharmaceuticals Limited (&ldquo;Cadila&rdquo;), CPL Biologics Private Limited (&ldquo;CPLB&rdquo;), is actively developing
	and manufacturing vaccine candidates in India that were genetically engineered by Novavax. CPLB is owned 20% by us and 80% by Cadila.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Seasonal Influenza
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	CPLB received marketing
	authorization, the Indian equivalent of approval of a Biologics License Application (&ldquo;BLA&rdquo;), for its recombinant trivalent
	seasonal VLP influenza vaccine in 2015. Because the market for seasonal influenza vaccines in India is limited and highly competitive,
	CPLB is currently evaluating its marketing strategy for this vaccine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Rabies
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	CPLB successfully completed
	Stage II of its 2-stage Phase 1/2 clinical trial in India of a rabies G protein vaccine candidate that we genetically engineered.
	The objective was to select a dose and regimen for a recombinant vaccine that can be administered both as a pre-exposure prophylaxis
	for residents of certain higher-risk geographies and travelers to such locations, and as a post-exposure prophylaxis using fewer
	doses than the current standard of care. In October 2014, CPLB presented clinical results from Stage I of the Phase 1/2 clinical
	trial, demonstrating that vaccine recipients, at various doses levels and schedules, showed seroprotective antibody levels at day
	14 that were sustained through day 180. The vaccine candidate, which was found to be well-tolerated, also induced seroprotective
	levels with two-dose and three-dose regimens. CPLB has received permission to conduct a Phase 3 clinical trial and is considering
	the optimal schedule for its conduct.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Discovery Programs
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our vaccine platform
	technology provides an efficient system that has the potential to rapidly develop antigens to selected targets, refine manufacturing
	processes and optimize development across multiple vaccine candidates. In conjunction with global health authorities and government
	agencies, we believe we can address emerging disease threats with pandemic potential. In addition to our response to the H7N9 influenza
	strain, we have developed a vaccine candidate to Middle East respiratory syndrome (&ldquo;MERS&rdquo;), caused by a novel coronavirus
	first identified in 2012. MERS emerged as a disease threat in 2013, and is currently being monitored by global health agencies,
	with the WHO reporting significant confirmed cases of infection and deaths. The MERS virus is a part of the coronavirus family
	that includes the severe acute respiratory syndrome coronavirus (&ldquo;SARS&rdquo;). Within weeks of obtaining the sequence of
	the circulating MERS strain, we successfully produced a vaccine candidate designed to provide protection. This vaccine candidate
	is based on the major surface spike protein, which we had previously identified as the antigen of choice in our work with a SARS
	vaccine candidate. In 2014, in collaboration with the University of Maryland, School of Medicine, we published results that showed
	our investigational vaccine candidates against both MERS and SARS blocked infection in laboratory studies. Although the development
	of a MERS vaccine candidate currently remains a preclinical program, we believe that our MERS vaccine candidate offers a viable
	option to interested global public health authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Vaccine Platform Technology
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our recombinant protein
	nanoparticle vaccine technology is based on self-assembly of surface protein antigens from pathogenic organisms including viruses,
	bacteria or parasites. The conformations of these nanoparticles are similar but not identical to the natural structure of surface
	antigens of disease organisms, and lack the genetic material required for replication and therefore are not infectious. One advantage
	of this technology is that the assembly of nanoparticles is done
<I>
	in vitro
</I>
	during the purification of these proteins. Potential
	immunological advantages of protein nanoparticles may be associated with the nanoparticle conformation and the presentation of
	key functional epitopes that are often immunologically hidden in the native pathogen. This leads to efficient recognition by the
	immune system&rsquo;s antigen presenting cells (&ldquo;APCs&rdquo;) that trigger robust immune responses. Recognition of the nanoparticle
	vaccine&rsquo;s repeating protein patterns by the APCs&rsquo; toll-like receptors to stimulate innate immunity and the high purity
	and lack of synthetic material adds to the potential safety of recombinant nanoparticle vaccines. Protein nanoparticle vaccine
	technology has expanded our early-stage vaccines in development to include both virus and non-virus disease targets. Our most advanced
	protein nanoparticle vaccine candidate is our RSV F Vaccine, which self-assembles from our highly purified F-protein antigen.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Matrix Adjuvants
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	Adjuvants
	are predominantly used to enable a vaccine to induce a strong immune response including a greater production of antibodies and
	longer lasting protection against viral and bacterial infections. Adjuvants may increase the amplitude of the immune response and
	qualitatively change it, broaden its specificity to provide protection against related microorganisms and allow for effective
	immunization with much lower doses of antigen. Novavax AB has developed a number of adjuvant formulations, all based on our proprietary
	Matrix&trade; technology. These adjuvant formulations possess excellent immunostimulatory features with the ability to increase
	and prolong the protective benefits of vaccines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	While
	adjuvants based on novel, poorly characterized substances have been hampered by safety concerns and limited efficacy, Matrix adjuvants
	stimulate strong antibody and cell-mediated immune responses. Matrix adjuvants may allow for lower antigen doses, longer-duration
	immune responses and carry a lower risk for allergic reactions or other adverse events. Our Matrix technology typically induces
	strong cellular activation of both Th1 and Th2 types, thereby generating all classes and subclasses of antibodies, as well as potent
	cellular responses, including cytotoxic T lymphocytes. Our Matrix-M adjuvant provides a potent adjuvant effect that has been well
	tolerated in clinical trials. We also believe that the strong immune response and opportunity to reduce the quantity of antigen
	dose can significantly reduce the production cost of our vaccines. This means that our Matrix-M adjuvant has the potential to be
	of immense value when there is inadequate vaccine manufacturing capacity during an emerging disease threat such as an influenza
	pandemic.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
<B>
	Competition in
	RSV, Influenza, EBOV and Other Vaccines
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The vaccine market
	is intensely competitive, characterized by rapid technological progress. Our technology is based upon utilizing the baculovirus
	expression system in insect cells to make recombinant vaccines. We believe this system offers many advantages when compared to
	other technologies and is uniquely well-suited for developing an RSV vaccine, seasonal and pandemic influenza vaccines, as well
	as vaccines against other infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There is currently
	no approved RSV vaccine for sale in the world; however, a number of vaccine manufacturers, academic institutions and other organizations
	currently have, or have had, programs to develop such a vaccine. In addition, many other companies are developing products to prevent
	disease caused by RSV using a variety of technology platforms, including various viral vector technologies and competitive recombinant
	technologies. We believe that our RSV vaccine candidate, utilizing a recombinant F-protein antigen, is more effective than RSV
	vaccine candidates in development by our competitors; however, such efficaciousness cannot be guaranteed. Although we are not aware
	of all our competitors&rsquo; efforts, we believe that MedImmune LLC, a subsidiary of AstraZeneca PLC, may have the second most
	advanced RSV vaccine program after Novavax, as it has reported testing in Phase 1 and Phase 1/2 clinical trials of an intranasal,
	recombinant, live attenuated, RSV vaccine for the prevention of lower respiratory tract disease caused by RSV, as well as a combination
	intranasal vaccine for the prevention of several infant respiratory illnesses, including RSV. Additional entities have also entered
	into early clinical trials including GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases, an institute
	under the U.S. National Institutes of Health (&ldquo;NIAID&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Unlike
	the comparatively low number of competitors developing RSV vaccines, there are a number of companies developing and
	selling vaccines for seasonal and pandemic influenza employing both historic and new vaccine technologies. There are many seasonal influenza vaccines currently approved and marketed, and most of these are marketed by
	major pharmaceutical companies that have significantly greater financial and technical resources, experience and expertise.
	Competition in the sale of these seasonal influenza vaccines is intense. Therefore, newly developed and approved products
	must be differentiated from existing vaccines in order to have commercial success. In order to show differentiation in the
	seasonal influenza market, a product may need to be more efficacious and/or be less expensive and quicker to manufacture.
	Many of our competitors are working on new products and new generations of current products, some by adding an adjuvant that
	is used to increase the immunogenicity of that product, each of which is intended to be more efficacious than currently
	marketed products. Another differentiating factor is recombinant manufacturing, which we believe can be quicker and
	less-expensive than traditional egg-based manufacturing. Despite the significant competition and advancing technologies, some
	of which are similar to our own, we believe that our seasonal influenza product will be as efficacious as, or more so
	than, current products or products being developed by our competitors, and that our manufacturing system provides savings in
	both time and money; however, there can be no guarantee that our seasonal influenza vaccine will prove to be efficacious or
	that our manufacturing system will prove to be sufficiently effective and differentiated to ensure commercial success.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Vaccine candidates
	against Ebola virus have been in development for more than a decade; however, with the recent epidemic in West Africa, focus on
	viable vaccine candidates has intensified. In addition to the Phase 1 clinical trial that we initiated in February 2015, WHO reports
	two other vaccine candidates that are currently being tested in humans: one by GlaxoSmithKline in collaboration with NIAID,
	and the other by a collaboration of NewLink Genetics, Merck Vaccines USA and the Public Health Agency of Canada. While these other
	vaccine candidates offer promise, we believe there are accompanying challenges, including: high-dose level requirements; utilization
	of glycoprotein from older strains that have a significant number of amino acid changes when compared to the 2014 Makona strain;
	difficult storage requirements at temperatures below &ndash;60&deg;C; and challenges associated with immunity to the viral vectors
	which could limit their multi-dose vaccine potential. In contrast, we have developed a Phase 1 vaccine candidate that has performed
	well with low doses utilizing our Matrix-M adjuvant, was derived from the 2014 Makona strain, appears to be stable at 2&ndash;8&deg;C
	and appears to provide enhanced immunogenicity as a multi-dose vaccine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In general, competition
	among pharmaceutical products is based in part on product efficacy, safety, reliability, availability, price and patent position.
	An important factor is the relative timing of the market introduction of our products and our competitors&rsquo; products. Accordingly,
	the speed with which we can develop products, complete the clinical trials and approval processes and supply commercial quantities
	of the products to the market is an important competitive factor. Our competitive position also may depend upon our ability to
	show differentiation with a product that is more efficacious, particularly in the relevant target populations and/or be less expensive
	and quicker to manufacture. Other factors affecting our competitive position include our ability to attract and retain qualified
	personnel, obtain patent protection or otherwise develop proprietary products or processes and secure sufficient capital resources
	for the lengthy period between technological conception and commercial sale.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Patents and Proprietary Rights
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We generally seek patent
	protection for our technology and product candidates in the U.S. and abroad. The patent position of biopharmaceutical firms generally
	is highly uncertain and involves complex legal and factual questions. Our success will depend, in part, on whether we can:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtain patents to protect
	our own technologies and product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtain licenses to
	use the technologies of third-parties, which may be protected by patents;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	protect our trade secrets
	and know-how; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	operate without infringing the intellectual
	property and proprietary rights of others.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Patent Rights;
	Licenses.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have intellectual
	property (patents, licenses, know-how) related to our vaccines, manufacturing processes and other technologies. Currently, we have
	or have rights to over 200 U.S. patents and corresponding foreign patents and patent applications relating to vaccines and biologics.
	Our core vaccine-related intellectual property extends beyond the year 2025.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Since 2007, we have
	maintained a non-exclusive license arrangement with Wyeth Holdings LLC (formerly Wyeth Holdings Corporation), a subsidiary of Pfizer
	Inc. (&ldquo;Wyeth&rdquo;), to a family of patents and patent applications covering VLP technology for use in human vaccines in certain fields,
	with expected patent expiration in early 2022.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In July 2010, U.S.
	Patent No. 7,763,450 for Functional Influenza Virus-Like Particles was issued by the U.S. Patent &amp; Trademark Office. The patent
	covers, in part, the use of influenza gene sequences for high-yield production of consistent influenza VLP vaccines to protect
	against current and future seasonal and pandemic strains of influenza viruses. In December 2011, European Patent No. 1644037 was
	issued by the European Patent Office covering this technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2011, U.S.
	Patent No. 8,080,255 for Functional Influenza Virus-Like Particles was issued by the U.S. Patent &amp; Trademark Office. The patent
	covers, in part, methods of inducing substantial immunity to an influenza virus infection in a human and administering to the human
	a VLP comprising M1, HA and NA proteins. The M1 protein is derived from a particular avian influenza strain, A/Indonesia/5/05.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In April 2013, European
	Patent No. 2343084 for Functional Influenza Virus-Like Particles was issued by the European Patent Office. The patent covers, in
	part, vaccine compositions containing VLPs that contain M1, HA, and NA proteins. The VLPs are self-assembled from host cells.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In August 2013, U.S.
	Patent No. 8,506,967 for Functional Influenza Virus-Like Particles was issued by the U.S. Patent &amp; Trademark Office. The patent
	covers, in part, methods of inducing substantial immunity to an influenza virus infection in a human and administering to the human
	a VLP comprising M1, HA and NA proteins. The M1 protein is from an avian influenza M1 protein from a different strain of influenza
	virus than the influenza HA protein and the influenza NA protein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In October 2013, U.S.
	Patent No. 8,551,756 for Avian influenza chimeric Virus-Like Particles was issued by the U.S. Patent &amp; Trademark Office. The
	patent covers, in part, methods of increasing the efficiency of VLP production using M1 proteins derived from strain A/Indonesia/5/05.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In November 2013, U.S.
	Patent No. 8,592,197 for Functional Influenza Virus-Like Particles was issued by the U.S. Patent &amp; Trademark Office. The patent
	covers, in part, influenza VLP vaccines containing M1, HA, and NA proteins where the M1 protein is from a different stain than
	the HA and NA proteins.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In April 2014, U.S.
	Patent No. 8,697,088 for Novel VLPs Derived From Cells That do not Express a Viral Matrix or Core Protein was issued by the U.S.
	Patent &amp; Trademark Office. The patent covers, in part, methods of making influenza VLP that contain HA and NA proteins but
	lack any viral matrix or core protein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In May 2014, U.S. Patent
	No. 8,715,692 for Modified RSV F Proteins and Methods of Their Use was issued by the U.S. Patent &amp; Trademark Office. The patent
	covers, in part, RSV F vaccines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Between February 2015
	and December 31, 2015, U.S. Patent Nos. 8,951,537, 8,992,939, 9,144,607, 9,050,290, and 9,180,180 were issued by the U.S. Patent
	&amp; Trademark Office. These patents all relate to aspects of our influenza VLP program. In addition, 9,205,147, directed to our
	Matrix Adjuvant program, issued in January 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Federal Technology
	Transfer Act of 1986 and related statutory guidance encourages the dissemination of science and technology innovation. While our
	recent contract with HHS BARDA provides us with the right to retain ownership in our inventions that may arise during performance
	of that contract, with respect to certain other collaborative research efforts with the U.S. government, certain developments and
	results that may have commercial potential are to be freely published, not treated as confidential, and we may be required to negotiate
	a license to developments and results in order to commercialize products. There can be no assurance that we will be able to successfully
	obtain any such license at a reasonable cost, or that such development and results will not be made available to our competitors
	on an exclusive or non-exclusive basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Trade Secrets.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We also rely significantly
	on trade secret protection and confidentiality agreements to protect our interests. It is our policy to require employees, consultants,
	contractors, manufacturers, collaborators and other advisors to execute confidentiality agreements upon the commencement of employment,
	consulting or collaborative relationships with us. We also require confidentiality agreements from any entity that is to receive
	confidential information from us. With respect to employees, consultants and contractors, the agreements generally provide that
	all inventions made by the individual while rendering services to us shall be assigned to us as our property.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Government Regulations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The development, production
	and marketing of biological products, which included the vaccine candidates being developed by Novavax or our collaborators, are
	subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries. As
	a U.S. based company, we focus on the U.S. regulatory process and the standards imposed by the FDA, International Conference on
	Harmonisation (&ldquo;ICH&rdquo;) and other agencies because we believe, for the most part, meeting U.S. and ICH standards will
	allow us to satisfy regulatory agencies in other countries where we intend to do business. We are aware that expectations in some
	venues, notably in the European Union, differ to some degree and we are taking proactive steps to address such differences. In
	the U.S., the development, manufacturing and marketing of human pharmaceuticals and vaccines are subject to extensive regulation
	under the Federal Food, Drug, and Cosmetic Act, and biological products are subject to regulation under provisions of that Act
	and the Public Health Service Act. The FDA not only assesses the safety and efficacy of these products but it also regulates, among
	other things, the testing, manufacture, labeling, storage, record-keeping, advertising and promotion of such products. The process
	of obtaining FDA licensure for a new vaccine is costly and time-consuming.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Vaccine clinical development
	follows the same general regulatory pathway as drugs and other biologics. Before applying for FDA licensure to market any new vaccine
	candidate, we must first submit an investigational new drug application (&ldquo;IND&rdquo;) that explains to the FDA, among other
	things, the results of preclinical toxicology testing conducted in laboratory animals, the method of manufacture, quality control
	tests for release, the stability of the investigational product and what we propose to do for human testing. At this stage, the
	FDA decides whether it is reasonably safe to move forward with testing the vaccine candidate in humans. We must then conduct Phase
	1 clinical trials and larger-scale Phase 2 and 3 clinical trials that demonstrate the safety, immunogenicity and efficacy of our
	vaccine candidate to the satisfaction of the FDA. Once these trials are complete, a Biologics License Application (&ldquo;BLA&rdquo;) can be
	submitted to the FDA requesting licensure of the vaccine for marketing based on the vaccine&rsquo;s safety and efficacy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During the FDA&rsquo;s
	review of a BLA, the proposed manufacturing facility undergoes a pre-approval inspection during which the FDA examines in detail
	the production of the vaccine, the manufacturing facility and the quality documentation related to the vaccine. Vaccine licensure
	also requires the provision of adequate product labeling to allow health care providers to understand the vaccine&rsquo;s proper
	use, including its potential benefits and risks, to communicate with patients and parents, and to safely deliver the vaccine to
	the public. Until a vaccine is given to the general population, all potential adverse events cannot be anticipated. Thus, the FDA
	typically requires Phase 4 post-marketing clinical trials for vaccines after licensure to continue gathering safety, and sometimes
	effectiveness/efficacy data in the indicated and additional populations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In order to ensure
	continuing safety, the FDA continues to oversee the production of vaccines even after the vaccine and manufacturing processes are
	approved. For example, monitoring of the vaccine and of production activities, including periodic facility inspections, must continue
	as long as the manufacturer holds a license for the product. Manufacturers may also be required to submit to the FDA the results
	of their own tests for potency, safety and purity for each vaccine lot, if requested by the FDA. They may also be required to submit
	samples of each vaccine lot to the FDA for testing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition to obtaining
	FDA licensure for each product, each domestic manufacturing establishment must be registered with the FDA, is subject to FDA inspection
	and must comply with cGMP regulations. To supply products for use either in the U.S. or outside the U.S., including clinical trials,
	U.S. and foreign manufacturing establishments, including third-party facilities, must comply with GMP regulations and are subject
	to periodic inspection by the FDA or by corresponding regulatory agencies in their home country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 1992, the FDA instituted
	regulations that allow approval of certain products that treat serious or life-threatening illnesses and provide meaningful therapeutic
	benefit over existing treatments based on a surrogate endpoint, versus a clinical outcome, which can take many more years to demonstrate.
	Surrogate endpoints, generally a laboratory measurement or other physical sign shown to have some correlation with clinical benefit,
	can considerably shorten the development time leading up to FDA licensure. The FDA bases its decision on whether to accept a proposed
	surrogate endpoint on the scientific support for that endpoint. The company developing the product is required to conduct further
	studies to confirm the clinical benefit in Phase 4 confirmatory efficacy trials. We plan to seek traditional approval for our quadrivalent
	seasonal influenza vaccine, but have not ruled out the potential use of accelerated approval for specific populations and for our
	pandemic influenza vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition to regulatory
	approvals that must be obtained in the U.S., an investigational product is also subject to regulatory approval in other countries
	in which it is intended to be marketed. No such product can be marketed in a country until the regulatory authorities of that country
	have approved an appropriate marketing application. FDA licensure does not assure approval by other regulatory authorities. In
	addition, in many countries, the government is involved in the pricing of the product. In such cases, the pricing review period
	often begins after market approval is granted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are also subject
	to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act,
	the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations, including national
	and local regulations that govern our facility in Sweden. These and other laws govern our use, handling and disposal of various
	biological and chemical substances used in, and waste generated by our operations. Our research and development involves the controlled
	use of hazardous materials, chemicals and viruses. Although we believe that our safety procedures for handling and disposing of
	such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury
	from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages
	that result and any such liability could exceed our resources. Additionally, for formulations containing controlled substances,
	we are subject to Drug Enforcement Act regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There have been numerous
	federal and state legislative changes made over the last few years regarding the pricing of pharmaceutical and biological products,
	the exertion of government control and other changes to the healthcare system of the U.S. It is uncertain how such legislative
	changes will be adopted or what actions federal, state or private payers for medical goods and services may take in response to
	such legislation. We cannot predict the effect such healthcare changes will have on our business, and no assurance can be given
	that any such reforms will not have a material adverse effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Manufacturing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our primary manufacturing
	facility is located at our corporate headquarters at 20 Firstfield Road in Gaithersburg, Maryland. The facility has 53,000 square
	feet of combined GMP manufacturing, laboratory and office space. Our Rockville, Maryland facility houses our 10,000 square foot
	GMP pilot manufacturing facility that produces early-stage clinical trial material. Novavax AB, located in Uppsala, Sweden, produces
	our Matrix adjuvants in an approximately 16,000 square foot facility comprised of GMP manufacturing, laboratory and office space.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Sources of Supply
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Most of the raw materials
	and other supplies required in our business are generally available from established vendors in quantities adequate to meet our
	needs. In some cases, we have only qualified one vendor for certain of our manufacturing components. Prior to the initiation of
	commercial production, we plan, where feasible, to qualify multiple vendors of critical raw materials. One key vendor is GE Healthcare
	Company (&ldquo;GEHC&rdquo;), which supplies disposable components, resins, media and buffers used in our manufacturing process.
	GEHC and other vendors that supply our key manufacturing materials have been or will be audited for compliance with GMP standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	An important component
	of our Matrix adjuvant technology is extracted from a species of soap-bark tree (
<I>
	Quillaja saponaria
</I>
	) that grows mainly in
	Chile, and we have been able to acquire high-quality quillaja extract as needed from our current suppliers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Business Development
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe our proprietary
	vaccine technology affords us a range of traditional and non-traditional commercialization options that are broader than those
	of existing vaccine companies. We strive to create sustainable value by working to obtain non-dilutive funding, similar to our
	agreements with HHS BARDA and BMGF, to fund future trials in our seasonal and pandemic influenza programs and our RSV program,
	to continue development of our vaccine candidates until such vaccines can be licensed, to retain commercial rights in one or more
	major markets and generate product sales revenue and, in certain markets, to commercialize our products through partners and other
	strategic relationships.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition to our
	aforementioned contracts with HHS BARDA and BMGF, another example of our strategic relationships is our joint venture we established
	with Cadila. CPLB is owned 20% by us and 80% by Cadila. It was established in 2009 to develop and manufacture certain vaccine candidates,
	biogeneric products and diagnostic products for the territory of India. CPLB operates a manufacturing facility in India for the
	production of vaccines and is actively developing a number of vaccine candidates that were genetically engineered by us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of February 24,
	2016, we have 443 full-time employees, of whom 95 hold M.D. or Ph.D. degrees and
	109 of whom hold other advanced degrees. Of our total workforce, 390 are engaged primarily in research, development and manufacturing
	activities and 53 are engaged primarily in executive, business development, finance and accounting, legal and administrative functions.
	None of our U.S. employees are represented by labor unions or covered by collective bargaining agreements; 32 of our 33 Swedish
	employees are covered by typical collective bargaining agreements. We consider our relations with our employees to be good.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Availability of
	Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our website address
	is
<U>
	www.novavax.com
</U>
	. We make available, free of charge and through our website, our Annual Reports on Form 10-K, Quarterly
	Reports on Form 10-Q, Current Reports on Form 8-K and our other filings with the SEC, and any amendments to any such reports filed
	or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable
	after filed with or furnished to the SEC. Further, a copy of this Annual Report on Form 10-K is located at the SEC&rsquo;s Public
	Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained
	by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements,
	and other information regarding issuers that file electronically with the SEC at
<U>
	www.sec.gov
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We use our website
	(www.novavax.com) as a means of disclosing material non-public information and for complying with our disclosure obligations under
	Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website (www.novavax.com) in the &ldquo;Investor
	Info&rdquo; or &ldquo;Newsroom&rdquo; sections. Accordingly, investors should monitor these portions of our website (www.novavax.com),
	in addition to following our press releases, SEC filings and public conference calls and webcasts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Also available on our
	website is information relating to corporate governance at Novavax and our Board of Directors, including our Code of Business Conduct
	and Ethics. We intend to disclose on our website any future amendments to and waivers from this code that apply to our Chief Executive
	Officer, Principal Financial Officer, Principal Accounting Officer and Controller, and persons performing similar functions, as
	promptly as practicable, as may be required under applicable SEC and NASDAQ rules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We webcast our earnings
	calls and certain events we participate in or host with members of the investment community on the investor relations section of
	our website. Additionally, we provide notifications of news or announcements regarding press and earnings releases as part of the
	investor relations section of our website. The contents of our website are not part of this Annual Report on Form 10-K, or any
	other report we file with, or furnish to, the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_003">
</A>
	Item
	1A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	RISK
	FACTORS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	You should carefully
	consider the following risk factors in evaluating our business. There are a number of risk factors that could cause our actual
	results to differ materially from those that are indicated by forward-looking statements. Some of the risks described relate principally
	to our business and the industry in which we operate. Others relate principally to the securities market and ownership of our common
	stock. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties that we
	are unaware of, or that we currently deem immaterial, also may become important factors that affect us. If any of the following
	risks occur, our business, financial condition or results of operations could be materially and adversely affected. You should
	also consider the other information included in this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	RISKS RELATED TO OUR BUSINESS AND INDUSTRY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We have a history
	of losses and our future profitability is uncertain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our expenses have exceeded
	our revenue since our formation in 1987, and our accumulated deficit at December 31, 2015 was $650 million. Our revenue for the
	last three fiscal years was $36.3 million in 2015, $30.7 million in 2014 and $20.9 million in 2013. Prior to 2011, we recorded
	limited revenue from research contracts, licenses and agreements to provide vaccine candidates, services and technologies. We cannot
	be certain that we will be successful in entering into strategic alliances or collaborative arrangements with other companies and
	government agencies that will result in significant revenue to offset our expenses. Our net losses for the last three fiscal years
	were $156.9 million in 2015, $82.9 million in 2014 and $52.0 million in 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our recent historical
	losses have predominantly resulted from research and development expenses for our vaccine candidates, manufacturing-related expenses,
	costs related to protection of our intellectual property and for other general operating expenses. Our expenses have exceeded our
	revenue since inception and we believe our expenses will continue to increase, as a result of higher research and development efforts
	to support the development of our vaccine candidates. For example, we have experienced a significant increase in research and development
	expenses in the fourth quarter of 2015 over prior years primarily due to additional RSV F Vaccine clinical trials in the primary
	indications of older adult immunization and infants via maternal immunization, as well as higher employee-related costs to support
	product development of our RSV F Vaccine and other potential vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Although certain specified
	costs associated with the development of our influenza vaccines may be reimbursed under our contract with HHS BARDA, and to a more
	limited extent, certain specified costs associated with the development of our RSV maternal vaccine may be reimbursed under our contract
	with BMGF, nevertheless we expect to continue to incur significant operating expenses and anticipate that our losses will increase
	in the foreseeable future as we seek to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conduct clinical trials for RSV and RSV-influenza
	combination respiratory vaccine candidates;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conduct preclinical studies for other
	vaccine candidates;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	comply with the FDA&rsquo;s manufacturing
	facility and compliance requirements in anticipation of commercialization;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	invest in our manufacturing process for
	commercial-scale and cost-efficiency; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	maintain, expand and protect our intellectual
	property portfolio.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a result, we expect
	our cumulative operating losses to increase until such time, if ever, that product sales, licensing fees, royalties, milestones,
	contract research and other sources generate sufficient revenue to fund our operations. We cannot predict when, if ever, we might
	achieve profitability and cannot be certain that we will be able to sustain profitability, if achieved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We have limited
	financial resources and we are not certain that we will be able to maintain our current level of operations or be able to fund
	the further development of our vaccine candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We do not expect to
	generate revenue from product sales, licensing fees, royalties, milestones, contract research or other sources in an amount sufficient
	to fully fund our operations for the foreseeable future, and we will therefore use our cash resources and expect to require additional
	funds to maintain our operations, continue our research and development programs, commence future preclinical studies and clinical
	trials, seek regulatory approvals and manufacture and market our products. We will seek such additional funds through public or
	private equity or debt financings, collaborative licensing and development arrangements, non-dilutive government contracts and
	grants and other sources. While we continue to apply for contracts or grants from academic institutions, non-profits and governmental
	entities, there are no assurances that we would be successful. We cannot be certain that adequate additional funding will be available
	to us on acceptable terms, if at all. If we cannot raise the additional funds required for our anticipated operations, we may be
	required to delay significantly, reduce the scope of or eliminate one or more of our research or development programs, downsize
	our general and administrative infrastructure, or seek alternative measures to avoid insolvency, including arrangements with collaborative
	partners or others that may require us to relinquish rights to certain of our technologies or vaccine candidates. If we raise additional
	funds through future offerings of shares of our common stock or other securities, such offerings would cause dilution of current
	stockholders&rsquo; percentage ownership in the Company, which could be substantial. Future offerings also could have a material
	and adverse effect on the price of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Economic uncertainty
	may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Generally, worldwide
	economic conditions remain uncertain. Access to capital markets is critical to our ability to operate. Traditionally, biopharmaceutical
	companies have funded their research and development expenditures through raising capital in the equity markets. Declines and uncertainties
	in these markets in the past have severely restricted raising new capital and have affected companies&rsquo; ability to continue
	to expand or fund existing research and development efforts. We require significant capital for research and development for our
	vaccine candidates and clinical trials. The general economic and capital market conditions, both in the U.S. and worldwide, have
	been volatile in the past and at times have adversely affected our access to capital and increased the cost of capital. There is
	no certainty that the capital and credit markets will be available to raise additional capital on favorable terms. If economic
	conditions become worse, our future cost of equity or debt capital and access to the capital markets could be adversely affected.
	In addition, if we are unable to access the capital markets on favorable terms, this could affect our ability to execute our business
	plan as scheduled. Moreover, we rely and intend to rely on third-parties, including our clinical research organizations and certain
	other important vendors and consultants. As a result of the global economic situation, there may be a disruption or delay in the
	performance of our third-party contractors and suppliers. If such third-parties are unable to adequately satisfy their contractual
	commitments to us in a timely manner, our business could be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Even with the
	Grant Agreement with BMGF, we may not be able to fully fund our RSV F Vaccine for infants via maternal immunization.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Grant Agreement
	reimburses a portion of specified expenses associated with the development of our RSV F Vaccine for infants via maternal immunization
	and there is no guarantee that additional activities will not be needed and, if so, that BMGF will partially reimburse us for these
	activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	The Grant Agreement
	with BMGF does not guarantee that we will be successful in future clinical trials associated with our RSV F Vaccine for infants
	via maternal immunization or that the vaccine candidate will be licensed by the FDA.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Grant Agreement
	reimburses a portion of specified expenses associated with the development of our RSV F Vaccine for infants via maternal immunization,
	but we remain fully responsible for conducting these development activities. The Grant Agreement does not guarantee that any of
	these activities will be successful. Our inability to be successful with certain key clinical or development activities could jeopardize
	our ability to obtain FDA licensure to sell this vaccine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Even with the
	HHS BARDA contract award, we may not be able to fully fund our influenza programs.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The HHS BARDA contract
	is a cost-plus-fixed-fee contract that only reimburses certain specified activities that have been previously authorized by HHS
	BARDA. There is no guarantee that additional activities will not be needed and, if so, that HHS BARDA will reimburse us for these
	activities. Performance under the HHS BARDA contract requires that we comply with appropriate regulations and operational mandates,
	which require us to engage internal and external expertise for compliance. Our ability to be regularly and fully reimbursed for
	our activities will depend on our ability to comply and demonstrate compliance with such requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	The HHS BARDA
	contract award does not guarantee that we will be successful in future clinical trials, that the vaccine candidates will be licensed
	by the FDA.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The HHS BARDA contract
	provides a cost-plus-fixed-fee reimbursement opportunity for certain specified clinical and development activities, but we remain
	fully responsible for conducting these approved activities. The award of the HHS BARDA contract does not guarantee that any of
	these activities will be successful. Our inability to be successful with certain key clinical or development activities could jeopardize
	our ability to obtain FDA licensure to sell our vaccines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	HHS BARDA could
	decide to potentially delay certain of our activities, and we may elect to move forward with certain activities at our own risk
	and without HHS BARDA reimbursement.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under the HHS BARDA
	contract, HHS BARDA regularly reviews our development efforts and clinical activities. Under certain circumstances, HHS BARDA may
	advise us to delay certain activities and invest additional time and resources before proceeding. If we follow such HHS BARDA advice,
	overall program delays and costs associated with additional resources for which we had not planned may result. Also, the costs
	associated with following such advice may or may not be reimbursed by HHS BARDA under our contract. Finally, we may decide not
	to follow the advice provided by HHS BARDA and instead pursue activities that we believe are in the best interest of the program
	and of the Company, even if HHS BARDA would not reimburse us under our contract.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	HHS BARDA may
	decide not to extend our contract beyond the exercised option period or may decide to terminate our contract.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The HHS BARDA contract
	was extended by an additional two years through the option period for a total performance period of approximately five and a half
	years. Depending on how we perform during the option period, HHS BARDA may decide whether or not to extend the contract to include
	additional periods of time to complete the contract deliverables or may decide to terminate the contract. For example, the HHS
	BARDA contract anticipates that we file BLAs for licensure of both our seasonal influenza vaccine and our pandemic influenza vaccine;
	however, there is no guarantee that we will successfully complete all of the tasks required to file BLAs during this period. There
	can be no guarantee that the HHS BARDA contract will not be terminated early or will be extended beyond September 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Because of changes
	to the influenza vaccine industry and regulatory environment, we do not expect to seek accelerated approval by the FDA of our seasonal
	influenza vaccine candidate.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	FDA regulations allow
	for the accelerated approval of a seasonal influenza vaccine based on a surrogate endpoint (i.e., HAI data) when there is a shortage
	of vaccine because influenza is a serious and sometimes, life-threatening disease. This may allow developers to obtain licensure
	well ahead of the timeline for demonstrating clinical efficacy, which is necessary for traditional approval. However, the seasonal
	influenza vaccine industry has made significant steps to provide sufficient supply to the recommended population in the U.S., and
	thus, we no longer expect to seek accelerated approval from the FDA for our seasonal influenza vaccine. Because we do not expect
	such approval, it is likely that we would need to conduct larger and more expensive efficacy clinical trials and that licensure
	of our seasonal vaccine will be materially delayed for a year or more, assuming such licensure occurs at all, which may, in turn,
	delay the FDA approval of our pandemic vaccine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Our wholly-owned
	subsidiary Novavax AB, collaborations with regional partners, such as Cadila and BMGF, as well as contracts with international
	providers, expose us to additional risks associated with doing business outside the U.S., and any adverse event could have a material
	negative impact on our operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Swedish-based Novavax
	AB is a wholly-owned subsidiary of Novavax, Inc. We have also formed a joint venture with Cadila in India, a clinical development
	agreement with BMGF and have entered into other agreements and arrangements with companies in other countries. We plan to continue
	to enter into collaborations or partnerships with companies, non-profit organizations and local governments in other parts of the
	world. Risks of conducting business outside the U.S. include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	multiple regulatory requirements could
	affect our ability to develop, manufacture and sell products in such local markets;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	compliance with anti-bribery laws such
	as the United States Foreign Corrupt Practices Act and similar anti-bribery laws in other jurisdictions;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	trade protections measures and import
	and export licensing requirements;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	difficulties in and costs of staffing,
	managing and operating our international operations;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in environmental, health and safety
	laws;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fluctuations in foreign currency exchange
	rates;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	potentially negative consequences from
	changes in or interpretations of tax laws;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	political instability and actual or anticipated
	military or potential conflicts;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	economic instability, inflation, recession
	and interest rate fluctuations;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	minimal or diminished protection of intellectual
	property; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	possible nationalization and expropriation.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	These risks, individually
	or in the aggregate, could have a material adverse effect on our business, financial conditions, results of operations and cash
	flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Current or future
	regional relationships may hinder our ability to engage in larger transactions.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have entered into
	regional collaborations to develop our vaccine candidates in certain parts of the world, and we may enter into additional regional
	collaborations. Our relationships with Cadila and BMGF are examples of these regional relationships. These relationships are likely
	to involve the licensing of our technology to our partner or entering into a distribution agreement, frequently on an exclusive
	basis. Generally, these exclusive agreements are restricted to certain territories. Because we have entered into exclusive license
	and distribution agreements, larger companies may not be interested, or able, to enter into collaborations with us on a worldwide-scale.
	Also, these regional relationships may make us an unattractive target for an acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We are a biopharmaceutical
	company and face significant risk in developing, manufacturing and commercializing our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We focus our research
	and development activities on vaccines, an area in which we have particular strengths and a technology that appears promising.
	The outcome of any research and development program is highly uncertain. Only a small fraction of biopharmaceutical development
	programs ultimately result in commercial products or even product candidates and a number of events could delay our development
	efforts and negatively impact our ability to obtain regulatory approval for, and to manufacture, market and sell, a vaccine. Vaccine
	candidates that initially appear promising often fail to yield successful products. In many cases, preclinical studies or clinical
	trials will show that a product candidate is not efficacious or that it raises safety concerns or has other side effects that outweigh
	its intended benefit. Success in preclinical or early clinical trials may not translate into success in large-scale clinical trials.
	Further, success in clinical trials will likely lead to increased investment, accelerating cumulative losses to bring such products
	to market. Even if clinical trial results appear positive, regulatory approval may not be obtained if the FDA does not agree with
	our interpretation of the results and we may face challenges when scaling-up the production process to commercial levels. Even
	after a product is approved and launched, general usage or post-marketing clinical trials may identify safety or other previously
	unknown problems with the product, which may result in regulatory approvals being suspended, limited to narrow indications or revoked,
	which may otherwise prevent successful commercialization. Intense competition in the vaccine industry could also limit the successful
	commercialization of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Many of our competitors
	have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our
	current and future licensees.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The biotechnology and
	pharmaceutical industries are subject to intense competition and rapid and significant technological change. We have many potential
	competitors, including major pharmaceutical companies, specialized biotechnology firms, academic institutions, government agencies
	and private and public research institutions. Many of our competitors have significantly greater financial and technical resources,
	experience and expertise in:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT SYMBOL; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	research and development;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	preclinical testing;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	designing and implementing clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	regulatory processes and approvals;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	production and manufacturing; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sales and marketing of approved products.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Principal competitive
	factors in our industry include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the quality and breadth of an organization&rsquo;s
	technology;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	management of the organization and the
	execution of the organization&rsquo;s strategy;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the skill and experience of an organization&rsquo;s
	employees and its ability to recruit and retain skilled and experienced employees;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	an organization&rsquo;s intellectual property
	portfolio;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the range of capabilities, from target
	identification and validation to drug discovery and development to manufacturing and marketing; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the availability of substantial capital
	resources to fund discovery, development and commercialization activities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Large and established
	companies, such as Merck &amp; Co., Inc., GlaxoSmithKline plc, CSL Ltd, Sanofi Pasteur, SA, Pfizer Inc. and MedImmune, LLC (a subsidiary
	of AstraZeneca PLC), among others, compete in the vaccine market. In particular, these companies have greater experience and expertise
	in securing government contracts and grants to support their research and development efforts, conducting testing and clinical
	trials, obtaining regulatory approvals to market products, manufacturing such products on a broad scale and marketing approved
	products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There are many seasonal
	influenza vaccines currently approved and marketed. Competition in the sale of these seasonal influenza vaccines is intense. Therefore,
	newly developed and approved products must be differentiated from existing vaccines in order to have commercial success. In order
	to show differentiation in the seasonal influenza market, a product may need to be more efficacious, particularly in older adults,
	and/or be less expensive and quicker to manufacture. Many of our competitors are working on new products and new generations of
	current products, each of which is intended to be more efficacious than products currently being marketed. Our seasonal influenza
	vaccine candidate may not prove to be more efficacious than current products or products under development by our competitors.
	Further, our manufacturing system may not provide enough savings of time or money to provide the required differentiation for commercial
	success.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are also aware that
	there are multiple companies with active RSV vaccine programs at various stages of development. Thus, while there is no RSV vaccine
	currently on the market, there is likely to be significant and consistent competition as these active programs mature. Different
	RSV vaccines may work better for different segments of the population, so it may be difficult for a single RSV vaccine manufacturer
	to provide vaccines that are marketable to multiple population segments. Geographic markets are also likely to vary significantly,
	which may make it difficult to market a single RSV vaccine worldwide. Even if a manufacturer brings an RSV vaccine to license,
	it is likely that competitors will continue to work on new products that could be more efficacious and/or less expensive. Our RSV
	vaccine candidate may not be as far along in development as other active RSV vaccine programs about which we are not aware, nor
	as efficacious as products under development by competing companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe that there
	are at least two EBOV vaccine candidates that are currently being tested in late stage clinical trials: one by GlaxoSmithKline
	in collaboration with the United States National Institute of Allergy and Infectious Diseases, and the other by a collaboration
	of NewLink Genetics, Merck Vaccines USA and the Public Health Agency of Canada. Additional vaccine candidates are also being tested,
	although in earlier stage clinical trials. Vaccine candidates against EBOV have been in development for more than a decade by large
	pharmaceutical companies, smaller biotech companies, government agencies and academic labs worldwide, and with the high visibility
	of the recent West Africa epidemic, continued development activities are likely to continue and potentially increase.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Regardless of the disease,
	smaller or early-stage companies and research institutions may also prove to be significant competitors, particularly through collaborative
	arrangements with large and established pharmaceutical companies. As these companies develop their technologies, they may develop
	proprietary positions, which may prevent or limit our product development and commercialization efforts. We will also face competition
	from these parties in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites
	and subject registration for clinical trials and in acquiring and in-licensing technologies and products complementary to our programs
	or potentially advantageous to our business. If any of our competitors succeed in obtaining approval from the FDA or other regulatory
	authorities for their products sooner than we do or for products that are more effective or less costly than ours, our commercial
	opportunity could be significantly reduced.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In order to effectively
	compete, we will have to make substantial investments in development, testing, manufacturing and sales and marketing or partner
	with one or more established companies. There is no assurance that we will be successful in gaining significant market share for
	any vaccine. Our technologies and vaccines also may be rendered obsolete or non-competitive as a result of products introduced
	by our competitors to the marketplace more rapidly and at a lower cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	If we are unable
	to attract or retain key management or other personnel, our business, operating results and financial condition could be materially
	adversely affected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We depend on our senior
	executive officers, as well as key scientific and other personnel. The loss of these individuals could harm our business and significantly
	delay or prevent the achievement of research, development or business objectives. We have had turnover situations in key executive
	positions and the lack of management continuity and resulting lack of long-term history with our Company along with the learning
	curve that executives experience when they join our management team could result in operational and administrative inefficiencies
	and added costs. If we were to experience additional turnover at the executive level, these risks could be exacerbated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We may not be able
	to attract qualified individuals for other key management or other personnel positions on terms acceptable to us. Competition for
	qualified employees is intense among pharmaceutical and biotechnology companies, and the loss of qualified employees, or an inability
	to attract, retain and motivate additional highly skilled employees required for the expansion of our activities, could hinder
	our ability to complete clinical trials successfully and develop marketable products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We also rely from time
	to time on outside advisors who assist us in formulating our research and development and clinical strategy. We may not be able
	to attract and retain these individuals on acceptable terms, which could have a material adverse effect on our business, financial
	condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may have product
	liability exposure.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The administration
	of drugs or vaccines to humans, whether in clinical trials or after marketing clearances are obtained, can result in product liability
	claims. We maintain product liability insurance coverage in the total amount of $20 million aggregate for all claims arising from
	the use of products in clinical trials prior to FDA approval. Coverage is relatively expensive, and the market pricing can significantly
	fluctuate. Therefore, we may not be able to maintain insurance at a reasonable cost. There can be no assurance that we will be
	able to maintain our existing insurance coverage or obtain coverage for the use of our other products in the future. This insurance
	coverage and our resources may not be sufficient to satisfy all liabilities resulting from product liability claims. A successful
	claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable items, if at all.
	Even if a claim is not successful, defending such a claim would be time-consuming and expensive, may damage our reputation in the
	marketplace and would likely divert management&rsquo;s attention.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Regardless of merit
	or eventual outcome, liability claims may result in:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	decreased demand for our products;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	impairment of our business reputation;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	withdrawal of clinical trial participants;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	costs of related litigation;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	substantial monetary awards to subjects
	or other claimants;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	loss of revenue; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability to commercialize our vaccine
	candidates.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may not be
	able to win government, academic institution or non-profit contracts or grants.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	From time to time,
	we may apply for contracts or grants from government agencies, academic institutions, and non-profit entities. Such contracts or
	grants can be highly attractive because they provide capital to fund the ongoing development of our technologies and vaccine candidates
	without diluting our stockholders. However, there is often significant competition for these contracts or grants. Entities offering
	contracts or grants may have requirements to apply for or to otherwise be eligible to receive certain contracts or grants that
	our competitors may be able to satisfy that we cannot. In addition, such entities may make arbitrary decisions as to whether to
	offer contracts or make grants, to whom the contracts or grants will be awarded and the size of the contracts or grants to each
	awardee. Even if we are able to satisfy the award requirements, there is no guarantee that we will be a successful awardee. Therefore,
	we may not be able to win any contracts or grants in a timely manner, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Raising additional
	capital by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders or
	require us to relinquish rights to our technologies or vaccine candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we are unable to
	partner with a third-party to advance the development of one or more of our vaccine candidates, we will need to raise money through
	additional debt or equity financings. To the extent that we raise additional capital by issuing equity securities, our stockholders
	will experience immediate dilution, which may be significant. There is also a risk that such equity issuances may cause an ownership
	change under the Internal Revenue Code of 1986, as amended, and similar state provisions, thus limiting our ability to use our
	net operating loss carryforwards and credits. To the extent that we raise additional capital through licensing arrangements or
	arrangements with collaborative partners, we may be required to relinquish, on terms that may not be favorable to us, rights to
	some of our technologies or vaccine candidates that we would otherwise seek to develop or commercialize ourselves. In addition,
	current economic conditions may also negatively affect the desire or ability of potential collaborators to enter into transactions
	with us. They may also have to delay or cancel research and development projects or reduce their overall budgets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Our business
	may be adversely affected if we do not successfully execute our business development initiatives.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We anticipate growing
	through both internal development projects, as well as external opportunities, which include the acquisition, partnering and in-licensing
	of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality
	opportunities is limited, and we may fail to identify candidates that we and our stockholders consider suitable or complete transactions
	on terms that prove advantageous. In order to pursue such opportunities, we may require significant additional financing, which
	may not be available to us on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions,
	like our business combination with Novavax AB, we may not be able to integrate the assets or take full advantage of the opportunities
	and, consequently, may not realize the benefits that we expect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	To effectively manage
	our current and future potential growth, we will need to continue to enhance our operational, financial and management processes
	and to effectively expand, train and manage our employee base. Supporting our growth initiatives will require significant expenditures
	and management resources, including investments in research and development, manufacturing and other areas of our business. If
	we do not successfully manage our growth and do not successfully execute our growth initiatives, then our business and financial
	results may be adversely impacted, and we may incur asset impairment or restructuring charges.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Litigation could
	have a material adverse impact on our results of operation and financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition to intellectual
	property litigation, from time to time, we may be subject to other litigation. Regardless of the merits of any claims that may
	be brought against us, litigation could result in a diversion of management&rsquo;s attention and resources and we may be required
	to incur significant expenses defending against these claims. If we are unable to prevail in litigation, we could incur substantial
	liabilities. Where we can make a reasonable estimate of the liability relating to pending litigation and determine that it is probable,
	we record a related liability. As additional information becomes available, we assess the potential liability and revise estimates
	as appropriate. However, because of uncertainties relating to litigation, the amount of our estimates could be wrong.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Security breaches
	and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation
	to suffer.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the ordinary course
	of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and
	data about our clinical subjects, suppliers, and business partners, and personally identifiable information. The secure maintenance
	of this information is critical to our operations and business strategy. Some of this information could be an attractive target
	of criminal attack by malicious third parties with a wide range of motives and expertise, including organized criminal groups,
	&ldquo;hactivists,&rdquo; patient groups, disgruntled current or former employees, and others. Hacker attacks are of ever-increasing
	levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to
	such attacks or may be breached due to employee error or malfeasance. Any such breach could compromise our networks and the information
	stored there could be accessed, publicly disclosed, lost or stolen. Furthermore, if our systems become compromised, we may not
	promptly discover the intrusion. Like other companies in our industry, we have experienced attacks to our data and systems, including
	malware and computer viruses. Attacks could have a material impact on our business, operations or financial results. Any access,
	disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy
	of personal information, disrupt our operations, and damage our reputation, which could adversely affect our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	PRODUCT DEVELOPMENT RISKS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Because our vaccine
	product development efforts depend on new and rapidly evolving technologies, we cannot be certain that our efforts will be successful.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our vaccine development
	efforts depend on new, rapidly evolving technologies and on the marketability and profitability of our products. Our development
	efforts and, if those are successful, commercialization of our vaccines could fail for a variety of reasons, and include the possibility
	that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our recombinant nanoparticle vaccine technologies,
	any or all of the products based on such technologies or our proprietary manufacturing process will be ineffective or unsafe, or
	otherwise fail to receive necessary regulatory clearances or commercial viability;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we are unable to scale-up our manufacturing
	capabilities in a cost-effective manner;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the products, if safe and effective, will
	be difficult to manufacture on a large-scale or uneconomical to market;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our manufacturing facility will fail to
	continue to pass regulatory inspections;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	proprietary rights of third-parties will
	prevent us or our collaborators from exploiting technologies, and manufacturing or marketing products; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	third-party competitors will gain greater
	market share due to superior products or marketing capabilities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We have not completed
	the development of vaccine products and we may not succeed in obtaining the FDA licensure necessary to sell such vaccine products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The development, manufacture
	and marketing of our pharmaceutical and biological products are subject to government regulation in the U.S. and other countries,
	including the European Medicines Agency and the Swedish Medical Products Agency with respect to our adjuvant product being developed
	in Sweden. In the U.S. and most foreign countries, we must complete rigorous preclinical testing and extensive clinical trials
	that demonstrate the safety and efficacy of a product in order to apply for regulatory approval to market the product. None of
	our vaccine candidates have yet gained regulatory approval in the U.S. or elsewhere. We also have vaccine candidates in clinical
	trials and preclinical laboratory or animal studies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The steps generally
	required by the FDA before our proposed investigational products may be marketed in the U.S. include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	performance of preclinical (animal and
	laboratory) tests;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	submissions to the FDA of an IND, which
	must become effective before clinical trials may commence;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	performance of adequate and well controlled
	clinical trials to establish the safety and efficacy of the investigational product in the intended target population;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	performance of a consistent and reproducible
	manufacturing process intended for commercial use, including appropriate manufacturing data and regulatory inspections;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	submission to the FDA of a BLA or a NDA;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FDA approval of the BLA or NDA before
	any commercial sale or shipment of the product.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The processes are expensive
	and can take many years to complete, and we may not be able to demonstrate the safety and efficacy of our vaccine candidates to
	the satisfaction of regulatory authorities. The start of clinical trials can be delayed or take longer than anticipated for many
	and varied reasons, many of which are out of our control. Safety concerns may emerge that could lengthen the ongoing clinical trials
	or require additional clinical trials to be conducted. Promising results in early clinical trials may not be replicated in subsequent
	clinical trials. Regulatory authorities may also require additional testing, and we may be required to demonstrate that our proposed
	products represent an improved form of treatment over existing therapies, which we may be unable to do without conducting further
	clinical trials. Moreover, if the FDA or a foreign regulatory body grants regulatory approval of a product, the approval may be
	limited to specific indications or limited with respect to its distribution. Expanded or additional indications for approved products
	may not be approved, which could limit our revenue. Foreign regulatory authorities may apply similar limitations or may refuse
	to grant any approval. Consequently, even if we believe that preclinical and clinical data are sufficient to support regulatory
	approval for our vaccine candidates, the FDA and foreign regulatory authorities may not ultimately grant approval for commercial
	sale in any jurisdiction. If our vaccine candidates are not approved, our ability to generate revenue will be limited and our business
	will be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	If we are unable
	to manufacture our vaccines in sufficient quantities, at sufficient yields or are unable to obtain regulatory approvals for a manufacturing
	facility for our vaccines, we may experience delays in product development, clinical trials, regulatory approval and commercial
	distribution.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Completion of our clinical
	trials and commercialization of our vaccine candidates require access to, or development of, facilities to manufacture our vaccine
	candidates at sufficient yields and at commercial-scale. We have limited experience manufacturing any of our vaccine candidates
	in the volumes that will be necessary to support large-scale clinical trials or commercial sales. Efforts to establish these capabilities
	may not meet initial expectations as to scheduling, scale-up, reproducibility, yield, purity, cost, potency or quality.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Manufacturing our vaccine
	candidates involves a complicated process with which we have limited experience. If we are unable to manufacture our vaccine candidates
	in clinical quantities or, when necessary, in commercial quantities and at sufficient yields, then we must rely on third-parties.
	Other third-party manufacturers must also receive FDA approval before they can produce clinical material or commercial products.
	Our vaccines may be in competition with other products for access to these facilities and may be subject to delays in manufacture
	if third-parties give other products greater priority. We may not be able to enter into any necessary third-party manufacturing
	arrangements on acceptable terms, or on a timely basis. In addition, we have to enter into technical transfer agreements and share
	our know-how with the third-party manufacturers, which can be time-consuming and may result in delays.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Influenza vaccines
	are seasonal in nature. If a vaccine is not available early enough in the influenza season, we would likely have difficulty selling
	the vaccine. Further, pandemic outbreaks present only short-term opportunities for us. There is no way to predict when there will
	be a pandemic outbreak, the strain of the influenza or how long the pandemic will last. For these reasons, any delay in the delivery
	of an influenza vaccine could result in lower sales volumes, lower sale prices, or no sales. Because the strain of the seasonal
	influenza changes annually, inventory of seasonal vaccine cannot be sold during a subsequent influenza season. Any delay in the
	manufacture of our influenza vaccines could adversely affect our ability to sell the vaccines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our reliance on contract
	manufacturers may adversely affect our operations or result in unforeseen delays or other problems beyond our control. Because
	of contractual restraints and the limited number of third-party manufacturers with the expertise, required regulatory approvals
	and facilities to manufacture our bulk vaccines on a commercial-scale, replacement of a manufacturer may be expensive and time-consuming
	and may cause interruptions in the production of our vaccine. A third-party manufacturer may also encounter difficulties in production.
	These problems may include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	difficulties with production costs, scale
	up and yields;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	availability of raw materials and supplies;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	quality control and assurance;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	shortages of qualified personnel;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	compliance with strictly enforced federal,
	state and foreign regulations that vary in each country where product might be sold; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	lack of capital funding.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a result, any delay
	or interruption could have a material adverse effect on our business, financial condition, results of operations and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We must identify
	vaccines for development with our technologies and establish successful third-party relationships.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The near and long-term
	viability of our vaccine candidates will depend in part on our ability to successfully establish new strategic collaborations with
	pharmaceutical and biotechnology companies, non-profit organizations and government agencies. Establishing strategic collaborations
	and obtaining government funding is difficult and time-consuming. Potential collaborators may reject collaborations based upon
	their assessment of our financial, regulatory or intellectual property position or based on their internal pipeline; government
	agencies may reject contract or grant applications based on their assessment of public need, the public interest, our products&rsquo;
	ability to address these areas, or other reasons beyond our expectations or control. If we fail to establish a sufficient number
	of collaborations or government relationships on acceptable terms, we may not be able to commercialize our vaccine candidates or
	generate sufficient revenue to fund further research and development efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even if we establish
	new collaborations or obtain government funding, these relationships may never result in the successful development or commercialization
	of any vaccine candidates for several reasons, including the fact that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we may not have the ability to control
	the activities of our partners and cannot provide assurance that they will fulfill their obligations to us, including with respect
	to the license, development and commercialization of vaccine candidates, in a timely manner or at all;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	such partners may not devote sufficient
	resources to our vaccine candidates or properly maintain or defend our intellectual property rights;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	any failure on the part of our partners
	to perform or satisfy their obligations to us could lead to delays in the development or commercialization of our vaccine candidates
	and affect our ability to realize product revenue; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	disagreements, including disputes over
	the ownership of technology developed with such collaborators, could result in litigation, which would be time consuming and expensive,
	and may delay or terminate research and development efforts, regulatory approvals and commercialization activities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our collaborators will
	be subject to the same regulatory approval of their manufacturing facility and process as Novavax. Before we could begin commercial
	manufacturing of any of our vaccine candidates, we and our collaborators must pass a pre-approval inspection before FDA approval
	and comply with the FDA&rsquo;s GMP regulations. If our collaborators fail to comply with these requirements, our vaccine candidates
	would not be approved. If our collaborators fail to comply with these requirements after approval, we could be subject to possible
	regulatory action and may be limited in the jurisdictions in which we are permitted to sell our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we or our collaborators
	fail to maintain our existing agreements or in the event we fail to establish agreements as necessary, we could be required to
	undertake research, development, manufacturing and commercialization activities solely at our own expense. These activities would
	significantly increase our capital requirements and, given our lack of sales, marketing and distribution capabilities, significantly
	delay the commercialization of our vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Because we depend
	on third-parties to conduct some of our laboratory testing, clinical trials, and manufacturing, we may encounter delays in or lose
	some control over our efforts to develop products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are dependent on
	third-party research organizations to conduct some of our laboratory testing, clinical trials and manufacturing activities. If
	we are unable to obtain any necessary services on acceptable terms, we may not complete our product development efforts in a timely
	manner. We may lose some control over these activities and become too dependent upon these parties. These third-parties may not
	complete testing or manufacturing activities on schedule, within budget, or when we request. We may not be able to secure and maintain
	suitable research organizations to conduct our laboratory testing, clinical trials and manufacturing activities. We have not manufactured
	any of our vaccine candidates at a commercial level and may need to identify additional third-party manufacturers to scale-up and
	manufacture our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are responsible
	for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol.
	Moreover, the FDA and foreign regulatory agencies require us to comply with regulations and standards, commonly referred to as
	good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported
	results are credible and accurate and that the clinical trial participants are adequately protected. The FDA and foreign regulatory
	agencies also require us to comply with good manufacturing practices. Our reliance on third-parties does not relieve us of these
	responsibilities and requirements. These third-parties may not successfully carry out their contractual duties or regulatory obligations
	or meet expected deadlines. In addition, these third-parties may need to be replaced or the quality or accuracy of the data they
	obtain may be compromised or the product they manufacture may be contaminated due to the failure to adhere to our clinical and
	manufacturing protocols, regulatory requirements or for other reasons. In any such event, our preclinical development activities
	or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval of,
	or commercially manufacture, our vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Even if licensed
	to market, our vaccine products may not be initially or ever profitable.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Whether Novavax makes
	a profit from the sale of its vaccine products is dependent on a number of variables, including the costs we incur manufacturing,
	testing and releasing, packaging and shipping such vaccine product. The Grant Agreement with BMGF necessitates that we commit to
	a specific amount of sales in certain specified middle and lower income countries, which may impact our ability to make profits.
	In addition, we have not yet determined pricing for our vaccine products, which is a complicated undertaking that necessitates
	both regulatory agency and payor support. We cannot predict when, if at all, our approved vaccine products will be profitable to
	the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Our collaborations
	may not be profitable.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We formed CPLB with
	Cadila in India and, in connection with it, entered into a master services agreement pursuant to which we may request certain services
	from Cadila in the areas of biologics research, preclinical development, clinical development, process development, manufacturing
	scale-up and general manufacturing related services in India. We cannot predict when, if at all, this relationship will lead to
	approved products, sales, or otherwise provide revenue to the Company or become profitable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We have limited
	marketing capabilities, and if we are unable to enter into collaborations with marketing partners or develop our own sales and
	marketing capability, we may not be successful in commercializing any approved products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Although we have initiated
	preliminary activities in anticipation of commercialization of our vaccine candidates, we currently have no dedicated sales, marketing
	or distribution capabilities. As a result, we will depend on collaborations with third-parties that have established distribution
	systems and sales forces. To the extent that we enter into co-promotion or other licensing arrangements, our revenue will depend
	upon the efforts of third-parties, over which we may have little or no control. If we are unable to reach and maintain agreements
	with one or more pharmaceutical companies or collaborators, we may be required to market our products directly. Developing a marketing
	and sales force is expensive and time-consuming and could delay a product launch. We cannot be certain that we will be able to
	attract and retain qualified sales personnel or otherwise develop this capability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Our vaccine candidates
	may never achieve market acceptance even if we obtain regulatory approvals.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even if we receive
	regulatory approvals for the commercial sale of our vaccine candidates, the commercial success of these vaccine candidates will
	depend on, among other things, their acceptance by physicians, patients, third-party payers, such as health insurance companies
	and other members of the medical community, as a vaccine and cost-effective alternative to competing products. If our vaccine candidates
	fail to gain market acceptance, we may be unable to earn sufficient revenue to continue our business. Market acceptance of, and
	demand for, any product that we may develop and commercialize will depend on many factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to provide acceptable evidence
	of safety and efficacy;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the prevalence and severity of adverse
	side effects;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	whether our vaccines are differentiated
	from other vaccines based on immunogenicity;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	availability, relative cost and relative
	efficacy of alternative and competing treatments;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the effectiveness of our marketing and
	distribution strategy;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	publicity concerning our products or competing
	products and treatments; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to obtain sufficient third
	party insurance coverage or reimbursement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In particular, there
	are significant challenges to market acceptance for seasonal influenza vaccines. For our seasonal vaccine to be accepted in the
	market, we must demonstrate differentiation from other seasonal vaccines that are currently approved and marketed. This can mean
	that the vaccine is more effective in certain populations, such as in older adults, or cheaper and quicker to produce. There are
	no assurances that our vaccine will be more efficacious than other vaccines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If our vaccine candidates
	do not become widely accepted by physicians, patients, third-party payers and other members of the medical community, our business,
	financial condition and results of operations could be materially and adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may not be
	able to secure sufficient supplies of a key component of our adjuvant technology.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because an important
	component of our adjuvant technology is extracted from a species of soap-bark tree (
<I>
	Quillaja saponaria
</I>
	) grown in Chile,
	we need long term access to quillaja extract with a consistent and sufficiently high quality. We need a secure supply of raw material,
	as well as back-up suppliers, or our adjuvant products may be delayed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	If reforms in
	the health care industry make reimbursement for our potential products less likely, the market for our potential products will
	be reduced, and we could lose potential sources of revenue.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our success may depend,
	in part, on the extent to which reimbursement for the costs of vaccines will be available from third-party payers, such as government
	health administration authorities, private health insurers, managed care programs and other organizations. Over the past decade,
	the cost of health care has risen significantly, and there have been numerous proposals by legislators, regulators and third-party
	health care payers to curb these costs. Some of these proposals have involved limitations on the amount of reimbursement for certain
	products. Similar federal or state health care legislation may be adopted in the future and any products that we or our collaborators
	seek to commercialize may not be considered cost-effective. Adequate third-party insurance coverage may not be available for us
	to establish and maintain price levels that are sufficient for realization of an appropriate return on our investment in product
	development. Moreover, the existence or threat of cost control measures could cause our corporate collaborators to be less willing
	or able to pursue research and development programs related to our vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	REGULATORY RISKS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may fail to
	obtain regulatory approval for our products on a timely basis or comply with our continuing regulatory obligations after approval
	is obtained.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Delays in obtaining
	regulatory approval can be extremely costly in terms of lost sales opportunities, loss of any potential marketing advantage of
	being early to market and increased clinical trial costs. The speed with which we begin and complete our preclinical studies necessary
	to begin clinical trials, clinical trials and our applications for marketing approval will depend on several factors, including
	the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to manufacture or obtain sufficient
	quantities of materials for use in necessary preclinical studies and clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	prior regulatory agency review and approval;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	approval of the protocol and the informed
	consent form by the review board of the institution conducting the clinical trial;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the rate of subject or patient enrollment
	and retention, which is a function of many factors, including the size of the subject or patient population, the proximity of subjects
	and patients to clinical sites, the eligibility criteria for the clinical trial and the nature of the protocol;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	negative test results or side effects
	experienced by clinical trial participants;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	analysis of data obtained from preclinical
	and clinical activities, which are susceptible to varying interpretations and which interpretations could delay, limit or prevent
	further studies or regulatory approval;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the availability of skilled and experienced
	staff to conduct and monitor clinical trials and to prepare the appropriate regulatory applications; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in the policies of regulatory
	authorities for drug or vaccine approval during the period of product development.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have limited experience
	in conducting and managing the preclinical studies and clinical trials necessary to obtain regulatory marketing approvals. We may
	not be permitted to continue or commence additional clinical trials. We also face the risk that the results of our clinical trials
	may be inconsistent with the results obtained in preclinical studies or clinical trials of similar products or that the results
	obtained in later phases of clinical trials may be inconsistent with those obtained in earlier phases. A number of companies in
	the biopharmaceutical and product development industry have suffered significant setbacks in advanced clinical trials, even after
	experiencing promising results in early animal and human testing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Regulatory agencies
	may require us or our collaborators to delay, restrict or discontinue clinical trials on various grounds, including a finding that
	the subjects or patients are being exposed to an unacceptable health risk. In addition, we or our collaborators may be unable to
	submit applications to regulatory agencies within the time frame we currently expect. Once submitted, applications must be approved
	by various regulatory agencies before we or our collaborators can commercialize the product described in the application. All statutes
	and regulations governing the conduct of clinical trials are subject to change in the future, which could affect the cost of such
	clinical trials. Any unanticipated costs or delays in our clinical trials could delay our ability to generate revenue and harm
	our financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Failure to obtain
	regulatory approval in foreign jurisdictions would prevent us from marketing our products internationally.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We intend to have our
	vaccine candidates marketed outside the U.S. In furtherance of this objective, we have entered into relationships with Cadila in
	India. In order to market our products in the European Union, India, Asia and many other non-U.S. jurisdictions, we must obtain
	separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among
	countries and can involve additional testing and data review. The time required to obtain foreign regulatory approval may differ
	from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with
	obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by a regulatory agency,
	such as the FDA, does not ensure approval by any other regulatory agencies, for example in other foreign countries. However, a
	failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process
	in other jurisdictions, including approval by the FDA. The failure to obtain regulatory approval in foreign jurisdictions could
	harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Even if regulatory
	approval is received for our vaccine candidates, the later discovery of previously unknown problems with a product, manufacturer
	or facility may result in restrictions, including withdrawal of the product from the market.
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Even if a product gains
	regulatory approval, such approval is likely to limit the indicated uses for which it may be marketed, and the product and the
	manufacturer of the product will be subject to continuing regulatory review, including adverse event reporting requirements and
	the FDA&rsquo;s general prohibition against promoting products for unapproved uses. Failure to comply with any post-approval requirements
	can, among other things, result in warning letters, product seizures, recalls, substantial fines, injunctions, suspensions or revocations
	of marketing licenses, operating restrictions and criminal prosecutions. Any of these enforcement actions, any unanticipated changes
	in existing regulatory requirements or the adoption of new requirements, or any safety issues that arise with any approved products,
	could adversely affect our ability to market products and generate revenue and thus adversely affect our ability to continue our
	business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We also may be restricted
	or prohibited from marketing or manufacturing a product, even after obtaining product approval, if previously unknown problems
	with the product or its manufacture are subsequently discovered and we cannot provide assurance that newly discovered or developed
	safety issues will not arise following any regulatory approval. With the use of any vaccine by a wide patient population, serious
	adverse events may occur from time to time that initially do not appear to relate to the vaccine itself, and only if the specific
	event occurs with some regularity over a period of time does the vaccine become suspect as having a causal relationship to the
	adverse event. Any safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to
	substantial liabilities, and adversely affect our ability to generate revenue and our financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Because we are
	subject to environmental, health and safety laws, we may be unable to conduct our business in the most advantageous manner.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are subject to various
	laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals,
	emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection
	with our research, including infectious disease agents. We also cannot accurately predict the extent of regulations that might
	result from any future legislative or administrative action. Any of these laws or regulations could cause us to incur additional
	expense or restrict our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our facilities in Maryland
	are subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing
	practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including
	chemicals, microorganisms and various hazardous compounds used in connection with our research and development activities. In the
	U.S., these laws include the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation
	and Recovery Act. Similar national and local regulations govern our facility in Sweden. We cannot eliminate the risk of accidental
	contamination or discharge or injury from these materials. Federal, state, and local laws and regulations govern the use, manufacture,
	storage, handling and disposal of these materials. We could be subject to civil damages in the event of an improper or unauthorized
	release of, or exposure of individuals to, these hazardous materials. In addition, claimants may sue us for injury or contamination
	that results from our use or the use by third-parties of these materials, and our liability may exceed our total assets. Compliance
	with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research,
	development or production efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Although we have general
	liability insurance, these policies contain exclusions from insurance against claims arising from pollution from chemicals or pollution
	from conditions arising from our operations. Our collaborators are working with these types of hazardous materials in connection
	with our collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury we or our collaborators
	cause to persons or property by exposure to, or release of, any hazardous materials. However, we believe that we are currently
	in compliance with all applicable environmental and occupational health and safety regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Even if we successfully
	commercialize any of our vaccine candidates, either alone or in collaboration, we face uncertainty with respect to pricing, third-party
	reimbursement and healthcare reform, all of which could adversely affect any commercial success of our vaccine candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our ability to collect
	revenue from the commercial sale of our vaccines may depend on our ability, and that of any current or potential future collaboration
	partners or customers, to obtain adequate levels of coverage and reimbursement for such products from third-party payers such as:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	government health administration authorities;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	private health insurers;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	health maintenance organizations;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	pharmacy benefit management companies;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	other healthcare related organizations.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Third-party payers
	are increasingly challenging the prices charged for medical products and may deny coverage or offer inadequate levels of reimbursement
	if they determine that a prescribed product has not received appropriate clearances from the FDA, or foreign equivalent, or other
	government regulators, is not used in accordance with cost-effective treatment methods as determined by the third-party payer,
	or is experimental, unnecessary or inappropriate. Prices could also be driven down by health maintenance organizations that control
	or significantly influence purchases of healthcare products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In both the U.S. and
	some foreign jurisdictions, there have been a number of legislative and regulatory proposals and initiatives to change the health
	care system in ways that could affect our ability to sell vaccines. Some of these proposed and implemented reforms could result
	in reduced reimbursement rates for medical products, and while we have no current vaccines available for commercial sale, the impact
	of such reform could nevertheless adversely affect our business strategy, operations and financial results. In March 2010, President
	Obama signed into law a legislative overhaul of the U.S. healthcare system, known as the Patient Protection and Affordable Care
	Act of 2010, as amended by the Healthcare and Education Affordability Reconciliation Act of 2010 (the &ldquo;PPACA&rdquo;). As
	a result of this new legislation, substantial changes could be made to the current system for paying for healthcare in the United
	States, including changes made in order to extend medical benefits to those who currently lack insurance coverage. The long-term
	ramifications of PPACA remain unclear and many details regarding implementation of PPACA are yet to be determined, however, the
	cost-containment measures that healthcare providers are instituting and the results of healthcare reforms may negatively impact
	the commercial prospects of one or more of our vaccine candidates currently in development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	INTELLECTUAL PROPERTY RISKS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Our success depends
	on our ability to maintain the proprietary nature of our technology.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our success in large
	part depends on our ability to maintain the proprietary nature of our technology and other trade secrets. To do so, we must prosecute
	and maintain existing patents, obtain new patents and pursue trade secret and other intellectual property protection. We also must
	operate without infringing the proprietary rights of third-parties or allowing third-parties to infringe our rights. We currently
	have or have rights to over 200 U.S. patents and corresponding foreign patents and patent applications covering our technologies.
	However, patent issues relating to pharmaceuticals and biologics involve complex legal, scientific and factual questions. To date,
	no consistent policy has emerged regarding the breadth of biotechnology patent claims that are granted by the U.S. Patent and Trademark
	Office or enforced by the federal courts. Therefore, we do not know whether our patent applications will result in the issuance
	of patents, or that any patents issued to us will provide us with any competitive advantage. We also cannot be sure that we will
	develop additional proprietary products that are patentable. Furthermore, there is a risk that others will independently develop
	or duplicate similar technology or products or circumvent the patents issued to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There is a risk that
	third-parties may challenge our existing patents or claim that we are infringing their patents or proprietary rights. We could
	incur substantial costs in defending patent infringement suits or in filing suits against others to have their patents declared
	invalid or claim infringement. It is also possible that we may be required to obtain licenses from third-parties to avoid infringing
	third-party patents or other proprietary rights. We cannot be sure that such third-party licenses would be available to us on acceptable
	terms, if at all. If we are unable to obtain required third-party licenses, we may be delayed in or prohibited from developing,
	manufacturing or selling products requiring such licenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Although our patent
	filings include claims covering various features of our vaccine candidates, including composition, methods of manufacture and use,
	our patents do not provide us with complete protection against the development of competing products. Some of our know-how and
	technology is not patentable. To protect our proprietary rights in unpatentable intellectual property and trade secrets, we require
	employees, consultants, advisors and collaborators to enter into confidentiality agreements. These agreements may not provide meaningful
	protection for our trade secrets, know-how or other proprietary information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Third parties
	may claim we infringe their intellectual property rights.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our research, development
	and commercialization activities, including any vaccine candidates resulting from these activities, may infringe or be claimed
	to infringe patents owned by third-parties and to which we do not hold licenses or other rights. There may be rights we are not
	aware of, including applications that have been filed, but not published that, when issued, could be asserted against us. These
	third-parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us,
	could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to
	stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the
	suit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a result of patent
	infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third-party.
	These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would
	likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result
	in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product,
	or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims,
	we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators,
	which would also impact the success of the collaboration and therefore us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There has been substantial
	litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology
	industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings,
	including interference proceedings declared by the U.S. Patent and Trademark Office and opposition proceedings in the European
	Patent Office, regarding intellectual property rights with respect to our products and technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may become
	involved in litigation to protect or enforce our patents or the patents of our collaborators or licensors, which could be expensive
	and time-consuming.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Competitors may infringe
	our patents or the patents of our collaborators or licensors. As a result, we may be required to file infringement claims to counter
	infringement for unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition,
	in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop
	the other party from using the technology at issue on the grounds that our patents do not cover its technology. An adverse determination
	of any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly
	and could put our patent applications at the risk of not issuing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Interference proceedings
	brought by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent
	applications or those of our collaborators or licensors. Litigation or interference proceedings may fail and, even if successful,
	may result in substantial costs and distraction to our management. We may not be able, alone or with our collaborators and licensors,
	to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as
	fully as in the U.S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Furthermore, because
	of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
	of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course
	of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings
	or developments. If investors perceive these results to be negative, the market price for our common stock could be significantly
	harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may need to
	license intellectual property from third-parties and, if our right to use the intellectual property we license is affected, our
	ability to develop and commercialize our vaccine candidates may be harmed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We expect that we will
	need to license intellectual property from third-parties in the future and that these licenses will be material to our business.
	We will not own the patents or patent applications that underlie these licenses, and we will not control the enforcement of the
	patents. We will rely upon our licensors to properly prosecute and file those patent applications and prevent infringement of those
	patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our license agreement
	with Wyeth, which gives us rights to a family of patents and patent applications that are expected to expire in early 2022, covering
	VLP technology for use in human vaccines in certain fields of use, is non-exclusive. These applications are very significant to
	our business. If each milestone is achieved for any particular vaccine candidate, we would likely be obligated to pay an aggregate
	of $15 million to Wyeth for each vaccine candidate developed and commercialized under the agreement. Achievement of each milestone
	is subject to many risks, including those described in these risk factors. Annual license fees under the Wyeth agreement aggregate
	to $0.3 million per year. In September 2015, the Company entered into an amendment to the license agreement with Wyeth. Among other
	things, the amendment restructured the $3 million milestone payment owed as a result of CPLB&rsquo;s initiation of a Phase 3 clinical
	trial for its recombinant trivalent seasonal VLP influenza vaccine candidate in 2014. Under the amendment, the milestone payment,
	which may increase slightly over time, shall be due in connection with the initiation of a Phase 3 clinical trial for the initial
	seasonal influenza VLP vaccine candidate being developed outside India, but in any case no later than December 31, 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	While many of the licenses
	under which we have rights provide us with rights in specified fields, the scope of our rights under these and other licenses may
	be subject to dispute by our licensors or third-parties. In addition, our rights to use these technologies and practice the inventions
	claimed in the licensed patents and patent applications are subject to our licensors abiding by the terms of those licenses and
	not terminating them. Any of our licenses may be terminated by the licensor if we are in breach of a term or condition of the license
	agreement, or in certain other circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our vaccine candidates
	and potential vaccine candidates will require several components that may each be the subject of a license agreement. The cumulative
	license fees and royalties for these components may make the commercialization of these vaccine candidates uneconomical.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	If patent laws
	or the interpretation of patent laws change, our competitors may be able to develop and commercialize our discoveries.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Important legal issues
	remain to be resolved as to the extent and scope of available patent protection for biopharmaceutical products and processes in
	the U.S. and other important markets outside the U.S., such as Europe and Japan. In addition, foreign markets may not provide the
	same level of patent protection as provided under the U.S. patent system. Litigation or administrative proceedings may be necessary
	to determine the validity and scope of certain of our and others&rsquo; proprietary rights. Any such litigation or proceeding may
	result in a significant commitment of resources in the future and could force us to do one or more of the following: cease selling
	or using any of our products that incorporate the challenged intellectual property, which would adversely affect our revenue; obtain
	a license from the holder of the intellectual property right alleged to have been infringed, which license may not be available
	on reasonable terms, if at all; and redesign our products to avoid infringing the intellectual property rights of third-parties,
	which may be time-consuming or impossible to do. In addition, changes in, or different interpretations of, patent laws in the U.S.
	and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products.
	We cannot provide assurance that the patents we obtain or the unpatented technology we hold will afford us significant commercial
	protection.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Risks
	Related to OUR Convertible SENIOR Notes
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Servicing our
	3.75% convertible senior unsecured notes due 2023 (the &ldquo;Notes&rdquo;) requires a significant amount of cash, and we may not
	have sufficient cash flow to pay our debt.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In 2016, we issued $325 million aggregate principal amount of Notes. Our ability to make scheduled payments of
	the principal of, to pay interest on, or to refinance our indebtedness, including the Notes, depends on our future performance,
	which is subject to economic, financial, competitive and other factors beyond our control. We do not expect our business to be
	able to generate cash flow from operations, in the foreseeable future, sufficient to service our debt and make necessary capital
	expenditures and may therefore be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining
	additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness, which is
	non-callable and matures in 2023, will depend on the capital markets and our financial condition at such time. We may not be able
	to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt
	obligations, and limit our flexibility in planning for and reacting to changes in our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We may not have
	the ability to raise the funds necessary to repurchase the Notes as required upon a fundamental change, and our future debt may
	contain limitations on our ability to repurchase the Notes.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Holders of the Notes
	will have the right to require us to repurchase their Notes for cash upon the occurrence of a fundamental change at a fundamental
	change repurchase price equal to 100% of the principal amount of the Notes to be repurchased,
<I>
	plus
</I>
	accrued and unpaid interest,
	if any. A fundamental change may also constitute an event of default or prepayment under, and result in the acceleration of the
	maturity of, our then-existing indebtedness. We cannot assure you that we will have sufficient financial resources, or will be
	able to arrange financing, to pay the fundamental change repurchase price in cash with respect to any Notes surrendered by holders
	for repurchase upon a fundamental change. In addition, restrictions in our then existing credit facilities or other indebtedness,
	if any, may not allow us to repurchase the Notes upon a fundamental change. Our failure to repurchase the Notes upon a fundamental
	change when required would result in an event of default with respect to the Notes which could, in turn, constitute a default under
	the terms of our other indebtedness, if any. If the repayment of the related indebtedness were to be accelerated after any applicable
	notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Capped call transactions
	entered into in connection with our Notes may affect the value of our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	our Notes, we entered into capped call transactions (the &ldquo;capped call transactions&rdquo;) with certain financial institutions.
	The capped call transactions are expected to generally reduce the potential dilution upon conversion of the Notes into shares of
	our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	establishing their initial hedges of the capped call transactions, these financial institutions or their respective affiliates
	entered into various derivative transactions with respect to our common stock and/or to purchase our common stock. The financial
	institutions, or their respective affiliates, may modify their hedge positions by entering into or unwinding various derivatives
	with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market
	transactions prior to the maturity of the Notes. This activity could also cause or avoid an increase or a decrease in the market
	price of our common stock or the Notes, which could affect the value of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	RISKS RELATED TO OUR COMMON STOCK AND
	ORGANIZATIONAL STRUCTURE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Because our stock
	price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile
	than expected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our stock price has
	been highly volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced
	extreme volatility that has often been unrelated to the operating performance of particular companies. From January 1, 2015 through
	December 31, 2015, the closing sale price of our common stock has been as low as $5.74 per share and as high as $14.14 per share.
	The market price of our common stock may be influenced by many factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	future announcements
	about us or our collaborators or competitors, including the results of testing, technological innovations or new commercial products;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	clinical trial results;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	depletion of our
	cash reserves;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sale of equity securities
	or issuance of additional debt;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcement by
	us of significant strategic partnerships, collaborations, joint ventures, capital commitments or acquisitions;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in government
	regulations;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	impact of competitor
	successes and in particular development success of vaccine candidates that compete with our own vaccine candidates;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	developments in
	our relationships with our collaboration partners;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT SYMBOL; MARGIN: 0PT 0.8PT 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT SYMBOL; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcements relating
	to health care reform and reimbursement levels for new vaccines and other matters affecting our business and results, regardless
	of accuracy;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sales of substantial
	amounts of our stock by existing stockholders (including stock by insiders or 5% stockholders);
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	development, spread
	or new announcements related to pandemic influenza;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	litigation;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	public concern as
	to the safety of our products;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	significant set-backs
	or concerns with the industry or the market as a whole;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	regulatory inquiries,
	reviews and potential action, including from the FDA or the SEC;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	recommendations
	by securities analysts or changes in earnings estimates; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the other factors described in this Risk
	Factors section.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, the stock
	market in general, and the market for emerging and biopharmaceutical companies in particular, have experienced extreme price and
	volume fluctuations that have particularly affected the market price for many of those companies. These fluctuations have often
	been unrelated to the operating performance of these companies. These broad market fluctuations may cause the market price of our
	common stock to be lower or more volatile than expected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Provisions of
	our Certificate of Incorporation and By-laws and Delaware law could delay or prevent the acquisition of the Company, even if such
	acquisition would be beneficial to stockholders, and could impede changes in our Board.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Provisions in our organizational
	documents could hamper a third-party&rsquo;s attempt to acquire, or discourage a third-party from attempting to acquire control
	of, the Company. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Our organizational
	documents also could limit the price investors are willing to pay in the future for our securities and make it more difficult to
	change the composition of our Board in any one year. Certain provisions include the right of the existence of a staggered board
	with three classes of directors serving staggered three-year terms and advance notice requirements for stockholders to nominate
	directors and make proposals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a Delaware corporation,
	we are also afforded the protections of Section 203 of the Delaware General Corporation Law, which will prevent us from engaging
	in a business combination with a person who acquires at least 15% of our common stock for a period of three years from the date
	such person acquired such common stock, unless advance board or stockholder approval was obtained.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Any delay or prevention
	of a change of control transaction or changes in our board or management could deter potential acquirers or prevent the completion
	of a transaction in which our stockholders could receive a substantial premium over the then current market price for their shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	We have never
	paid dividends on our capital stock, and we do not anticipate paying any such dividends in the foreseeable future.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have never paid
	cash dividends on our common stock. We currently anticipate that we will retain all of our earnings for use in the development
	of our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation,
	if any, of our common stock would be the only source of gain for stockholders until dividends are paid, if at all.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V431853_10K_HTM_A_004">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	1B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	UNRESOLVED
	STAFF COMMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	None.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.7IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -50.35PT">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V431853_10K_HTM_A_005">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	2.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PROPERTIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We lease three facilities
	in Gaithersburg, Maryland and one in Rockville, Maryland. In conjunction with our acquisition of Novavax AB in 2013, we acquired
	a facility lease in Uppsala, Sweden. A summary of our current facilities is set forth below. Although we believe that our facilities
	are suitable and adequate for our present needs, the Company&rsquo;s management continues to review and assess real property expansion
	opportunities that may be necessary to address our expectations for future growth.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Property
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Approximate
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 48%; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Brief Property
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Location
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Square Footage
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Rockville, MD
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	51,000
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Vaccine research and development and manufacturing facility
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	20FF Gaithersburg, MD
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	53,000
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Corporate headquarters, vaccine research and development and manufacturing facility
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	21FF Gaithersburg, MD
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	40,000
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Research and development laboratory facility and offices
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	22FF Gaithersburg, MD
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	40,000
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive, administrative, clinical and regulatory offices
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Uppsala, Sweden
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	16,000
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Adjuvant manufacturing facility and research and development and administrative offices
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total square footage
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	200,000
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V431853_10K_HTM_A_006">
</A>
	Item
	3.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	LEGAL
	PROCEEDINGS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We currently have no
	material pending legal proceedings.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V431853_10K_HTM_A_007">
</A>
	Item
	4.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	MINE
	SAFETY DISCLOSURES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V431853_10K_HTM_A_008">
</A>
	PART II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 49.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -49.5PT">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V431853_10K_HTM_A_009">
</A>
	Item
	5.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	MARKET
	FOR REGISTRANT&rsquo;S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our common stock trades
	on The NASDAQ Global Select Market under the symbol &ldquo;NVAX.&rdquo; The following table sets forth the range of high and low
	closing sale prices for our common stock as reported on The NASDAQ Global Select Market for each quarter in the two most recent
	years:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Quarter Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	December 31, 2015
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8.77
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6.59
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	June 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.66
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	March 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.71
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.74
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.98
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.05
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.08
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	June 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.69
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	March 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On February 24, 2016,
	the last sale price reported on The NASDAQ Global Select Market for our common stock was $4.79. Our common stock was held by approximately
	391 stockholders of record as of February 24, 2016, one of which is Cede &amp; Co., a nominee for Depository Trust Company (or
	DTC). All of the shares of common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial
	owners are deposited into participant accounts at DTC, and are therefore considered to be held of record by Cede &amp; Co. as one
	stockholder. We have not paid any cash dividends on our common stock since our inception. We do not anticipate declaring or paying
	any cash dividends in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Securities Authorized for Issuance under
	our Equity Compensation Plans
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Information regarding
	our equity compensation plans, including both stockholder approved plans and non-stockholder approved plans, is included in Item
	12 of this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Performance Graph
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The graph below compares
	the cumulative total stockholders return on our common stock for the last five fiscal years with the cumulative total return on
	the NASDAQ Composite Index and the Russell 2000 Growth Biotechnology Index (which includes Novavax) over the same period, assuming
	the investment of $100 in our common stock, the NASDAQ Composite Index and the Russell 2000 Growth Biotechnology Index on December
	31, 2010, and reinvestments of all dividends.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/29/0001144204-16-084770_TPG38.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Value of $100 invested on December 31,
	2010 in stock or index, including reinvestment of dividends, for fiscal years ended December 31:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12/31/10
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12/31/11
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12/31/12
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12/31/13
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12/31/14
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12/31/15
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 22%; TEXT-ALIGN: LEFT">
	Novavax, Inc.
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	51.85
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	77.78
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	210.70
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	244.03
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	345.27
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	NASDAQ Composite Index
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.53
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	116.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	166.19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	188.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	199.95
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	RUSSELL 2000 Growth Biotechnology Index
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	96.86
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	173.74
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	215.91
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	240.03
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This graph is not &ldquo;soliciting
	material,&rdquo; is not deemed &ldquo;filed&rdquo; with the SEC and is not to be incorporated by reference in any filing of the
	Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective
	of any general incorporation language in any such filing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_MARKET>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_010">
</A>
	Item
	6.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SELECTED
	FINANCIAL DATA
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table
	sets forth selected financial data for each of the years in the five-year period ended December 31, 2015, which has been derived
	from our audited financial statements. The information below should be read in conjunction with our financial statements and notes
	thereto and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; included
	elsewhere in this Annual Report. These historical results are not necessarily indicative of results that may be expected for future
	periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="18" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For The Years Ended December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015(1)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014(2)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013(3)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2011
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(in thousands, except per share amounts)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Statements of Operations Data:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	36,250
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	30,659
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	20,915
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	22,076
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	14,688
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(28,507
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,364
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Basic and diluted net loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Weighted average shares used in computing basic and diluted net loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	262,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	225,848
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	169,658
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	131,726
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	113,610
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="18" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As of December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015(1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014(2)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013(3)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2011
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Balance Sheet Data:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Cash and marketable securities(4)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	230,656
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	168,056
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	133,068
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	50,344
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	18,309
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	287,257
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	188,158
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,408
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Working capital(5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	210,763
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	154,042
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	126,879
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,733
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	386,038
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	276,002
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	235,125
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102,345
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,576
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Long-term debt, less current portion(6)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,199
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	990
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(650,030
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(493,093
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(410,146
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(358,163
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(329,656
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total stockholders&rsquo; equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	292,669
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	229,618
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	203,234
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80,240
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	53,849
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	In 2015, we had sales of 29,163,620 shares of common stock resulting in net proceeds of approximately
	$204 million.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	In 2014, we had sales of 28,750,000 shares of common stock resulting in net proceeds of approximately
	$108 million.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	In 2013, we completed the acquisition of Novavax AB (see Note 4 to consolidated financial statements
	in Item 8) and had sales of 44,452,343 shares of common stock resulting in net proceeds of approximately $129 million.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Includes non-current marketable securities of $6,233 at December 31, 2012.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(5)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Working capital is computed as the excess of current assets over current liabilities.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(6)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Includes non-current portion of capital leases.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_011">
</A>
	Item
	7.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	MANAGEMENT&rsquo;S
	DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Any statements in the
	discussion below and elsewhere in this Annual Report, about expectations, beliefs, plans, objectives, assumptions or future events
	or performance of Novavax, Inc. (&ldquo;Novavax&rdquo;, and together with its wholly owned subsidiary Novavax AB, the &ldquo;Company,&rdquo;
	&ldquo;we&rdquo; or &ldquo;us&rdquo;) are not historical facts and are forward-looking statements. Such forward-looking statements
	include, without limitation, statements with respect to our capabilities, goals, expectations regarding future revenue and expense
	levels; potential market sizes and demand for our product candidates; the efficacy, safety and intended utilization of our product
	candidates; the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies; the
	development of our preclinical product candidates; the conduct, timing and potential results from clinical trials and other preclinical
	studies; plans for and potential timing of regulatory filings; the expected timing and content of regulatory actions; reimbursement
	by the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (&ldquo;HHS BARDA&rdquo;);
	payments under our license with Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation), a subsidiary of Pfizer Inc.
	(&ldquo;Wyeth&rdquo;); payments by the Bill &amp; Melinda Gates Foundation (&ldquo;BMGF&rdquo;); our available cash resources and
	the availability of financing generally, plans regarding partnering activities, business development initiatives and the adoption
	of stock incentive plans, and other factors referenced herein. You generally can identify these forward-looking statements by the
	use of words or phrases such as &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
	&ldquo;possible,&rdquo; &ldquo;can,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;consider,&rdquo;
	&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;expect,&rdquo;
	&ldquo;should,&rdquo; &ldquo;would,&rdquo; or &ldquo;assume&rdquo; or the negative of these terms, or other comparable terminology,
	although not all forward-looking statements contain these words.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because the risk factors
	discussed in this Annual Report, and other risk factors of which we are not aware or currently deem immaterial, could cause actual
	results or outcomes to differ materially from those expressed in any forward-looking statements, you should not place undue reliance
	on any such forward-looking statements. These statements are subject to risks and uncertainties, known and unknown, which could
	cause actual results and developments to differ materially from those expressed or implied in such statements. We have included
	important factors in the cautionary statements included in this Annual Report, particularly those identified in Part I, Item 1A,
	&ldquo;Risk Factors&rdquo; of this Annual Report, that we believe could cause actual results or events to differ materially from
	the forward-looking statements that we make. These and other risks may also be detailed and modified or updated in our reports
	and other documents filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) from time to time. You are encouraged
	to read these filings as they are made.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We cannot guarantee
	future results, events, levels of activity, performance or achievement. Further, any forward-looking statement speaks only as of
	the date on which it is made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result
	of new information, future events or otherwise, unless required by law. New factors emerge from time to time, and it is not possible
	for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent
	to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recent Events
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In February 2016, Novavax
	completed the issuance of $325 million of 3.75% Convertible Senior Notes due in 2023, resulting in net proceeds of approximately
	$315 million, after deducting initial purchasers&rsquo; discounts and commissions, and approximately $314 million after deducting
	offering expenses. We used approximately $38 million of the net proceeds to pay the costs of a capped call transaction, which will
	function to reduce dilution from issuance of additional shares upon conversion of the notes between the note conversion price
	of $6.81 and the cap price of $9.73 per share. The resulting final net proceeds to the company were approximately $276 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our cash, cash equivalents
	and marketable securities on December 31, 2015 of approximately $231 million, as adjusted to give effect to the final net proceeds
	of the Convertible Senior Note offering of approximately $276 million, before giving effect to the anticipated use of the final
	net proceeds, would result in an as adjusted cash, cash equivalents and marketable securities balance of approximately $507 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are a clinical-stage
	vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
	Using innovative proprietary recombinant nanoparticle vaccine platform technology, we produce vaccine candidates to efficiently
	and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional
	nanostructures that incorporate recombinant proteins critical to disease pathogenesis. Our product pipeline targets a variety of
	infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (&ldquo;RSV&rdquo;),
	seasonal influenza, pandemic influenza and Ebola virus (&ldquo;EBOV&rdquo;). We have additional preclinical stage programs for
	a variety of infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are also developing
	proprietary technology for the production of immune stimulating saponin-based adjuvants through our wholly owned Swedish subsidiary,
	Novavax AB. Our lead adjuvant, Matrix-M&trade;, has been successfully tested in a Phase 1/2 clinical trial for our pandemic H7N9
	influenza virus-like particle vaccine candidate, and in a Phase 1 clinical trial for our EBOV vaccine candidate. Genocea Biosciences,
	Inc. (&ldquo;Genocea&rdquo;) has licensed rights to our Matrix technology and is now conducting Phase 2 clinical trials with its
	herpes simplex 2 vaccine candidate using Matrix-M.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Clinical Product Pipeline
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our clinical product
	pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
	Our nanoparticle technology platform targets antigens with conserved epitopes essential for viral function. Unlike traditional
	vaccines that &lsquo;mimic&rsquo; viruses and elicit naturally occurring immune responses to them, our nanoparticles are engineered
	to elicit differentiated immune responses, which may be more efficacious than naturally-occurring immunity. Our vaccine technology
	has the potential to be applied broadly to a wide variety of human infectious diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A current summary of
	our significant research and development programs, along with the programs of our joint venture, CPLB, and status of the related
	products in development follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Program
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 28%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Development Stage
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 28%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Funding Collaborator
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Respiratory Syncytial Virus (RSV)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Older Adults
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Infants via Maternal Immunization
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	BMGF*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Pediatrics
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Influenza
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Seasonal Quadrivalent
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	HHS BARDA
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Pandemic H7N9
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	HHS BARDA
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Combination (Influenza/RSV)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Preclinical
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Ebola Virus (EBOV)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	*As detailed herein, our funding and development
	arrangement with PATH expired in April 2015; we entered into a grant agreement with BMGF in September 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Respiratory Syncytial Virus (RSV)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are developing
	our respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (&ldquo;RSV F Vaccine&rdquo;) for three
	susceptible target populations: older adults (60 years of age and older), infants via maternal immunization and children six
	months to five years of age (&ldquo;pediatrics&rdquo;). We estimate RSV F Vaccine peak revenue potential of six to eight
	billion dollars worldwide. Currently there is no approved RSV Vaccine available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Repeat infection and
	lifelong susceptibility to RSV are common and we currently estimate the global cost burden of RSV in excess of $88 billion. Despite
	decades of effort to develop an RSV vaccine, there are currently no licensed vaccines. Although the monoclonal antibody palivizumab
	(Synagis&reg;) is effective in pre-term infants, it is not indicated for use in other populations. Novavax made a breakthrough
	in developing a vaccine that targets the fusion protein, or F-protein, of the virus. The F-protein has a highly conserved amino
	acid sequence called antigenic site II, which we believe is an ideal vaccine target. Palivizumab, which also targets antigenic
	site II, has demonstrated protection in five randomized clinical trials. We genetically engineered a novel F-protein antigen and
	enhanced its immunogenicity by exposing antigenic site II. Novavax&rsquo; RSV F Vaccine assembles into a recombinant protein nanoparticle
	optimized for F-protein antigen presentation. The RSV F Vaccine elicits palivizumab-competing antibodies at levels that we expect
	to confer protection. The Novavax RSV F Vaccine is the first RSV vaccine to demonstrate efficacy in a clinical trial and Novavax
	is positioned to bring the first RSV vaccine to market to combat the 64 million RSV infections that occur globally each year.
<SUP>
	20
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	,21
</FONT>
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	RSV Older Adults
	Program
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Adults
	60 years of age and older are at increased risk for RSV disease due to age related declines in their immune systems. In this population,
	RSV is an important respiratory virus, distinct from influenza viruses, that is responsible for serious lower respiratory tract
	disease and may lead to hospitalization or even death. Additionally, RSV infection can lead to exacerbation of underlying co-morbidities
	such as chronic obstructive pulmonary disease, asthma and congestive heart failure. RSV infection occurs as a recurrent and predictable
	annual epidemic throughout the world. In the U.S., the incidence rate is 2.5 million infections per year, and RSV is increasingly
	recognized as a significant cause of morbidity and mortality in the population of 64 million older adults.
<SUP>
	22,23
</SUP>
	Based on our analysis of published literature applied to 2014 population estimates, the disease causes 207,000 hospitalizations
	and 16,000 deaths among adults older than 65. Annually, we estimate that there are approximately 900,000 medical interventions
	directly caused by RSV disease across all populations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	August 2015, we announced positive top-line data from a Phase 2 clinical trial of our RSV F Vaccine in 1,600 older adults. The
	clinical trial was designed to prospectively examine the incidence of all symptomatic respiratory illnesses associated with RSV
	infection, in community-living older adults who were treated with placebo. The trial also evaluated safety and immunogenicity of
	our RSV F Vaccine compared to placebo. Finally, the trial estimated the efficacy of our RSV F Vaccine in reducing the incidence
	of respiratory illness due to RSV. The trial was the first to demonstrate efficacy of an active RSV immunization in any clinical
	trial population. In the per protocol population, the clinical trial showed statistically significant vaccine efficacy in prevention
	of all symptomatic RSV disease (41%) and, in an
<I>
	ad hoc
</I>
	analysis, showed a decrease in RSV disease with any symptoms of lower
	respiratory tract infection (45%) in older adults. The clinical trial established an attack rate for symptomatic RSV disease of
	4.9% in older adults, 95% of which included lower respiratory track symptoms. Efficacy against more severe RSV illness, defined
	by the presence of multiple lower respiratory tract symptoms or signs associated with difficulty breathing, was 64% in ad hoc analyses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	We
	initiated a pivotal Phase 3 clinical trial, known as Resolve&trade;, of our RSV F Vaccine in older adults in November 2015, and
	in December 2015, we completed enrollment of 11,850 older adult subjects at 60 sites in the U.S. The primary objective of the clinical
	trial is the prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple
	lower respiratory tract symptoms. We expect to provide top-line data from this clinical trial in the third quarter of 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	October 2015, we completed enrollment of 1,330 older adults in our Phase 2 rollover clinical trial of our RSV F Vaccine in
	the older adults who had participated in the recently concluded prior Phase 2 clinical trial. This trial is designed to
	evaluate safety and immunogenicity in response to immunization with the RSV F Vaccine during a second RSV season. We expect
	to provide top-line data from this trial in the second half of 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	20
</SUP>
</FONT>
	Nair, H., et al., (2010) Lancet. 375:1545 - 1555
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	21
</SUP>
	WHO Acute Respiratory Infections
	September 2009 Update: http://apps.who.int/vaccine_research/diseases/ari/en/index2.html
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	22
</SUP>
	Falsey, A.R.
<I>
	et al.
</I>
	(2005) NEJM. 352:1749&ndash;59 extrapolated to 2015 census population
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	23
</SUP>
	Falsey, A.R.
<I>
	et al.
</I>
	(1995) JID
<I>
	.
</I>
	172:389-94
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	RSV Infants via
	Maternal Immunization Program
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	RSV is the most common
	cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and
	young children worldwide.
<SUP>
	24
</SUP>
	In the U.S., RSV is the leading cause of hospitalization of infants, and globally, is
	second only to malaria as a cause of death in children under one year of age.
<SUP>
	25
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	,26
</FONT>
</SUP>
	Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common.
<SUP>
	27,28
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September
	2015, we announced
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	positive top-line data from a Phase 2 clinical trial of our RSV F
	Vaccine in 50 healthy pregnant women and their infants.
</FONT>
	This clinical trial evaluated the safety and immunogenicity of
	our RSV F Vaccine in pregnant women in their third trimester, and assessed the transplacental transfer of maternal antibodies
	induced by the vaccine. The trial also examined the impact of maternal immunization on infant safety during the first year of
	life and RSV-specific antibody levels through the infants' first six months of life. Immunized women demonstrated a geometric
	mean 14-fold rise in anti-F IgG, 29-fold rise in palivizumab-competing antibodies and a 2.7 and 2.1-fold rise in
	microneutralization titers against RSV/A and RSV/B, respectively. In contrast, women who received placebo demonstrated no
	significant change in antibody levels. The infants&rsquo; antibody levels at delivery averaged 90-100% of the mothers&rsquo;
	levels, indicating efficient transplacental transfer of antibodies from mother to infant. The estimated half-lives of infant
	PCA, anti-F IgG, RSV/A and RSV/B microneutralizing antibodies, based on data through day 60, were 41, 30, 36 and 34 days,
	respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We announced the initiation
	of a global pivotal Phase 3 clinical trial, known as Prepare&trade;, of the RSV F Vaccine in 5,000 to 8,255 healthy pregnant women
	in December 2015. The primary objective of the Prepare trial is to determine the efficacy of maternal immunization with the RSV
	F Vaccine against symptomatic RSV lower respiratory tract infection with hypoxemia in infants through the first 90 days of life.
	This Phase 3 trial utilizes a group sequential design and is expected to take between two and four years to complete. This trial
	is supported by a grant (the &ldquo;Grant&rdquo;) of up to $89.1 million from the Bill &amp; Melinda Gates Foundation. The Grant
	will support development activities, product licensing efforts and WHO prequalification of our RSV F Vaccine. We concurrently entered
	into a Global Access Commitments Agreement (&ldquo;GACA&rdquo;) with BMGF as a part of the grant agreement (the &ldquo;Grant Agreement&rdquo;).
	Under the terms of the GACA, we agreed to make the RSV F Vaccine available and accessible at affordable pricing to people in certain
	low and middle income countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In November 2014, the
	U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (&ldquo;FDA&rdquo;) granted Fast Track designation
	to our RSV F Vaccine for protection of infants via maternal immunization. Fast Track designation is intended for products that
	treat serious or life-threatening diseases or conditions, and that demonstrate the potential to address unmet medical needs for
	such diseases or conditions. The program is designed to facilitate development and expedite review of drugs to treat serious and
	life-threatening conditions so that an approved product can reach the market expeditiously.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	RSV Pediatrics
	Program
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	There
	are currently approximately 18 million children in the U.S. between six months and five years of age.
<SUP>
	29
</SUP>
	In the U.S.,
	RSV is responsible for approximately 57,000 hospitalizations of children under five years of age annually, the vast majority of
	which occur in infants less than one year old, and especially those under six months of age.
<SUP>
	30,31,32,33,34
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<SUP>
	&nbsp;
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	24
</SUP>
	Nair, H., et al., (2010) Lancet.
	375:1545 - 1555
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	25
</SUP>
	Hall, C.B.
<I>
	et al
</I>
	. (2013)
	Pediatrics; 132(2):E341-348
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	26
</SUP>
	Oxford Vaccine Group: http://www.ovg.ox.ac.uk/rsv
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	27
</SUP>
	Glezen, W.P.
<I>
	et al
</I>
	.
	(1986) Am J Dis Child; 140:543-546
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	28
</SUP>
	Glenn, G.M.
<I>
	et al.
</I>
	(2016)
	JID; 213(3):411-12
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	29
</SUP>
	U.S. Census. www.census.go/population/international/data/idb/informationGateway.php
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	30
</SUP>
	Stockman, L.J. et al (2012)
	Pediatr Infect Dis J. 31: 5-9
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	31
</SUP>
	CDC update May 5, 2015. http://www.cdc.gov/rsv/research/us-surveillance.html
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	32
</SUP>
	Boyce, T.G. et al (2000) Pediatrics;
	137: 865-870
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	33
</SUP>
	Hall, C.B. et al (2009) NEJM;
	360(6): 588-98
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	34
</SUP>
	Hall, C.B. et al (2013) Pediatrics;
	132(2): E341-8
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<SUP>
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September 2015,
	we announced positive top-line data from a Phase 1 clinical trial of our RSV F Vaccine in healthy children between two and six
	years of age. This clinical trial evaluated the safety and immunogenicity of our RSV F Vaccine, with one or two doses, with or
	without aluminum phosphate adjuvant. Trial enrollment was concluded with a smaller than planned cohort so that dosing could be
	completed ahead of the 2014-15 RSV season. The vaccine was well-tolerated and serum samples collected from a subset of 18 immunized
	children in the per-protocol population, demonstrated that the RSV F Vaccine was highly immunogenic at all formulations and regimens.
	There were greater than 10-fold increases in both anti-F IgG and PCA antibody titers in the adjuvanted group and greater than 6-fold
	increases in anti-F IgG and PCA antibody titers in the unadjuvanted group. We are assessing the data from this clinical trial and
	evaluating the next steps in the development of our RSV F Vaccine for pediatrics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Influenza
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Influenza is a world-wide
	infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness
	occurs not only in susceptible populations such as pediatrics and older adults, but also in the general population because of unique
	strains of influenza for which most humans have not developed protective antibodies. We are developing vaccine candidates for both
	seasonal and pandemic influenza. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan,
	France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in the 2012/13 season to $5.3
	billion by the 2021/2022 season.
<SUP>
	35
</SUP>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Traditional vaccine
	manufacturing methods utilize live influenza virus to infect eggs in order to produce trivalent seasonal influenza vaccine candidates.
	Our egg-free recombinant nanoparticle technology does not utilize either a live influenza virus or eggs, but rather a recombinant
	baculovirus and insect cells, which allows for the product to potentially be rapidly manufactured and quickly adapted to changing
	influenza strains. Further, we are developing a quadrivalent seasonal vaccine candidate, which we expect to elicit broader protection
	from circulating influenza strains. We are also exploring the development of novel influenza nanoparticle vaccine candidates. There
	are currently four quadrivalent seasonal influenza vaccines licensed in the U.S., although additional quadrivalent seasonal influenza
	vaccines are expected to be licensed over the next several years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Quadrivalent
	Seasonal Influenza Vaccine
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Advisory Committee
	for Immunization Practices of the Center for Disease Control and Prevention (&ldquo;CDC&rdquo;) recommends that all persons aged
	six months and older be vaccinated annually against seasonal influenza. Influenza is a major burden on public health worldwide:
	an estimated one million deaths each year are attributed to influenza.
<SUP>
	36
</SUP>
	It is further estimated that, each year,
	influenza attacks between 5% and 10% of adults and 20% to 30% of children, causing significant levels of illness, hospitalization
	and death.
<SUP>
	37
</SUP>
	Recombinant seasonal influenza vaccines, like the candidate we are developing, have an important advantage:
	once licensed for commercial sale, large quantities of vaccines can potentially be manufactured quickly and in a cost-effective
	manner, without the use of either the live influenza virus or eggs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In July 2015, we reported
	positive data from our Phase 2 clinical trial of our quadrivalent seasonal influenza virus-like-particle (&ldquo;VLP&rdquo;) vaccine
	candidate in 400 healthy adults that we initiated in November 2014. These data show that our quadrivalent seasonal influenza VLP
	vaccine candidate is well-tolerated, and can induce influenza antibody responses that met the immunogenicity targets. These results
	demonstrate the potential for our quadrivalent seasonal influenza VLP vaccine candidate to meet the FDA criteria for accelerated
	approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	35
</SUP>
	Influenza Vaccines Forecasts.
	Datamonitor (2013)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	36
</SUP>
	Resolution of the World Health
	Assembly. (2003) WHA56.19. 28
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<SUP>
	37
</SUP>
	WHO position paper (2012) Weekly
	Epidemiol Record;87(47):461&ndash;76
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We were awarded a contract
	by HHS BARDA in 2011 to fund the development of both our quadrivalent seasonal influenza and pandemic influenza VLP vaccine candidates.
	This is a cost-plus-fixed-fee contract, which reimburses us for allowable direct contract costs incurred plus allowable indirect
	costs and a fixed-fee earned in the ongoing clinical development and product scale-up of our vaccine candidates. We announced that
	HHS BARDA had exercised and initiated a two-year option to our contract in September 2014, which not only extended the expected
	term of the contract until September 2016, but also added scope to support our development activities leading up to planned Phase
	3 clinical trials and $70 million of funding on top of the remainder of the $97 million base period funding. In June 2015, the
	contract was amended to increase the funding by $7.7 million to allow for the recovery of additional costs under the contract relating
	to the settlement of indirect rates for fiscal years 2011 and 2012. This additional amount was received and recorded as revenue
	in the second quarter of 2015. During 2015, we recognized revenue of $33.3 million and have recognized approximately $112 million
	in revenue since the inception of the contract. In recent meetings with HHS BARDA, we have been discussing the next steps in both
	our seasonal influenza VLP vaccine program and our pandemic influenza VLP vaccine program, as well as some of the delays associated
	with our development of both vaccine candidates. We expect to continue discussions with HHS BARDA during 2016 and to present plans
	for continued clinical and product development, although there can be no guarantee that the HHS BARDA contract will not be terminated
	early or will be extended beyond September 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	Pandemic H7N9 Influenza
	Vaccine
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Burden
	of Disease
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Prevention of the potential
	devastation of a human influenza pandemic remains a key priority with both governmental health authorities and influenza vaccine
	manufacturers. In the U.S. alone, the 2009 H1N1 influenza pandemic led to the production of approximately 126 million doses of
	monovalent (single strain) vaccine. Public health awareness and government preparedness for the next potential influenza pandemic
	are driving development of vaccines that can be manufactured quickly against a potentially threatening influenza strain. Industry
	and health experts have focused attention on developing a monovalent influenza vaccine against either the H5N1 strain or the H7N9
	strain as potential key defenses against future pandemic disease threats.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Clinical
	Trial Update
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have developed and
	delivered compelling safety and immunogenicity data on two pandemic vaccine candidates, H5N1 and H7N9. In September 2014, we announced
	positive results from a Phase 1/2 clinical trial of our H7N9 influenza VLP vaccine candidate adjuvanted with Matrix-M in 610 healthy
	adults. The Phase 1/2 clinical trial was designed as a dose-ranging, randomized, observer-blinded, placebo-controlled clinical
	trial, to determine the contribution of Matrix-M to potential antigen dose sparing regimens. Our H7N9 influenza vaccine candidate,
	with and without Matrix-M, was highly immunogenic and well-tolerated. Matrix-M adjuvanted formulations demonstrated immunogenicity
	and dose-sparing benefits relative to unadjuvanted antigen. Hemagglutination-inhibiting antibody titers were comparable to those
	reported in prior clinical trials, and the vaccine elicited significant anti-neuraminidase antibodies. In October 2014, the FDA
	granted Fast Track designation to our H7N9 influenza vaccine candidate with Matrix-M.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our pandemic influenza
	vaccine program is supported by our HHS BARDA contract. Like our seasonal influenza vaccine program, we expect to continue discussions
	with HHS BARDA during 2016 and to present plans for continued clinical and product development of our pandemic influenza vaccine
	candidate, although there can be no guarantee that the HHS BARDA contract will not be terminated early or will be extended beyond
	September 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Combination Respiratory (Influenza
	and RSV)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Given the ongoing development
	of our seasonal influenza vaccine candidate and our RSV F Vaccine, we see an important opportunity to develop a combination respiratory
	vaccine candidate. Early preclinical development efforts have given us confidence that such a combination vaccine is viable, and
	in animal models, provides acceptable immunogenicity. We expect to initiate a Phase 1 clinical trial of a combination respiratory
	vaccine in the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Ebola Virus (EBOV)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	EBOV,
	formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. Multiple strains of EBOV have been
	identified, the most recent of which, the Makona EBOV strain, is associated with a case fatality rate of 50% to
	90%.
<SUP>
	38
</SUP>
	There are currently no licensed treatments proven to neutralize the virus, but a range of blood,
	immunological and drug therapies are under development. Despite the development of such therapies, current vaccine approaches
	target either a previous strain of the virus or were initially developed to be delivered by genetic vectors. In contrast, our
	EBOV glycoprotein vaccine candidate (&ldquo;Ebola GP Vaccine&rdquo;) was developed using the Makona EBOV strain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In July 2015, we announced
	data from our Phase 1 clinical trial of our Ebola GP Vaccine in ascending doses, with and without our Matrix-M adjuvant, in 230
	healthy adults. Participants received either one or two intramuscular injections ranging from 6.5&micro;g to 50&micro;g of antigen,
	with or without adjuvant, or placebo. Immunogenicity was assessed at multiple time points, including days 28 and 35. These Phase
	1 data demonstrated that our Ebola GP Vaccine is highly immunogenic, well-tolerated and, in conjunction with our proprietary Matrix-M
	adjuvant, resulted in significant antigen dose-sparing. Although the adjuvanted Ebola GP Vaccine was highly immunogenic at all
	dose levels, the adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000
	ELISA units, representing a 500 to 750-fold rise over baseline at day 35. In 2015, we also announced successful data from two separate
	non-human primate challenge studies of our Ebola GP Vaccine
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	in which, in both cases, the
	challenge was lethal for the control animal, whereas 100% of the immunized animals were protected
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	CPLB Programs (India)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	CPL Biologicals Private
	Limited (&ldquo;CPLB&rdquo;), our joint venture company with Cadila Pharmaceuticals Limited (&ldquo;Cadila&rdquo;) in India, is
	actively developing a number of vaccine candidates that were genetically engineered by us. CPLB is owned 20% by us and 80% by Cadila.
	CPLB operates a manufacturing facility in India for the production of vaccines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Seasonal Influenza
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	CPLB received marketing
	authorization, the Indian equivalent of approval of a Biologics License Application (&ldquo;BLA&rdquo;), for its recombinant trivalent
	seasonal VLP influenza vaccine in 2015. Because the market for seasonal influenza in India is limited and highly competitive, CPLB
	is currently evaluating its marketing strategy for this vaccine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Rabies
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	CPLB successfully completed
	Stage II of its 2-stage Phase 1/2 clinical trial in India of a rabies G protein vaccine candidate that we genetically engineered.
	The objective was to select a dose and regimen for a recombinant vaccine that can be administered both as a pre-exposure prophylaxis
	for residents of certain higher-risk geographies and travelers to such locations, and as a post-exposure prophylaxis using fewer
	doses than the current standard of care. In October 2014, CPLB presented clinical results from Stage I of the Phase 1/2 clinical
	trial, demonstrating that vaccine recipients, at various doses levels and schedules, showed seroprotective antibody levels at day
	14 that were sustained through day 180. The vaccine candidate, which was found to be well-tolerated, also induced seroprotective
	levels with two-dose and three-dose regimens. CPLB has received permission to conduct a Phase 3 clinical trial and is considering
	the optimal schedule for its conduct.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 35%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<SUP>
	38
</SUP>
	WHO.
<U>
	http://www.who.int/mediacentre/factsheets/fs103/en/
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Discovery Programs
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our vaccine platform
	technology provides an efficient system that has the potential to rapidly develop antigens to selected targets, refine manufacturing
	processes and optimize development across multiple vaccine candidates. In conjunction with government and/or global health authorities,
	we believe we can address emerging disease threats with pandemic potential. In addition to our response to the H7N9 influenza strain,
	we have developed a vaccine candidate to Middle East respiratory syndrome (&ldquo;MERS&rdquo;), caused by a novel coronavirus first
	identified in 2012. MERS emerged as a disease threat in 2013, and is currently being monitored by global health agencies, with
	the WHO reporting significant confirmed cases of infection and deaths. The MERS virus is a part of the coronavirus family that
	includes the severe acute respiratory syndrome coronavirus (&ldquo;SARS&rdquo;). Within weeks of obtaining the sequence of the
	circulating MERS strain, we successfully produced a vaccine candidate designed to provide protection. This vaccine candidate is
	based on the major surface spike protein, which we had previously identified as the antigen of choice in our work with a SARS vaccine
	candidate. In 2014, in collaboration with the University of Maryland, School of Medicine, we published results that showed our
	investigational vaccine candidates against both MERS and SARS blocked infection in laboratory studies. Although the development
	of a MERS vaccine candidate currently remains a preclinical program, we believe that our MERS vaccine candidate offers a viable
	option to interested global public health authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Sales of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In March 2015, we
	completed a public offering of 27,758,620 shares of our common stock, including 3,620,689 shares of common stock that were issued
	upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $7.25 per share
	resulting in net proceeds of approximately $190 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2012, we entered
	into an At Market Issuance Sales Agreement (&ldquo;Sales Agreement&rdquo;), under which we sold an aggregate of $50 million in
	gross proceeds of our common stock. During 2015, we sold 1.4 million shares at an average sales price of $10.63 per share, resulting
	in approximately $15 million in net proceeds. The Sales Agreement was fully utilized at that time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<B>
	Convertible Senior
	Notes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2016, we issued
	$325 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the &ldquo;Notes&rdquo;).
	The Notes will bear cash interest at a rate of 3.75%, payable on February 1 and August 1 of each year, beginning on August 1,
	2016. The Notes are not redeemable prior to maturity and are convertible into shares of Novavax common stock. The initial conversion
	rate for the Notes is 146.8213 shares of Novavax&rsquo; common stock per $1,000 principal amount of the Notes, which is equivalent
	to an initial conversion price of approximately $6.81 per share of Novavax&rsquo; common stock, representing an approximate 22.5%
	conversion premium based on the last reported sale price of Novavax&rsquo; common stock of $5.56 per share on January 25, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	the issuance of the Notes, we paid approximately $38 million to enter into privately negotiated capped call transactions with
	certain financial institutions (the &ldquo;capped call transactions&rdquo;). The capped call transactions are expected generally
	to reduce the potential dilution upon conversion of the Notes in the event that the market price per share of our common stock,
	as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions,
	which initially corresponds to the conversion price of the Notes, and is subject to anti-dilution adjustments generally similar
	to those applicable to the conversion rate of the Notes. The cap price of the capped call transactions will initially be $9.73
	per share, which represents a premium of approximately 75% based on the last reported sale price of our common stock of $5.56
	per share on January 25, 2016, and is subject to certain adjustments under the terms of the capped call transactions. If, however,
	the market price per share of Novavax&rsquo; common stock, as measured under the terms of the capped call transactions, exceeds
	the cap price of the capped call transactions, there would nevertheless be dilution upon conversion of the Notes to the extent
	that such market price exceeds the cap price of the capped call transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Critical Accounting
	Policies and Use of Estimates
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The discussion and
	analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have
	been prepared in accordance with accounting principles generally accepted in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The preparation of
	our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts
	of assets, liabilities and equity and disclosure of contingent assets and liabilities at the date of the financial statements
	and the reported amounts of revenue and expenses during the reporting period. These estimates, particularly estimates relating
	to accounting for revenue, the valuation of our marketable securities, stock-based compensation, long-lived assets and goodwill
	have a material impact on our consolidated financial statements and are discussed in detail throughout our analysis of the results
	of operations discussed below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We base our estimates
	on historical experience and various other assumptions that we believe are reasonable under the circumstances, the results of
	which form the basis for making judgments about the carrying value of assets, liabilities and equity that are not readily apparent
	from other sources. Actual results and outcomes could differ from these estimates and assumptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Revenue
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We recognize revenue
	under research contracts when a contract has been executed, the contract price is fixed or determinable, delivery of services or
	products has occurred and collection of the contract price is reasonably assured. Payments received in advance of work performed
	are recorded as deferred revenue and losses on contracts, if any, are recognized in the period in which they become known.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are currently performing
	a research and development contract for a U.S. Government agency under a cost reimbursable fixed price contract. Under such cost
	reimbursable contracts, we are reimbursed and recognize revenue as allowable costs are incurred plus a portion of the fixed-fee
	earned. We consider fixed-fees under cost reimbursable contracts to be earned in proportion to the allowable costs incurred in
	performance of the work as compared to total estimated contract costs, with such costs incurred representing a reasonable measurement
	of the proportional performance of the work completed. Under our HHS BARDA contract, certain activities must be pre-approved by
	HHS BARDA in order for their costs to be deemed allowable direct costs. Direct costs incurred under cost reimbursable contracts
	are recorded as research and development expenses. Our HHS BARDA contract provides the U.S. government the ability to terminate
	the contract for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement
	of work. We believe that if the government were to terminate the HHS BARDA contract for convenience, the costs incurred through
	the effective date of such termination and any settlement costs resulting from such termination would be allowable costs. Payments
	to us under cost reimbursable contracts, such as the HHS BARDA contract, are provisional payments subject to adjustment upon annual
	audit by the government. An audit by the U.S government of fiscal years 2011 and 2012 was completed in the first quarter of 2014,
	which resulted in $7.7 million revenue recognized in 2015 relating to the recovery of additional costs for the settlement of indirect
	rates for such fiscal years as collection of the amount became reasonably assured. An audit of fiscal years 2013 and 2014 has been
	initiated, but has not been completed as of the date of this filing. Management believes that revenue for periods not yet audited
	has been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of
	the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment
	is known.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under our Grant Agreement
	with BMGF, we are reimbursed for certain costs that support development activities, including our global Phase 3 clinical trial
	in pregnant women in their third trimester, product licensing efforts and WHO prequalification of our RSV F Vaccine. Payments received
	under the Grant Agreement are recognized as revenue in the period in which such research and development activities are performed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our collaborative research
	and development agreements may include an upfront payment, payments for research and development services, milestone payments and
	royalties. Agreements with multiple deliverables are evaluated to determine if the deliverables can be divided into more than one
	unit of accounting. A deliverable can generally be considered a separate unit of accounting if both of the following criteria are
	met: (1) the delivered item(s) has value to the customer on a stand-alone basis; and (2) if the arrangement includes a general
	right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and
	substantially in our control. Deliverables that cannot be divided into separate units are combined and treated as one unit of accounting.
	Consideration received is allocated among the separate units of accounting based on the relative selling price method. Deliverables
	under these arrangements typically include rights to intellectual property, research and development services and involvement by
	the parties in steering committees. Historically, deliverables under our collaborative research and development agreements have
	been deemed to have no stand-alone value and as a result have been treated as a single unit of accounting. In addition, we analyze
	our contracts and collaborative agreements to determine whether the payments received should be recorded as revenue or as a reduction
	to research and development expenses. In reaching this determination, management considers a number of factors, including whether
	we are the principal under the arrangement, and whether the arrangement is significant to, and part of, our core operations. Historically,
	payments received under its contracts and collaborative agreements have been recognized as revenue since we act as a principal
	in the arrangement and the activities are core to our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	When the performance
	under a fixed price contract can be reasonably estimated, revenue for fixed price contracts is recognized under the proportional
	performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated
	contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the
	work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses.
	If the performance under a fixed price contract cannot be reasonably estimated, we recognize the revenue on a straight-line basis
	over the contract term.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenue associated
	with upfront payments under arrangements is recognized over the contract term or when all obligations associated with the upfront
	payment have been satisfied.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenue from the achievement
	of research and development milestones, if deemed substantive, is recognized as revenue when the milestones are achieved and the
	milestone payments are due and collectible. If not deemed substantive, we would recognize such milestone as revenue upon its achievement
	on a straight-line basis over the remaining expected term of the research and development period. Milestones are considered substantive
	if all of the following conditions are met: (1) the milestone is non-refundable; (2) there is substantive uncertainty of achievement
	of the milestone at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone and such achievement
	relates to past performance; and (4) the amount of the milestone appears reasonable in relation to the effort expended and all
	of the deliverables and payment terms in the arrangement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Marketable Securities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our marketable
	securities are classified as available-for-sale securities and are carried at fair value. Unrealized gains and losses on
	these securities, if determined not to be &ldquo;other-than-temporary,&rdquo; are included in accumulated other comprehensive
	income (loss) in stockholders&rsquo; equity. Investments are evaluated periodically to determine whether a decline in value
	is other-than-temporary. Management reviews criteria, such as the magnitude and duration of the decline, as well as the
	Company&rsquo;s ability to hold the securities until market recovery, to predict whether the loss in value is
	other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the security is reduced
	and the impairment is recorded in the statements of operations. For marketable securities carried at fair value, we disclose
	the level within the fair value hierarchy as prescribed by Accounting Standard Codification (&ldquo;ASC&rdquo;) Topic 820,
<I>
	Fair
	Value Measurements and Disclosures
</I>
	. We evaluate the types of securities in our investment portfolio to determine the
	proper classification in the fair value hierarchy based on trading activity and market inputs. We generally obtain
	information from an independent third-party to help us determine the fair value of securities in Level 2 of the fair
	value hierarchy. Investment income is recorded when earned and included in investment income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We account for
	our stock-based compensation under our equity compensation plans in accordance with ASC Topic 718,
<I>
	Compensation-Stock
	Compensation
</I>
	. This standard requires us to measure the cost of employee services received in exchange for equity awards
	based on the grant-date fair value of the award. Employee stock-based compensation is estimated at the date of grant based on
	the award&rsquo;s fair value using the Black-Scholes option-pricing model and is recognized as an expense on a straight-line
	basis over the requisite service period for those awards expected to vest. The Black-Scholes option-pricing model requires
	the use of certain assumptions, the most significant of which are our estimates of the expected volatility of the market
	price of our common stock and the expected term of the award. Our estimate of the expected volatility is based on historical
	volatility over the look-back period corresponding to the expected term. The expected term represents the period during which
	our stock-based awards are expected to be outstanding. We estimate this amount based on historical experience of similar
	awards, giving consideration to the contractual terms of the awards, vesting requirements and expectation of future employee
	behavior, including post-vesting exercise and forfeiture history. We review our valuation assumptions at each grant date and,
	as a result, our assumptions in future periods may change. Also, the accounting estimate of stock-based compensation expense
	is reasonably likely to change from period to period as further equity awards are made and adjusted for cancellations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Impairments of Long-Lived
	Assets
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We account for the
	impairment of long-lived assets (including finite-lived intangible assets) by performing an evaluation of the recoverability of
	the carrying value of long-lived asset (group) whenever events or changes in circumstances indicate that the carrying value of
	the asset (group) may not be recoverable. Examples of events or changes in circumstances that indicate that the recoverability
	of the carrying value of an asset (group) should be assessed include, but are not limited to, the following: a significant decrease
	in the market value of an asset, a significant change in the extent or manner in which an asset is used, a significant physical
	change in an asset, a significant adverse change in legal factors or in the business climate that could affect the value of an
	asset, an adverse action or assessment by a regulator, an accumulation of costs significantly in excess of the amount originally
	expected to acquire or construct an asset, a current period operating or cash flow loss combined with a history of operating or
	cash flow losses and/or a projection or forecast that demonstrates continuing losses associated with an asset used for the purpose
	of producing revenue. We consider historical performance and anticipated future results in our evaluation of potential impairment.
	Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets (group) in relation to the
	operating performance of the business and future undiscounted cash flows expected to result from the use of these asset (groups).
	Impairment losses are recognized when the sum of expected future cash flows is less than the assets&rsquo; (group&rsquo;s) carrying
	value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Goodwill
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Goodwill was generated
	from two business acquisitions. Our goodwill is not amortized, but is subject to impairment tests annually, or more frequently
	should indicators of impairment arise. Because the Company&rsquo;s only business is the development of recombinant vaccines, the
	Company operates as a single operating segment and has one reporting unit. We utilize the market approach and, if considered necessary,
	the income approach to determine if we have an impairment of our goodwill. The market approach serves as the primary approach and
	is based on market value of invested capital. To ensure that our capital stock is the appropriate measurement of fair value, we
	have considered factors such as, our trading volume, diversity of investors and analyst coverage. The concluded fair value of our
	reporting unit significantly exceeded the carrying value at December 31, 2015 and 2014. The income approach is used as a confirming
	look to the market approach, if considered necessary. Goodwill impairment may exist if the carrying value of a reporting unit exceeds
	its estimated fair value, which we test annually at December 31. If the carrying value of the reporting unit exceeds its fair value,
	step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess
	of the carrying value of the reporting unit&rsquo;s goodwill over its implied fair value should such a circumstance arise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Given the current economic
	conditions and the uncertainties regarding their impact on us, there can be no assurance that the estimates and assumptions made
	for purposes of our goodwill impairment testing will prove to be accurate predictions of the future, or that any change in the
	assumptions or the current economic conditions will not trigger more frequently than on an annual basis. If our assumptions are
	not achieved or economic conditions deteriorate further, we may be required to record goodwill impairment charges in future periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Recent Accounting Guidance
	Not Yet Adopted
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have considered
	the applicability and impact of all Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards Updates
	(ASUs).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In May 2014, the FASB
	issued ASU 2014-09,
<I>
	Revenue from Contracts with Customers (Topic 606)
</I>
	(&ldquo;ASU 2014-09&rdquo;), which supersedes nearly
	all existing revenue recognition guidance under Topic 605,
<I>
	Revenue Recognition
</I>
	. The new standard requires a company to recognize
	revenue when it transfers goods and services to customers in an amount that reflects the consideration that the company expects
	to receive for those goods or services. ASU 2014-09 defines a five-step process that includes identifying the contract with the
	customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction
	price to the performance obligations in the contract and recognizing revenue when (or as) the entity satisfies the performance
	obligations. In July 2015, the FASB approved a one-year deferral of the effective date of the new standard to 2018 for public companies,
	with an option that would permit companies to adopt the new standard as early as the original effective date of 2017. Early adoption
	prior to the original effective date is not permitted. We are evaluating the potential impact that ASU 2014-09 will have on our
	consolidated financial position and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In April 2015, the
	FASB issued ASU No. 2015-03,
<I>
	Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
	Costs
</I>
	(&ldquo;ASU 2015-03&rdquo;). The new standard requires that debt issuance costs related to a recognized debt liability
	be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts.
	This ASU is effective for the Company beginning January 1, 2016. The adoption of ASU 2015-03 will not have a material effect of
	the Company&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Results of Operations
	for Fiscal Years 2015, 2014 and 2013
</B>
<FONT STYLE="FONT-SIZE: 10PT">
	(amounts in tables are presented in thousands, except per
	share information)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following is a
	discussion of the historical financial condition and results of operations of Novavax, including Novavax AB&rsquo;s operations
	since the acquisition date of July 31, 2013, and should be read in conjunction with the consolidated financial statements and notes
	thereto set forth in this Annual Report. Additional information concerning factors that could cause actual results to differ materially
	from those in our forward-looking statements is described under Part I, Item 1A, &ldquo;Risk Factors&rdquo; of this Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Revenue:
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
<BR>
	2014 to
<BR>
<U STYLE="TEXT-DECORATION: NONE">
	2015
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
<BR>
	2013 to
<BR>
<U STYLE="TEXT-DECORATION: NONE">
	2014
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Revenue:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Total revenue
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	36,250
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	30,659
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	20,915
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	5,591
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	9,744
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenue for
	2015 was $36.3 million as compared to $30.7 million for 2014, an increase of $5.6 million, or 18%. Revenue for 2015 and 2014
	was primarily comprised of services performed under the HHS BARDA contract, and to a much lesser extent, the Grant
	Agreement, PATH clinical development agreement and revenue from Novavax AB. The increase in revenue is primarily due to $7.7
	million from the recovery of additional costs for the settlement of indirect rates for fiscal years 2011 and 2012 under the
	HHS BARDA contract and $3.1 million relating to our Phase 2 clinical trial of our quadrivalent seasonal influenza VLP vaccine
	candidate in Australia (&ldquo;205 Trial&rdquo;) as collection of the amount became reasonably assured in 2015. These
	increases in revenue were partially offset by a lower level of activity in 2015 associated with our Phase 2 quadrivalent
	seasonal influenza VLP vaccine candidate clinical trial as compared to our Phase 1/2 clinical trial of our pandemic H7N9
	influenza VLP vaccine candidate adjuvanted with Matrix-M in 2014 under the HHS BARDA contract and a decrease in revenue
	under the prior PATH clinical development agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenue for
	2014 was $30.7 million as compared to $20.9 million for 2013, an increase of $9.7 million, or 47%. Revenue for 2014 and 2013
	was primarily comprised of services performed under the HHS BARDA contract, and to a much lesser extent, the PATH
	clinical development agreement and revenue from Novavax AB. The increase in revenue is primarily due to the higher level of
	activity in 2014 associated with our Phase 1/2 clinical trial of our pandemic H7N9 influenza VLP vaccine candidate
	adjuvanted with Matrix-M and manufacturing work for our Phase 2 quadrivalent seasonal influenza VLP vaccine candidate
	clinical trial under the HHS BARDA contract, as compared to 2013. We also had increased revenue in 2014 associated with
	Novavax AB resulting from twelve months of activity in 2014 as compared to only five months in 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	For 2016, we expect
	our revenue, relative to 2015, to be driven by the outcome of our ongoing discussions with HHS BARDA relating to the next steps
	in the development of our quadrivalent seasonal and pandemic influenza vaccine candidates. We also expect revenue in 2016 under
	the Grant Agreement to be significantly higher than in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Expenses:
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
<BR>
	2014 to
<BR>
<U STYLE="TEXT-DECORATION: NONE">
	2015
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
<BR>
	2013 to
<U STYLE="TEXT-DECORATION: NONE">
<BR>
	2014
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	162,644
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	94,422
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	58,530
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	68,222
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	35,892
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	30,842
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,928
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,819
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,914
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,109
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	193,486
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	114,350
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	73,349
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	79,136
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	41,001
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Research and
	Development Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Research and
	development expenses include salaries, laboratory supplies, consultants and subcontractors and other expenses associated with
	our process development, manufacturing, clinical, regulatory and quality assurance activities for our programs. In addition,
	indirect costs such as fringe benefits and overhead expenses, are also included in research and development expenses.
	Research and development expenses increased to $162.6 million for 2015 from $94.4 million for 2014, an increase of $68.2
	million, or 72%. The increase in research and development expenses was primarily due to increased costs associated with our
	RSV F Vaccine clinical trials and higher employee-related costs, including non-cash stock-based compensation. This increase
	was partially offset by a lower level of activity in 2015 associated with our Phase 2 quadrivalent seasonal influenza VLP
	vaccine candidate clinical trial as compared to our Phase 1/2 clinical trial of our pandemic H7N9 influenza VLP vaccine
	candidate adjuvanted with Matrix-M in 2014. At December 31, 2015, we had 369 employees dedicated to our research and
	development programs versus 261 employees as of December 31, 2014. For 2016, we expect a significant increase in research and
	development expenses primarily due to our ongoing RSV F Vaccine candidate clinical trials and employee-related and facility
	costs to support product development of our RSV F Vaccine candidate and other potential vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Research and
	development expenses increased to $94.4 million for 2014 from $58.5 million for 2013, an increase of $35.9 million, or 61%.
	Excluding the increase in research and development expenses of $3.6 million from Novavax AB resulting from twelve months of
	activity in 2014 as compared to only five months in 2013, the increase in research and development expenses was primarily due
	to higher employee-related costs, the preparation and initiation of three RSV F Vaccine candidate clinical trials in 2014,
	the initiation of our EBOV GP Vaccine candidate program and a $3.0 million milestone payment accrued under the Wyeth
	agreement. The increase also resulted from the costs of our Phase 1/2 clinical trial of our pandemic H7N9 influenza VLP
	vaccine candidate adjuvanted with Matrix-M and manufacturing work for our Phase 2 quadrivalent seasonal influenza VLP
	vaccine candidate clinical trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Expenses by Functional
	Area
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We track our research
	and development expenses by the type of costs incurred in identifying, developing, manufacturing and testing vaccine candidates.
	We evaluate and prioritize our activities according to functional area and therefore believe that project-by-project information
	would not form a reasonable basis for disclosure to our investors. Historically, we did not account for internal research and development
	expenses by project, since our employees&rsquo; work time is spread across multiple programs and our internal manufacturing clean-room
	facility produces multiple vaccine candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following summarizes
	our research and development expenses by functional area for the years ended December 31, 2015, 2014 and 2013 (in millions).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Manufacturing
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	81.2
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	53.5
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	31.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Vaccine Discovery
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Clinical and Regulatory
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	75.2
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	34.7
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	21.9
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total research and development expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	162.6
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	94.4
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	58.5
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We do not provide forward-looking
	estimates of costs and time to complete our research programs due to the many uncertainties associated with vaccine development.
	As we obtain data from preclinical studies and clinical trials, we may elect to discontinue or delay clinical trials in order to
	focus our resources on more promising vaccine candidates. Completion of clinical trials may take several years or more, but the
	length of time can vary substantially depending upon the phase, size of clinical trial, primary and secondary endpoints and the
	intended use of the vaccine candidate. The cost of clinical trials may vary significantly over the life of a project as a result
	of a variety of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the number of patients who participate
	in the clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the number of sites included in the clinical
	trials;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	if clinical trial locations are domestic,
	international or both;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the time to enroll patients;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the duration of treatment and follow-up;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the safety and efficacy profile of the
	vaccine candidate; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the cost and timing of, and the ability
	to secure, regulatory approvals.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 33.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 33.1PT">
	As a result of these
	uncertainties, we are unable to determine with any significant degree of certainty the duration and completion costs of our research
	and development projects or when, and to what extent, we will generate future cash flows from our research projects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	General and Administrative
	Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	General and
	administrative expenses increased to $30.8 million for 2015 from $19.9 million for 2014, an increase of $10.9 million, or
	55%. The increase was primarily due to higher employee-related costs, including non-cash stock-based compensation, driven by
	the administrative requirements needed to support our expanding research and development activities, and professional fees
	for pre-commercialization activities. At December 31, 2015, we had 49 employees dedicated to general and administrative
	functions versus 35 employees as of December 31, 2014. For 2016, we expect general and administrative expenses to continue to
	increase primarily due to increased employee costs and activities related to the anticipated commercialization of our RSV F
	Vaccine.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	General and administrative
	expenses increased to $19.9 million for 2014 from $14.8 million for 2013, an increase of $5.1 million, or 34%. Excluding the increase
	in general and administrative expenses of approximately $0.7 million from Novavax AB resulting from twelve months of activity in
	2014 as compared to only five months in 2013, the increase was primarily due to higher employee-related costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Other Income (Expense):
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014 to
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	2015
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013 to
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	2014
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Other Income (Expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Investment income
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	660
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	187
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	374
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	99
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(241
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(84
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income (expense), net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(120
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	182
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(120
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(182
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Realized gains on marketable securities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	615
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(615
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	615
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in fair value of warrant liability
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	267
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(267
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total other income, net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	299
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	744
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	476
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(445
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	268
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We had total other
	income, net of $0.3 million for 2015 compared to total other income, net of $0.7 million for 2014, a decrease of $0.4 million.
	Our investment income increased in 2015 as compared to 2014 due to higher cash, cash equivalents and marketable securities balances.
	For 2014, we sold our auction rate security and received proceeds of $1.8 million resulting in a realized gain of $0.6 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We had total other
	income, net of $0.7 million for 2014 compared to total other income, net of $0.5 million for the same period in 2013. For 2014,
	we sold our auction rate security and received proceeds of $1.8 million resulting in a realized gain of $0.6 million. The change
	in fair value of our warrant liability resulted in a $0.3 million decrease in total other income, net for 2014, as compared to
	the same period in 2013. The warrants expired unexercised on July 31, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Net Loss:
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
<BR>
	2014 to
<BR>
<U STYLE="TEXT-DECORATION: NONE">
	2015
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
<BR>
	2013 to
<U STYLE="TEXT-DECORATION: NONE">
<BR>
	2014
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net Loss:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(73,990
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(30,964
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.06
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Weighted average shares outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	262,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	225,848
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	169,658
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	56,190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Net loss for 2015 was
	$156.9 million, or $0.60 per share, as compared to $82.9 million, or $0.37 per share, for 2014, an increased net loss of $74.0
	million. The increased net loss was primarily due to higher research and development spending, including increased costs relating
	to clinical trials of our RSV F Vaccine and higher employee-related costs, as compared to 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Net loss for 2014 was
	$82.9 million, or $0.37 per share, as compared to $52.0 million, or $0.31 per share, for 2013, an increased net loss of $31.0 million.
	The increased net loss was primarily due to higher research and development spending, including increased costs relating to our
	RSV F Vaccine candidate and higher employee-related costs, as compared to 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The increase in weighted
	average shares outstanding for 2015 and 2014 is primarily a result of sales of our common stock in 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Liquidity Matters and Capital Resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our future capital
	requirements depend on numerous factors including, but not limited to, the commitments and progress of our research and development
	programs, the progress of preclinical and clinical testing, the time and costs involved in obtaining regulatory approvals, the
	costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights and manufacturing costs.
	We plan to continue to have multiple vaccines and products in various stages of development, and we believe our operating expenses
	and capital requirements will fluctuate depending upon the timing of certain events, such as the scope, initiation, rate and progress
	of our preclinical studies and clinical trials and other research and development activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of December 31,
	2015, we had $230.7 million in cash and cash equivalents and marketable securities as compared to $168.1 million as of December
	31, 2014. These amounts consisted of $93.1 million in cash and cash equivalents and $137.5 million in marketable securities as
	of December 31, 2015 as compared to $32.3 million in cash and cash equivalents and $135.7 million in marketable securities as of
	December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table
	summarizes cash flows for 2015 and 2014 (in thousands):
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 92%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change 2014
<U STYLE="TEXT-DECORATION: NONE">
<BR>
	to 2015
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Summary of Cash Flows:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net cash (used in) provided by:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Operating activities
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(126,090
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(67,014
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(59,076
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,270
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(129,833
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	108,563
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	208,283
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	109,717
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	98,566
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Effect on exchange rate on cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(150
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(144
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net increase (decrease) in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,773
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(87,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	147,909
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	32,335
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	119,471
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(87,136
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	93,108
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	32,335
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	60,773
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Net cash used in operating
	activities increased to $126.1 million for 2015, as compared to $67.0 million for 2014. The increase in cash usage was primarily
	due to increased research and development expenses relating to our RSV F Vaccine, higher employee-related costs and timing of customer
	and vendor payments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During 2015 and 2014,
	our investing activities consisted primarily of purchases and maturities of marketable securities and capital expenditures. Capital
	expenditures for 2015 and 2014 were $18.3 million and $7.3 million, respectively. The increase in capital expenditures was primarily
	due to the purchase of laboratory equipment for process development, analytical development and manufacturing scale-up required
	to support our maturing product portfolio. In 2016, we expect our level of capital expenditures to be significantly higher than
	our 2015 spending as we continue to invest in our core operational infrastructure. If we receive positive data from our ongoing
	RSV F Vaccine Phase 3 clinical trial in older adults (Resolve), expected in the third quarter of 2016, this may result in
	a significant increase in capital expenditures as we prepare for initial commercialization and plan ahead for the additional manufacturing
	capacity necessary to meet expected demand in the upcoming years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our financing
	activities consisted primarily of sales of our common stock, our issuance of the Notes, which occurred in 2016, subsequent to
	our year-end, and to a lesser extent, stock option exercises and purchases under our employee stock purchase plan. In 2015,
	we received net proceeds of approximately $190 million through our public offering at $7.25 per share and approximately $15
	million through our Sales Agreement at an average sales price of $10.63 per share. In 2014, we received net proceeds of
	approximately $108 million through our public offering at $4.00 per share. We sold the remaining common stock under the Sales
	Agreement in July 2015. The Sales Agreement has now been fully utilized. In 2016, we received net proceeds of approximately
	$315 million, before deducting offering expenses, through the issuance of the Notes, and used approximately $38 million of
	such proceeds in connection with our entry into the capped call transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In August 2015, we
	amended the lease for our new facility located in Gaithersburg, Maryland to increase the amount of space leased by us to now include
	the entire facility. Under the terms of the amended lease, the landlord shall provide us with a tenant improvement allowance of
	approximately $3.9 million. In 2015, we were funded $1.4 million under this tenant improvement allowance. Under the terms of another
	facility lease, we were reimbursed $1.4 million in the fourth quarter of 2015 for facility improvements made at the facility, and
	such reimbursement will be repaid back to the landlord during the remaining term of the lease through additional rent payments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2007, we entered
	into an agreement to license certain rights from Wyeth. The Wyeth license is a non-exclusive, worldwide license to a family of
	patents and patent applications covering VLP technology for use in human vaccines in certain fields, with expected patent expiration
	in early 2022. The Wyeth license provides for us to make an upfront payment (previously made), ongoing annual license fees, sublicense
	payments, milestone payments on certain development and commercialization activities and royalties on any product sales. Except
	in certain circumstances in which we continuously market multiple products in a country within the same vaccine program, the milestone
	payments are one-time only payments applicable to each related vaccine program. At present, our seasonal influenza VLP vaccine
	program (including CPLB&rsquo;s seasonal influenza program) and our pandemic influenza VLP vaccine program are the only two programs
	to which the Wyeth license applies. The license may be terminated by Wyeth only for cause and may be terminated by us only after
	we have provided ninety (90) days&rsquo; notice that we have absolutely and finally ceased activity, including through any affiliate
	or sublicense, related to the manufacturing, development, marketing or sale of products covered by the license. In September 2015,
	we amended the license agreement with Wyeth. Among other things, the amendment restructured the $3 million milestone payment (&ldquo;Milestone&rdquo;)
	owed as a result of CPLB&rsquo;s initiation of a Phase 3 clinical trial for its recombinant trivalent seasonal VLP influenza vaccine
	candidate in 2014. Under the amendment, the milestone payment, which may increase slightly over time, shall be due in connection
	with the initiation of a Phase 3 clinical trial for the initial seasonal influenza VLP vaccine candidate being developed outside
	India, but in any case no later than December 31, 2017. The amendment also restructured the final milestone payment to apply to
	the initial seasonal influenza VLP vaccine candidate being developed outside India. Thus, the aggregate milestone payments for
	a seasonal influenza VLP vaccine candidate developed and commercialized was increased from $14 million to up to $15 million. In
	connection with the execution of the amendment, we agreed to pay a one-time only payment to Wyeth. The amendment also increased
	annual license maintenance fees associated with VLP vaccine candidates from $0.2 million to $0.3 million per year. Payments under
	the agreement to Wyeth as of December 31, 2015 aggregated $7.3 million. The Milestone was accrued for on the consolidated balance
	sheet in other current liabilities at December 31, 2014. As a result of the September 2015 amendment discussed above, the Milestone
	payment is not expected to occur within the next 12 months. Therefore, the Milestone has been accrued for, on a discounted basis
	calculated based on the probable future payment date, in other non-current liabilities at December 31, 2015. The milestone was
	recorded as a research and development expense in the third quarter of 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Based on our December
	31, 2015 cash and cash equivalents and marketable securities balances, the proceeds from our Notes, along with anticipated revenue
	under the contract with HHS BARDA and Grant Agreement and other resources, we believe we have adequate capital to fund our operating
	plans for a minimum of twelve months. Additional capital may be required in the future to develop our vaccine candidates through
	clinical development, manufacturing and commercialization. Our ability to obtain such additional capital will likely be subject
	to various factors, including our ability to perform and thus generate revenue under the HHS BARDA contract and Grant Agreement,
	our overall business performance and market conditions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Any capital raised
	by an equity offering or convertible securities has the potential to be substantially dilutive to the existing stockholders and
	any licensing or development arrangement may require us to give up rights to a product or technology at less than its full potential
	value. We cannot provide any assurance that new financing will be available on commercially acceptable terms, if at all. If we
	are unable to perform under the HHS BARDA contract and Grant Agreement or obtain additional capital, we will assess our capital
	resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs,
	and/or downsize our organization, including our general and administrative infrastructure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Contractual Obligations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table
	summarizes our contractual obligations as of December 31, 2015 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 89%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Contractual Obligations:
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Less than
<U STYLE="TEXT-DECORATION: NONE">
<BR>
	One Year
</U>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	1 &ndash; 3
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	Years
</U>
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	3 &ndash; 5
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	Years
</U>
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	More than
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	5 Years
</U>
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Operating leases
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	40,699
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6,159
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	9,641
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	9,428
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	15,471
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Capital lease
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	108
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Research funding payment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,527
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,527
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Accrued milestone payment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total contractual obligations
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	46,729
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,152
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,678
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	9,428
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	15,471
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our research funding
	payment includes the research funding received under the Genocea agreement (see Note 4 to consolidated financial statements in
	Item 8) and accrued milestone payment includes the milestone payment incurred in 2014 under the Wyeth agreement (see above for
	further discussion).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are not involved
	in any off-balance sheet agreements that have or are reasonably likely to have a material future effect on our financial condition,
	changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 49.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -49.5PT">
<B>
	&nbsp;
</B>
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item
	7A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_024">
</A>
	QUANTITATIVE
	AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The primary objective
	of our investment activities is preservation of capital, with the secondary objective of maximizing income. As of December 31,
	2015, we had cash and cash equivalents of $93.1 million, marketable securities of $137.5 million, all of which are short-term,
	and working capital of $210.8 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our exposure to market
	risk is primarily confined to our investment portfolio. As of December 31, 2015, our investments were classified as available-for-sale.
	We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our
	investment portfolio. Changes in interest rates may affect the investment income we earn on our marketable securities when they
	mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of
	operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Interest and dividend
	income is recorded when earned and included in investment income. Premiums and discounts, if any, on marketable securities are
	amortized or accreted to maturity and included in investment income. The specific identification method is used in computing realized
	gains and losses on the sale of our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are headquartered
	in the U.S. where we conduct the vast majority of our business activities. We have one foreign consolidated subsidiary, Novavax
	AB, which is located in Sweden. A 10% decline in the exchange rate between the U.S. dollar and Swedish Krona would result in a
	reduction of stockholders&rsquo; equity of approximately $2.8
<B>
</B>
	million at December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	At December 31, 2015,
	we did not have material debt and, as such, do not believe that we are exposed to any material interest rate risk as a result of
	our borrowing activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_MARKET_RISK>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_012">
</A>
	Item
	8.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	FINANCIAL
	STATEMENTS AND SUPPLEMENTARY DATA
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The information required
	by this item is set forth on pages F-1 to F-28.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_013">
</A>
	Item
	9.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CHANGES
	IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT">
	None.
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_014">
</A>
	Item
	9A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CONTROLS
	AND PROCEDURES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Evaluation of
	Disclosure Controls and Procedures
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The term &ldquo;disclosure
	controls and procedures&rdquo; (defined in SEC Rule 13a-15(e)) refers to the controls and other procedures of a company that are
	designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange
	Act of 1934 (the &ldquo;Exchange Act&rdquo;) is recorded, processed, summarized and reported, within time periods specified in
	the rules and forms of the Securities and Exchange Commission. &ldquo;Disclosure controls and procedures&rdquo; include, without
	limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that
	it files or submits under the Exchange Act is accumulated and communicated to the company&rsquo;s management, including its principal
	executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding
	required disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55IN">
	The Company&rsquo;s
	management, with the participation of the chief executive officer and the chief financial officer, has evaluated the effectiveness
	of the Company&rsquo;s disclosure controls and procedures as of the end of the period covered by this Annual Report (the &ldquo;Evaluation
	Date&rdquo;). Based on that evaluation, the Company&rsquo;s chief executive officer and chief financial officer have concluded
	that, as of the Evaluation Date, such controls and procedures were effective at the reasonable assurance level.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Management&rsquo;s
	Report on Internal Control over Financial Reporting
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our management is responsible
	for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
	is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, as a process designed by, or under the supervision
	of, the Company&rsquo;s principal executive officer and principal financial officer and effected by the Company&rsquo;s board of
	directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and
	the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the
	United States (&ldquo;GAAP&rdquo;). Such internal control includes those policies and procedures that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	provide reasonable assurance regarding prevention or timely detection of an unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because of its inherent
	limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of
	effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or
	that the degree of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our management assessed
	the effectiveness of our internal control over financial reporting as of December 31, 2015. In making this assessment, our management
	used the criteria set forth in the 2013
<I>
	Internal Control-Integrated Framework
</I>
	issued by the Committee of Sponsoring Organizations
	of the Treadway Commission (COSO). Based on its assessment, our management has determined that, as of December 31, 2015, our internal
	controls over financial reporting are effective based on those criteria.
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Ernst &amp; Young LLP
	has issued an attestation report on our internal control over financial reporting. This report is included in the Reports of Independent
	Registered Public Accounting Firm in Item 15.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Changes in Internal
	Control over Financial Reporting
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our management, including
	our chief executive officer and chief financial officer, has evaluated any changes in our internal control over financial reporting
	that occurred during the quarterly period ended December 31, 2015, and has concluded that there was no change that occurred during
	the quarterly period ended December 31, 2015 that materially affected, or is reasonably likely to materially affect, our internal
	control over financial reporting.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="V431853_10K_HTM_A_015">
</A>
<B>
	Item
	9B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	OTHER
	INFORMATION
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	None.
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<A NAME="V431853_10K_HTM_A_016">
</A>
<B>
	PART III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_017">
</A>
	Item
	10.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DIRECTORS,
	EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The information required
	by this item is incorporated by reference from our definitive Proxy Statement for our 2016 Annual Meeting of Stockholders scheduled
	to be held
<B>
</B>
	in
<B>
</B>
	June 2016 (the &ldquo;2016 Proxy Statement&rdquo;). We expect to file the 2016 Proxy Statement within
	120 days after the close of the fiscal year ended December 31, 2015.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_018">
</A>
	Item
	11.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXECUTIVE
	COMPENSATION
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We incorporate herein
	by reference the information required by this item concerning executive compensation to be contained in the 2016 Proxy Statement.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_019">
</A>
	Item
	12.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SECURITY
	OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We incorporate herein
	by reference the information required by this item concerning security ownership of certain beneficial owners and management and
	related stockholder matters to be contained in the 2016 Proxy Statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table
	provides our equity compensation plan information as of December 31, 2015. Under these plans, our common stock may be issued upon
	the exercise of options and purchases under our Employee Stock Purchase Plan (&ldquo;ESPP&rdquo;). See also the information regarding
	our stock options and ESPP in Note 12
<B>
</B>
	to the financial statements included herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Equity Compensation Plan Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Plan Category
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Number of Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	to be Issued
<BR>
	Upon Exercise of
<BR>
	Outstanding Options,
<BR>
	Warrants and Rights
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	(a)
</U>
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-Average
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exercise Price of
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Outstanding Options,
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Warrants
	and Rights
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(b)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Number of Securities
<BR>
	Remaining Available for
<BR>
	Future Issuance Under
<BR>
	Equity Compensation
<BR>
	Plans (Excluding
<BR>
	Securities Reflected in
<BR>
	Column (a))
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(c)
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by security holders(1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	23,807,545
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	5.29
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	17,733,007
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Equity compensation plans not approved by security holders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	N/A
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	N/A
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	N/A
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes our 2015 Stock Incentive Plan, 2005 Stock Incentive Plan and ESPP.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SECURITY_OWNERS>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_020">
</A>
	Item
	13.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTAIN
	RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 49.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -49.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We incorporate herein
	by reference the information required by this item concerning certain related party transactions set forth in Note 16 to our financial
	statements included herewith. We incorporate herein by reference other information required by this item concerning certain other
	relationships and related transactions and director independence to be contained in the 2016 Proxy Statement.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<A NAME="V431853_10K_HTM_A_021">
</A>
	Item
	14.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PRINCIPAL
	ACCOUNTING FEES AND SERVICES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 49.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -49.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We incorporate herein
	by reference the information required by this item concerning principal accountant fees and services to be contained in the 2016
	Proxy Statement.
</P>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
<A NAME="V431853_10K_HTM_A_022">
</A>
	PART IV
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<B>
	I
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="V431853_10K_HTM_A_023">
</A>
	tem
	15.
</FONT>
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBITS
	AND FINANCIAL STATEMENT SCHEDULES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 49.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -49.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The following documents are filed as part of the Annual Report:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
<U>
	Index to Financial Statements
</U>
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT">
	Reports of Independent Registered Public Accounting Firms
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-2
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Consolidated Balance Sheets as of December 31, 2015 and 2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December 31, 2015, 2014 and 2013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Consolidated Statements of Stockholders&rsquo; Equity for the years ended December 31, 2015, 2014 and 2013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-7
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2014 and 2013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-8
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes to Consolidated Financial Statements
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-9
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
<U>
	Financial Statement Schedules
</U>
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Financial statement
	schedules are omitted because they are not applicable, not required under the instructions or all the information required is set
	forth in the financial statements or notes thereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
<U>
	Exhibits
</U>
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Exhibits marked with
	a single asterisk (*) are filed herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Exhibits marked with
	a double plus sign (&dagger;&dagger;) refer to management contracts, compensatory plans or arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Confidential treatment
	has been granted for portions of exhibits marked with a double asterisk (**).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	All other exhibits
	listed have previously been filed with the Commission and are incorporated herein by reference.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Exhibit
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Number
</P>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 4PT; TEXT-ALIGN: JUSTIFY">
	Description
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.1
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Second Amended and Restated Certificate of Incorporation of the Registrant dated June 18, 2015 (Incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.2
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated By-Laws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 12, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.1
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Specimen stock certificate for shares of common stock of the Registrant, par value $.01 per share (Incorporated by reference to Exhibit 4.1 to the Registrant&rsquo;s Registration Statement on Form 10, File No. 0-26770, filed on September 14, 1995)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.2
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Registration Rights Agreement between Novavax, Inc. and Satellite Overseas (Holdings) Limited, dated March 31, 2009 (Incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, filed on May 11, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.3
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Indenture (including form of Notes) with respect to Novavax&rsquo; 3.75% Convertible Senior Notes due 2023, dated as of January 29, 2016, between Novavax and The Bank of New York Mellon Trust Company, N.A., as trustee (Incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, filed on January 29, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.1&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Novavax, Inc.
	Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Annual
	Report on Form 10-K for the year ended December 31, 2012, filed on March 12, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.2&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Appendix 1 of the Registrant&rsquo;s Definitive Proxy Statement filed April 30, 2014 in connection with the Annual Meeting held on June 12, 2014)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.3&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of
	Non-Statutory Stock Option Award Agreement granted under the Novavax, Inc. Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Company&rsquo;s Annual Report on Form 10-K for
	the year ended December 31, 2014, filed on February 27, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.4&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Incentive
	Stock Option Award Agreement granted under the Novavax, Inc. Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Company&rsquo;s Annual Report on Form 10-K for the year
	ended December 31, 2014, filed on February 27, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.5&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2013 Employee Stock Purchase Plan (Incorporated by reference to Appendix C to the Registrant&rsquo;s Definitive Proxy Statement filed on April 30, 2013 in connection with the Annual Meeting held on June 13, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.6&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Appendix B of the Company&rsquo;s Definitive Proxy Statement filed April 30, 2015 in connection with the Annual Meeting held on June 18, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.7&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of
	Non-Statutory Stock Option Award Agreement granted under the Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by
	reference to Exhibit 10.3 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed
	on August 10, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.8&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Incentive
	Stock Option Award Agreement granted under the Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit
	10.4 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10,
	2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.9&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Restricted Stock Award Agreement granted under the Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Registrant&rsquo;s Quarterly Report for the quarter ended June 30, 2015, filed on August 10, 2015)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.10&dagger;&dagger;*
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Director Deferred Fee Agreement
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.11&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement between Novavax, Inc. and Stanley C. Erck, dated as of February 15, 2010 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed on June 1, 2010)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.12&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment
	Agreement between Novavax, Inc. and Stanley C. Erck, dated as of June 22, 2011 (Incorporated by reference to Exhibit 10.2 to
	the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, filed on August 9,
	2011)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.13&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement between Novavax, Inc. and Gregory M. Glenn dated July 1, 2010 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed on July 6, 2010)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.14&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement between Novavax, Inc. and Russell P. Wilson dated November 7, 2011 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed on November 14, 2011)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.15&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement between Novavax, Inc. and Timothy J. Hahn dated June 22, 2011 (Incorporated by reference to Exhibit 10.12 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 14, 2012)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.16&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment agreement between Novavax, Inc. and Barclay A. Phillips dated June 24, 2013 (Incorporated by reference to Exhibit 99.2 to the Registrant&rsquo;s Current Report on Form 8-K, filed on June 28, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.17&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Novavax, Inc. Amended and Restated Change in Control Severance Benefit Plan, (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed on January 5, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.18&dagger;&dagger;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Indemnification Agreement entered into between the Registrant and its directors and officers&nbsp;&nbsp;(Incorporated by reference to Exhibit 10.19 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2009, filed on March 16, 2010)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.19
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lease Agreement
	between GP Rock One, LLC and Novavax, Inc., dated as of May 7, 2007 (Incorporated by reference to Exhibit 10.4 to the
	Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed on August 11, 2008)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.20
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	First Amendment to
	Lease Agreement between GP Rock One, LLC and Novavax, Inc., dated as of May 30, 2008 (Incorporated by reference to Exhibit
	10.5 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed on August 11,
	2008)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.21
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Second Amendment to
	Lease Agreement between BMR-9920 Belward Campus Q, LLC (formerly GP Rock One, LLC) and Novavax, Inc., dated as of June 26,
	2008 (Incorporated by reference to Exhibit 10.6 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended
	June 30, 2008, filed on August 11, 2008)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.22
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lease Agreement for space at 20 Firstfield between ARE-20/22/1300 Firstfield Quince Orchard, LLC and Novavax, Inc., dated as of November 18, 2011 (Incorporated by reference to Exhibit 10.23 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 14, 2012)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.23
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lease Agreement for space at 22 Firstfield between ARE-20/22/1300 Firstfield Quince Orchard, LLC and Novavax, Inc., dated as of November 18, 2011 (Incorporated by reference to Exhibit 10.25 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 14, 2012)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.24
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lease Agreement for space at 21 Firstfield Road between Firstfield Holdco, LLC and Novavax, Inc., dated as of February 4, 2015 (Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed on August 21, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.25
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 2.75PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.75PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	First Amendment to Lease Agreement for space at 21 Firstfield Road between Firstfield Holdco, LLC and Novavax, Inc., dated as of August 17, 2015 (Incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed on August 21, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.75PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.75PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.26**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract, effective as of February 24, 2011, between Novavax, Inc. and HHS/OS/ASPR/BARDA (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended on March 31, 2011, filed on November 4, 2011)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.27**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract Amendment/Modification No. 5 between Novavax, Inc. and HHS/OS/ASPR/BARDA, dated February 21, 2014 (Incorporated by reference to Exhibit 10.25 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2013, filed on March 12, 2014)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.28**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract Amendment/Modification No. 6 between Novavax, Inc. and HHS/OS/ASPR/BARDA, dated September 22, 2014 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed on November 6, 2014)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.29**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract Amendment/Modification No. 8 between Novavax, Inc. and HHS/OS/ASPR/BARDA, dated June 5, 2015 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.30**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	License Agreement, entered in February 25, 2011, effective as of December 9, 2010, between Novavax, Inc. and LG Life Sciences, Ltd. (Incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2011, filed on November 4, 2011)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.31**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	License Agreement, dated July 5, 2007, between Novavax, Inc. and Wyeth Holdings Corporation (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed on August 9, 2007)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.32**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 1 to License Agreement, effective as of March 17, 2010, between Novavax, Inc. and Wyeth Holdings Corporation (Incorporated by reference to Exhibit 10.49 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, filed on August 6, 2010)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.33**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Second Amendment to License Agreement between Wyeth Holdings LLC and Novavax, Inc., dated as of September 1, 2015 (Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed on September 8, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.34
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stock Purchase Agreement between Novavax, Inc. and Satellite Overseas (Holdings) Limited, dated March 31, 2009 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, filed on May 11, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.35**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Joint Venture Agreement between Novavax Inc. and Cadila Pharmaceuticals Limited, dated as of June 29, 2009 (Incorporated by reference to Exhibit 10.4 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed on August 10, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.36**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Limited, dated as of June 29, 2009 (Incorporated by reference to Exhibit 10.5 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed on August 10, 2009)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.37
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 4.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%; PADDING-LEFT: 4.3PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 1 to Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Limited dated July 27, 2011 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 8, 2011)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4.3PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.38
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 2 to Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Limited dated March 7, 2013 (Incorporated by reference to Exhibit 10.32 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 12, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.39
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 3 to Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Ltd. dated October 29, 2013 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Report on Form 8-K, filed on October 30, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.40
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 4 to Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Ltd. dated March 5, 2014 (Incorporated by reference to Exhibit 10.37 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2013, filed on March 12, 2014)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.41
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 5 to Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Ltd. dated February 25, 2015 (Incorporated by reference to Exhibit 10.35 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2014, filed on February
</FONT>
	&nbsp;
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	27, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.42**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Supply Agreement between Novavax, Inc. and CPL Biologicals Limited, dated as of June 29, 2009 (Incorporated by reference to Exhibit 10.6 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed on August 10, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.43**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Technical Services Agreement between Novavax, Inc. and CPL Biologicals Limited, dated as of June 29, 2009 (Incorporated by reference to Exhibit 10.7 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed on August 10, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.44**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Seasonal / Other License Agreement between Novavax, Inc. and CPL Biologicals Limited, dated as of June 29, 2009 (Incorporated by reference to Exhibit 10.8 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed on August 10, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.45**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Option to Obtain License between Novavax, Inc. and CPL Biologicals Limited, dated as of June 29, 2009 (Incorporated by reference to Exhibit 10.9 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, filed on August 10, 2009)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.46**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	H1N1 License to Agreement between Novavax, Inc. and CPL Biologicals Private Limited, dated October 6, 2009 (Incorporated by reference to Exhibit 10.45 to the Registrant&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2009, filed on March 16, 2010)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.47**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Grant Agreement between Bill and Melinda Gates Foundation and Novavax, Inc., dated as of September 25, 2015 (Incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 9, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.48**
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Global Access Commitments Agreement between Bill and Melinda Gates Foundation and Novavax, Inc., dated as of September 25, 2015 (Incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 9, 2015)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.49
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Base Call Option Transaction Confirmation, dated as of January 25, 2016, between Novavax and JPMorgan Chase Bank, National Association, London Branch (Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed January 29, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.50
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Base Call Option Transaction Confirmation, dated as of January 25, 2016, between Novavax and Morgan Stanley &amp; Co. LLC (Incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed January 29, 2016)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.51*
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 87%; PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Additional Base Call Option Transaction Confirmation, dated as of February 2, 2016, between Novavax and JPMorgan Chase Bank, National Association, London Branch
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.52*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Additional Base Call Option Transaction Confirmation, dated as of February 2, 2016, between Novavax and Morgan Stanley &amp; Co. LLC
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Code of Business Conduct and Ethics
<B>
</B>
	(Incorporated by reference to Exhibit 14 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, filed on August 9, 2011)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Subsidiaries of the Registrant
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23.1*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23.2*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.1*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of chief executive officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.2*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of chief financial officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.1*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of chief executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.2*
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	101*
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	The following financial information from our Annual Report on Form 10-K
	for the year ended December 31, 2015, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated
	Balance Sheets as of December 31, 2015 and 2014, (ii) the Consolidated Statements of Operations for the three years in the
	period ended December 31, 2015, (iii) the Consolidated Statements of Comprehensive Loss for the three years in the
	period ended December 31, 2015, (iv) the Consolidated Statements of Changes in Stockholders&rsquo; Equity for the three
	years in the period ended December 31, 2015, (v) the Consolidated Statements of Cash Flows for the
	three years in the period ended December 31, 2015, and (vi) the Notes to Consolidated
	Financial Statements.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Pursuant to the requirements
	of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
	by the undersigned, thereunto duly authorized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOVAVAX, INC.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Stanley C. Erck
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	and Director
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Date: February 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Pursuant to the requirements
	of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant
	and in the capacities and on the dates indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Title
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 17%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Date
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Stanley C. Erck
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President and Chief Executive Officer and
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stanley C. Erck
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director (Principal Executive Officer)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Barclay A. Phillips
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Senior Vice President, Chief Financial
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Barclay A. Phillips
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Officer and Treasurer (Principal Financial and Principal Accounting Officer)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;James F. Young
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman of the Board of Directors
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	James F. Young
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Gail K. Boudreaux
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Gail K. Boudreaux
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Richard H. Douglas
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Richard H. Douglas
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Gary C. Evans
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Gary C. Evans
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Michael A. McManus
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Michael A. McManus
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;Rajiv
	I. Modi
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	February 29, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Rajiv I. Modi
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	INDEX TO FINANCIAL STATEMENTS
<BR>
	Years ended December 31, 2015, 2014 and 2013
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Contents
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 94%; PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V431853_10K_HTM_B_001">
	Reports of Independent Registered Public Accounting Firms
</A>
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-2
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V431853_10K_HTM_B_002">
	Consolidated Balance Sheets as of December 31, 2015 and 2014
</A>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A HREF="#V431853_10K_HTM_B_003">
	Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December 31, 2015, 2014 and 2013
</A>
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V431853_10K_HTM_CASHFLOW">
	Consolidated Statements of Stockholders&rsquo; Equity for the years ended December 31, 2015, 2014 and 2013
</A>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V431853_10K_HTM_FG">
	Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2014 and 2013
</A>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-8
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V431853_10K_HTM_GHH">
	Notes to Consolidated Financial Statements
</A>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 1.75PT; PADDING-LEFT: 1.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-9
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
<A NAME="V431853_10K_HTM_B_001">
</A>
	Report of Ernst &amp; Young LLP,
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Independent Registered Public Accounting
	Firm,
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	on the Audited Consolidated Financial
	Statements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors and Stockholders
	of
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novavax, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have audited the
	accompanying consolidated balance sheets of Novavax, Inc. as of December 31, 2015 and 2014, and the related consolidated statements
	of operations, comprehensive loss, changes in stockholders&rsquo; equity, and cash flows for each of the two years in the period
	ended December 31, 2015. These financial statements are the responsibility of the Company's management. Our responsibility is to
	express an opinion on these financial statements based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We conducted our audits
	in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
	we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
	An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
	also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the
	overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In our opinion, the
	financial statements referred to above present fairly, in all material respects, the consolidated financial position of Novavax,
	Inc. at December 31, 2015 and 2014, and the consolidated results of its operations and its cash flows for each of the two years
	in the period ended December 31, 2015 in conformity with U.S. generally accepted accounting principles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	We
	also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Novavax Inc.&rsquo;s
	internal control over financial reporting as of December 31, 2015, based on criteria established in the Internal Control
</FONT>
	&mdash;
<FONT STYLE="FONT-SIZE: 10PT">
	Integrated
	Framework
<I>
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report
	dated February 29, 2016 expressed an unqualified opinion thereon.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ Ernst &amp; Young LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Baltimore, MD
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	February 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Report of Ernst &amp; Young LLP,
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Independent Registered Public Accounting
	Firm,
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Regarding Internal Control Over Financial
	Reporting
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors and Stockholders
	of
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novavax, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have audited Novavax
	Inc.&rsquo;s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control&mdash;Integrated
	Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).
	Novavax Inc.&rsquo;s management is responsible for maintaining effective internal control over financial reporting, and for its
	assessment of the effectiveness of internal control over financial reporting, included in Item 9A, Management&rsquo;s Report on
	Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&rsquo;s internal control
	over financial reporting based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We conducted our audit
	in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
	we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting
	was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting,
	assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control
	based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that
	our audit provides a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A company&rsquo;s internal
	control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
	and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
	A company&rsquo;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance
	of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
	(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
	with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
	with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely
	detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect on the
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because of its inherent
	limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation
	of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
	or that the degree of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In our opinion, Novavax
	Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on
	the COSO criteria.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We also have audited,
	in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets
	of Novavax Inc. as of December 31, 2015 and 2014, and the related consolidated statements of operations, comprehensive loss, changes
	in stockholders&rsquo; equity, and cash flows for each of the two years in the period ended December 31, 2015 of Novavax Inc. and
	our report dated February 29, 2016 expressed an unqualified opinion thereon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ Ernst &amp; Young LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Baltimore, MD
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	February 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Board of Directors and Stockholders of
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novavax, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have audited the
	accompanying consolidated statements of operations, comprehensive loss, changes in stockholders&rsquo; equity, and cash flows of
	Novavax Inc. (a Delaware corporation) and subsidiary (the &ldquo;Company&rdquo;) for the year ended December 31, 2013. These financial
	statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements
	based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We conducted our
	audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
	require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of
	material misstatement. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in
	the financial statements, assessing the accounting principles used and significant estimates made by management, as well as
	evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our
	opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In our opinion, the
	consolidated financial statements referred to above present fairly, in all material respects, the results of Novavax, Inc. and
	its subsidiary&rsquo;s operations and their cash flows for the year ended December 31, 2013 in conformity with accounting principles
	generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ Grant Thornton LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	McLean, Virginia
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	March 12, 2014
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 69 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V431853_10K_HTM_B_002">
</A>
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	(in thousands, except share and per share information)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</EFX_AUDITORS_OPINION>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 0 -0.25IN; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
</TD>
</TR>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="8" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<A NAME="FIS_BALANCE_SHEET"></A>
<B>
	ASSETS
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Current assets:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	93,108
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	32,335
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	137,548
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	135,721
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Restricted cash
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	34,964
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	297
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Accounts receivable &ndash; billed
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,449
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,510
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Accounts receivable &ndash; unbilled
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	871
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,100
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,317
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,195
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Total current assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	287,257
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	188,158
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Restricted cash
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,537
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Property and equipment, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	32,342
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,737
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Intangible assets, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	10,793
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	12,577
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Goodwill
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	53,065
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	54,612
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 1.75PT">
	Other non-current assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,044
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	918
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 11.75PT">
	Total assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	386,038
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	276,002
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="8" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-LEFT: 0">
	LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Current liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Accounts payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	11,889
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	12,908
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	26,734
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,397
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Deferred revenue
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	34,469
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Current portion of notes payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	603
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Deferred rent
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,409
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,138
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Other current liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,598
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	70
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 16.25PT">
	Total current liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	76,494
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	34,116
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Deferred revenue
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,171
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,500
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Non-current portion of notes payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Deferred rent
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,534
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,734
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 1.75PT">
	Other non-current liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,170
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,639
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 16.25PT">
	Total liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	93,369
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	46,384
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 16.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Commitments and contingencies
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Stockholders&rsquo; equity:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Preferred stock, $0.01 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31, 2015 and 2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2015 and 300,000,000 shares authorized at December 31, 2014; and 270,426,662 shares issued and 269,971,232 shares outstanding at December 31, 2015 and 239,287,294 shares issued and 238,831,864 shares outstanding at December 31, 2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,704
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,393
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Additional paid-in capital
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	951,569
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	729,373
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(650,030
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(493,093
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Treasury stock, 455,430 shares, cost basis at both December 31, 2015 and 2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,450
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,450
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Accumulated other comprehensive loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(9,124
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(6,605
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 16.25PT">
	Total stockholders&rsquo; equity
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	292,669
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	229,618
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 16.25PT">
	Total liabilities and stockholders&rsquo; equity
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	386,038
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	276,002
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 70 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V431853_10K_HTM_B_003">
</A>
<B>
	CONSOLIDATED STATEMENTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	(in thousands, except per share information)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Revenue:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Government contracts
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	33,344
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	26,213
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	17,708
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.75PT">
	Research and development collaborations
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,446
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,207
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20.75PT">
	Total revenue
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	36,250
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	30,659
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	20,915
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Expenses:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Research and development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	162,644
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	94,422
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	58,530
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.75PT">
	General and administrative
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	30,842
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,928
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	14,819
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20.75PT">
	Total expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	193,486
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	114,350
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	73,349
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Loss from operations
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(157,236
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(83,691
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(52,434
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Other income (expense):
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Investment income
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	660
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	187
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Interest expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(241
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(157
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(160
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Other income (expense), net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(120
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	182
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.75PT">
	Realized gains on marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	615
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.75PT">
	Change in fair value of warrant liability
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	267
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Loss from operations before income tax expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(51,958
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 1.75PT">
	Income tax expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 1.75PT">
	Net loss
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(156,937
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(82,947
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(51,983
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 1.75PT">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(0.60
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(0.37
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(0.31
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 1.75PT">
	Basic and diluted weighted average number of common
<BR>
	shares outstanding
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	262,248
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	225,848
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	169,658
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE
	LOSS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -7.25PT; PADDING-LEFT: 7.25PT">
	Other comprehensive income (loss):
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Net unrealized gains (losses) on marketable securities
<BR>
	available-for-sale
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	42
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(65
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	186
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Reclassification adjustment for gains included
<BR>
	in net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(615
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Foreign currency translation adjustment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,561
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(6,764
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	223
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 1.75PT">
	Other comprehensive income (loss)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,519
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(7,444
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 1.75PT">
	Comprehensive loss
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(159,456
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(90,391
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(51,574
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V431853_10K_HTM_CASHFLOW">
</A>
	CONSOLIDATED STATEMENTS OF CHANGES IN
	STOCKHOLDERS&rsquo; EQUITY
<BR>
	For the Years ended December 31, 2015, 2014 and 2013
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Accumulated
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Additional
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Other
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Total
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Common
	Stock
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Paid-in
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Accumulated
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Treasury
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Comprehensive
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Stockholders&rsquo;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Amount
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Capital
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Deficit
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Income(Loss)
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Equity
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 23%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Balance at December 31, 2012
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	148,398,747
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1,484
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	438,939
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(358,163
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(2,450
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	430
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	80,240
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Non-cash compensation cost for stock options, ESPP and restricted stock
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,480
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,480
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Exercise of stock options
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	667,867
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,491
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,498
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Issuance of common stock, net of issuance costs of $6,067
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	60,044,130
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	600
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	169,990
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	170,590
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Unrealized gain on marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	186
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	186
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Foreign currency translation adjustment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	223
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	223
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Balance at December 31, 2013
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	209,110,744
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	2,091
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	612,900
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(410,146
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(2,450
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	839
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	203,234
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Non-cash compensation cost for stock options, ESPP and restricted stock
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,090
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,090
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Exercise of stock options/Purchase under ESPP
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,411,550
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,776
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,790
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Restricted stock issued as compensation
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Issuance of common stock, net of issuance costs of $7,105
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	28,750,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	288
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	107,607
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	107,895
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Unrealized loss on marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(680
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(680
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Foreign currency translation adjustment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(6,764
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(6,764
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Balance at December 31, 2014
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	239,287,294
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	2,393
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	729,373
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(493,093
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(2,450
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(6,605
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	229,618
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Non-cash compensation cost for stock options, ESPP and restricted stock
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,431
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,431
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Exercise of stock options/Purchase under ESPP
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,950,748
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,782
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,801
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Restricted stock issued as compensation
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	25,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Issuance of common stock, net of issuance costs of $11,912
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	29,163,620
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	292
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	203,983
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	204,275
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Unrealized gain on marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	42
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	42
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Foreign currency translation adjustment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,561
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,561
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.1PT; PADDING-LEFT: 8.1PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	270,426,662
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	2,704
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	951,569
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(650,030
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(2,450
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(9,124
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	292,669
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V431853_10K_HTM_FG">
</A>
<B>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Operating Activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Reconciliation of net loss to net cash used in operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Change in fair value of warrant liability
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(267
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,983
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,424
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,591
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Loss (Gain) on disposal of property and equipment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	681
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	534
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(32
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Amortization of net premiums on marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,217
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	415
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	507
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Deferred rent
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(721
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(552
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Non-cash stock-based compensation
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,431
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,090
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,480
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Realized gains on marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(615
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Other
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	243
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	60
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(200
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Changes in operating assets and liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Restricted cash
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(36,204
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,120
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(431
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Accounts receivable &ndash; billed
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,250
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(5,705
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(451
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Accounts receivable &ndash; unbilled
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,229
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,888
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3,418
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Prepaid expenses and other assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(10,269
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(5,904
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	402
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Accounts payable and accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,075
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,979
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,184
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20.75PT">
	Deferred revenue
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	36,140
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(253
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(341
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20.75PT">
	Lease incentives received
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,792
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	452
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	703
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(126,090
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(67,014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(45,359
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Investing Activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Capital expenditures
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(18,286
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(7,268
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(5,785
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Proceeds from disposal of property and equipment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	116
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Net cash received from acquisition
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,034
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Purchases of marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(228,521
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(176,469
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(14,754
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Proceeds from sales, maturities and redemptions of marketable securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	225,519
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	53,865
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	33,781
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Net cash provided by (used in) investing activities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(21,270
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(129,833
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	16,392
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Financing Activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Principal payments of capital leases
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(67
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(124
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(87
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Principal payments of notes payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(600
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(671
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(473
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Proceeds from notes payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,450
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Changes in restricted cash
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(126
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 16.25PT">
	Cash paid with acquisition
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(171
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.375IN; TEXT-INDENT: -0.25IN">
	Net proceeds from sales of common stock, net of offering costs of $11.9 million,
<BR>
	$7.1 million and $6.1 million, respectively
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	204,275
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	107,896
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	128,648
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Proceeds from the exercise of stock options and employee stock purchases
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,801
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,789
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,498
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	208,283
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	109,717
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	131,035
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Effect of exchange rate on cash and cash equivalents
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(150
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 7.25PT">
	Net increase (decrease) in cash and cash equivalents
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	60,773
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(87,136
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	102,072
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 7.25PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	32,335
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	119,471
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	17,399
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 7.25PT">
	Cash and cash equivalents at end of year
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	93,108
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	32,335
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	119,471
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Supplemental disclosure of non-cash activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 7.25PT">
	Common stock issued in connection with acquisition
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; TEXT-UNDERLINE-STYLE: DOUBLE">
<U STYLE="TEXT-DECORATION: NONE">
	&#8213;
</U>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
<U STYLE="TEXT-DECORATION: NONE">
	&#8213;
</U>
</FONT>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	41,942
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 7.25PT">
	Capital expenditures included in accounts payable and accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,797
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,615
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	379
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Supplemental disclosure of cash flow information:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 7.25PT">
	Cash interest payments
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	96
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	179
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	177
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOVAVAX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V431853_10K_HTM_GHH">
</A>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
<BR>
	December 31, 2015, 2014 and 2013
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Note 1 &ndash; Organization
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Novavax, Inc. (&ldquo;Novavax,&rdquo;
	and together with its wholly owned subsidiary, &ldquo;Novavax AB,&rdquo; the &ldquo;Company&rdquo;) is a clinical-stage vaccine
	company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Using innovative
	proprietary recombinant nanoparticle vaccine platform technology, the Company produces vaccine candidates to efficiently and effectively
	respond to both known and emerging disease threats. The Company&rsquo;s vaccine candidates are genetically engineered three-dimensional
	nanostructures that incorporate recombinant protein antigens critical to disease pathogenesis. The Company&rsquo;s product pipeline
	targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus
	(&ldquo;RSV&rdquo;), seasonal influenza, pandemic influenza and Ebola virus (&ldquo;EBOV&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Note 2 &ndash; Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	vaccine candidates currently under development, some of which include adjuvants, will require significant additional research and
	development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial
	use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As a clinical-stage
	vaccine company, the Company has primarily funded its operations from proceeds through the sale of its common stock in equity offerings,
	convertible debt issuance (in 2016) and revenue under its contract with the Department of Health and Human Services, Biomedical
	Advanced Research and Development Authority (&ldquo;HHS BARDA&rdquo;) and, to a lesser degree, revenue under its prior contract
	with PATH Vaccine Solutions (&ldquo;PATH&rdquo;)
<B>
</B>
	and the grant agreement with the Bill &amp; Melinda Gates Foundation (&ldquo;BMGF&rdquo;).
<B>
</B>
	Management regularly reviews the Company&rsquo;s cash and cash equivalents and marketable securities relative to its operating
	budget and forecast to monitor the sufficiency of the Company&rsquo;s working capital, and anticipates continuing to draw upon
	available sources of capital to support its product development activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 3 &ndash; Summary of Significant
	Accounting Policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Basis of Presentation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The consolidated financial
	statements include the accounts of Novavax, Inc. and its wholly owned subsidiary, Novavax AB, since July 31, 2013. All intercompany
	accounts and transactions have been eliminated in consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Use of Estimates
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The preparation of
	the consolidated financial statements in conformity with accounting principles generally accepted in the United States, requires
	management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
	assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during
	the reporting period. Actual results could differ materially from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Cash and Cash Equivalents
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Cash and cash equivalents
	consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash and cash equivalents
	consist of the following at (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0">
	Cash
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	29,569
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,481
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0">
	Money market funds
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	14,950
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	20,354
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0">
	Government-backed security
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,500
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0">
	Asset-backed securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,185
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT">
	Corporate debt securities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	20,404
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	93,108
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	32,335
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Cash equivalents are
	recorded at cost, which approximate fair value due to their short-term nature.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Marketable Securities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Marketable securities
	consist of commercial paper, asset-backed securities and corporate notes. Classification of marketable securities between current
	and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&rsquo;s ability
	and intent to hold the investment to maturity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Interest and dividend
	income is recorded when earned and included in investment income in the consolidated statements of operations. Premiums and discounts,
	if any, on marketable securities are amortized or accreted to maturity and included in investment income in the consolidated statements
	of operations. The specific identification method is used in computing realized gains and losses on the sale of the Company&rsquo;s
	securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company classifies
	its marketable securities with readily determinable fair values as &ldquo;available-for-sale.&rdquo; Investments in securities
	that are classified as available-for-sale are measured at fair market value in the consolidated balance sheets, and unrealized
	holding gains and losses on marketable securities are reported as a separate component of stockholders&rsquo; equity until realized.
	Marketable securities are evaluated periodically to determine whether a decline in value is &ldquo;other-than-temporary.&rdquo;
	The term &ldquo;other-than-temporary&rdquo; is not intended to indicate a permanent decline in value. Rather, it means that the
	prospects for a near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair
	values equal to, or greater than, the carrying value of the security. Management reviews criteria, such as the magnitude and duration
	of the decline, as well as the Company&rsquo;s ability to hold the securities until market recovery, to predict whether the loss
	in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the security is
	reduced and the impairment is recorded as other income (expense), net in the consolidated statements of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Concentration of Credit
	Risk
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Financial instruments,
	which possibly expose the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable
	securities. The Company&rsquo;s investment policy limits investments to certain types of instruments, including auction rate securities,
	high-grade corporate debt securities and money market instruments, places restrictions on maturities and concentrations in certain
	industries and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in
	financial institutions, which may exceed federally insured limits. The Company has not experienced any losses relating to such
	accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Fair Value Measurements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company applies
	Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 820,
<I>
	Fair Value Measurements and Disclosures
</I>
	, for financial
	and non-financial assets and liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	ASC 820 discusses valuation
	techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash
	flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair
	value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following
	is a brief description of those three levels:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 1: Observable inputs such as quoted
	prices (unadjusted) in active markets for identical assets or liabilities.
</LI>
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 2: Inputs other than quoted prices
	that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or
	liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
</LI>
<LI STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 3: Unobservable inputs that reflect
	the reporting entity&rsquo;s own assumptions.
</LI>
</UL STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Restricted Cash
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	current and noncurrent restricted cash includes payments received under the BMGF grant agreement (See Note 8). The Company will
	utilize these funds as it incurs expenses for services performed under the agreement. In addition, the Company&rsquo;s non-current
	restricted cash with respect to its manufacturing, laboratory and office space functions as collateral for letters of credit,
	which serve as security deposits for the duration of the leases. At December 31, 2015 and 2014, non-current restricted cash is
	$0.9 million and $0.8 million, respectively, and is recorded as other non-current assets on the consolidated balance sheets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Accounts Receivable &ndash;
	Billed
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Accounts receivable
	&ndash; billed arise primarily from the Company&rsquo;s contract with HHS BARDA and are reported at amounts expected to be collected
	in future periods. No allowance for doubtful accounts is deemed necessary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Accounts Receivable &ndash;
	Unbilled
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Accounts receivable
	&ndash; unbilled relate to service contracts and agreements for which work has been performed, though invoicing has not yet occurred.
	All of the Accounts receivable &ndash; unbilled are expected to be billed and collected within the next 12 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Property and equipment
	are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the assets, generally
	three to seven years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the
	estimated useful lives of the improvements or the remaining term of the lease. Repairs and maintenance costs are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Impairment of Long-Lived
	Assets
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Long-lived assets are
	reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group
	may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic
	360,
<I>
	Property, Plant and Equipment.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Impairment of Goodwill
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Goodwill is subject
	to impairment tests annually or more frequently should indicators of impairment arise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company has determined
	since its only business is the development of recombinant vaccines that it operates as a single operating segment and has one reporting
	unit. The Company utilizes primarily the market approach and, if considered necessary, the income approach to determine if it has
	an impairment of its goodwill. The market approach is based on market value of invested capital. To ensure that the Company&rsquo;s
	capital stock is the appropriate measurement of fair value, the Company considers factors such as its trading volume, diversity
	of investors and analyst coverage. When utilized, the income approach is used as a confirming look to the market approach, if considered
	necessary. Goodwill impairment may exist if the carrying value of the reporting unit exceeds its estimated fair value. If the carrying
	value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis,
	an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&rsquo;s goodwill over its implied
	fair value should such a circumstance arise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	At December 31, 2015
	and 2014, the Company used the market approach to determine if the Company had an impairment of its goodwill. Step one of the impairment
	test states that if the fair value of a reporting unit exceeds its carrying amount, goodwill is considered not to be impaired.
	The fair value of the Company&rsquo;s reporting unit was substantially higher than the carrying value, resulting in no impairment
	to goodwill at December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Equity Method Investment
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;The Company has
	an equity investment in CPL Biologicals Private Limited (&ldquo;CPLB&rdquo;). The Company accounts for this investment using the
	equity method (see Note 8). Under the equity method of accounting, investments are stated at initial cost and are adjusted for
	subsequent additional investments and the Company&rsquo;s proportionate share of earnings or losses and distributions up to the
	amount initially invested or advanced.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company performs
	research and development for U.S. Government agencies and other collaborators under cost reimbursable and fixed price contracts,
	including license, grant and clinical development agreements. The Company recognizes revenue under research contracts when a contract
	has been executed, the contract price is fixed or determinable, delivery of services or products has occurred and collection of
	the contract price is reasonably assured. Payments received in advance of work performed are recorded as deferred revenue and losses
	on contracts, if any, are recognized in the period in which they become known.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under cost reimbursable
	contracts with U.S. Government agencies, the Company is reimbursed and recognizes revenue as allowable costs are incurred plus
	a portion of the fixed-fee earned. The Company considers fixed-fees under cost reimbursable contracts to be earned in proportion
	to the allowable costs incurred in performance of the work as compared to total estimated contract costs, with such costs incurred
	representing a reasonable measurement of the proportional performance of the work completed. Under its HHS BARDA contract, certain
	activities must be pre-approved by HHS BARDA in order for their costs to be deemed allowable direct costs. Direct costs incurred
	under cost reimbursable contracts are recorded as research and development expenses. The Company&rsquo;s HHS BARDA contract provides
	the U.S. government the ability to terminate the contract for convenience or to terminate for default if the Company fails to meet
	its obligations as set forth in the statement of work. The Company believes that if the government were to terminate the HHS BARDA
	contract for convenience, the costs incurred through the effective date of such termination and any settlement costs resulting
	from such termination would be allowable costs. Payments to the Company under cost reimbursable contracts with agencies of the
	U.S. Government, such as the HHS BARDA contract, are provisional payments subject to adjustment upon annual audit by the government.
	An audit of fiscal years 2013 and 2014 has been initiated, but has not been completed as of the date of this filing. Management
	believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit
	and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted
	accordingly in the period that the adjustments are known and collection is probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under its grant agreement
	with BMGF, the Company is reimbursed for certain costs that support development activities, including the Company&rsquo;s global
	Phase 3 clinical trial in pregnant women in their third trimester, product licensing efforts and WHO prequalification of the RSV
	F Vaccine. Payments received under the grant agreement are recognized as revenue in the period in which such research and development
	activities are performed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	collaborative research and development agreements may include an upfront payment, payments for research and development services,
	milestone payments and royalties. Agreements with multiple deliverables are evaluated to determine if the deliverables can be divided
	into more than one unit of accounting. A deliverable can generally be considered a separate unit of accounting if both of the following
	criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis; and (2) if the arrangement includes
	a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable
	and substantially in control of the Company. Deliverables that cannot be divided into separate units are combined and treated as
	one unit of accounting. Consideration received is allocated among the separate units of accounting based on the relative selling
	price method. Deliverables under these arrangements typically include rights to intellectual property, research and development
	services and involvement by the parties in steering committees. Historically, deliverables under the Company&rsquo;s collaborative
	research and development agreements have been deemed to have no stand-alone value and as a result have been treated as a single
	unit of accounting. In addition, the Company analyzes its contracts and collaborative agreements to determine whether the payments
	received should be recorded as revenue or as a reduction to research and development expenses. In reaching this determination,
	management considers a number of factors, including whether the Company is principal under the arrangement, and whether the arrangement
	is significant to, and part of, the Company&rsquo;s core operations. Historically, payments received under its contracts and collaborative
	agreements have been recognized as revenue since the Company acts as a principal in the arrangement and the activities are core
	to its operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	When the performance
	under a fixed price contract can be reasonably estimated, revenue for fixed price contracts is recognized under the proportional
	performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated
	contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the
	work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses.
	If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line
	basis over the contract term.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenue associated
	with upfront payments under arrangements is recognized over the contract term or when all obligations associated with the upfront
	payment have been satisfied.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenue from the achievement
	of research and development milestones, if deemed substantive, is recognized as revenue when the milestones are achieved and the
	milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue upon
	its achievement on a straight-line basis over the remaining expected term of the research and development period. Milestones are
	considered substantive if all of the following conditions are met: (1) the milestone is non-refundable; (2) there is substantive
	uncertainty of achievement of the milestone at the inception of the arrangement; (3) substantive effort is involved to achieve
	the milestone and such achievement relates to past performance; and (4) the amount of the milestone appears reasonable in relation
	to the effort expended and all of the deliverables and payment terms in the arrangement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company accounts
	for stock-based compensation related to grants of stock options, restricted stock awards and purchases under its Employee Stock
	Purchase Plan (the &ldquo;ESPP&rdquo;) at fair value. The Company recognizes compensation expense related to such awards on a straight-line
	basis over the requisite service period (generally the vesting period) of the equity awards that are expected to vest, which typically
	occurs ratably over periods ranging from six months to four years. See Note 12&nbsp;for a further discussion on stock-based compensation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The expected term of
	stock options granted was based on the Company&rsquo;s historical option exercise experience and post-vesting forfeiture experience
	using the historical expected term from the vesting date, whereas the expected term for purchases under the ESPP was based on the
	purchase periods included in the offering. The expected volatility was determined using historical volatilities based on stock
	prices over a look-back period corresponding to the expected term. The risk-free interest rate was determined using the yield available
	for zero-coupon U.S. government issues with a remaining term equal to the expected term. The forfeiture rate was determined using
	historical pre-vesting forfeiture rates since the inception of the plans. The Company has never paid a dividend, and as such, the
	dividend yield is zero, and the Company does not intend to pay dividends in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Restricted stock awards
	have been recorded as compensation expense over the expected vesting period based on the fair value at the award date and the number
	of shares ultimately expected to vest using the straight-line method of amortization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 78 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company accounts
	for share-based awards issued to non-employees by determining the fair value of equity awards given as consideration for services
	rendered to be recognized as compensation expense over the shorter of the vesting or service periods. In cases where an equity
	award is not fully vested, such equity award is revalued on each subsequent reporting date until vesting is complete with a cumulative
	catch-up adjustment recognized for any changes in its estimated fair value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Research and Development
	Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Research and development
	expenses include salaries, laboratory supplies, consultants and subcontractors and other expenses associated with the Company&rsquo;s
	process development, manufacturing, clinical, regulatory and quality assurance activities for its programs. In addition, indirect
	costs such as, fringe benefits and overhead expenses, are also included in research and development expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Income Taxes
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company accounts
	for income taxes in accordance with ASC Topic 740,
<I>
	Income Taxes
</I>
	. Under the liability method, deferred income taxes are recognized
	for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
	and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured
	using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be
	recovered or settled. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in income in the
	period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount
	expected to be realized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Tax benefits associated
	with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1)&nbsp;the more
	likely than not recognition threshold is satisfied; (2)&nbsp;the position is ultimately settled through negotiation or litigation;
	or (3)&nbsp;the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits
	associated with an uncertain tax position are reversed in the period in which the more likely than not recognition threshold is
	no longer satisfied.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Interest and penalties
	related to income tax matters are recorded as income tax expense. At December 31, 2015 and 2014, the Company had no accruals for
	interest or penalties related to income tax matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Net Loss per Share
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Net loss per share
	is computed using the weighted average number of shares of common stock outstanding. All outstanding stock options and unvested
	restricted stock awards totaling 23,832,545, 16,978,098 and 11,992,918 shares at December 31, 2015, 2014 and 2013, respectively,
	are excluded from the computation for 2015, 2014 and 2013, as their effect is anti-dilutive.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Foreign Currency
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The accompanying consolidated
	financial statements are presented in U.S. dollars. The functional currency of Novavax AB, which is located in Sweden, is the local
	currency (Swedish Krona). The translation of assets and liabilities of Novavax AB to U.S. dollars is made at the exchange rate
	in effect at the consolidated balance sheet date, while equity accounts are translated at historical rates. The translation of
	the statement of operations data is made at the average exchange rate in effect for the period. The translation of operating cash
	flow data is made at the average exchange rate in effect for the period, and investing and financing cash flow data is translated
	at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component
	of accumulated other comprehensive loss in the accompanying consolidated balance sheets. The foreign currency translation adjustment
	balance included in accumulated other comprehensive loss was $9.1 million and $6.5 million at December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Segment Information
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company manages
	its business as one operating segment: developing recombinant vaccines. The Company does not operate separate lines of business
	with respect to its vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC
	Topic 280,
<I>
	Segment Reporting
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Recent Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
<U>
	Recently Adopted
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In November 2015, the
	Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU 2015-17,
<I>
	Balance Sheet Classification of Deferred Taxes
</I>
	(&ldquo;ASU 2015-07&rdquo;). ASU 2015-17 simplifies the presentation of deferred income taxes and requires that deferred tax
	assets and liabilities, as well as any related valuation allowance, be classified as noncurrent in a classified statement of financial
	position. The Company adopted ASU 2015-17 during the fourth quarter of 2015 and applied it retrospectively to all periods presented,
	which had no impact to the prior period amounts. For additional information, please see Note 14, Income Taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
<U>
	Not Yet Adopted
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In May 2014, the FASB
	issued ASU 2014-09,
<I>
	Revenue from Contracts with Customers (Topic 606)
</I>
	(&ldquo;ASU 2014-09&rdquo;), which supersedes nearly
	all existing revenue recognition guidance under Topic 605,
<I>
	Revenue Recognition
</I>
	. The new standard requires a company to recognize
	revenue when it transfers goods and services to customers in an amount that reflects the consideration that the company expects
	to receive for those goods or services. ASU 2014-09 defines a five-step process that includes identifying the contract with the
	customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction
	price to the performance obligations in the contract and recognizing revenue when (or as) the entity satisfies the performance
	obligations. In July&nbsp;2015, the FASB approved a one-year deferral of the effective date of the new standard to 2018 for public
	companies, with an option that would permit companies to adopt the new standard as early as the original effective date of 2017.
	Early adoption prior to the original effective date is not permitted. The Company is evaluating the potential impact that ASU 2014-09
	will have on its consolidated financial position and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In April 2015, the
	FASB issued ASU No. 2015-03,
<I>
	Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
	Costs
</I>
	(&ldquo;ASU 2015-03&rdquo;). The new standard requires that debt issuance costs related to a recognized debt liability
	be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts.
	This ASU is effective for the Company beginning January 1, 2016. The adoption of ASU 2015-03 will not have a material effect of
	the Company&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Reclassifications
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Cost of government
	contracts revenue of $15.0 million and 8.2 million for 2014 and 2013, respectively, have been reclassified to research and development
	expenses. This reclassification has been made to conform to the current year presentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 4 &ndash; Acquisition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On July 31, 2013 (the
	&ldquo;Acquisition Date&rdquo;), Novavax acquired 99.5% of all of the outstanding shares, warrants and stock options of Isconova
	AB through the issuance of approximately 15.6 million shares of its Common Stock valued at $41.9 million (based on the closing
	price of Novavax&rsquo; Common Stock on the Acquisition Date) and cash of approximately $22,000. Upon the acquisition, Isconova
	AB was renamed Novavax AB. During the second quarter of 2014, the Company completed its purchase of the remaining 0.5% shares outstanding
	from the holders of such securities of Novavax AB. This transaction has been accounted for using the purchase method of accounting,
	with Novavax as the acquirer. The results of Novavax AB&rsquo;s operations have been included in the consolidated financial statements
	since the Acquisition Date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	A
	substantial portion of the assets acquired consisted of intangible assets relating to its proprietary adjuvant technology and collaboration
	agreements. The fair values of the proprietary technology and agreements were determined based on estimates of expected future
	discounted net cash flows. The fair value measurements are based on significant unobservable inputs that were developed by the
	Company using publicly available information, market participant assumptions, cost and development assumptions, expected synergies
	and other cost savings that a market participant would be expected to realize as a result of the combination and certain other
	high-level assumptions. Amortization expense for intangible assets is being recorded on a straight-line basis over the expected
	useful lives of the assets, ranging from seven to 20 years. The weighted average useful lives for the proprietary adjuvant technology
	and collaboration agreements are 20 years and 12 years, respectively. The weighted average useful life for all acquired intangible
	assets is 17 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Novavax AB entered
	into a license and collaboration agreement and received research funding prior to the acquisition that is required to be repaid
	upon notice in the first quarter of 2016. At December 31, 2015, such research funding liability is $1.5 million and is included
	in other current liabilities in the consolidated balance sheet, which was paid in February 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 5 &ndash; Fair Value Measurements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table
	represents the Company&rsquo;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring
	basis:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fair
	Value at December 31, 2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fair
	Value at December 31, 2014
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Assets
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	1
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	2
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	3
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	1
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	2
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	3
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Money market funds
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14,950
</P>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8213;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	20,354
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Government-backed security
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	20,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	7,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Asset-backed securities(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28,924
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	46,624
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Corporate debt
	securities(2)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	137,213
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	89,097
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total
	cash equivalents and marketable securities
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	14,950
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	186,137
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; TEXT-UNDERLINE-STYLE: DOUBLE">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	20,354
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	143,221
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; TEXT-UNDERLINE-STYLE: DOUBLE">
	&#8213;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes $8,185 classified as cash and cash equivalents (See Note 3).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes $20,404 classified as cash and cash equivalents (See Note 3).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During the years ended
	December 31, 2015 and 2014, the Company did not have any transfers between levels.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The amounts in the
	Company&rsquo;s consolidated balance sheet for accounts receivable &ndash; billed, accounts receivable &ndash; unbilled and accounts
	payable approximate fair value due to their short-term nature. Based on borrowing rates available to the Company, the fair value
	of capital lease and notes payable approximates their carrying value. The Company&rsquo;s milestone payment due to Wyeth (See Note
	15) approximates its fair value at December 31, 2015, as the liability has been calculated based on an anticipated future payment
	date discounted at borrowing rates available to the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 6 &ndash; Marketable Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Marketable securities
	classified as available-for-sale as of December 31, 2015 and 2014 were comprised of (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="14" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<P STYLE="MARGIN: 0PT 0">
<B>
	December 31,
	2015
</B>
</P>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="14" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	December 31, 2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Amortized
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Cost
</B>
</P>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Gross
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Unrealized
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Gains
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Gross
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Unrealized
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Losses
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Fair Value
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Amortized
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Cost
</B>
</P>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Gross
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Unrealized
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Gains
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Gross
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Unrealized
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Losses
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Fair Value
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 12%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Asset-backed securities
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	20,748
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(9
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20,739
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46,660
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(36
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46,624
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Corporate debt securities
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	116,821
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	29
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(41
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	116,809
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	89,126
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(37
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	89,097
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	137,569
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	29
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(50
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	137,548
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	135,786
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(73
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	135,721
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 81 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2014, the Company
	sold its remaining auction rate security and received proceeds of $1.8 million resulting in a realized gain of $0.6 million, all
	of which resulted from reclassification adjustments out of accumulated other comprehensive income (loss) in 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Marketable Securities
	&ndash; Unrealized Losses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company owned 47
	available-for-sale securities as of December 31, 2015. Of these 47 securities, 35 had combined unrealized losses of less than $0.1
	million as of December 31, 2015. The Company did not have any investments in a loss position for greater than 12 months as of December
	31, 2015. The Company has evaluated its marketable securities and has determined that none of these investments has an other-than-temporary
	impairment, as it has no intent to sell securities with unrealized losses and it is not more likely than not that the Company will
	be required to sell any securities with unrealized losses, given the Company&rsquo;s current and anticipated financial position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Note 7 &ndash; Goodwill and Intangible
	Assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Goodwill
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The changes in the carrying
	amounts of goodwill for the years ended December 31, 2015 and 2014 were as follows (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING: 0 0 1PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 10.1PT 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Year Ended
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 10.1PT 0PT 0; TEXT-ALIGN: CENTER">
<B>
	December 31,
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 66%; PADDING-LEFT: 0.125IN; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Beginning balance
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	54,612
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	58,707
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Currency translation
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1,547
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4,095
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ending balance
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	53,065
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	54,612
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Intangible
	Assets
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Purchased intangible assets
	consisted of the following as of December 31, 2015 and 2014 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Gross
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Carrying
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Amount
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Accumulated
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Amortization
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Intangible
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Assets,
	Net
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Gross
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Carrying
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Amount
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Accumulated
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Amortization
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Intangible
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Assets,
	Net
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Finite-lived intangible assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: LEFT">
	Proprietary adjuvant technology
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	8,858
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(1,070
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	7,788
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	9,565
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(678
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	8,887
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Collaboration agreements
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,999
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(994
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,005
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,319
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(629
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,690
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total identifiable intangible assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,857
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,064
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,793
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,884
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,307
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,577
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Amortization expense
	for the years ended December 2015, 2014 and 2013 was $0.9 million, $1.1 million and $0.5 million, respectively. Estimated amortization
	expense for existing intangible assets for each of the five succeeding years ending December 31, is as follows (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: 0">
	Year
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 89%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	854
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	2017
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	854
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	2018
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	854
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	2019
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	854
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	2020
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	730
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 8 &ndash; U.S. Government Agreement,
	Joint Venture and Collaborations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	HHS BARDA Contract for
	Recombinant Influenza Vaccines
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	HHS BARDA initially
	awarded the Company a contract in 2011, which funds the development of both the Company&rsquo;s quadrivalent seasonal and pandemic
	influenza virus-like particle (&ldquo;VLP&rdquo;) vaccine candidates. The contract with HHS BARDA is a cost-plus-fixed-fee contract,
	which reimburses the Company for allowable direct contract costs incurred plus allowable indirect costs and a fixed-fee earned
	in the ongoing clinical development and product scale-up of its multivalent seasonal and monovalent pandemic H7N9 influenza VLP
	vaccine candidates. In September 2014, HHS BARDA exercised and initiated a two-year option to the contract, which included scope
	to support development activities leading up to planned Phase 3 clinical studies, added $70 million of funding on top of the remainder
	of the $97 million base period funding, and extended the contract until September 2016. In June 2015, the contract was amended
	to increase the funding by $7.7 million to allow for the recovery of additional costs under the contract relating to the settlement
	of indirect rates for fiscal years 2011 and 2012. This additional amount was received and recorded as revenue in the three months
	ended June 30, 2015. During 2015, the Company recognized revenue of $33.3 million, and has recognized approximately $112 million
	in revenue since the inception of the contract. Billings under the contract are based on approved provisional indirect billing
	rates, which permit recovery of fringe benefits, overhead and general and administrative expenses. These indirect rates are subject
	to audit by HHS BARDA on an annual basis. An audit of fiscal years 2013 and 2014 has been initiated, but has not been completed
	as of the date of this filing. Management believes that revenue for periods not yet audited has been recorded in amounts that are
	expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been
	made, revenue and billings may be adjusted accordingly in the period that the adjustments are known and collection is probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2012, HHS BARDA
	withheld payment on the outside costs of the Company&rsquo;s Phase 2 clinical trial of its seasonal quadrivalent influenza VLP
	vaccine candidate in Australia (&ldquo;205 Trial&rdquo;). Such outside costs were recorded as expenses in the period incurred and
	the Company did not record revenue relating to such outside costs prior to the first quarter of 2015 because collection of the
	amount was not reasonably assured. In late 2014, the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research
	(&ldquo;FDA&rdquo;) accepted the data from the 205 Trial as part of the Company&rsquo;s investigational new drug (&ldquo;IND&rdquo;)
	application for its seasonal quadrivalent influenza VLP vaccine candidate. In the first quarter of 2015, HHS BARDA approved the
	reimbursement of the 205 Trial costs, and the Company recorded revenue of $3.1 million as collection of the amount became reasonably
	assured during the period. The Company also collected this amount in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	CPLB Joint Venture
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2009, the Company
	formed a joint venture with Cadila Pharmaceuticals Limited (&ldquo;Cadila&rdquo;) named CPL Biologicals Private Limited (&ldquo;CPLB&rdquo;)
	to develop and manufacture vaccines, biological therapeutics and diagnostics in India. CPLB is owned 20% by the Company and 80%
	by Cadila. The Company accounts for its investment in CPLB using the equity method. Because CPLB&rsquo;s activities and operations
	are controlled and funded by Cadila, the Company accounts for its investment using the equity method. Since the carrying value
	of the Company&rsquo;s initial investment was nominal and there is no guarantee or commitment to provide future funding, the Company
	has not recorded nor expects to record losses related to this investment in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	LG Life Sciences, Ltd.
	(&ldquo;LGLS&rdquo;) License Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2011, the Company
	entered into a license agreement with LGLS that allows LGLS to use the Company&rsquo;s technology to develop and commercially sell
	influenza vaccines exclusively in South Korea and non-exclusively in certain other specified countries. At its own cost, LGLS is
	responsible for funding both its clinical development of the influenza VLP vaccines and a manufacturing facility to produce such
	vaccines in South Korea. Under the license agreement, the Company is obligated to provide LGLS with information and materials related
	to the manufacture of the licensed products, provide on-going project management and regulatory support and conduct clinical trials
	of its influenza vaccines in order to obtain FDA approval in the U.S. The term of the license agreement is expected to terminate
	in 2027. Payments to the Company under the license agreement include an upfront payment of $2.5 million, reimbursements of certain
	development and product costs, payments related to the achievement of certain milestones and royalty payments in the high single
	digits from LGLS&rsquo;s future commercial sales of influenza VLP vaccines. The upfront payment has been deferred and recorded
	in deferred revenue in the consolidated balance sheets and will be recognized when the previously mentioned obligations in the
	agreement are satisfied, which may not occur until the end of the term of the agreement. Payments for milestones under the agreement
	will be recognized on a straight-line basis over the remaining term of the research and development period upon achievement of
	such milestone. Any royalties under the agreement will be recognized as earned.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Bill &amp; Melinda Gates
	Foundation Grant Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In support of the Company&rsquo;s
	development of its respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (&ldquo;RSV F Vaccine&rdquo;)
	for infants via maternal immunization, in September 2015, the Company entered into an agreement (&ldquo;Grant Agreement&rdquo;)
	with BMGF, under which it was awarded a grant totaling up to $89.1 million (the &ldquo;Grant&rdquo;). The Grant will support development
	activities, including the Company&rsquo;s global Phase 3 clinical trial in pregnant women in their third trimester, product licensing
	efforts and WHO prequalification of the RSV F Vaccine. The Company concurrently entered into a Global Access Commitments Agreement
	(&ldquo;GACA&rdquo;) with BMGF as a part of the Grant Agreement. Under the terms of the GACA, among other things, the Company agreed
	to make the RSV F Vaccine available and accessible at affordable pricing to people in certain low and middle income countries.
	Unless earlier terminated by BMGF, the GACA will continue in effect until the latter of 15 years from its effective date, or 10
	years after the first sale of a product under defined circumstances. The term of the GACA may be extended in certain circumstances,
	by a period of up to five additional years. Payments received under the Grant Agreement are being recognized in the period in which
	the research and development activities are performed. Payments received in advance that are related to future performance are
	deferred and recognized as revenue when the research and development activities are performed. Cash payments received under the
	Grant are restricted as to their use until expenditures contemplated in the Grant are incurred. The Company recognized revenue
	from the Grant of $1.6 million in 2015. At December 31, 2015, the Company&rsquo;s current restricted cash and deferred revenue
	balances on the consolidated balance sheet represent its estimate of costs to be reimbursed and incurred, respectively, in 2016
	under the Grant Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	PATH Vaccine Solutions
	Clinical Development Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2012, the Company
	entered into a clinical development agreement with PATH to develop its RSV F Vaccine for infants via maternal immunization in certain
	low-resource countries. Under the terms of the PATH agreement, which expired in April 2015, the Company was awarded $6.8 million
	by PATH to partially support Phase 2 clinical trials in women of childbearing age, reproductive toxicology studies and the development
	of a Phase 3 clinical trial strategy. The Company recognized revenue of $0.5 million in 2015 and has recognized $6.8 million in
	revenue since the inception of the agreement. Revenue under this arrangement was being recognized under the proportional performance
	method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract
	costs. Costs incurred under this agreement represented a reasonable measurement of proportional performance of the services being
	performed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 9 &ndash; Other Financial Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Prepaid Expenses
	and Other Current Assets
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Prepaid expenses and other
	current assets consist of the following at December 31 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Laboratory supplies
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	12,968
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,564
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Other prepaid expenses and other current assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,349
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,631
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,317
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,195
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Property and
	Equipment, net
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Property and equipment
	is comprised of the following at December 31 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Machinery and equipment
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	26,461
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	16,712
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Leasehold improvements
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	12,440
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,843
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Computer software and hardware
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,091
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,733
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 1.75PT">
	Construction in progress
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,167
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,719
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	48,159
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	31,007
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 1.75PT">
	Less &#8213; accumulated depreciation and amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(15,817
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(11,270
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 1.75PT">
	Property and equipment, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	32,342
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,737
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Depreciation and amortization
	expense was approximately $6.0 million, $4.4 million and $2.6 million for the years ended December 31, 2015, 2014 and 2013, respectively.
	Machinery and equipment included $0.4 million of equipment acquired under a capital lease with accumulated depreciation of $0.3
	million and $0.2 million as of December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
<B>
<I>
	Accrued Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Accrued expenses consist
	of the following at December 31 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Employee benefits and compensation
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	11,255
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,597
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Research and development accruals
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,814
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,826
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Other accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,665
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	974
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	26,734
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	19,397
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.75PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 10 &ndash; Long-Term Debt
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	Notes Payable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Notes payable consist
	of the following at December 31 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 74%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Equipment loan; 12.1%, principal payments due in monthly installments totaling $48 through December 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	395
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	967
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Bank loans; repaid in 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	31
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	395
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	998
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Less &#8213; current portion
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(395
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(603
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Long-term portion
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	395
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 85 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Equipment Loan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September 2012,
	the Company entered into a master security agreement with General Electric Capital Corporation (&ldquo;GE&rdquo;), whereby the
	Company could borrow up to $2.0 million to finance the purchases of equipment (each, an &ldquo;Equipment Loan&rdquo;). Each Equipment
	Loan bears interest at the three-year U.S. Government treasury rate plus 11.68%, provided that the rate shall not be less than
	12.1%, and is to be repaid over forty-two (42) months. GE will maintain a security interest in all equipment financed under the
	Equipment Loan. Interest accrues on the outstanding balance until paid in full. As of December 31, 2013, the Company financed $2.0
	million in total under the Equipment Loans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Aggregate future minimum
	principal payments on long-term debt at December 31, 2015 are as follows (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	Year
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Total minimum principal payments
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Note 11 &ndash; Stockholders&rsquo; Equity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On June 18, 2015, the
	Company&rsquo;s stockholders of record as of April 20, 2015 approved the amendment to the Company&rsquo;s Amended and Restated
	Certificate of Incorporation (the &ldquo;Charter Amendment&rdquo;) to increase the total number of shares of common stock that
	the Company is authorized to issue from 300,000,000 shares to 600,000,000 shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In March 2015, the
	Company completed a public offering of 27,758,620 shares of its common stock, including 3,620,689 shares of common stock that were
	issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $7.25 per
	share resulting in proceeds, net of offering costs of $11.6 million, of approximately $190 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In June 2014, the Company
	completed a public offering of 28,750,000 shares of its common stock, including 3,750,000 shares of common stock that were issued
	upon the exercise in full of an option to purchase additional shares granted to the underwriters, at a price of $4.00 per share
	resulting in net proceeds of approximately $108 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In September 2013,
	the Company completed a public offering of 31,846,950 shares of its common stock, including 4,153,950 shares of common stock that
	were issued upon the exercise in full of the over-allotment granted to the underwriters, at a price of $3.14 per share resulting
	in net proceeds of approximately $95 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	I
<FONT STYLE="FONT-SIZE: 10PT">
	n
	2012, the Company entered into an At Market Issuance Sales Agreement (&ldquo;Sales Agreement&rdquo;), under which Company sold
	an aggregate of $50 million in gross proceeds of its common stock. During 2013, the Company sold 12.6 million shares at sales prices
	ranging from $2.06 to $3.38 per share, resulting in $34.0 million in net proceeds. During 2015, the Company sold 1.4 million shares
	at an average sales price of $10.63 per share, resulting in $14.6 million in net proceeds. The Sales Agreement was fully utilized
	at that time.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Note 12 &ndash; Stock-Based Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Stock Options
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Amended and Restated
	2005 Stock Incentive Plan (&ldquo;2005 Plan&rdquo;) expired in February 2015 and no new awards may be made under such plan, although
	awards will continue to be outstanding in accordance with their terms. The Board adopted the 2015 Stock Incentive Plan (&ldquo;2015
	Plan&rdquo;) in March 2015 and, consistent with historical practice, granted annual and new equity awards prior to the Company&rsquo;s
	annual meeting of stockholders in June 2015 under the 2015 Plan; however, these awards were contingent upon stockholder approval
	of both the 2015 Plan and the Company&rsquo;s Charter Amendment (See Note 11), both of which were approved at the Company&rsquo;s
	annual meeting of stockholders in June 2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees
	and consultants of and advisors to the Company and any present or future subsidiary. The 2015 Plan authorizes the issuance of up
	to 25,000,000 shares of common stock under equity awards granted under the plan. All such shares authorized for issuance under
	the 2015 Plan have been reserved. The 2015 Plan will expire on March 4, 2025.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The 2015 Plan permits
	and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, stock appreciation
	rights, and restricted stock units. In addition, under the 2015 Plan, unrestricted stock, stock units and performance awards may
	be granted. Stock options and stock appreciation rights generally have a maximum term of 10 years and may be or were granted with
	an exercise price that is no less than 100% of the fair market value of the Company&rsquo;s common stock at the time of grant.
	Grants of stock options are generally subject to vesting over periods ranging from six months to four years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	Stock Options Awards
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The following is a summary
	of option activity under the 2015 Plan, 2005 Plan and the 1995 Stock Option Plan (&ldquo;1995 Plan&rdquo;) for the year ended December
	31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 5PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2015
	Plan
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	2005 Plan&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	1995 Plan
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING: 0 0 1PT 5PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Stock
	Options
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Weighted-Average
	Exercise Price
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Stock
	Options
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Weighted-Average
	Exercise Price
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Stock
	Options
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Weighted-Average
	Exercise Price
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 34%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5PT; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding
	at January 1, 2015
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16,928,098
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.24
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	35,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.21
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5PT; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8,5
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	02,941
</FONT>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	8.97
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	22,500
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	6.70
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5PT; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Exercised
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(1,286,556
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	2.36
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(35,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	2.21
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT 5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Canceled
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(145,938
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	9.03
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(213,500
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3.79
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT 5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Outstanding
	at
<BR>
	December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	8,357,003
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	8.97
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	15,450,542
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3.31
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT 5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Vested
	and expected to vest at
<BR>
	December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	6,812,836
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	8.97
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	14,948,571
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3.25
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT 5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Shares
	exercisable at
<BR>
	December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	280,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	8.97
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	8,423,167
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	2.56
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT 5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Shares
	available for grant at
<BR>
	December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	16,642,997
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As discussed in the
	&ldquo;Stock Options&rdquo; section above, prior to the Company&rsquo;s annual meeting of stockholders in June 2015, the Company
	granted 7,014,441 stock options with a weighted-average exercise price of $8.94 under the 2015 Plan. Since the 2015 Plan and the
	Charter Amendment were approved at the Company&rsquo;s annual meeting of stockholders in June 2015, the Company began to record
	stock-based compensation expense for these awards at that time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The fair value of stock
	options granted under the 2015 Plan and 2005 Plan was estimated at the date of grant or the date upon which the 2015 Plan was approved
	by the Company&rsquo;s stockholders for stock options granted prior to that time using the Black-Scholes option-pricing model with
	the following assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Weighted average fair value of options granted
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	$4.38
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	$2.39
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	$1.07
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Risk-free interest rate
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.19%-2.13%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.24%-2.22%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.54%-1.36%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 49%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Dividend yield
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Volatility
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	53.58%-68.39%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	52.47%-67.93%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	51.55%-73.72%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Expected term (in years)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.98-7.34
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.04-6.96
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.91-7.05
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 1.75PT">
	Expected forfeiture rate
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0%-16.33%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0%-23.15%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0%-23.15%
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The total aggregate
	intrinsic value and weighted-average remaining contractual term of stock options exercisable under the 2015 Plan and 2005 Plan
	as of December 31, 2015 was approximately $49 million and 6.3 years, respectively. The total aggregate intrinsic value and weighted-average
	remaining contractual term of stock options vested and expected to vest under the 2015 Plan and 2005 Plan as of December 31, 2015
	was approximately $77 million and 7.6 years, respectively. The aggregate intrinsic value represents the total intrinsic value (the
	difference between the Company&rsquo;s closing stock price on the last trading day of the period and the exercise price, multiplied
	by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their
	options on December 31, 2015. This amount is subject to change based on changes to the closing price of the Company&rsquo;s common
	stock. The aggregate intrinsic value of options exercised and vesting of restricted stock awards for 2015, 2014 and 2013 was $9.7
	million, $3.4 million and $0.6 million, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
<B>
<I>
	Employee
	Stock Purchase Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2013, the Company
	adopted an Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo;), which authorized an aggregate of 2,000,000 shares of common stock
	to be purchased, which will increase 5% on each anniversary of its adoption up to a maximum of 3,000,000 shares. The ESPP allows
	employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum
	of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price
	on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible
	to participate). At December 31, 2015, there were 1,090,010 shares available for issuance under the ESPP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The ESPP is considered
	compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using
	the Black-Scholes option-pricing model with the following assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; PADDING: 0">
	Range of Black-Scholes fair values of ESPP shares granted
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
	$1.06-$3.38
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
	$
<FONT STYLE="FONT-SIZE: 10PT">
	0.78-$2.08
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
	$0.78
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0.05%-0.35
</FONT>
	%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0.04%-0.24%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	0.04%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0">
	Dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	40.79%-64.24
</FONT>
	%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	50.80%-67.57%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	50.80%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0">
	Expected term (in years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0.5-2.0
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0.5-1.5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0">
	Expected forfeiture rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	5%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	5%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	5%
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	Restricted Stock
	Awards
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following is a
	summary of restricted stock awards activity for the year ended December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 1.95PT 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Number of Shares
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Per Share Weighted-Average Grant-Date Fair Value
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 74%; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Outstanding and Unvested at January 1, 2015
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.48
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Restricted stock granted
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8.72
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Restricted stock vested
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(15,000
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.48
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Restricted stock forfeited
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Outstanding and Unvested at December 31, 2015
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8.72
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company recorded
	stock-based compensation expense for awards issued under the above mentioned plans in the statements of operations as follows (in
	thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,771
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,843
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,262
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	General and administrative
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,660
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,247
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,218
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Total stock-based compensation expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,431
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,090
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,480
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of December 31,
	2015, there was approximately $33.5 million of total unrecognized compensation expense (net of estimated forfeitures) related to
	unvested stock options, ESPP and restricted stock awards. This unrecognized non-cash compensation expense is expected to be recognized
	over a weighted-average period of 1.3 years, and will be allocated between research and development and general and administrative
	expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future
	periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 13 &ndash; Employee Benefits
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company maintains
	a defined contribution 401(k) retirement plan, pursuant to which employees who have completed 90 days of service may elect to contribute
	up to 100% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986,
	as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company matches
	50% of the first 6% of the participants&rsquo; deferral. Contributions to the 401(k) plan vest equally over a three-year period.
	The Company has recorded expense, net of forfeitures, of approximately $0.8 million, $0.5 million and $0.4 million in 2015, 2014
	and 2013, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	foreign subsidiary has a pension plan under local tax and labor laws and is obligated to make contributions to this plan. Contributions
	and other expenses related to this plan were approximately $0.5 million, $0.4 million and $0.2 million in 2015, 2014 and 2013,
	respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 14 &ndash; Income Taxes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	loss from operations before income tax expense by jurisdiction are as follows (in thousands):
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Domestic
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(150,227
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(76,742
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(48,691
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	Foreign
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(6,710
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(6,205
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(3,292
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(156,937
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(82,947
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(51,983
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The components of the
	income tax provision are as follows (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Current U.S.
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Current foreign
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Deferred
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net provision
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Deferred tax assets
	(liabilities) consist of the following at December 31 (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net operating losses U.S.
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	203,284
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	148,451
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net operating losses foreign
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,360
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,535
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Research tax credits
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	16,491
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	11,068
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Other
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	12,903
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,963
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Total deferred tax assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	241,038
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	176,017
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Intangibles
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,415
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,773
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Other
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(1,767
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(321
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Total deferred tax liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(4,182
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3,094
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net deferred tax assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	236,856
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	172,923
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Less valuation allowance
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(236,856
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(172,923
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 2.5PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Deferred tax assets, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The valuation allowance
	increased by $63.9 million, $30.4 million and $7.1 million for the years ended December 31, 2015, 2014 and 2013, respectively,
	due to increases in net deferred tax assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 89 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The differences between
	the U.S. federal statutory tax rate and the Company&rsquo;s effective tax rate are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Statutory federal tax rate
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(34
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(34
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(34
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	State income taxes, net of federal benefit
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Research and development and other tax credits
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(7
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Expiration of net operating losses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Release of FIN 48 liability
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Other
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0 0 1PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Change in valuation allowance
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING: 0 0 2.5PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Realization of net
	deferred tax assets is dependent on the Company&rsquo;s ability to generate future taxable income, which is uncertain. Accordingly,
	a full valuation allowance was recorded against these assets as of December 31, 2015 and 2014 as management believes it is more
	likely than not that the assets will not be realizable. The increase in the valuation allowance was due to increased continued
	losses and credits in the current year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of December 31,
	2015, the Company had tax return reported federal net operating losses and tax credits available as follows (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Federal net operating losses expiring through the year 2035
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	551,433
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Foreign net operating losses (no expiration)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	38,001
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Research tax credits expiring through the year 2035
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	16,397
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-TOP: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Alternative-minimum tax credit (no expiration)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	94
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Utilization of the
	net operating loss carryforwards and credits may be subject to an annual limitation due to prior ownership change of the Company.
	The Company does not expect such limitation, if any, to impact the use of the net operating losses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Beginning in 2006,
	the windfall equity-based compensation deductions are tracked, but will not be recorded to the balance sheet until management determines
	more likely than not that such amounts will be utilized. As of December 31, 2015 and 2014, the Company had $13.9 million and $5.0
	million of windfall stock compensation deductions, respectively. When realized, the tax benefit associated with these deductions
	will be credited to additional paid-in capital. These excess benefit deductions are included in the total federal and state net
	operating losses disclosed above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Tabular Reconciliation of Unrecognized Tax
	Benefits (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Unrecognized tax benefits as of January 1, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,801
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Gross increases &mdash; tax positions in prior period
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Gross decreases &mdash; tax positions in prior period
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#8213;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Gross increases &mdash; current-period tax positions
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Increases (decreases) from settlements
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Unrecognized tax benefits as of December 31, 2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,801
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Gross increases &mdash; tax positions in prior period
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Gross decreases &mdash; tax positions in prior period
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,587
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Gross increases &mdash; current-period tax positions
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Increases (decreases) from settlements
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Unrecognized tax benefits as of December 31, 2015
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	214
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 90 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	To the extent these
	unrecognized tax benefits are ultimately recognized, it would affect the annual effective income tax rate unless otherwise offset
	by a corresponding change in the valuation allowance. The Company does not expect that the amounts of unrecognized tax benefits
	will change significantly within the next twelve months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company files income
	tax returns in the U.S. federal jurisdiction and in various states, as well as in Sweden. The Company had tax net operating losses
	and credit carryforwards that are subject to examination from 1998 through 2015. The statute extends for a number of years beyond
	the year in which the losses were generated for tax purposes. Since a portion of these carryforwards may be utilized in the future,
	many of these attribute carryforwards remain subject to examination. The returns in Sweden are subject to examination from 2010
	through 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2015 and
	2014, the Company had no accruals for interest or penalties related to income tax matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 15 &ndash; Commitments and Contingencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Operating Leases
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company conducts
	its operations from leased facilities, under operating leases with terms expiring from 2017 to 2026, unless terminated early at
	the Company&rsquo;s discretion in 2023. The leases contain provisions for future rent increases and periods in which rent payments
	are reduced (abated). Also, the leases obligate the Company to pay building operating costs. Under the terms of one lease agreement,
	the landlord provided the Company with a tenant improvement allowance of $3.9 million (the &ldquo;Improvement Allowance&rdquo;).
	The Company has been funded $1.4 million in 2015 under the Improvement Allowance. The Company records a deferred rent liability
	to account for the funding under the Improvement Allowance and to record rent expense on a straight-line basis for these operating
	leases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Future minimum rental
	commitments under non-cancelable leases as of December 31, 2015 are as follows (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Operating Leases
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 87%; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,159
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2017
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,923
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2018
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,718
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2019
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,741
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2020
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,687
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Thereafter
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15,471
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total minimum lease payments
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	40,699
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Total rent expenses
	approximated $4.2 million, $3.6 million and $3.4 million for the years ended December 31, 2015, 2014 and 2013, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Purchase Obligations
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company and Cadila
	entered into a master services agreement pursuant to which the Company may request services from Cadila in the areas of biologics
	research, preclinical development, clinical development, process development, manufacturing scale-up and general manufacturing
	related services in India. Under the terms of the agreement, the Company was obligated to purchase $7.5 million of such services,
	which included services provided, since the beginning of 2013, by CPLB to the Company on behalf of Cadila pursuant to an October
	2013 amendment authorizing such CPLB services as provided by Cadila. The Company fulfilled its financial obligation under the agreement
	in the fourth quarter of 2015 and has no further financial obligations under the agreement or any other agreements related to CPLB.
	During 2015, the Company purchased $2.2 million in services from Cadila pursuant to this agreement, all of which were provided
	by CPLB on behalf of Cadila. The Company has recognized as an expense the entire amount of purchases to date related to CPLB as
	the Company has not recorded any equity income (loss) of CPLB (see Note 8).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
<I>
	Contingencies
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2007, the Company
	entered into an agreement to license certain rights from Wyeth Holdings Corporation, a subsidiary of Pfizer Inc. (&ldquo;Wyeth&rdquo;).
	The Wyeth license is a non-exclusive, worldwide license to a family of patents and patent applications covering VLP technology
	for use in human vaccines in certain fields, with expected patent expiration in early 2022. The Wyeth license provides for the
	Company to make an upfront payment (previously made), ongoing annual license fees, sublicense payments, milestone payments on certain
	development and commercialization activities and royalties on any product sales. Except in certain circumstances in which the Company
	continuously markets multiple products in a country within the same vaccine program, the milestone payments are one-time only payments
	applicable to each related vaccine program. At present, the Company&rsquo;s seasonal influenza VLP vaccine program (including CPLB&rsquo;s
	seasonal influenza program) and its pandemic influenza VLP vaccine program are the only two programs to which the Wyeth license
	applies. The license may be terminated by Wyeth only for cause and may be terminated by the Company only after it has provided
	ninety (90) days&rsquo; notice that the Company has absolutely and finally ceased activity, including through any affiliate or
	sublicense, related to the manufacturing, development, marketing or sale of products covered by the license. In September 2015,
	the Company entered into an amendment to the license agreement with Wyeth. Among other things, the amendment restructured the $3
	million milestone payment (&ldquo;Milestone&rdquo;) owed as a result of CPLB&rsquo;s initiation of a Phase 3 clinical trial for
	its recombinant trivalent seasonal VLP influenza vaccine candidate in 2014. Under the amendment, the milestone payment, which may
	increase slightly over time, would be due in connection with the initiation of a Phase 3 clinical trial for the initial seasonal
	influenza VLP vaccine candidate being developed outside India, but in any case no later than December 31, 2017. The amendment also
	restructured the final milestone payment to apply to the initial seasonal influenza VLP vaccine candidate being developed outside
	India. Thus, the aggregate milestone payments for a seasonal influenza VLP vaccine candidate developed and commercialized was increased
	from $14 million to up to $15 million. In connection with the execution of the amendment, the Company agreed to pay a one-time
	only payment to Wyeth. The amendment also increased annual license maintenance fees associated with VLP vaccine candidates from
	$0.2 million to $0.3 million per year. Payments under the agreement to Wyeth as of December 31, 2015 aggregated $7.3&nbsp;million.
	The Milestone was accrued for on the consolidated balance sheet in other current liabilities at December 31, 2014. As a result
	of the September 2015 amendment discussed above, the Milestone payment is not expected to occur within the next 12 months. Therefore,
	the Milestone has been accrued for, on a discounted basis calculated based on the probable future payment date, in other non-current
	liabilities at December 31, 2015. The milestone was recorded as a research and development expense in the third quarter of 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 16 &ndash; Related Party Transactions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dr.&nbsp;Rajiv Modi,
	a director of Novavax, is also the managing director of Cadila. The Company and Cadila have formed the CPLB joint venture (see
	Note 8). The Company and Cadila also have entered into a master services agreement, pursuant to which Cadila may perform certain
	research, development and manufacturing services for the Company up to $7.5&nbsp;million. A subsidiary of Cadila owns 2.5 million
	shares of the Company&rsquo;s outstanding common stock as of December 31, 2015. Since entering into the master services agreement
	and through December 31, 2015, the Company has incurred $7.9 million under the agreement (see Note 15). The amount due and unpaid
	for services performed under the master services agreement at both December 31, 2015 and 2014 was $0.7 million and $0.4 million,
	respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Note 17 &ndash; Convertible Senior Notes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In 2016, the Company
	issued
<FONT STYLE="BACKGROUND-COLOR: WHITE">
</FONT>
	$325 million
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;aggregate principal
	amount of convertible senior unsecured notes that will mature on&nbsp;
</FONT>
	February 1, 2023
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;(the
	&ldquo;Notes&rdquo;).&nbsp;The Notes will bear cash interest at a rate of 3.75%, payable on&nbsp;
</FONT>
	February 1
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;and&nbsp;
</FONT>
	August
	1
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;of each year, beginning on&nbsp;
</FONT>
	August 1, 2016
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	.
	The Notes are not redeemable prior to maturity and are convertible into shares of&nbsp;
</FONT>
	Novavax
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;common
	stock. The initial conversion rate for the Notes is 146.8213 shares of Novavax&rsquo; common stock per&nbsp;
</FONT>
	$1,000
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;principal
	amount of the Notes, which is equivalent to an initial conversion price of approximately&nbsp;
</FONT>
	$6.81
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;per
	share of Novavax&rsquo; common stock, representing an approximately 22.5% conversion premium based on the last reported sale price
	of Novavax&rsquo; common stock of&nbsp;
</FONT>
	$5.56
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;per share on&nbsp;
</FONT>
	January
	25, 2016
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	the issuance of the Notes,&nbsp;the Company&nbsp;also paid approximately $38 million to enter into privately negotiated capped
	call transactions with certain financial institutions (the &ldquo;capped call transactions&rdquo;). The capped call transactions
	are expected generally to reduce the potential dilution upon conversion of the Notes in the event that the market price per share
	of the Company&rsquo;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price
	of the capped call transactions, which initially corresponds to the conversion price of the Notes, and is subject to anti-dilution
	adjustments generally similar to those applicable to the conversion rate of the Notes. The cap price of the capped call transactions
	will initially be&nbsp;$9.73&nbsp;per share, which represents&nbsp;a premium of approximately 75% based on the last reported sale
	price of the Company&rsquo;s common stock of&nbsp;$5.56&nbsp;per share on&nbsp;January 25, 2016, and is subject to certain adjustments
	under the terms of the capped call transactions. If, however, the market price per share of the Company&rsquo;s common stock, as
	measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless
	be dilution upon conversion of the Notes to the extent that such market price exceeds the cap price of the capped call transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 92 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 18 &ndash; Quarterly Financial
	Information (Unaudited)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company&rsquo;s
	unaudited quarterly information for the years ended December 31, 2015 and 2014 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Quarter Ended
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	March 31
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	June 30
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	(in thousands, except per share data)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	2015:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9,877
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	13,996
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,525
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,853
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(24,370
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(20,641
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(33,120
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(78,806
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net loss per share
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.08
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.12
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.29
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Quarter Ended
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	March 31
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	June 30
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	(in thousands, except per share data)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	2014:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,462
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,259
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,214
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,724
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(13,810
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(17,864
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(19,727
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(31,546
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0; PADDING-RIGHT: 0; TEXT-INDENT: 0">
	Net loss per share
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.07
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.08
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.08
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The net loss per share
	was calculated for each three-month period on a stand-alone basis. As a result, the sum of the net loss per share for the four
	quarters may not equal the net loss per share for the respective twelve-month period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage94"></A>
<A NAME="V431853_EX10-10_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.10
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/29/0001144204-16-084770_IMAGE_001.JPG" ALT="" STYLE="HEIGHT: 70PX; WIDTH: 318PX">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	THIS AGREEMENT is entered into as of December ___, 2015 by and
	between Novavax, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and [&#9679;] (the &ldquo;Director&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	W I T N E S S E T H:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	WHEREAS, Director serves as a Director of the Company and will
	earn remuneration (&ldquo;Director&rsquo;s Fees&rdquo;) from the Company in that capacity; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	WHEREAS, Director and the Company desire to enter into an agreement
	to provide for the deferral of Director&rsquo;s Fees in a manner consistent with the requirements of Section 409A of the Internal
	Revenue Code;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	NOW, THEREFORE, it is agreed as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	1.&#9;Director irrevocably elects to defer
	receipt, subject to the provisions of this Agreement, of (select one)
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	___
</B>
</FONT>
	50%
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	___
</B>
</FONT>
	100%
	of any and all Director&rsquo;s Fees earned for services performed after the date of this Agreement. Such election shall continue
	in effect with respect to any Director&rsquo;s Fees earned in calendar years subsequent to 2015 unless, prior to January 1 of the
	year in question, Director shall have delivered to the Secretary of the Company a written revocation of such election with respect
	to any Director&rsquo;s Fees to be earned in connection with services in such year. Director&rsquo;s Fees with respect to which
	Director shall have elected to defer receipt and shall not have revoked such election are hereinafter referred to as &ldquo;Deferred
	Fees.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	2.&#9;The Company shall credit the amount
	of Deferred Fees to a book reserve account (the &ldquo;Deferred Fee Account&rdquo;) as of the date such fees would have been paid
	(i.e., as of the 15
<SUP>
	th
</SUP>
	day of the month following the end of each calendar quarter) to Director had this Agreement not
	been in effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	3.&#9;The value of the Deferred Fee Account
	as of any date shall be equal to the value such account would have had as of such date if the amounts credited thereto had been
	invested and reinvested as provided in the attached Investment Election Agreement, as may be amended from time to time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	4.&#9;The Company&rsquo;s obligation to
	make payments from the Deferred Fee Account shall be a general obligation of the Company, and such payments shall be made from
	the Company&rsquo;s general assets and property. Director&rsquo;s relationship to the Company under this Agreement shall be only
	that of a general unsecured creditor, and this Agreement shall not, in and of itself, create or be construed to create a trust
	or fiduciary relationship of any kind between the Company and Director or any other person, or a security interest of any kind
	in any property of the Company in favor of Director or any other person. The Company shall not be required to purchase, hold or
	dispose of any investments pursuant to this Agreement. If, in order to cover its obligations hereunder, the Company elects to purchase
	any investments, the same shall continue for all purposes to be a part of the general assets and property of the Company, subject
	to the claims of its general creditors, and no person other than the Company shall, by virtue of the provisions of this Agreement,
	have any interest in such assets other than an interest as a general creditor. The Company shall provide an annual statement to
	the Director showing such information as is appropriate, including the aggregate amount credited to the Deferred Fee Account, as
	of a reasonably current date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	5.&#9;Deferred Fees, including all earnings
	and losses credited or charged with respect thereto, shall be paid in or upon the earliest to occur of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD>
	Director&rsquo;s &ldquo;separation from service&rdquo; as that term is defined in Section 1.409A-1(h) of the Treasury Regulations
	from the Company, whether such separation from service should occur through retirement, resignation or termination of Director
	as a member of the Board of Directors of the Company or otherwise;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD>
	the death of Director;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD>
	the merger of the Company into another entity or its consolidation with one or more other entities, or the voluntary sale,
	conveyance or transfer of all or substantially all of the assets of the Company, provided such merger, consolidation, sale, conveyance
	or transfer of assets is an event constituting a change in ownership or effective control of the Company, or a change in the ownership
	of a substantial portion of the assets of the Company, as defined in section 1.409A-3(i)(5) of the Treasury Regulations; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(d)
</TD>
<TD>
	any designated year between 2016 and 2025, as indicated below:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	____________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PT">
</TD>
<TD STYLE="WIDTH: 0PT">
</TD>
<TD>
	If no year is designated in (d) above, the Deferred Fees will be paid upon the earliest to occur of the events described in
	(a) through (c) above.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Director hereby elects to have all Deferred Fees paid in the
	following form (select one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
<TD>
	in a lump sum; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
<TD>
	in _________ annual installments (not to exceed 10).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If Director has selected a lump sum payment, such payment shall
	be made in January of the year following the calendar year of a payment event described (a), (b) or (c) above or in January of
	the year designated in (d) above, if any. If distribution of the Deferred Fee Account is to be made in installments, annual installment
	payments shall commence in January of the year following the calendar year of a payment event described (a), (b) or (c) above or
	in January of the year designated in (d) above, if any. The amount of each installment shall be: (i) in the case of each installment
	payment other than the final installment payment, the &ldquo;Scheduled Annual Distribution&rdquo; as hereinafter defined, and (ii)
	in the case of the final installment payment, the entire remaining balance of the Deferred Fee Account. As used herein, the &ldquo;Scheduled
	Annual Distribution&rdquo; shall mean the quotient determined by dividing (x) the balance of the Deferred Fee Account as of the
	end of the calendar year immediately preceding the date of the distribution by (y) the total number of installments remaining to
	be paid to Director. Until complete payment of amounts credited to the Deferred Fee Account, the unpaid balance of such Deferred
	Fee Account shall be adjusted to reflect earnings and losses in accordance with paragraph 3 above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Director&rsquo;s election made pursuant to this paragraph
	5 regarding whether payments shall be made in a lump sum or in a specified number of annual installments may be changed at any
	time by Director provided such change (i) does not take effect until at least twelve months after the date on which the election
	is made, (ii) is made on or before the date that is one year prior to January 1 of the year designated in 5(d) above, if any, and
	(iii) except with respect to payments as a result of death, defers for a period of not less than five years the payment of a lump
	sum or the commencement of installment payments, as selected by Director, from the date a lump sum payment would otherwise have
	been made or installment payments would otherwise have commenced. Any such change must be made by written notice thereof from Director
	to the Secretary of the Company, which change shall become irrevocable only on the last day upon which such change could otherwise
	be made in accordance with this paragraph, unless an earlier effective date is otherwise specified by Director in the Director&rsquo;s
	notice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	6.&#9;Payments of the balance credited to
	the Deferred Fee Account shall be made in the form of a check or by wire transfer. Such payments shall be made to Director except
	that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD>
	in the event that Director shall be determined by a court of competent jurisdiction to be incapable of managing Director&rsquo;s
	financial affairs, and if the Company has actual notice of such determination, payment shall be made to Director&rsquo;s personal
	representative; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD>
	in the event of Director&rsquo;s death, payment shall be made to the last beneficiary designated by Director for purposes of
	receiving such payment in such event in a written notice delivered to the Secretary of the Company; provided that if such beneficiary
	has not survived Director, payment shall instead be made to the last designated secondary beneficiary, or if none, to Director&rsquo;s
	estate.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company shall deduct from the payment of the Deferred Fee
	Account any amounts required for federal and/or state tax withholding purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	7.&#9;The balance credited to the Deferred
	Fee Account shall not in any way be subject to the debts or other obligations of Director and may not be sold, transferred, pledged
	or assigned by Director except as provided in paragraph 6(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	8.&#9;This Agreement shall not be construed
	to confer any right on the part of Director to be or remain a Director of the Company or to receive any, or any particular rate
	of, Director&rsquo;s Fees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	9.&#9;Interpretations of, and determinations
	related to, this Agreement, including any determinations of the amounts credited to the Deferred Fee Account, shall be made by
	the Board of Directors of the Company and, if made in good faith, shall be conclusive and binding upon all parties; and the Company
	shall not incur any liability to Director for any such interpretation or determination so made or for any other action taken by
	it in connection with this Agreement in good faith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	10.&#9;This Agreement contains the entire
	understanding and agreement between the parties with respect to the subject matter hereof, and may not be amended, modified or
	supplemented in any respect except by subsequent written agreement entered into by both parties. The obligations of the Company
	to make, and the rights of Director to receive, payments hereunder shall not be represented by any form of certificate or instrument.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	11.&#9;This Agreement shall be binding upon,
	and shall inure to the benefit of, the Company and its successors and assigns and Director and Director&rsquo;s heirs, executors,
	administrators and personal representatives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	12.&#9;This Agreement is being entered into
	in, and shall be construed in accordance with the laws of, the State of Maryland.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	13.&#9;This Agreement is intended to comply
	with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and shall be construed accordingly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	IN WITNESS WHEREOF, the Company has caused this Agreement to
	be executed on its behalf by its duly authorized officer, and Director has executed this Agreement, on the date first written above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	NOVAVAX, INC.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 4%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 36%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	By:&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0">
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	John A. Herrmann III
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	SVP, General Counsel &amp; Corporate Secretary
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	DESIGNATION OF BENEFICIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dated as of ____________, 2015
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	To the Secretary of Novavax, Inc. (the &ldquo;Company&rdquo;)
	with respect to the Deferred Fee Agreement dated as of _____________, 2015 between the Undersigned and the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dear Secretary of Novavax, Inc.:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In accordance with the provisions of the above-referenced Deferred
	Fee Agreement, I hereby designate __________________
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
	1
</SUP>
</FONT>
	as my beneficiary to receive payments thereunder in the event of my death before payments in full thereunder have been made. In
	the event that the said beneficiary predeceases me, I hereby designate in his or her stead, ____________________ as my beneficiary
	thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	Yours truly,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	_________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 20%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 12PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
	1
</SUP>
</FONT>
</TD>
<TD>
	If more than one beneficiary is to be designated, add a page listing the beneficiaries and specify the percentage of each payment
	to be received by each beneficiary.
<I>
	If any beneficiary is a minor or otherwise under a legal disability, the Company may make
	all or any part of a distribution payable to such a beneficiary to (i) the parent of the beneficiary; (ii) the guardian, conservator,
	or other legal representative, wherever appointed, of the beneficiary; (iii) a custodial account established under a Uniform Gifts
	to Minors Act, Uniform Transfers to Minors Act, or similar act; (iv) any person having control or custody of the beneficiary; or
	(v) to the beneficiary directly.
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	INVESTMENT ELECTION AGREEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	THIS INVESTMENT ELECTION AGREEMENT, dated as of ____________,
	2015, is entered into by and between Novavax, Inc. (the &ldquo;Company&rdquo;), a Delaware corporation, and the undersigned Director
	of the Company (the &ldquo;Director&rdquo;). This Investment Election Agreement is intended to comply with the requirements of
	Section 409A of the Internal Revenue Code of 1986, as amended, and shall be construed accordingly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company and the Director have entered into, effective
	as of the first day of the:
<BR>
	1
<SUP>
	st&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SUP>
	&#9;2
<SUP>
	nd &nbsp;&nbsp;&nbsp;&nbsp;
</SUP>
	&#9;3
<SUP>
	rd&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
</SUP>
	4
<SUP>
	th
</SUP>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;(circle
	one) calendar quarter of 2016, a Deferred Fee Agreement pursuant to which the Company and Director have agreed that the value
	of the Deferred Fee Account (as defined in the Deferred Fee Agreement) attributable to Director shall be equal to the value
	such account would have had if amounts credited thereto had been invested and reinvested in the investments specified below
	in this Investment Election Agreement, as may be amended or superseded from time to time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Until altered by further written agreement, the Company and
	the undersigned Director hereby agree that from the effective date hereof Director&rsquo;s Deferred Fee Account shall be valued
	as if such Deferred Fee Account had been invested as follows (select one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 60PT">
	100% in the Company&rsquo;s common stock, $.01 par value (&ldquo;Stock&rdquo;), which shall be
	deemed to be acquired, together with notional rights to the value of all dividends and other distributions with respect to such
	Stock, at the closing price for such Stock on the date the Director&rsquo;s Fees are credited to the Deferred Fee Account in accordance
	with Section 2 of the Deferred Fee Agreement.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 60PT">
	100% in Interest compounded quarterly at the start of each calendar quarter at the IRS Applicable
	Federal Rate (AFR) for short-term debt instruments for the last month of such calendar quarter.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 60PT">
	50% in Stock, as described above, and 50% in the AFR account.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 60PT 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 60PT 0PT 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	IN WITNESS WHEREOF, the Company has caused this Agreement to
	be executed on its behalf by its duly authorized officer, and Director has executed this Agreement, as of the date first written
	above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	NOVAVAX, INC.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 4%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 36%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	By:&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0">
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	John A. Herrmann III
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	SVP, General Counsel &amp; Corporate Secretary
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage101"></A>
<A NAME="V431853_EX10-51_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit
	10.51
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/02/29/0001144204-16-084770_IMAGE_002.JPG" ALT="" STYLE="HEIGHT: 31PX; WIDTH: 152PX">
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	JPMorgan Chase Bank, National Association
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	London Branch
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	25 Bank Street
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Canary Wharf
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	London E14 5JP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	England
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 4.5IN">
	February 2, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 4.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 4.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	To:
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Novavax, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	20 Firstfield Road
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Gaithersburg, Maryland 20878
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; WIDTH: 5%">
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; WIDTH: 10%">
	Attention:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; WIDTH: 85%">
	Chief Financial Officer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Telephone No.:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	(240) 268-2030
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Facsimile No.:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	(240) 268-2100
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Re:
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Additional Call Option Transaction
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 4.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The purpose of this
	letter agreement (this &ldquo;
<B>
	Confirmation
</B>
	&rdquo;) is to confirm the terms and conditions of the call option transaction
	entered into between JPMorgan Chase Bank, National Association, London Branch (&ldquo;
<B>
	Dealer
</B>
	&rdquo;) and Novavax, Inc.
<B>
</B>
	(&ldquo;
<B>
	Counterparty
</B>
	&rdquo;) as of the Trade Date specified below (the &ldquo;
<B>
	Transaction
</B>
	&rdquo;). This letter
	agreement constitutes a &ldquo;Confirmation&rdquo; as referred to in the ISDA Master Agreement specified below. This Confirmation
	shall replace any previous agreements and serve as the final documentation for the Transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The definitions and
	provisions contained in the 2002 ISDA Equity Derivatives Definitions (the &ldquo;
<B>
	Equity Definitions
</B>
	&rdquo;), as published
	by the International Swaps and Derivatives Association, Inc. (&ldquo;
<B>
	ISDA
</B>
	&rdquo;) are incorporated into this Confirmation.
	In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain
	defined terms used herein are based on terms that are defined in the Offering Memorandum dated January 25, 2016 (the &ldquo;
<B>
	Offering
	Memorandum
</B>
	&rdquo;) relating to the Convertible Senior Notes due 2023 (as originally issued by Counterparty, the &ldquo;
<B>
	Convertible
	Notes
</B>
	&rdquo; and each USD 1,000 principal amount of Convertible Notes, a &ldquo;
<B>
	Convertible Note
</B>
	&rdquo;) issued by Counterparty
	in an aggregate initial principal amount of USD 300,000,000 (as increased by an aggregate principal amount of USD 25,000,000 pursuant
	to the exercise by the Initial Purchasers (as defined herein) of their option to purchase additional Convertible Notes pursuant
	to the Purchase Agreement (as defined herein)) pursuant to an Indenture dated January 29, 2016 between Counterparty and The Bank
	of New York Mellon Trust Company, N.A., as trustee (the &ldquo;
<B>
	Indenture
</B>
	&rdquo;). In the event of any inconsistency between
	the terms defined in the Offering Memorandum, the Indenture and this Confirmation, this Confirmation shall govern. The parties
	acknowledge that this Confirmation is entered into on the date hereof with the understanding that (i) definitions set forth in
	the Indenture that are also defined herein by reference to the Indenture and (ii) sections of the Indenture that are referred to
	herein will conform to the descriptions thereof in the Offering Memorandum. If any such definitions in the Indenture or any such
	sections of the Indenture differ from the descriptions thereof in the Offering Memorandum, the descriptions thereof in the Offering
	Memorandum will govern for purposes of this Confirmation. The parties further acknowledge that the Indenture section numbers used
	herein are based on the Indenture as executed. Subject to the foregoing, references to the Indenture herein are references to the
	Indenture as in effect on the date of its execution, and if the Indenture is amended or supplemented following such date (other
	than any amendment or supplement (x) pursuant to Section 10.01(h) of the Indenture that, as determined by the Calculation Agent,
	conforms the Indenture to the description of Convertible Notes in the Offering Memorandum or (y) pursuant to Section 14.07 of the
	Indenture, subject, in the case of this clause (y), to the second paragraph under &ldquo;Method of Adjustment&rdquo; in Section
	3), any such amendment or supplement will be disregarded for purposes of this Confirmation unless the parties agree otherwise in
	writing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	JPMorgan Chase Bank, National Association
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Organised under the laws of the United States
	as a National Banking Association.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Main Office 1111 Polaris Parkway, Columbus,
	Ohio 43240
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Registered as a branch in England &amp;
	Wales branch No. BR000746
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Registered Branch Office 25 Bank Street,
	Canary Wharf, London E14 5JP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Authorised by the Office of the Comptroller
	of the Currency in the jurisdiction of the USA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Authorised by the Prudential Regulation
	Authority. Subject to regulation by the Financial Conduct
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Authority and to limited regulation by the
	Prudential Regulation Authority. Details about the
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	extent of our regulation by the Prudential
	Regulation Authority are available from us on request.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Each party is hereby
	advised, and each such party acknowledges, that the other party has engaged in, or refrained from engaging in, substantial financial
	transactions and has taken other material actions in reliance upon the parties&rsquo; entry into the Transaction to which this
	Confirmation relates on the terms and conditions set forth below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	This Confirmation evidences a complete and binding agreement between Dealer and Counterparty as to the terms of the Transaction
	to which this Confirmation relates. This Confirmation shall supplement, form a part of, and be subject to an agreement in the form
	of the 2002 ISDA Master Agreement (the &ldquo;
<B>
	Agreement
</B>
	&rdquo;) as if Dealer and Counterparty had executed an agreement
	in such form (but without any Schedule except for (i) the election of US Dollars (&ldquo;USD&rdquo;) as the Termination Currency,
	(ii) the election of the laws of the State of New York as the governing law (without reference to choice of law doctrine), (iii)
	the election that the &ldquo;Cross Default&rdquo; provisions of Section 5(a)(vi) of the Agreement shall apply to Dealer with a
	&ldquo;Threshold Amount&rdquo; of 3% of Dealer&rsquo;s shareholders&rsquo; equity (
<I>
	provided
</I>
	that (a) the phrase &ldquo;,
	or becoming capable at such time of being declared,&rdquo; shall be deleted from clause (1) of such Section 5(a)(vi) of the Agreement,
	(b) &ldquo;Specified Indebtedness&rdquo; shall have the meaning specified in Section 14 of the Agreement, except that such term
	shall not include obligations in respect of deposits received in the ordinary course of Dealer&rsquo;s banking business and (c)
	the following sentence shall be added to the end of Section 5(a)(vi) of the Agreement: &ldquo;Notwithstanding the foregoing, a
	default under subsection (2) hereof shall not constitute an Event of Default if (x) the default was caused solely by error or omission
	of an administrative or operational nature; (y) funds were available to enable the relevant party to make the payment when due;
	and (z) the payment is made within two Local Business Days of such party&rsquo;s receipt of written notice of its failure to pay.&rdquo;)
	on the Trade Date. In the event of any inconsistency between provisions of the Agreement and this Confirmation, this Confirmation
	will prevail for the purpose of the Transaction to which this Confirmation relates. The parties hereby agree that no transaction
	other than the Transaction to which this Confirmation relates shall be governed by the Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; FONT-SIZE: 10PT">
	2.
</TD>
<TD STYLE="WIDTH: 82%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; FONT-SIZE: 10PT">
	The terms of the particular Transaction to which this Confirmation relates are as follows:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<I>
<U>
</U>
</I>
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<I>
<U>
	General Terms
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Trade Date:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	February 2, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Effective Date:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Trade Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Option Style:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&ldquo;Modified American&rdquo;, as described under &ldquo;Procedures for Exercise&rdquo; below
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Option Type:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Call
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Buyer:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Counterparty
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Seller:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Dealer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Shares:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	The common stock of Counterparty, par value USD 0.01 per share&nbsp;&nbsp;(Exchange symbol &ldquo;NVAX&rdquo;).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Number of Options:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	25,000.&nbsp;&nbsp;For the avoidance of doubt, the Number of Options shall be reduced by any Options exercised by Counterparty.&nbsp;&nbsp;In no event will the Number of Options be less than zero.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Applicable Percentage:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	60%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Option Entitlement:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	A number equal to the product of the Applicable Percentage and 146.8213
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Strike Price:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	USD 6.8110
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Cap Price:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	USD 9.7300
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Premium:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	USD 1,734,000
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Premium Payment Date:
</TD>
<TD STYLE="WIDTH: 50%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	February 5, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Exchange:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	The NASDAQ Global Select Market
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Related Exchange(s):
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	All Exchanges
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Excluded Provisions:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Section 14.04(g) and Section 14.03 of the Indenture.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<I>
<U>
</U>
</I>
</TD>
<TD STYLE="WIDTH: 82%; PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<I>
<U>
	Procedures for Exercise
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Conversion Date:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	With respect to any conversion of a Convertible Note (other than any conversion of Convertible Notes with a Conversion Date occurring prior to the Cut-Off Date (any such conversion, an &ldquo;
<B>
	Early Conversion
</B>
	&rdquo;), to which the provisions of Section 9(i)(i) of this Confirmation shall apply), the date on which the &ldquo;Holder&rdquo; (as such term is defined in the Indenture) of such Convertible Note satisfies all of the requirements for conversion thereof as set forth in Section 14.02(b) of the Indenture.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Cut-Off Date:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The 45th &ldquo;Scheduled Trading Day&rdquo; (as defined in the Indenture) immediately preceding the &ldquo;Maturity Date&rdquo; (as defined in the Indenture).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Expiration Time:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Valuation Time
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Expiration Date:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	February 1, 2023, subject to earlier exercise.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Multiple Exercise:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable, as described under &ldquo;Automatic Exercise&rdquo; below.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Automatic Exercise:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding Section 3.4 of the Equity Definitions, on each Conversion Date occurring on or after the Cut-Off Date in respect of which a &ldquo;Notice of Conversion&rdquo; (as defined in the Indenture) that is effective as to Counterparty has been delivered by the relevant converting &ldquo;Holder&rdquo; (as such term is defined in the Indenture), a number of Options equal to (i) the number of Convertible Notes in denominations of USD 1,000 as to which such Conversion Date has occurred
<I>
	minus
</I>
	(ii) the number of Options that are or are deemed to be automatically exercised on such Conversion Date under the Base Call Option Transaction Confirmation letter agreement dated January 25, 2016 between Dealer and Counterparty (the &ldquo;
<B>
	Base Call Option Confirmation
</B>
	&rdquo;), shall be deemed to be automatically exercised;
<I>
	provided
</I>
	that such Options shall be exercised or deemed exercised only if Counterparty has provided a Notice of Exercise to Dealer in accordance with &ldquo;Notice of Exercise&rdquo; below.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding the foregoing, in no event shall the number of Options that are exercised or deemed exercised hereunder exceed the Number of Options.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notice of Exercise:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding anything to the contrary in the Equity Definitions or under &ldquo;Automatic Exercise&rdquo; above, in order to exercise any Options relating to Convertible Notes with a Conversion Date occurring on or after the Cut-Off Date, Counterparty must notify Dealer in writing before 5:00 p.m. (New York City time) on the second Scheduled Valid Day immediately preceding the Expiration Date of the number of such Options being exercised.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Valuation Time:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	At the close of trading of the regular trading session on the Exchange.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Market Disruption Event:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Section 6.3(a) of the Equity Definitions is hereby replaced in its entirety by the following:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&ldquo;&lsquo;Market Disruption Event&rsquo; means, in respect of a Share, (i) a failure by the principal United States national or regional securities exchange or market on which the Shares are listed for trading to open for trading or (ii) the occurrence or existence for more than one half-hour period in the aggregate on any Scheduled Valid Day of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Shares or in any options contracts or futures contracts relating to the Shares, and such suspension or limitation occurs or exists at any time before 1:00 p.m. (New York City time) on such Scheduled Valid Day.&rdquo;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-DECORATION: NONE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
</TD>
<TD STYLE="WIDTH: 82%; PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<I>
<U>
	Settlement Terms
</U>
</I>
	.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Settlement Method:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Net Share Settlement.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Net Share Settlement:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Dealer will deliver to Counterparty, on the relevant Settlement Date, a number of Shares equal to the Net Shares in respect of any Option exercised or deemed exercised hereunder.&nbsp;&nbsp;In no event will the Net Shares be less than zero.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Net Shares:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In respect of any Option exercised or deemed exercised, a number of Shares equal to the sum of the quotients, for each Valid Day during the Settlement Averaging Period for such Option, of (i) (A) the Option Entitlement on such Valid Day
<I>
	multiplied by
</I>
	(B) (1) the amount by which the Cap Price exceeds the Strike Price, if the Relevant Price on such Valid Day is equal to or greater than the Cap Price, (2) the amount by which such Relevant Price exceeds the Strike Price, if such Relevant Price is greater than the Strike Price but less than the Cap Price or (3) zero, if such Relevant Price is less than or equal to the Strike Price,
<I>
	divided by
</I>
	(C) such Relevant Price,
<I>
	divided by
</I>
	(ii) the number of Valid Days in the Settlement Averaging Period;
<I>
	provided
</I>
	that in no event shall the Net Shares for any Option exceed a number of Shares equal to the Applicable Limit for such Option
<I>
	divided by
</I>
	the Applicable Limit Price on the Settlement Date for such Option.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Dealer will pay cash in lieu of delivering any fractional Shares to be delivered with respect to any Net Shares valued at the Relevant Price for the last Valid Day of the Settlement Averaging Period.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Applicable Limit:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	For any Option, an amount of cash equal to the Applicable Percentage
<I>
	multiplied by
</I>
	the excess of (i) the number of Shares delivered to the Holder of the related Convertible Note upon conversion of such Convertible Note
<I>
	multiplied by
</I>
	the Applicable Limit Price on the Settlement Date for such Option, over (ii) USD 1,000.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable Limit Price:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On any day, the opening price as displayed under the heading &ldquo;Op&rdquo; on Bloomberg page NVAX &lt;equity&gt; (or any successor thereto).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Valid Day:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	A day on which (i) there is no Market Disruption Event and (ii) the principal U.S. national or regional securities exchange on which the Shares are listed or admitted for trading is open for trading with a Scheduled Closing Time of 4:00 p.m. (New York City time) or the then-standard closing time for regular trading on such exchange, or, if the Shares are not listed on a U.S. national or regional securities exchange, any Business Day.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Scheduled Valid Day:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	A day that is scheduled to be a Valid Day on the principal U.S. national or regional securities exchange on which the Shares are listed or admitted for trading.&nbsp;&nbsp;If the Shares are not so listed or admitted for trading, &ldquo;Scheduled Valid Day&rdquo; means a Business Day.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Business Day:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Any day other than a Saturday, a Sunday or a day on which state or federally chartered banking institutions in New York, New York are not required to be open.&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Relevant Price:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On any Valid Day, the per Share volume-weighted average price as displayed under the heading &ldquo;Bloomberg VWAP&rdquo; on Bloomberg page &ldquo;NVAX Equity AQR&rdquo; (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the Scheduled Closing Time of the Exchange on such Valid Day or, if such volume-weighted average price is unavailable, the market value of one Share on such Valid Day, as determined by the Calculation Agent using, if practicable, a volume-weighted average price method. The Relevant Price will be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Settlement Averaging Period:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	For any Option being exercised hereunder, the 40 consecutive Valid Days commencing on, and including, the 42nd Scheduled Valid Day immediately prior to the Expiration Date.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Settlement Date:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	For any Option, the third Business Day immediately following the final Valid Day of the Settlement Averaging Period for such Option.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Settlement Currency:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	USD
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Other Applicable Provisions:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The provisions of Sections 9.1(c), 9.8, 9.9 and 9.11 of the Equity Definitions will be applicable, except that all references in such provisions to &ldquo;Physically-settled&rdquo; shall be read as references to &ldquo;Net Share Settled&rdquo;.&nbsp;&nbsp;&ldquo;Net Share Settled&rdquo; in relation to any Option means that Net Share Settlement is applicable to that Option.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Representation and Agreement:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	Notwithstanding anything to the contrary in the Equity Definitions (including, but not limited to, Section 9.11 thereof), the parties acknowledge that (i) any Shares delivered to Counterparty may be, upon delivery, subject to restrictions and limitations arising from Counterparty&rsquo;s status as issuer of the Shares under applicable securities laws, (ii) Dealer may deliver any Shares required to be delivered hereunder in certificated form in lieu of delivery through the Clearance System and (iii) any Shares delivered to Counterparty may be &ldquo;restricted securities&rdquo; (as defined in Rule 144 under the Securities Act of 1933, as amended (the &ldquo;
<B>
	Securities Act
</B>
	&rdquo;)).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; FONT-SIZE: 10PT">
<B>
	3.
</B>
</TD>
<TD STYLE="WIDTH: 82%; PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; FONT-SIZE: 10PT">
<B>
<U>
	Additional Terms applicable to the Transaction
</U>
	.
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	Adjustments applicable to the Transaction:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Potential Adjustment Events:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding Section 11.2(e) of the Equity Definitions, a &ldquo;Potential Adjustment Event&rdquo; means an occurrence of any event or condition, as set forth in any Dilution Adjustment Provision, that would result in an adjustment under the Indenture to the &ldquo;Conversion Rate&rdquo; or the composition of a &ldquo;unit of Reference Property&rdquo; or to any &ldquo;Last Reported Sale Price&rdquo; ,&nbsp;&ldquo;Daily VWAP,&rdquo; &ldquo;Daily Conversion Value&rdquo; or &ldquo;Daily Settlement Amount&rdquo; (each as defined in the Indenture).&nbsp;&nbsp;For the avoidance of doubt, Dealer shall not have any delivery or payment obligation hereunder, and no adjustment shall be made to the terms of the Transaction, on account of (x)&nbsp;any distribution of cash, property or securities by Counterparty to &ldquo;Holders&rdquo; (as such term is defined in the Indenture) of the Convertible Notes (upon conversion or otherwise) or (y)&nbsp;any other transaction in which &ldquo;Holders&rdquo; (as such term is defined in the Indenture) of the Convertible Notes are entitled to participate, in each case, in lieu of an adjustment under the Indenture of the type referred to in the immediately preceding sentence (including, without limitation, pursuant to the fourth sentence of the second paragraph of Section 14.04(c) of the Indenture or the fourth sentence of the second paragraph of Section 14.04(d) of the Indenture).
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Method of Adjustment:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Calculation Agent Adjustment, which means that, notwithstanding Section 11.2(c) of the Equity Definitions, upon any Potential Adjustment Event, the Calculation Agent shall make (A) an adjustment corresponding to the adjustment to be made pursuant to the Indenture (or, if no Convertible Notes are outstanding, that would have been made if Convertible Notes were outstanding) to any one or more of the Strike Price, Number of Options, and/or Option Entitlement and (B) proportionate adjustment to the Cap Price to the extent any adjustment is made to the Strike Price pursuant to clause (A) above (which adjustment, for the avoidance of doubt, shall not prohibit Dealer from making any further adjustments to the Cap Price in accordance with, and subject in all respects to, Section 9(x));
<I>
	provided
</I>
	that in no event shall the Strike Price be adjusted to be greater than the Cap Price.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	Notwithstanding the foregoing and &ldquo;Consequences of Merger Events / Tender Offers&rdquo; below, if the Calculation Agent in good faith disagrees with any adjustment to the Convertible Notes that involves an exercise of discretion by Counterparty or its board of directors (including, without limitation, pursuant to Section 14.05 of the Indenture, Section 14.07 of the Indenture or any supplemental indenture entered into thereunder or in connection with any proportional adjustment or the determination of the fair value of any securities, property, rights or other assets), then in each such case, the Calculation Agent will determine (A) an adjustment to be made to any one or more of the Strike Price, Number of Options, and/or Option Entitlement in a commercially reasonable manner and (B) a proportionate adjustment to be made to the Cap Price to the extent any adjustment is made to the Strike Price pursuant to clause (A) above (which adjustment, for the avoidance of doubt, shall not prohibit Dealer from making any further adjustments to the Cap Price in accordance with, and subject in all respects to, Section 9(x));
<I>
	provided
</I>
	that in no event shall the Strike Price be adjusted to be greater than the Cap Price.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	For the avoidance of doubt, whenever the Calculation Agent or Determining Party, as the case may be, is called upon to make an adjustment pursuant to the terms of this Confirmation or the Equity Definitions (other than any adjustment required to be made by reference to the terms of the Convertible Notes or the Indenture) to take into account the effect of an event, the Calculation Agent or Determining Party, as the case may be, shall make such adjustment by reference to the effect of such event on the Hedging Party, assuming that the Hedging Party maintains a commercially reasonable hedge position.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Dilution Adjustment Provisions:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Sections 14.04(a), (b), (c), (d) and (e) and Section 14.05 of the Indenture.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 82%; PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	Extraordinary Events applicable to the Transaction:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Merger Events:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable;
<I>
	provided
</I>
	that notwithstanding Section 12.1(b) of the Equity Definitions, a &ldquo;Merger Event&rdquo; means the occurrence of any event or condition set forth in the definition of &ldquo;Share Exchange Event&rdquo; in Section 14.07 of the Indenture.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Tender Offers:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable;
<I>
	provided
</I>
	that notwithstanding Section 12.1(d) of the Equity Definitions, a &ldquo;Tender Offer&rdquo; means the occurrence of any event or condition set forth in Section 14.04(e) of the Indenture.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_56"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Consequences of Merger Events /
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Tender Offers:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	Notwithstanding Section 12.2 and Section 12.3 of the Equity Definitions, upon the occurrence of a Merger Event or a Tender Offer that is required under the terms of the Indenture to result in an adjustment to the terms of the Convertible Notes, the Calculation Agent shall make (A) a corresponding adjustment to any one or more of the nature of the Shares, Strike Price, Number of Options and Option Entitlement, in each case, to the extent an analogous adjustment would be made pursuant to the Indenture in connection with such Merger Event or Tender Offer, or to the definitions of &ldquo;Exchange&rdquo;, &ldquo;Relevant Price&rdquo;, and &ldquo;Settlement Averaging Period&rdquo; of this Confirmation and any other variable relevant to the exercise, settlement or payment for the Transaction, subject to the second paragraph under &ldquo;Method of Adjustment&rdquo; and (B) a proportionate adjustment to the Cap Price to the extent any adjustment is made to the Strike Price pursuant to clause (A) above (which adjustment, for the avoidance of doubt, shall not prohibit Dealer from making any further adjustments to the Cap Price in accordance with, and subject in all respects to, Section 9(x));
<I>
	provided
</I>
	that in no event shall the Strike Price be adjusted to be greater than the Cap Price;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that such adjustment shall be made without regard to any adjustment to the Conversion Rate pursuant to any Excluded Provision. Notwithstanding the foregoing, if, with respect to a Merger Event or a Tender Offer, (i) the consideration for the Shares includes (or, at the option of a holder of Shares, may include) shares of an entity or person that is not a corporation or is not organized under the laws of the United States, any State thereof or the District of Columbia or (ii) the Counterparty to the Transaction following such Merger Event or Tender Offer will not be a corporation or will not be either (A) the Issuer following such Merger Event or Tender Offer or (B) a wholly owned subsidiary of the Issuer (1) that is a corporation organized under the laws of the United States, any State thereof or the District of Columbia, (2) whose obligations under the Transaction are fully and unconditionally guaranteed by the Issuer and (3) with respect to which the Calculation Agent determines that treating such wholly owned subsidiary as the Counterparty will not have a material adverse effect on Dealer&rsquo;s rights or obligations hereunder, Dealer&rsquo;s hedging activities, or the costs of engaging in any of the foregoing, then, in either case, Cancellation and Payment (Calculation Agent Determination) may apply at Dealer&rsquo;s sole reasonable election;
<I>
	provided
</I>
	that Dealer shall consult with Counterparty prior to declaring an Early Termination Date with respect to the Transaction. For the avoidance of doubt, the foregoing provisions will apply regardless of whether any Merger Event or Tender Offer gives rise to an Early Conversion.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_57"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Consequences of Announcement Events:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	Modified Calculation Agent Adjustment as set forth in Section 12.3(d) of the Equity Definitions;
<I>
	provided
</I>
	that, in respect of an Announcement Event, (v)&nbsp;references to &ldquo;Tender Offer&rdquo; shall be replaced by references to &ldquo;Announcement Event&rdquo; and references to &ldquo;Tender Offer Date&rdquo; shall be replaced by references to &ldquo;date of such Announcement Event&rdquo;, (w)&nbsp;the word &ldquo;shall&rdquo; in the second line shall be replaced with &ldquo;may&rdquo;, (x) the phrase &ldquo;exercise, settlement, payment or any other terms of the Transaction (including, without limitation, the spread)&rdquo; shall be replaced by the phrase &ldquo;Cap Price (
<I>
	provided
</I>
	that in no event shall the Cap Price be less than the Strike Price)&rdquo;, (y) the fifth and sixth lines shall be deleted in their entirety and replaced with the words &ldquo;effect, taken cumulatively on the Option, of such Announcement Event solely to account for changes in volatility, expected dividends, stock loan rate or liquidity relevant to the Shares or such Option&rdquo;, and (z)&nbsp;for the avoidance of doubt, the Calculation Agent may adjust the terms of the Transaction for a single Announcement Event on one or more occasions on or after the date of such Announcement Event up to, and including, the Expiration Date, any Early Termination Date and/or any other date of cancellation, it being understood that any adjustment in respect of an Announcement Event shall take into account any earlier adjustment relating to the same Announcement Event and any adjustment in respect of an Announcement Event hereunder shall be without duplication in respect of any other adjustment or cancellation valuation made pursuant to the Equity Definitions or hereunder. An Announcement Event shall be an &ldquo;Extraordinary Event&rdquo; for purposes of the Equity Definitions, to which Article 12 of the Equity Definitions is applicable.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Announcement Event:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(i) The public announcement by any entity of any transaction or event that, if completed, would constitute a Merger Event or Tender Offer, or (ii) any subsequent public announcement by any entity of a change to a transaction that is the subject of an announcement of the type described in clause (i) of this sentence (including, without limitation, a new announcement, whether or not by the same party, relating to such a transaction or the announcement of a withdrawal from, or the abandonment or discontinuation of, such a transaction), as determined by the Calculation Agent.&nbsp;&nbsp;For the avoidance of doubt, the occurrence of an Announcement Event with respect to any transaction shall not preclude the occurrence of a later Announcement Event with respect to such transaction. For purposes of this definition of &ldquo;Announcement Event,&rdquo; (A) &ldquo;Merger Event&rdquo; shall mean such term as defined under Section 12.1(b) of the Equity Definitions (but, for the avoidance of doubt, the remainder of the definition of &ldquo;Merger Event&rdquo; in Section 12.1(b) of the Equity Definitions following the definition of &ldquo;Reverse Merger&rdquo; therein shall be disregarded) and (B) &ldquo;Tender Offer&rdquo; shall mean such term as defined under Section 12.1(d) of the Equity Definitions.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_58"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Nationalization, Insolvency or Delisting:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	Cancellation and Payment (Calculation Agent Determination);
<I>
	provided
</I>
	that, in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it will also constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors); if the Shares are immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors), such exchange or quotation system shall thereafter be deemed to be the Exchange.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_59"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 92%; PADDING: 0; TEXT-INDENT: 0">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additional Disruption Events:&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 40%">
	Change in Law:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 50%">
	Applicable;
<I>
	provided
</I>
	that Section 12.9(a)(ii) of the Equity Definitions is hereby amended by (i)&nbsp;replacing the word &ldquo;Shares&rdquo; with the phrase &ldquo;Hedge Positions&rdquo; in clause (X) thereof; (ii)&nbsp;inserting the parenthetical &ldquo;(including, for the avoidance of doubt and without limitation, adoption or promulgation of new regulations authorized or mandated by existing statute)&rdquo; at the end of clause (A) thereof; (iii) replacing the phrase &ldquo;the interpretation&rdquo; in the third line thereof with the phrase &ldquo;or announcement of the formal or informal interpretation&rdquo;; and (iv) immediately following the word &ldquo;Transaction&rdquo; in clause (X) thereof, adding the phrase &ldquo;in the manner contemplated by the Hedging Party on the Trade Date&rdquo;.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Failure to Deliver:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Insolvency Filing:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Hedging Disruption:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Applicable;
<I>
	provided
</I>
	that:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(i)
</TD>
<TD STYLE="WIDTH: 45%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Section 12.9(a)(v) of the Equity Definitions is hereby amended by (a)&nbsp;inserting the following words at the end of clause (A) thereof:&nbsp;&nbsp;&ldquo;in the manner contemplated by the Hedging Party on the Trade Date&rdquo; and (b)&nbsp;inserting the following language at the end of such Section:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&ldquo;,
<I>
	provided
</I>
	that any such inability that occurs solely due to the deterioration of the creditworthiness of the Hedging Party shall not be deemed a Hedging Disruption. For the avoidance of doubt, the term &ldquo;equity price risk&rdquo; shall be deemed to include, but shall not be limited to, stock price and volatility risk. And, for the further avoidance of doubt, any such transactions or assets referred to in phrases (A) or (B) above must be available on commercially reasonable pricing terms.&rdquo;; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(ii)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Section 12.9(b)(iii) of the Equity Definitions is hereby amended by inserting in the third line thereof,&nbsp;&nbsp;after the words &ldquo;to terminate the Transaction&rdquo;, the words &ldquo;or a portion of the Transaction affected by such Hedging Disruption&rdquo;.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_60"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
	Hedging Party:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
	For all applicable Additional Disruption Events, Dealer;
<I>
	provided
</I>
	that all calculations and determinations by the Hedging Party shall be made in good faith and in a commercially reasonable manner;
<I>
	provided further
</I>
	that nothing herein shall limit or alter, or be deemed to limit or alter, the ability of Dealer (whether acting as Dealer, the Hedging Party, the Determining Party or the Calculation Agent) to hedge its obligations under the Transaction in a manner it deems appropriate, as determined by Dealer in its sole discretion. The parties agree that they will comply with the provisions set forth in the second paragraph under &ldquo;Calculation Agent&rdquo; below.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 42%; PADDING-RIGHT: 0; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	Determining Party:
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	For all applicable Extraordinary Events, Dealer;
<I>
	provided
</I>
	that all calculations and determinations by the Determining Party shall be made in good faith and in a commercially reasonable manner. The parties agree that they will comply with the provisions set forth in the second paragraph under &ldquo;Calculation Agent&rdquo; below.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	Non-Reliance:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Applicable
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Agreements and Acknowledgments
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: LEFT">
	Regarding Hedging Activities:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Applicable
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	Additional Acknowledgments:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Applicable
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	4.
</B>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
<U>
	Calculation Agent
</U>
	.
</B>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Dealer;
<I>
	provided
</I>
	that, following the occurrence and during the continuance of an Event of Default of the type described in Section 5(a)(vii) of the Agreement with respect to which Dealer is the sole Defaulting Party, Counterparty shall have the right to designate a nationally recognized independent equity derivatives dealer to replace Dealer as the Calculation Agent, and the parties shall work in good faith to execute any appropriate documentation required by such replacement Calculation Agent. All calculations, adjustments, specifications, choices and determinations by the Calculation Agent shall be made in good faith and in a commercially reasonable manner. The parties agree that they will comply with the provisions set forth in the immediately following paragraph.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	In the case of any calculation, adjustment or determination by the Determining Party or the Calculation Agent, as the case may be, following any written request from Counterparty, the Determining Party or the Calculation Agent, as the case may be, shall promptly provide to Counterparty a written explanation describing in reasonable detail the basis for such calculation, adjustment or determination (including any quotation, market data or information from internal or external sources used in making such calculation, adjustment or determination), but without disclosing any proprietary or confidential models used by it for such calculation, adjustment or determination or any information that is subject to an obligation not to disclose such information.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<B>
	5.
</B>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<B>
<U>
	Account Details
</U>
	.
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; WIDTH: 10%">
	(a)
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; WIDTH: 82%">
	Account for payments to Counterparty:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Bank:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	ABA#:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Acct No.:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Acct Name:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	For final credit
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	to account:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Account for delivery of Shares to Counterparty:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	To be advised.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	(b)
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Account for payments to Dealer:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Bank:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	ABA#:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Acct No.:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Beneficiary:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Ref:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	Account for delivery of Shares from Dealer:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<B>
	6.
</B>
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<B>
<U>
	Offices
</U>
	.
</B>
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-DECORATION: NONE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	(a)
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	The Office of Counterparty for the Transaction is:&nbsp;&nbsp;Inapplicable, Counterparty is not a Multibranch Party.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	(b)
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	The Office of Dealer for the Transaction is: London
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	JPMorgan Chase Bank, National Association
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	London Branch
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	25 Bank Street
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	Canary Wharf
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING: 0">
	London E14 5JP
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	England
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	7.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; PADDING: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	Notices
</U>
	.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 72%; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Address for notices or
	communications to Counterparty:
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Novavax, Inc.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	20 Firstfield Road
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Gaithersburg, Maryland 20878&nbsp;
</FONT>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<A NAME="FIS_UNIDENTIFIED_TABLE_61"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Attention:
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Telephone No.:
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	(240) 268-2030
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Facsimile No.:
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	(240) 268-2100
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Email:
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	bphillips@Novavax.com
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 8%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 12%">
<FONT STYLE="FONT-SIZE: 10PT">
	With a copy to:
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 70%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_62"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	Ropes &amp; Gray LLP
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	Attention: Isabel Dische, Esq. and Thomas Holden, Esq.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	Telephone No: (212) 596-9000
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	Facsimile No: (212) 596-9090
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	Email: isabel.dische@ropesgray.com; thomas.holden@ropesgray.com
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	(b)
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Address for notices or communications to Dealer:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	JPMorgan Chase Bank, National Association
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	EDG Marketing Support
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%">
	Email:&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 70%">
	edg_notices@jpmorgan.com
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	edg.us.flow.corporates.mo@jpmorgan.com
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	Facsimile No:&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	1-866-886-4506
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	With a copy to:
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Attention:&nbsp;&nbsp;
</TD>
<TD>
	Santosh Sreenivasan
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Title:&nbsp;&nbsp;
</TD>
<TD>
	Managing Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Telephone No:&nbsp;&nbsp;
</TD>
<TD>
	(212) 622-5604
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Email:
</TD>
<TD>
	santosh.sreenivasan@jpmorgan.com
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<B>
	8.
</B>
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<B>
<U>
	Representations and Warranties of Counterparty
</U>
	.
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; PADDING-LEFT: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Each of the representations and warranties of Counterparty set forth in Section 1 of the Purchase Agreement (the &ldquo;
<B>
	Purchase
</B>
<B>
	Agreement
</B>
	&rdquo;) dated as of January 25, 2016, among Counterparty, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives of the Initial Purchasers party thereto (the &ldquo;
<B>
	Initial Purchasers
</B>
	&rdquo;), are true and correct and are hereby deemed to be repeated to Dealer as if set forth herein, except to the extent that such representations and warranties, if not true or correct, would not have a material adverse effect on the power or ability of Company to execute and deliver this Confirmation or to perform its obligations hereunder.&nbsp;&nbsp;Counterparty hereby further represents and warrants to Dealer on the date hereof and on and as of the Premium Payment Date that:&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING-LEFT: 0; WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING-LEFT: 0; WIDTH: 5%">
	(a)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING-LEFT: 0; WIDTH: 87%">
	Counterparty has all necessary corporate power and authority to execute, deliver and perform its obligations in respect of the Transaction; such execution, delivery and performance have been duly authorized by all necessary corporate action on Counterparty&rsquo;s part; and this Confirmation has been duly and validly executed and delivered by Counterparty and constitutes its valid and binding obligation, enforceable against Counterparty in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors&rsquo; rights and remedies generally, and subject, as to enforceability, to general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity) and except that rights to indemnification and contribution hereunder may be limited by federal or state securities laws or public policy relating thereto.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING-LEFT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING-LEFT: 0">
	(b)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0; PADDING-LEFT: 0">
	Neither the execution and delivery of this Confirmation nor the incurrence or performance of obligations of Counterparty hereunder will conflict with or result in a breach of (i) the Certificate of Incorporation or the Amended and Restated By-Laws of Counterparty (or any equivalent documents), (ii) any applicable law or regulation, or any order, writ, injunction or decree of any court or governmental authority or agency, or (iii) any agreement or instrument filed as an exhibit to Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (as updated by any subsequent filings) to which Counterparty or any of its subsidiaries is a party or by which Counterparty or any of its subsidiaries is bound or to which Counterparty or any of its subsidiaries is subject, or constitute a default under, or result in the creation of any lien under, any such agreement or instrument except, in the case of clause (iii) above, for any such conflict, breach, default or lien that would not, individually or in the aggregate, have a material adverse effect on (x) Counterparty and its subsidiaries, taken as a whole, (y) Dealer&rsquo;s rights or obligations relating to the Transaction, or (z) the power or ability of Counterparty to execute and deliver this Confirmation or perform its obligations hereunder.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(c)
</TD>
<TD STYLE="WIDTH: 87%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	No consent, approval, authorization, or order of, or filing with, any governmental agency or body or any court is required in connection with the execution, delivery or performance by Counterparty of this Confirmation, except such as have been obtained or made and such as may be required under the Securities Act or state securities laws.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(d)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Counterparty is not and, after consummation of the transactions contemplated hereby, will not be required to register as an &ldquo;investment company&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(e)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Counterparty is an &ldquo;eligible contract participant&rdquo; (as such term is defined in Section 1a(18) of the Commodity Exchange Act, as amended, other than a person that is an eligible contract participant under Section 1a(18)(C) of the Commodity Exchange Act).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(f)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Each of it and its affiliates is not, on the date hereof, in possession of any material non-public information with respect to Counterparty or the Shares.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(g)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The documents incorporated by reference in the Offering Memorandum, when they were filed with the U.S. Securities Exchange Commission (the &ldquo;
<B>
	Commission
</B>
	&rdquo;) conformed in all material respects to the requirements of the Exchange Act, and the Offering Memorandum does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(h)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	To Counterparty&rsquo;s knowledge, no state or local (including any non-U.S. jurisdiction&rsquo;s) law, rule, regulation or regulatory order applicable to the Shares would give rise to any reporting, consent, registration or other requirement (including without limitation a requirement to obtain prior approval from any person or entity) by Dealer as a result of Dealer owning or holding (however defined) Shares except for the reporting requirements of the Exchange Act and the rules promulgated thereunder;
<I>
	provided
</I>
	that Counterparty makes no representation or warranty regarding any such requirement that is applicable generally to the ownership of equity securities by Dealer solely as a result of it being a financial institution or broker-dealer.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(i)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Counterparty understands that no obligations of Dealer to it hereunder will be entitled to the benefit of deposit insurance and that such obligations as of the date hereof are not guaranteed by any Affiliate of Dealer or any governmental agency.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(j)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	COUNTERPARTY UNDERSTANDS THAT THE TRANSACTION IS SUBJECT TO COMPLEX RISKS THAT MAY ARISE WITHOUT WARNING AND MAY AT TIMES BE VOLATILE AND THAT LOSSES MAY OCCUR QUICKLY AND IN UNANTICIPATED MAGNITUDE AND IS WILLING TO ACCEPT SUCH TERMS AND CONDITIONS AND ASSUME (FINANCIALLY AND OTHERWISE) SUCH RISKS.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(k)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Counterparty (A) is capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities; (B) will exercise independent judgment in evaluating the recommendations of any broker-dealer or its associated persons, unless it has otherwise notified the broker-dealer in writing; and (C) has total assets of at least USD 50 million.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(l)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Counterparty is not as of the Trade Date, and Counterparty shall not be after giving effect to the transactions contemplated hereby, &ldquo;insolvent&rdquo; (as such term is defined in Section 101(32) of the U.S. Bankruptcy Code (Title 11 of the United States Code) (the &ldquo;
<B>
	Bankruptcy Code
</B>
	&rdquo;)) and Counterparty would be able to purchase 2,202,320 Shares in compliance with the laws of the jurisdiction of Counterparty&rsquo;s incorporation or organization.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(m)
</TD>
<TD STYLE="WIDTH: 87%; PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Counterparty understands, agrees and acknowledges that Dealer has no obligation or intention to register the Transaction under the Securities Act, any state securities law or other applicable federal securities law.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	(n)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Without limiting the generality of Section 3(a)(iii) of the Agreement, the Transaction will not violate Rule 13e-1 or Rule 13e-4 under the Exchange Act.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: UNDERLINE; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Other Provisions
</U>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
</TD>
<TD STYLE="WIDTH: 5%">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 87%">
	[
<I>
	Reserved
</I>
	.]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
</TD>
<TD STYLE="WIDTH: 5%">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 87%">
<I>
<U>
	Repurchase Notices
</U>
</I>
	. Counterparty shall, on any day on which Counterparty effects
	any repurchase of Shares, promptly give Dealer a written notice of such repurchase (a &ldquo;
<B>
	Repurchase Notice
</B>
	&rdquo;) on
	such day if following such repurchase, the number of outstanding Shares as determined on such day is (i) less than 257.9 million
	(in the case of the first such notice) or (ii) thereafter more than 11.0 million less than the number of Shares included in the
	immediately preceding Repurchase Notice. Counterparty agrees to indemnify and hold harmless Dealer and its affiliates and their
	respective officers, directors, employees, affiliates, advisors, agents and controlling persons (each, an &ldquo;
<B>
	Indemnified
	Person
</B>
	&rdquo;) from and against any and all direct losses (including losses relating to Dealer&rsquo;s commercially reasonable
	hedging activities as a consequence of becoming, or of the risk of becoming, a Section 16 &ldquo;insider&rdquo;, including without
	limitation, any forbearance from commercially reasonable hedging activities or cessation of commercially reasonable hedging activities
	and any losses in connection therewith with respect to the Transaction), claims, damages, judgments, liabilities and reasonable
	expenses (including commercially reasonable attorney&rsquo;s fees of one outside counsel in each relevant jurisdiction), joint
	or several, which an Indemnified Person may become subject to, as a result of Counterparty&rsquo;s failure to provide Dealer with
	a Repurchase Notice on the day and in the manner specified in this paragraph, and to reimburse, within 30 days, upon written request,
	each of such Indemnified Persons for any reasonable legal or other expenses incurred in connection with investigating, preparing
	for, providing testimony or other evidence in connection with or defending any of the foregoing. If any suit, action, proceeding
	(including any governmental or regulatory investigation), claim or demand shall be brought or asserted against the Indemnified
	Person as a result of Counterparty&rsquo;s failure to provide Dealer with a Repurchase Notice in accordance with this paragraph,
	such Indemnified Person shall promptly notify Counterparty in writing, and Counterparty, upon request of the Indemnified Person,
	shall retain counsel reasonably satisfactory to the Indemnified Person to represent the Indemnified Person and any others Counterparty
	may designate in such proceeding and shall pay the commercially reasonable fees and expenses of such counsel related to such proceeding.
	Counterparty shall not be liable for any settlement of any proceeding contemplated by this paragraph that is effected without its
	written consent, but if settled with such consent or if there be a final judgment for the plaintiff, Counterparty agrees to indemnify
	any Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Counterparty shall not,
	without the prior written consent of the Indemnified Person (such consent not to be unreasonably withheld, conditioned or delayed),
	effect any settlement of any pending or threatened proceeding contemplated by this paragraph that is in respect of which any Indemnified
	Person is a party and indemnity could have been sought hereunder by such Indemnified Person, unless such settlement includes an
	unconditional release of such Indemnified Person from all liability on claims that are the subject matter of such proceeding on
	terms reasonably satisfactory to such Indemnified Person. If the indemnification provided for in this paragraph is unavailable
	to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then Counterparty
	hereunder, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified
	Person as a result of such losses, claims, damages or liabilities. The remedies provided for in this paragraph (b) are not exclusive
	and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. The
	indemnity and contribution agreements contained in this paragraph shall remain operative and in full force and effect regardless
	of the termination of the Transaction.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
</TD>
<TD STYLE="WIDTH: 5%">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 87%">
<I>
<U>
	Regulation M
</U>
</I>
	. Counterparty is not on the Trade Date engaged in a distribution, as
	such term is used in Regulation M under the Securities Exchange Act of 1934, as amended (the &ldquo;
<B>
	Exchange Act
</B>
	&rdquo;),
	of any securities of Counterparty, other than a distribution meeting the requirements of the exception set forth in Rules 101(b)(10)
	and 102(b)(7) of Regulation M. Counterparty shall not, until the second Scheduled Trading Day immediately following the Effective
	Date, engage in any such distribution.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
</TD>
<TD STYLE="WIDTH: 5%">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 87%">
<I>
<U>
	No Manipulation
</U>
</I>
	. Counterparty is not entering into the Transaction to create actual
	or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress
	or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares) or otherwise
	in violation of the Exchange Act.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
</TD>
<TD STYLE="WIDTH: 5%">
	(e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 87%">
<I>
<U>
	Transfer or Assignment
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall have the right to transfer or assign any of its rights or obligations hereunder
	with respect to all, but not less than all, of the Options hereunder (such Options, the &ldquo;
<B>
	Transfer Options
</B>
	&rdquo;);
<I>
	provided that
</I>
	such transfer or assignment shall be subject to reasonable conditions that Dealer may impose, including but
	not limited, to the following conditions:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(A)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	With respect to any Transfer Options, Counterparty shall not be released from its notice and indemnification
	obligations pursuant to Section 9(b) or any obligations under Section 9(n) or 9(s) of this Confirmation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(B)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such transfer or assignment shall be effected on terms, including any reasonable undertakings by
	such third party (including, but not limited to, an undertaking with respect to compliance with applicable securities laws in a
	manner that, in the reasonable judgment of Dealer, will not expose Dealer to material risks under applicable securities laws) and
	execution of any reasonable documentation and delivery of legal opinions with respect to securities laws and other matters by such
	third party and Counterparty, as are reasonably requested and reasonably satisfactory to Dealer;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(C)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dealer will not, as a result of such transfer and assignment, be required to pay the transferee
	on any payment date an amount under Section 2(d)(i)(4) of the Agreement greater than an amount that Dealer would have been required
	to pay to Counterparty in the absence of such transfer and assignment;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(D)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	An Event of Default, Potential Event of Default or Termination Event will not occur as a result
	of such transfer and assignment;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(E)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall cause the transferee to make such Payee Tax Representations and to provide such
	tax documentation as may be reasonably requested by Dealer to permit Dealer to determine that results described in clauses (C)
	and (D) will not occur upon or after such transfer and assignment; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(F)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall be responsible for all reasonable costs and expenses, including reasonable counsel
	fees, incurred by Dealer in connection with such transfer or assignment.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dealer may transfer or assign all or any part of its rights or obligations under the Transaction
	(A) without Counterparty&rsquo;s consent to any affiliate of Dealer (1) that has a long-term issuer rating or a rating for its
	long term, unsecured and unsubordinated indebtedness, in either case, that is equal to or better than Dealer&rsquo;s credit rating
	at the time of such transfer or assignment, or (2) whose obligations hereunder will be guaranteed, pursuant to the terms of a customary
	guarantee in a form used by Dealer generally for similar transactions, by Dealer or Dealer&rsquo;s ultimate parent, or (B) with
	Counterparty&rsquo;s consent (such consent not to be unreasonably withheld or delayed) to any other third party with a long-term
	issuer rating or a rating for its long term, unsecured and unsubordinated indebtedness, as the case may be, equal to or better
	than the lesser of (1) the credit rating of Dealer at the time of such transfer or assignment and (2) A- by Standard and Poor&rsquo;s
	Rating Group, Inc. or its successor (&ldquo;
<B>
	S&amp;P
</B>
	&rdquo;), or A3 by Moody&rsquo;s Investor Service, Inc. (&ldquo;
<B>
	Moody&rsquo;s
</B>
	&rdquo;)
	or, if either S&amp;P or Moody&rsquo;s ceases to rate such debt, at least an equivalent rating or better by a substitute rating
	agency mutually agreed by Counterparty and Dealer;
<I>
	provided
</I>
	that any transfer or assignment described in clause (A) or (B)
	above shall not result in a deemed exchange by Counterparty within the meaning of Section 1001 of the Code;
<I>
	provided further
</I>
	that (x) Counterparty will not be required, as a result of such transfer or assignment, to pay the transferee or assignee on any
	payment date an amount under Section 2(d)(i)(4) of the Agreement greater than the amount, if any, that Counterparty would have
	been required to pay Dealer in the absence of such transfer or assignment and (y) Dealer shall cause the transferee or assignee
	to make such Payee Tax Representations and to provide such tax documentation as may be reasonably requested by Counterparty to
	permit Counterparty to determine that the results described in clause (x) of this proviso will not occur upon or after such transfer
	and assignment. If at any time at which (A) the Section 16 Percentage exceeds 8.5%, (B) the Option Equity Percentage exceeds 14.5%,
	or (C) the Share Amount exceeds the Applicable Share Limit (if any applies) (any such condition described in clauses (A), (B) or
	(C), an &ldquo;
<B>
	Excess Ownership Position
</B>
	&rdquo;), Dealer is unable after using its commercially reasonable efforts to effect
	a transfer or assignment of Options to a third party on pricing terms reasonably acceptable to Dealer and within a time period
	reasonably acceptable to Dealer such that no Excess Ownership Position exists, then Dealer may designate any Exchange Business
	Day as an Early Termination Date with respect to a portion of the Transaction (the &ldquo;
<B>
	Terminated Portion
</B>
	&rdquo;), such
	that following such partial termination no Excess Ownership Position exists. In the event that Dealer so designates an Early Termination
	Date with respect to a portion of the Transaction, a payment shall be made pursuant to Section 6 of the Agreement as if (1) an
	Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and a Number of
	Options equal to the number of Options underlying the Terminated Portion, (2) Counterparty were the sole Affected Party with respect
	to such partial termination and (3) the Terminated Portion were the sole Affected Transaction (and, for the avoidance of doubt,
	the provisions of Section 9(l) shall apply to any amount that is payable by Dealer to Counterparty pursuant to this sentence as
	if Counterparty was not the Affected Party). Dealer shall notify Counterparty of an Excess Ownership Position with respect to which
	it intends to seek a transfer or assignment as soon as reasonably practicable after becoming aware of such an Excess Ownership
	Position. The &ldquo;
<B>
	Section 16 Percentage
</B>
	&rdquo; as of any day is the fraction, expressed as a percentage, (A) the numerator
	of which is the number of Shares that Dealer and any of its affiliates or any other person subject to aggregation with Dealer for
	purposes of the &ldquo;beneficial ownership&rdquo; test under Section 13 of the Exchange Act, or any &ldquo;group&rdquo; (within
	the meaning of Section 13 of the Exchange Act) of which Dealer is or may be deemed to be a part beneficially owns (within the meaning
	of Section 13 of the Exchange Act), without duplication, on such day (or, to the extent that for any reason the equivalent calculation
	under Section 16 of the Exchange Act and the rules and regulations thereunder results in a higher number, such higher number) and
	(B) the denominator of which is the number of Shares outstanding on such day. The &ldquo;
<B>
	Option Equity Percentage
</B>
	&rdquo;
	as of any day is the fraction, expressed as a percentage, (A) the numerator of which is the sum of (1) the product of the Number
	of Options and the Option Entitlement and (2) the aggregate number of Shares underlying any other call option transaction sold
	by Dealer to Counterparty, and (B) the denominator of which is the number of Shares outstanding. The &ldquo;
<B>
	Share Amount
</B>
	&rdquo;
	as of any day is the number of Shares that Dealer and any person whose ownership position would be aggregated with that of Dealer
	(Dealer or any such person, a &ldquo;
<B>
	Dealer Person
</B>
	&rdquo;) under any law, rule, regulation, regulatory order or organizational
	documents or contracts of Counterparty that are, in each case, applicable to ownership of Shares (&ldquo;
<B>
	Applicable Restrictions
</B>
	&rdquo;),
	owns, beneficially owns, constructively owns, controls, holds the power to vote or otherwise meets a relevant definition of ownership
	under any Applicable Restriction, as determined by Dealer in its reasonable discretion. The &ldquo;
<B>
	Applicable Share Limit
</B>
	&rdquo;
	means a number of Shares equal to (A) the minimum number of Shares that would give rise to reporting or registration obligations
	(except for any filings of Form 13F, Schedule 13D or Schedule 13G under the Exchange Act) or other requirements (including obtaining
	prior approval from any person or entity) of a Dealer Person, or is reasonably likely to result in an adverse effect on a Dealer
	Person, under any Applicable Restriction, as determined by Dealer in its reasonable discretion,
<I>
	minus
</I>
	(B) 1% of the number
	of Shares outstanding.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding any other provision in this Confirmation to the contrary requiring or allowing
	Dealer to purchase, sell, receive or deliver any Shares or other securities, or make or receive any payment in cash, to or from
	Counterparty, Dealer may designate any of its affiliates to purchase, sell, receive or deliver such Shares or other securities,
	or to make or receive such payment in cash, and otherwise to perform Dealer&rsquo;s obligations in respect of the Transaction and
	any such designee may assume such obligations; provided that Counterparty shall have recourse to Dealer in the event of failure
	by such assignee to perform any of such obligations hereunder. Dealer shall be discharged of its obligations to Counterparty to
	the extent of any such performance to Counterparty by such affiliate of Dealer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Staggered Settlement
</U>
</I>
	. If upon advice of counsel with respect to applicable legal
	and regulatory requirements, including any requirements relating to Dealer&rsquo;s hedging activities hereunder, Dealer reasonably
	determines that it would not be practicable or advisable to deliver, or to acquire Shares to deliver, any or all of the Shares
	to be delivered by Dealer on any Settlement Date for the Transaction, Dealer may, by notice to Counterparty on or prior to any
	Settlement Date (a &ldquo;
<B>
	Nominal Settlement Date
</B>
	&rdquo;), elect to deliver the Shares on two or more dates (each, a &ldquo;
<B>
	Staggered
	Settlement Date
</B>
	&rdquo;) only to the extent reasonably necessary, as reasonably determined by Dealer in good faith, to avoid
	an Excess Ownership Position as follows:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	in such notice, Dealer will specify to Counterparty the related Staggered Settlement Dates (each
	of which will be on or prior to such Nominal Settlement Date) and the number of Shares that it will deliver on each Staggered Settlement
	Date;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the aggregate number of Shares that Dealer will deliver to Counterparty hereunder on all such Staggered
	Settlement Dates will equal the number of Shares that Dealer would otherwise be required to deliver on such Nominal Settlement
	Date; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the Net Share Settlement terms will apply on each Staggered Settlement Date, except that the Net
	Shares will be allocated among such Staggered Settlement Dates as specified by Dealer in the notice referred to in clause (i) above.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Role of Agent.
</U>
</I>
	Each party agrees and acknowledges that (i) J.P. Morgan Securities
	LLC, an affiliate of Dealer (&ldquo;
<B>
	JPMS
</B>
	&rdquo;), has acted solely as agent for Dealer and not as principal with respect
	to the Transaction and (ii) JPMS has no obligation or liability, by way of guaranty, endorsement or otherwise, in any manner in
	respect of the Transaction (including, if applicable, in respect of the settlement thereof). Each party agrees it will look solely
	to the other party (or any guarantor in respect thereof) for performance of such other party&rsquo;s obligations under the Transaction.
	For the avoidance of doubt, any performance by Dealer of its obligations hereunder solely to JPMS shall not relieve Dealer of such
	obligations. Any performance by Counterparty of its obligations (including notice obligations) through or by means of JPMS&rsquo;
	agency for Dealer shall constitute good performance of Counterparty&rsquo;s obligations hereunder to Dealer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(h)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	[
<I>
	Reserved
</I>
	.]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Additional Termination Events
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in this Confirmation, upon any Early Conversion in respect
	of which a &ldquo;Notice of Conversion&rdquo; (as such term is defined in the Indenture) that is effective as to Counterparty has
	been delivered by the relevant converting &ldquo;Holder&rdquo; (as such term is defined in the Indenture):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(A)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall, within five Scheduled Trading Days of the Conversion Date for such Early Conversion,
	provide written notice (an &ldquo;
<B>
	Early Conversion Notice
</B>
	&rdquo;) to Dealer specifying the number of Convertible Notes surrendered
	for conversion on such Conversion Date (such Convertible Notes, the &ldquo;
<B>
	Affected Convertible Notes
</B>
	&rdquo;)
<FONT STYLE="FONT-WEIGHT: NORMAL">
	,
	and the giving of such Early Conversion Notice
</FONT>
<B>
</B>
	shall constitute an Additional Termination Event as provided in this
	clause (i);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(B)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	upon receipt of any such Early Conversion Notice, Dealer shall designate an Exchange Business Day
	as an Early Termination Date (which Exchange Business Day shall be on or as promptly as reasonably practicable after the related
	settlement date for such Affected Convertible Notes) with respect to the portion of the Transaction corresponding to a number of
	Options (the &ldquo;
<B>
	Affected Number of Options
</B>
	&rdquo;) equal to the lesser of (x) the number of Affected Convertible Notes
<I>
	minus
</I>
	the &ldquo;Affected Number of Options&rdquo; (as defined in the Base Call Option Confirmation), if any, that relate
	to such Affected Convertible Notes and (y) the Number of Options as of the Conversion Date for such Early Conversion;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(C)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any payment hereunder with respect to such termination shall be calculated pursuant to Section
	6 of the Agreement as if (x) an Early Termination Date had been designated in respect of a Transaction having terms identical to
	the Transaction and a Number of Options equal to the Affected Number of Options, (y) Counterparty were the sole Affected Party
	with respect to such Additional Termination Event and (z) the terminated portion of the Transaction were the sole Affected Transaction
	(and, for the avoidance of doubt, the provisions of Section 9(l) shall apply to any amount that is payable by Dealer to Counterparty
	pursuant to this Section 9(i)(i) as if Counterparty were not the Affected Party) (and, in determining the amount payable pursuant
	to Section 6 of the Agreement, the Calculation Agent shall not take into account any adjustments to the Conversion Rate pursuant
	to any Excluded Provision);
<I>
	provided
</I>
	that the amount payable with respect to such termination shall not be greater than
	(1) the Applicable Percentage,
<I>
	multiplied by
</I>
	(2) the Affected Number of Options,
<I>
	multiplied by
</I>
	(3) the excess of
	(I) the Conversion Rate (after taking into account any applicable adjustments to the Conversion Rate pursuant to Section 14.03
	of the Indenture),
<I>
	multiplied by
</I>
	the Applicable Limit Price on the settlement date for the Shares to be delivered pursuant
	to the Indenture in respect of the Affected Convertible Note,
<I>
	minus
</I>
	(II) USD 1,000;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(D)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	for the avoidance of doubt, in determining the amount payable
	in respect of such Affected Transaction pursuant to Section 6 of the Agreement, the Calculation Agent shall assume that (x) the
	relevant Early Conversion and any conversions, adjustments, agreements, payments, deliveries or acquisitions by or on behalf of
	Counterparty leading thereto had not occurred, (y) no adjustments to the Conversion Rate have occurred pursuant to any Excluded
	Provision and (z) the corresponding Convertible Notes remain outstanding; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(E)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the Transaction shall remain in full force and effect, except that, as of the Conversion Date for
	such Early Conversion, the Number of Options shall be reduced by the Affected Number of Options
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in this Confirmation if an event of default with respect
	to Counterparty occurs under the terms of the Convertible Notes as set forth in Section 6.01 of the Indenture, and such event of
	default results in the Convertible Notes becoming or being declared due and payable pursuant to the Indenture, then such event
	of default shall constitute an Additional Termination Event applicable to the Transaction and, with respect to such Additional
	Termination Event, (A) Counterparty shall be deemed to be the sole Affected Party, (B) the Transaction shall be the sole Affected
	Transaction and (C) Dealer shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement
	(which Early Termination Date shall be on or as promptly as reasonably practicable after Dealer becomes aware of the occurrence
	of such acceleration).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Promptly (but in any event within five Scheduled Trading Days) following any Repurchase Event (as
	defined below), Counterparty may notify Dealer of such Repurchase Event and the aggregate principal amount of Convertible Notes
	subject to such Repurchase Event (any such notice, a &ldquo;
<B>
	Convertible Notes Repurchase Notice
</B>
	&rdquo;);
<I>
	provided
</I>
	that any such Convertible Notes Repurchase Notice shall contain an acknowledgment by Counterparty of its responsibilities under
	applicable securities laws, and in particular Section 9 and Section 10(b) of the Exchange Act and the rules and regulations thereunder,
	in respect of such Repurchase Event and the delivery of such Convertible Notes Repurchase Notice. The receipt by Dealer from Counterparty
	of any Convertible Notes Repurchase Notice shall constitute an Additional Termination Event as provided in this Section 9(i)(iii).
	Upon receipt of any such Convertible Notes Repurchase Notice, Dealer shall designate an Exchange Business Day following receipt
	of such Convertible Notes Repurchase Notice (which Exchange Business Day shall be on or as promptly as reasonably practicable after
	the related settlement date for the relevant Repurchase Event) as an Early Termination Date with respect to the portion of the
	Transaction corresponding to a number of Options (the &ldquo;
<B>
	Repurchase Options
</B>
	&rdquo;) equal to the lesser of (A) (x) the
	aggregate principal amount of such Convertible Notes specified in such Convertible Notes Repurchase Notice,
<I>
	divided by
</I>
	USD
	1,000,
<I>
	minus
</I>
	(y) the number of Repurchase Options (as defined in the Base Call Option Confirmation), if any, that relate
	to such Convertible Notes, and (B) the Number of Options as of the date Dealer designates such Early Termination Date and, as of
	such date, the Number of Options shall be reduced by the number of Repurchase Options. Any payment hereunder with respect to such
	termination (the &ldquo;
<B>
	Repurchase Unwind Payment
</B>
	&rdquo;) shall be calculated pursuant to Section 6 of the Agreement as
	if (1) an Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and
	a Number of Options equal to the number of Repurchase Options, (2) Counterparty were the sole Affected Party with respect to such
	Additional Termination Event and (3) the terminated portion of the Transaction were the sole Affected Transaction (and, for the
	avoidance of doubt, the provisions of Section 9(l) shall apply to any amount that is payable by Dealer to Counterparty pursuant
	to this Section 9(i)(iii) as if Counterparty was not the Affected Party). &ldquo;
<B>
	Repurchase Event
</B>
	&rdquo; means that (i)
	any Convertible Notes are repurchased (whether pursuant to Section 15.02 of the Indenture or otherwise) by Counterparty or any
	of its subsidiaries, (ii) any Convertible Notes are delivered to Counterparty in exchange for delivery of any property or assets
	of Counterparty or any of its subsidiaries (howsoever described), (iii) any principal of any of the Convertible Notes is repaid
	prior to the final maturity date of the Convertible Notes (other than upon acceleration of the Convertible Notes described in Section
	9(i)(ii)), or (iv) any Convertible Notes are exchanged by or for the benefit of the Holders (as defined in the Indenture) thereof
	for any other securities of Counterparty or any of its Affiliates (or any other property, or any combination thereof) pursuant
	to any exchange offer or similar transaction;
<I>
	provided
</I>
	that neither (i) any conversion of Convertible Notes pursuant to
	the terms of the Indenture, nor (ii) any exchange of Convertible Notes pursuant to Section 15.06 of the Indenture, shall in either
	case constitute a Repurchase Event.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(j)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Amendments to Equity Definitions
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 11.2(e)(vii) of the Equity Definitions is hereby amended by (x) inserting the words &ldquo;similar
	corporate&rdquo; immediately prior to the word &ldquo;event&rdquo; and (y) deleting the words &ldquo;diluting or concentrative&rdquo;
	and replacing them with the word &ldquo;material&rdquo;; and adding the phrase &ldquo;or the Options&rdquo; at the end of the sentence.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 12.9(b)(i) of the Equity Definitions is hereby amended by replacing &ldquo;either party
	may elect&rdquo; with &ldquo;Dealer may elect or, if Counterparty represents that it and its officers and directors are not aware
	of any material nonpublic information with respect to Counterparty or the Shares, Counterparty may elect,&rdquo;.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(k)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	No Collateral or Setoff
</U>
</I>
	. Neither party shall have the right to set off any obligation
	that it may have to the other party under the Transaction against any obligation such other party may have to it, whether arising
	under the Agreement, this Confirmation or any other agreement between the parties hereto, by operation of law or otherwise.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(l)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Alternative Calculations and Payment on Early Termination and on Certain Extraordinary Events
</U>
</I>
	.
	If (a) an Early Termination Date (whether as a result of an Event of Default or a Termination Event) occurs or is designated with
	respect to the Transaction or (b) the Transaction is cancelled or terminated upon the occurrence of an Extraordinary Event (except
	as a result of (i) a Nationalization, Insolvency or Merger Event in which the consideration to be paid to holders of Shares consists
	solely of cash, (ii) a Merger Event that is within Counterparty&rsquo;s control, or (iii) an Event of Default in which Counterparty
	is the Defaulting Party or a Termination Event in which Counterparty is the Affected Party other than an Event of Default of the
	type described in Section 5(a)(iii), (v), (vi), (vii) or (viii) of the Agreement or a Termination Event of the type described in
	Section 5(b) of the Agreement, in each case that resulted from an event or events outside Counterparty&rsquo;s control), and if
	Dealer would owe any amount to Counterparty pursuant to Section 6(d)(ii) and 6(e) of the Agreement or any Cancellation Amount pursuant
	to Article 12 of the Equity Definitions (any such amount, a &ldquo;
<B>
	Payment Obligation
</B>
	&rdquo;), then Dealer shall satisfy
	the Payment Obligation by the Share Termination Alternative (as defined below), unless (a)&nbsp;Counterparty gives irrevocable
	telephonic notice to Dealer, confirmed in writing within one Scheduled Trading Day, no later than 12:00 p.m. (New York City time)
	on the Merger Date, Announcement Date (in the case of a Nationalization, Insolvency or Delisting), Early Termination Date or date
	of cancellation, as applicable, of its election that the Share Termination Alternative shall not apply, (b) Counterparty remakes
	the representation set forth in Section 8(f) as of the date of such election and (c) Dealer agrees, in its commercially reasonable
	discretion, to such election, in which case the provisions of Section 12.7 or Section 12.9 of the Equity Definitions, or the provisions
	of Section 6(d)(ii) and 6(e) of the Agreement, as the case may be, shall apply.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_63"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Share Termination Alternative:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	If applicable, Dealer shall deliver to Counterparty
	the Share Termination Delivery Property on, or within a commercially reasonable period of time after, the date when the relevant
	Payment Obligation would otherwise be due pursuant to Section 12.7 or 12.9 of the Equity Definitions or Section 6(d)(ii) and 6(e)
	of the Agreement, as applicable, in satisfaction of such Payment Obligation in the manner reasonably requested by Counterparty
	free of payment.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Share Termination Delivery Property:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A number of Share Termination Delivery Units, as calculated
	by the Calculation Agent, equal to the Payment Obligation divided by the Share Termination Unit Price. The Calculation Agent shall
	adjust the Share Termination Delivery Property by replacing any fractional portion of a security therein with an amount of cash
	equal to the value of such fractional security based on the values used to calculate the Share Termination Unit Price.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Share Termination Unit Price:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The value to Dealer of property contained in one Share
	Termination Delivery Unit, as determined by the Calculation Agent in good faith and by commercially reasonable means and notified
	by the Calculation Agent to Dealer at the time of notification of the Payment Obligation. For the avoidance of doubt, the parties
	agree that in determining the Share Termination Delivery Unit Price the Calculation Agent may consider the purchase price paid
	in connection with the purchase of Share Termination Delivery Property.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_64"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Share Termination Delivery Unit:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	One Share or, if the Shares have changed into cash
	or any other property or the right to receive cash or any other property as the result of a Nationalization, Insolvency or Merger
	Event (any such cash or other property, the &ldquo;
<B>
	Exchange Property
</B>
	&rdquo;), a unit consisting of the type and amount
	of such Exchange Property received by a holder of one Share (without consideration of any requirement to pay cash or other consideration
	in lieu of fractional amounts of any securities) in such Nationalization, Insolvency or Merger Event, as determined by the Calculation
	Agent.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Failure to Deliver:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_65"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Other applicable provisions:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	If Share Termination Alternative is applicable, the
	provisions of Sections 9.8, 9.9 and 9.11 (as modified above) of the Equity Definitions and the provisions set forth opposite the
	caption &ldquo;Representation and Agreement&rdquo; in Section 2 will be applicable, except that all references in such provisions
	to &ldquo;Physically-settled&rdquo; shall be read as references to &ldquo;Share Termination Settled&rdquo; and all references
	to &ldquo;Shares&rdquo; shall be read as references to &ldquo;Share Termination Delivery Units&rdquo;. &ldquo;Share Termination
	Settled&rdquo; in relation to the Transaction means that the Share Termination Alternative is applicable to the Transaction.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(m)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Waiver of Jury Trial
</U>
</I>
	. Each party waives, to the fullest extent permitted by applicable
	law, any right it may have to a trial by jury in respect of any suit, action or proceeding relating to the Transaction. Each party
	(i) certifies that no representative, agent or attorney of either party has represented, expressly or otherwise, that such other
	party would not, in the event of such a suit, action or proceeding, seek to enforce the foregoing waiver and (ii) acknowledges
	that it and the other party have been induced to enter into the Transaction, as applicable, by, among other things, the mutual
	waivers and certifications provided herein.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(n)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Registration
</U>
</I>
	. Counterparty hereby agrees that if, in the good faith reasonable judgment
	of Dealer based on the advice of counsel, the Shares (&ldquo;
<B>
	Hedge Shares
</B>
	&rdquo;) acquired by Dealer for the purpose of
	hedging its obligations pursuant to the Transaction cannot be sold in the public market by Dealer without registration under the
	Securities Act, Counterparty shall, at its election, either (i) in order to allow Dealer to sell the Hedge Shares in a registered
	offering, make available to Dealer an effective registration statement under the Securities Act and enter into an agreement, in
	form and substance reasonably satisfactory to Dealer, substantially in the form of an underwriting agreement for a registered secondary
	offering of a similar size;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that if Dealer, in its sole reasonable discretion, is not satisfied
	with access to due diligence materials, the results of its due diligence investigation, or the procedures and documentation for
	the registered offering referred to above, then clause (ii) or clause (iii) of this paragraph shall apply at the election of Counterparty,
	(ii) in order to allow Dealer to sell the Hedge Shares in a private placement, enter into a private placement agreement substantially
	similar to private placement purchase agreements customary for private placements of equity securities of similar size, in form
	and substance reasonably satisfactory to Dealer (in which case, the Calculation Agent shall make any adjustments to the terms of
	the Transaction that are necessary, in its commercially reasonable judgment, to account for any commercially reasonable discount
	from the public market price of the Shares incurred on the sale of Hedge Shares in a private placement), or (iii) purchase the
	Hedge Shares from Dealer at the Relevant Price on such Exchange Business Days, and in the amounts, requested by Dealer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(o)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Tax Disclosure
</U>
</I>
	. Effective from the date of commencement of discussions concerning
	the Transaction, Counterparty and each of its employees, representatives, or other agents may disclose to any and all persons,
	without limitation of any kind, the tax treatment and tax structure of the Transaction and all materials of any kind (including
	opinions or other tax analyses) that are provided to Counterparty relating to such tax treatment and tax structure.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(p)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Right to Extend
</U>
</I>
	. Dealer may postpone or add, in whole or in part, any Valid Day or
	Valid Days during the Settlement Averaging Period or any other date of valuation, payment or delivery by Dealer, with respect to
	some or all of the Options hereunder, if Dealer reasonably determines, in its commercially reasonable judgment and, in respect
	of clause (ii) below, based on the advice of counsel, that such action is reasonably necessary or advisable (i) to preserve Dealer&rsquo;s
	hedging or hedge unwind activity hereunder in light of existing liquidity conditions (but only if there is a material decrease
	in liquidity relative to Dealer&rsquo;s expectations on the Trade Date) or (ii) to enable Dealer to effect transactions in Shares
	in connection with its hedging, hedge unwind or settlement activity hereunder in a manner that would, if Dealer were Issuer or
	an affiliated purchaser of Issuer, be in compliance with applicable legal or regulatory requirements, requirements of self-regulatory
	organizations with jurisdiction over Dealer or its affiliates, or related policies and procedures adopted in good faith by Dealer
	(so long as such policies and procedures would generally be applicable to counterparties similar to Counterparty and transactions
	similar to the Transaction);
<I>
	provided
</I>
	that no such Valid Day or other date of valuation, payment or delivery may be postponed
	or added more than 50 Valid Days after the original Valid Day or other date of valuation, payment or delivery, as the case may
	be.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(q)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Status of Claims in Bankruptcy
</U>
</I>
	.
<I>
</I>
	Dealer acknowledges and agrees that this
	Confirmation is not intended to convey to Dealer rights against Counterparty with respect to the Transaction that are senior to
	the claims of common stockholders of Counterparty in any United States bankruptcy proceedings of Counterparty;
<I>
	provided
</I>
	that nothing herein shall limit or shall be deemed to limit Dealer&rsquo;s right to pursue remedies in the event of a breach by
	Counterparty of its obligations and agreements with respect to the Transaction;
<I>
	provided
</I>
	,
<I>
	further
</I>
	, that nothing herein
	shall limit or shall be deemed to limit Dealer&rsquo;s rights in respect of any transactions other than the Transaction.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(r)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Securities Contract; Swap Agreement
</U>
</I>
	. The parties hereto intend for (i) the Transaction
	to be a &ldquo;securities contract&rdquo; and a &ldquo;swap agreement&rdquo; as defined in the Bankruptcy Code, and the parties
	hereto to be entitled to the protections afforded by, among other Sections, Sections 362(b)(6), 362(b)(17), 546(e), 546(g), 555
	and 560 of the Bankruptcy Code, (ii) a party&rsquo;s right to liquidate the Transaction and to exercise any other remedies upon
	the occurrence of any Event of Default under the Agreement with respect to the other party to constitute a &ldquo;contractual right&rdquo;
	as described in the Bankruptcy Code, and (iii) each payment and delivery of cash, securities or other property hereunder to constitute
	a &ldquo;margin payment&rdquo; or &ldquo;settlement payment&rdquo; and a &ldquo;transfer&rdquo; as defined in the Bankruptcy Code.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(s)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Notice of Certain Other Events
</U>
</I>
	. Counterparty covenants and agrees that:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	promptly following the public announcement of the results of any election by the holders of Shares
	with respect to the consideration due upon consummation of any Merger Event, Counterparty shall give Dealer written notice of (x)
	the weighted average of the types and amounts of consideration that holders of Shares have elected to receive upon consummation
	of such Merger Event or (y) if no holders of Shares affirmatively make such election, the types and amounts of consideration actually
	received by holders of Shares (the date of such notification, the &ldquo;
<B>
	Consideration Notification Date
</B>
	&rdquo;);
<I>
	provided
</I>
	that in no event shall the Consideration Notification Date be later than the date on which such Merger Event is consummated; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	promptly following any adjustment to the Convertible Notes in connection with any Potential Adjustment
	Event, Merger Event or Tender Offer, Counterparty shall give Dealer written notice of the details of such adjustment.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(t)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Wall Street Transparency and Accountability Act
</U>
</I>
	. In connection with Section 739 of
	the Wall Street Transparency and Accountability Act of 2010 (&ldquo;
<B>
	WSTAA
</B>
	&rdquo;), the parties hereby agree that neither
	the enactment of WSTAA or any regulation under the WSTAA, nor any requirement under WSTAA or an amendment made by WSTAA, shall
	limit or otherwise impair either party&rsquo;s otherwise applicable rights to terminate, renegotiate, modify, amend or supplement
	this Confirmation or the Agreement, as applicable, arising from a termination event, force majeure, illegality, increased costs,
	regulatory change or similar event under this Confirmation, the Equity Definitions incorporated herein, or the Agreement (including,
	but not limited to, rights arising from Change in Law, Hedging Disruption, an Excess Ownership Position, or Illegality (as defined
	in the Agreement)).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(u)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Agreements and Acknowledgements Regarding Hedging
</U>
</I>
	. Counterparty understands, acknowledges
	and agrees that: (A) at any time on and prior to the Expiration Date, Dealer and its affiliates may buy or sell Shares or other
	securities or buy or sell options or futures contracts or enter into swaps or other derivative securities in order to adjust its
	hedge position with respect to the Transaction; (B) Dealer and its affiliates also may be active in the market for Shares other
	than in connection with hedging activities in relation to the Transaction; (C) Dealer shall make its own determination as to whether,
	when or in what manner any hedging or market activities in securities of Issuer shall be conducted and shall do so in a manner
	that it deems appropriate to hedge its price and market risk with respect to the Relevant Prices; and (D) any market activities
	of Dealer and its affiliates with respect to Shares may affect the market price and volatility of Shares, as well as the Relevant
	Prices, each in a manner that may be adverse to Counterparty.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(v)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Early Unwind
</U>
	.
</I>
	In the event the sale of the &ldquo;Option Securities&rdquo; (as defined
	in the Purchase Agreement) is not consummated with the Initial Purchasers for any reason by 5:00 p.m. (New York City time) on the
	Premium Payment Date, or such later date as agreed upon by the parties (the Premium Payment Date or such later date, the &ldquo;
<B>
	Early
	Unwind Date
</B>
	&rdquo;),
<B>
</B>
	the Transaction shall automatically terminate (the &ldquo;
<B>
	Early Unwind
</B>
	&rdquo;)
<B>
</B>
	on
	the Early Unwind Date and (i) the Transaction and all of the respective rights and obligations of Dealer and Counterparty under
	the Transaction shall be cancelled and terminated and (ii) each party shall be released and discharged by the other party from
	and agrees not to make any claim against the other party with respect to any obligations or liabilities of the other party arising
	out of and to be performed in connection with the Transaction either prior to or after the Early Unwind Date. Each of Dealer and
	Counterparty represents and acknowledges to the other that, upon an Early Unwind, all obligations with respect to the Transaction
	shall be deemed fully and finally discharged.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(w)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Payment by Counterparty
</U>
</I>
	. In the event that, following payment of the Premium, (i)
	an Early Termination Date occurs or is designated with respect to the Transaction as a result of a Termination Event or an Event
	of Default (other than an Event of Default arising under Section 5(a)(ii) or 5(a)(iv) of the Agreement) and, as a result, Counterparty
	owes to Dealer an amount calculated under Section 6(e) of the Agreement, or (ii) Counterparty owes to Dealer, pursuant to Section
	12.7 or Section 12.9 of the Equity Definitions, an amount calculated under Section 12.8 of the Equity Definitions, such amount
	shall be deemed to be zero.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(x)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Other Adjustments Pursuant to the Equity Definitions
</U>
	.
</I>
	Notwithstanding anything to
	the contrary in this Confirmation, solely for purposes of this Section 9(x), the terms &ldquo;Potential Adjustment Event,&rdquo;
	&ldquo;Merger Event,&rdquo; and &ldquo;Tender Offer&rdquo; shall each have the meanings assigned to such term in the Equity Definitions
	(as amended by Section 9(j)(i)), and upon the occurrence of a Merger Date, the occurrence of a Tender Offer Date, or the declaration
	by Counterparty of the terms of any Potential Adjustment Event, respectively, as such terms are defined in the Equity Definitions,
	the Calculation Agent may, in its sole discretion, adjust the Cap Price to preserve the fair value of the Options to Dealer;
<I>
	provided
</I>
	that in no event shall the Cap Price be less than the Strike Price;
<I>
	provided further
</I>
	that any adjustment to the Cap Price
	made pursuant to this Section 9(x) shall be made without duplication of any other adjustment or determination hereunder (including,
	for the avoidance of doubt, adjustments or determinations made in accordance with &ldquo;Method of Adjustment,&rdquo; &ldquo;Consequences
	of Merger Events / Tender Offers&rdquo; and &ldquo;Consequences of Announcement Events&rdquo; in Section 3 above).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(y)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Tax Forms
</U>
</I>
	. Counterparty shall provide to Dealer a valid U.S. Internal Revenue Service
	(&ldquo;
<B>
	IRS
</B>
	&rdquo;) Form W-9 on or before the date of execution of this Confirmation and will promptly tender an updated
	IRS Form W-9 or applicable IRS Form W-8 if the previously tendered IRS Form W-9 becomes incorrect as a result of a change in facts.
	Dealer shall provide Counterparty a valid IRS Form W-9 or applicable IRS Form W-8 on or before the date of execution of this Confirmation
	and will promptly tender an updated IRS Form W-9 or applicable IRS Form W-8 if the previously tendered IRS Form W-9 or applicable
	IRS Form W-8 becomes incorrect as a result of a change in facts.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(z)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Certain Withholding Taxes
</U>
</I>
	. &ldquo;Indemnifiable Tax&rdquo; as defined in Section
	14 of the Agreement shall not include any tax imposed or collected pursuant to Section 871(m) of the Code or Sections 1471 through
	1474 of the Code, any current or future regulations or official interpretations thereof, any agreement entered into pursuant to
	Section 1471(b) of the Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental
	agreement entered into in connection with the implementation of such Sections of the Code (a &ldquo;
<B>
	FATCA Withholding Tax
</B>
	&rdquo;).
	For the avoidance of doubt, a FATCA Withholding Tax is a Tax the deduction or withholding of which is required by applicable law
	for the purposes of Section 2(d) of the Agreement.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Please
<FONT STYLE="FONT-SIZE: 10PT">
	confirm
	that the foregoing correctly sets forth the terms of our agreement by executing this Confirmation and returning it to Dealer
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	Very truly yours,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	J.P. MORGAN SECURITIES LLC, as agent
<BR>
	for JPMORGAN CHASE BANK, NATIONAL
<BR>
	ASSOCIATION
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 36%; PADDING: 0; TEXT-INDENT: 0; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Santosh Sreenivasan
</TD>
<TD STYLE="WIDTH: 10%; PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Authorized Signatory
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:&#9;&nbsp;&nbsp;&nbsp;Santosh Sreenivasan
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Accepted and confirmed
<BR>
	as of the Trade Date:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NOVAVAX, INC.
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 36%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Stanley C. Erck
</FONT>
</TD>
<TD STYLE="WIDTH: 60%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Authorized Signatory
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:&#9;&nbsp;&nbsp;&nbsp;President and CEO
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage127"></A>
<A NAME="V431853_EX10-52_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_3"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.52
</B>
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Morgan Stanley &amp; Co. LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	1585 Broadway, 5th Floor
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	New York, NY 10036
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6IN">
	February 2, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	To:
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Novavax, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	20 Firstfield Road
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Gaithersburg, Maryland 20878
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; WIDTH: 5%">
<A NAME="FIS_UNIDENTIFIED_TABLE_66"></A>
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; WIDTH: 10%">
	Attention:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0; WIDTH: 85%">
	Chief Financial Officer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Telephone No.:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	(240) 268-2030
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	Facsimile No.:
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
	(240) 268-2100
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Re:
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Additional Call Option Transaction
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 6IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The purpose of this
	letter agreement (this &ldquo;
<B>
	Confirmation
</B>
	&rdquo;) is to confirm the terms and conditions of the call option transaction
	entered into between Morgan Stanley &amp; Co. LLC (&ldquo;
<B>
	Dealer
</B>
	&rdquo;) and Novavax, Inc.
<B>
</B>
	(&ldquo;
<B>
	Counterparty
</B>
	&rdquo;)
	as of the Trade Date specified below (the &ldquo;
<B>
	Transaction
</B>
	&rdquo;). This letter agreement constitutes a &ldquo;Confirmation&rdquo;
	as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve
	as the final documentation for the Transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The definitions and
	provisions contained in the 2002 ISDA Equity Derivatives Definitions (the &ldquo;
<B>
	Equity Definitions
</B>
	&rdquo;), as published
	by the International Swaps and Derivatives Association, Inc. (&ldquo;
<B>
	ISDA
</B>
	&rdquo;) are incorporated into this Confirmation.
	In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain
	defined terms used herein are based on terms that are defined in the Offering Memorandum dated January 25, 2016 (the &ldquo;
<B>
	Offering
	Memorandum
</B>
	&rdquo;) relating to the Convertible Senior Notes due 2023 (as originally issued by Counterparty, the &ldquo;
<B>
	Convertible
	Notes
</B>
	&rdquo; and each USD 1,000 principal amount of Convertible Notes, a &ldquo;
<B>
	Convertible Note
</B>
	&rdquo;) issued by Counterparty
	in an aggregate initial principal amount of USD 300,000,000 (as increased by an aggregate principal amount of USD 25,000,000 pursuant
	to the exercise by the Initial Purchasers (as defined herein) of their option to purchase additional Convertible Notes pursuant
	to the Purchase Agreement (as defined herein)) pursuant to an Indenture dated January 29, 2016 between Counterparty and The Bank
	of New York Mellon Trust Company, N.A., as trustee (the &ldquo;
<B>
	Indenture
</B>
	&rdquo;). In the event of any inconsistency between
	the terms defined in the Offering Memorandum, the Indenture and this Confirmation, this Confirmation shall govern. The parties
	acknowledge that this Confirmation is entered into on the date hereof with the understanding that (i) definitions set forth in
	the Indenture that are also defined herein by reference to the Indenture and (ii) sections of the Indenture that are referred to
	herein will conform to the descriptions thereof in the Offering Memorandum. If any such definitions in the Indenture or any such
	sections of the Indenture differ from the descriptions thereof in the Offering Memorandum, the descriptions thereof in the Offering
	Memorandum will govern for purposes of this Confirmation. The parties further acknowledge that the Indenture section numbers used
	herein are based on the Indenture as executed. Subject to the foregoing, references to the Indenture herein are references to the
	Indenture as in effect on the date of its execution, and if the Indenture is amended or supplemented following such date (other
	than any amendment or supplement (x) pursuant to Section 10.01(h) of the Indenture that, as determined by the Calculation Agent,
	conforms the Indenture to the description of Convertible Notes in the Offering Memorandum or (y) pursuant to Section 14.07 of the
	Indenture, subject, in the case of this clause (y), to the second paragraph under &ldquo;Method of Adjustment&rdquo; in Section
	&lrm;3), any such amendment or supplement will be disregarded for purposes of this Confirmation unless the parties agree otherwise
	in writing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Each party is hereby
	advised, and each such party acknowledges, that the other party has engaged in, or refrained from engaging in, substantial financial
	transactions and has taken other material actions in reliance upon the parties&rsquo; entry into the Transaction to which this
	Confirmation relates on the terms and conditions set forth below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Confirmation
	evidences a complete and binding agreement between Dealer and Counterparty as to the terms of the Transaction to which this Confirmation
	relates. This Confirmation shall supplement, form a part of, and be subject to an agreement in the form of the 2002 ISDA Master
	Agreement (the &ldquo;
<B>
	Agreement
</B>
	&rdquo;) as if Dealer and Counterparty had executed an agreement in such form (but without
	any Schedule except for (i) the election of US Dollars (&ldquo;USD&rdquo;) as the Termination Currency, (ii) the election of the
	laws of the State of New York as the governing law (without reference to choice of law doctrine), (iii) the election that the &ldquo;Cross
	Default&rdquo; provisions of Section 5(a)(vi) of the Agreement shall apply to Dealer with a &ldquo;Threshold Amount&rdquo; of 3%
	of Dealer&rsquo;s shareholders&rsquo; equity (
<I>
	provided
</I>
	that (a) the phrase &ldquo;, or becoming capable at such time of
	being declared,&rdquo; shall be deleted from clause (1) of such Section 5(a)(vi) of the Agreement, (b) &ldquo;Specified Indebtedness&rdquo;
	shall have the meaning specified in Section 14 of the Agreement, except that such term shall not include obligations in respect
	of deposits received in the ordinary course of Dealer&rsquo;s banking business and (c) the following sentence shall be added to
	the end of Section 5(a)(vi) of the Agreement: &ldquo;Notwithstanding the foregoing, a default under subsection (2) hereof shall
	not constitute an Event of Default if (x) the default was caused solely by error or omission of an administrative or operational
	nature; (y) funds were available to enable the relevant party to make the payment when due; and (z) the payment is made within
	two Local Business Days of such party&rsquo;s receipt of written notice of its failure to pay.&rdquo;) on the Trade Date. In the
	event of any inconsistency between provisions of the Agreement and this Confirmation, this Confirmation will prevail for the purpose
	of the Transaction to which this Confirmation relates. The parties hereby agree that no transaction other than the Transaction
	to which this Confirmation relates shall be governed by the Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms of the
	particular Transaction to which this Confirmation relates are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
<U>
	General Terms
</U>
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Trade Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	February 2, 2016
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Effective Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Trade Date
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Option Style:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;Modified American&rdquo;, as described under &ldquo;Procedures for Exercise&rdquo; below
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Option Type:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Call
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Buyer:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Seller:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dealer
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Shares:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The common stock of Counterparty, par value USD 0.01 per share (Exchange symbol &ldquo;NVAX&rdquo;).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_67"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Number of Options:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	25,000. For the avoidance of doubt, the Number of Options shall be reduced by any Options exercised
	by Counterparty. In no event will the Number of Options be less than zero.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Applicable Percentage:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	40%
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Option Entitlement:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A number equal to the product of the Applicable Percentage and 146.8213
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Strike Price:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	USD 6.8110
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Cap Price:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	USD 9.7300
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Premium:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	USD 1,156,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Premium Payment Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	February 5, 2016
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Exchange:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The NASDAQ Global Select Market
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Related Exchange(s):
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All Exchanges
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Excluded Provisions:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 14.04(g) and Section 14.03 of the Indenture.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_68"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Procedures for Exercise
</U>
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Conversion Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	With respect to any conversion of a Convertible Note (other than any conversion of Convertible
	Notes with a Conversion Date occurring prior to the Cut-Off Date (any such conversion, an &ldquo;
<B>
	Early Conversion
</B>
	&rdquo;),
	to which the provisions of Section &lrm;9(i)(i) of this Confirmation shall apply), the date on which the &ldquo;Holder&rdquo; (as
	such term is defined in the Indenture) of such Convertible Note satisfies all of the requirements for conversion thereof as set
	forth in Section 14.02(b) of the Indenture.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Cut-Off Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The 45th &ldquo;Scheduled Trading Day&rdquo; (as defined in the Indenture) immediately preceding
	the &ldquo;Maturity Date&rdquo; (as defined in the Indenture).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Expiration Time:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Valuation Time
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Expiration Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	February 1, 2023, subject to earlier exercise.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Multiple Exercise:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable, as described under &ldquo;Automatic Exercise&rdquo; below.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_69"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Automatic Exercise:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding Section 3.4 of the Equity Definitions, on each Conversion Date occurring on or
	after the Cut-Off Date in respect of which a &ldquo;Notice of Conversion&rdquo; (as defined in the Indenture) that is effective
	as to Counterparty has been delivered by the relevant converting &ldquo;Holder&rdquo; (as such term is defined in the Indenture),
	a number of Options equal to (i) the number of Convertible Notes in denominations of USD 1,000 as to which such Conversion Date
	has occurred
<I>
	minus
</I>
	(ii) the number of Options that are or are deemed to be automatically exercised on such Conversion Date
	under the Base Call Option Transaction Confirmation letter agreement dated January 25, 2016 between Dealer and Counterparty (the
	&ldquo;
<B>
	Base Call Option Confirmation
</B>
	&rdquo;), shall be deemed to be automatically exercised;
<I>
	provided
</I>
	that such Options
	shall be exercised or deemed exercised only if Counterparty has provided a Notice of Exercise to Dealer in accordance with &ldquo;Notice
	of Exercise&rdquo; below.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding
	the foregoing, in no event shall the number of Options that are exercised or deemed exercised hereunder exceed the Number of Options.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_70"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Notice of Exercise:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in the Equity
	Definitions or under &ldquo;Automatic Exercise&rdquo; above, in order to exercise any Options relating to Convertible Notes with
	a Conversion Date occurring on or after the Cut-Off Date, Counterparty must notify Dealer in writing before 5:00 p.m. (New York
	City time) on the second Scheduled Valid Day immediately preceding the Expiration Date of the number of such Options being exercised.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Valuation Time:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	At the close of trading of the regular trading session on the Exchange.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN; TEXT-ALIGN: LEFT">
	Market Disruption Event:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 6.3(a) of the Equity Definitions is hereby replaced
	in its entirety by the following:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&ldquo;&lsquo;Market
	Disruption Event&rsquo; means, in respect of a Share, (i) a failure by the principal United States national or regional securities
	exchange or market on which the Shares are listed for trading to open for trading or (ii) the occurrence or existence for more
	than one half-hour period in the aggregate on any Scheduled Valid Day of any suspension or limitation imposed on trading (by reason
	of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Shares or in any options contracts
	or futures contracts relating to the Shares, and such suspension or limitation occurs or exists at any time before 1:00 p.m. (New
	York City time) on such Scheduled Valid Day.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_71"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Settlement Terms
</U>
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Settlement Method:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Net Share Settlement.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Net Share Settlement:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dealer will deliver to Counterparty, on the relevant Settlement Date, a number of Shares equal
	to the Net Shares in respect of any Option exercised or deemed exercised hereunder. In no event will the Net Shares be less than
	zero.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Net Shares:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In respect of any Option exercised or deemed exercised, a number of Shares equal to the sum of
	the quotients, for each Valid Day during the Settlement Averaging Period for such Option, of (i) (A) the Option Entitlement on
	such Valid Day
<I>
	multiplied by
</I>
	(B) (1) the amount by which the Cap Price exceeds the Strike Price, if the Relevant Price on
	such Valid Day is equal to or greater than the Cap Price, (2) the amount by which such Relevant Price exceeds the Strike Price,
	if such Relevant Price is greater than the Strike Price but less than the Cap Price or (3) zero, if such Relevant Price is less
	than or equal to the Strike Price,
<I>
	divided by
</I>
	(C) such Relevant Price,
<I>
	divided by
</I>
	(ii) the number of Valid Days in
	the Settlement Averaging Period;
<I>
	provided
</I>
	that in no event shall the Net Shares for any Option exceed a number of Shares
	equal to the Applicable Limit for such Option
<I>
	divided by
</I>
	the Applicable Limit Price on the Settlement Date for such Option.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Dealer will
	pay cash in lieu of delivering any fractional Shares to be delivered with respect to any Net Shares valued at the Relevant Price
	for the last Valid Day of the Settlement Averaging Period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_72"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Applicable Limit:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For any Option, an amount of cash equal to the Applicable Percentage
<I>
	multiplied by
</I>
	the excess
	of (i) the number of Shares delivered to the Holder of the related Convertible Note upon conversion of such Convertible Note
<I>
	multiplied
	by
</I>
	the Applicable Limit Price on the Settlement Date for such Option, over (ii) USD 1,000.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Applicable Limit Price:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On any day, the opening price as displayed under the heading &ldquo;Op&rdquo; on Bloomberg page
	NVAX &lt;equity&gt; (or any successor thereto).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Valid Day:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A day on which (i) there is no Market Disruption Event and (ii) the principal U.S. national or
	regional securities exchange on which the Shares are listed or admitted for trading is open for trading with a Scheduled Closing
	Time of 4:00 p.m. (New York City time) or the then-standard closing time for regular trading on such exchange, or, if the Shares
	are not listed on a U.S. national or regional securities exchange, any Business Day.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_73"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Scheduled Valid Day:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A day that is scheduled to be a Valid Day on the principal U.S. national or regional securities
	exchange on which the Shares are listed or admitted for trading. If the Shares are not so listed or admitted for trading, &ldquo;Scheduled
	Valid Day&rdquo; means a Business Day.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Business Day:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Any day other than a Saturday, a Sunday or a day on which state or federally chartered banking
	institutions in New York, New York are not required to be open.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_74"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Relevant Price:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On any Valid Day, the per Share volume-weighted average price as displayed under the heading &ldquo;Bloomberg
	VWAP&rdquo; on Bloomberg page &ldquo;NVAX Equity AQR&rdquo; (or its equivalent successor if such page is not available) in respect
	of the period from the scheduled open of trading until the Scheduled Closing Time of the Exchange on such Valid Day or, if such
	volume-weighted average price is unavailable, the market value of one Share on such Valid Day, as determined by the Calculation
	Agent using, if practicable, a volume-weighted average price method. The Relevant Price will be determined without regard to after-hours
	trading or any other trading outside of the regular trading session trading hours.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Settlement Averaging Period:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For any Option being exercised hereunder, the 40 consecutive Valid Days commencing on, and including,
	the 42nd Scheduled Valid Day immediately prior to the Expiration Date.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Settlement Date:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For any Option, the third Business Day immediately following the final Valid Day of the Settlement
	Averaging Period for such Option.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Settlement Currency:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	USD
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_75"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Other Applicable Provisions:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The provisions of Sections 9.1(c), 9.8, 9.9 and 9.11 of the Equity Definitions will be applicable,
	except that all references in such provisions to &ldquo;Physically-settled&rdquo; shall be read as references to &ldquo;Net Share
	Settled&rdquo;. &ldquo;Net Share Settled&rdquo; in relation to any Option means that Net Share Settlement is applicable to that
	Option.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_76"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Representation and Agreement:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in the Equity Definitions (including, but not limited
	to, Section 9.11 thereof), the parties acknowledge that (i) any Shares delivered to Counterparty may be, upon delivery, subject
	to restrictions and limitations arising from Counterparty&rsquo;s status as issuer of the Shares under applicable securities laws,
	(ii) Dealer may deliver any Shares required to be delivered hereunder in certificated form in lieu of delivery through the Clearance
	System and (iii) any Shares delivered to Counterparty may be &ldquo;restricted securities&rdquo; (as defined in Rule 144 under
	the Securities Act of 1933, as amended (the &ldquo;
<B>
	Securities Act
</B>
	&rdquo;)).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	3.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Additional Terms applicable to the Transaction
</U>
	.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Adjustments applicable to the
	Transaction:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_77"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Potential Adjustment Events:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding Section 11.2(e) of the Equity Definitions, a &ldquo;Potential Adjustment Event&rdquo;
	means an occurrence of any event or condition, as set forth in any Dilution Adjustment Provision, that would result in an adjustment
	under the Indenture to the &ldquo;Conversion Rate&rdquo; or the composition of a &ldquo;unit of Reference Property&rdquo; or to
	any &ldquo;Last Reported Sale Price&rdquo; ,&nbsp;&ldquo;Daily VWAP,&rdquo; &ldquo;Daily Conversion Value&rdquo; or &ldquo;Daily
	Settlement Amount&rdquo; (each as defined in the Indenture). For the avoidance of doubt, Dealer shall not have any delivery or
	payment obligation hereunder, and no adjustment shall be made to the terms of the Transaction, on account of (x)&nbsp;any distribution
	of cash, property or securities by Counterparty to &ldquo;Holders&rdquo; (as such term is defined in the Indenture) of the Convertible
	Notes (upon conversion or otherwise) or (y)&nbsp;any other transaction in which &ldquo;Holders&rdquo; (as such term is defined
	in the Indenture) of the Convertible Notes are entitled to participate, in each case, in lieu of an adjustment under the Indenture
	of the type referred to in the immediately preceding sentence (including, without limitation, pursuant to the fourth sentence of
	the second paragraph of Section 14.04(c) of the Indenture or the fourth sentence of the second paragraph of Section 14.04(d) of
	the Indenture).
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Method of Adjustment:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Calculation Agent Adjustment, which means that, notwithstanding Section 11.2(c) of the Equity Definitions,
	upon any Potential Adjustment Event, the Calculation Agent shall make (A) an adjustment corresponding to the adjustment to be made
	pursuant to the Indenture (or, if no Convertible Notes are outstanding, that would have been made if Convertible Notes were outstanding)
	to any one or more of the Strike Price, Number of Options, and/or Option Entitlement and (B) proportionate adjustment to the Cap
	Price to the extent any adjustment is made to the Strike Price pursuant to clause (A) above (which adjustment, for the avoidance
	of doubt, shall not prohibit Dealer from making any further adjustments to the Cap Price in accordance with, and subject in all
	respects to, Section &lrm;9(x));
<I>
	provided
</I>
	that in no event shall the Strike Price be adjusted to be greater than the Cap
	Price.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding
	the foregoing and &ldquo;Consequences of Merger Events / Tender Offers&rdquo; below, if the Calculation Agent in good faith disagrees
	with any adjustment to the Convertible Notes that involves an exercise of discretion by Counterparty or its board of directors
	(including, without limitation, pursuant to Section 14.05 of the Indenture, Section 14.07 of the Indenture or any supplemental
	indenture entered into thereunder or in connection with any proportional adjustment or the determination of the fair value of any
	securities, property, rights or other assets), then in each such case, the Calculation Agent will determine (A) an adjustment to
	be made to any one or more of the Strike Price, Number of Options, and/or Option Entitlement in a commercially reasonable manner
	and (B) a proportionate adjustment to be made to the Cap Price to the extent any adjustment is made to the Strike Price pursuant
	to clause (A) above (which adjustment, for the avoidance of doubt, shall not prohibit Dealer from making any further adjustments
	to the Cap Price in accordance with, and subject in all respects to, Section &lrm;9(x));
<I>
	provided
</I>
	that in no event shall
	the Strike Price be adjusted to be greater than the Cap Price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For the avoidance of doubt, whenever the Calculation Agent or Determining Party, as the case may
	be, is called upon to make an adjustment pursuant to the terms of this Confirmation or the Equity Definitions (other than any adjustment
	required to be made by reference to the terms of the Convertible Notes or the Indenture) to take into account the effect of an
	event, the Calculation Agent or Determining Party, as the case may be, shall make such adjustment by reference to the effect of
	such event on the Hedging Party, assuming that the Hedging Party maintains a commercially reasonable hedge position.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_78"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Dilution Adjustment Provisions:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Sections 14.04(a), (b), (c), (d) and (e) and Section 14.05 of the Indenture.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Extraordinary Events applicable
	to the Transaction:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Merger Events:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable;
<I>
	provided
</I>
	that notwithstanding Section 12.1(b) of the Equity Definitions, a &ldquo;Merger
	Event&rdquo; means the occurrence of any event or condition set forth in the definition of &ldquo;Share Exchange Event&rdquo; in
	Section 14.07 of the Indenture.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Tender Offers:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable;
<I>
	provided
</I>
	that notwithstanding Section 12.1(d) of the Equity Definitions, a &ldquo;Tender
	Offer&rdquo; means the occurrence of any event or condition set forth in Section 14.04(e) of the Indenture.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_79"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	Consequences
	of Merger Events /
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Tender Offers:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding Section 12.2 and Section 12.3 of the Equity Definitions, upon the occurrence of
	a Merger Event or a Tender Offer that is required under the terms of the Indenture to result in an adjustment to the terms of the
	Convertible Notes, the Calculation Agent shall make (A) a corresponding adjustment to any one or more of the nature of the Shares,
	Strike Price, Number of Options and Option Entitlement, in each case, to the extent an analogous adjustment would be made pursuant
	to the Indenture in connection with such Merger Event or Tender Offer, or to the definitions of &ldquo;Exchange&rdquo;, &ldquo;Relevant
	Price&rdquo;, and &ldquo;Settlement Averaging Period&rdquo; of this Confirmation and any other variable relevant to the exercise,
	settlement or payment for the Transaction, subject to the second paragraph under &ldquo;Method of Adjustment&rdquo; and (B) a proportionate
	adjustment to the Cap Price to the extent any adjustment is made to the Strike Price pursuant to clause (A) above (which adjustment,
	for the avoidance of doubt, shall not prohibit Dealer from making any further adjustments to the Cap Price in accordance with,
	and subject in all respects to, Section &lrm;9(x));
<I>
	provided
</I>
	that in no event shall the Strike Price be adjusted to be greater
	than the Cap Price;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that such adjustment shall be made without regard to any adjustment to the
	Conversion Rate pursuant to any Excluded Provision. Notwithstanding the foregoing, if, with respect to a Merger Event or a Tender
	Offer, (i) the consideration for the Shares includes (or, at the option of a holder of Shares, may include) shares of an entity
	or person that is not a corporation or is not organized under the laws of the United States, any State thereof or the District
	of Columbia or (ii) the Counterparty to the Transaction following such Merger Event or Tender Offer will not be a corporation or
	will not be either (A) the Issuer following such Merger Event or Tender Offer or (B) a wholly owned subsidiary of the Issuer (1)
	that is a corporation organized under the laws of the United States, any State thereof or the District of Columbia, (2) whose obligations
	under the Transaction are fully and unconditionally guaranteed by the Issuer and (3) with respect to which the Calculation Agent
	determines that treating such wholly owned subsidiary as the Counterparty will not have a material adverse effect on Dealer&rsquo;s
	rights or obligations hereunder, Dealer&rsquo;s hedging activities, or the costs of engaging in any of the foregoing, then, in
	either case, Cancellation and Payment (Calculation Agent Determination) may apply at Dealer&rsquo;s sole reasonable election;
<I>
	provided
</I>
	that Dealer shall consult with Counterparty prior to declaring an Early Termination Date with respect to the Transaction. For the
	avoidance of doubt, the foregoing provisions will apply regardless of whether any Merger Event or Tender Offer gives rise to an
	Early Conversion.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Consequences of Announcement Events:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Modified Calculation Agent Adjustment as set forth in Section 12.3(d) of the Equity Definitions;
<I>
	provided
</I>
	that, in respect of an Announcement Event, (v)&nbsp;references to &ldquo;Tender Offer&rdquo; shall be replaced
	by references to &ldquo;Announcement Event&rdquo; and references to &ldquo;Tender Offer Date&rdquo; shall be replaced by references
	to &ldquo;date of such Announcement Event&rdquo;, (w)&nbsp;the word &ldquo;shall&rdquo; in the second line shall be replaced with
	&ldquo;may&rdquo;, (x) the phrase &ldquo;exercise, settlement, payment or any other terms of the Transaction (including, without
	limitation, the spread)&rdquo; shall be replaced by the phrase &ldquo;Cap Price (
<I>
	provided
</I>
	that in no event shall the Cap
	Price be less than the Strike Price)&rdquo;, (y) the fifth and sixth lines shall be deleted in their entirety and replaced with
	the words &ldquo;effect, taken cumulatively on the Option, of such Announcement Event solely to account for changes in volatility,
	expected dividends, stock loan rate or liquidity relevant to the Shares or such Option&rdquo;, and (z)&nbsp;for the avoidance of
	doubt, the Calculation Agent may adjust the terms of the Transaction for a single Announcement Event on one or more occasions on
	or after the date of such Announcement Event up to, and including, the Expiration Date, any Early Termination Date and/or any other
	date of cancellation, it being understood that any adjustment in respect of an Announcement Event shall take into account any earlier
	adjustment relating to the same Announcement Event and any adjustment in respect of an Announcement Event hereunder shall be without
	duplication in respect of any other adjustment or cancellation valuation made pursuant to the Equity Definitions or hereunder.
	An Announcement Event shall be an &ldquo;Extraordinary Event&rdquo; for purposes of the Equity Definitions, to which Article 12
	of the Equity Definitions is applicable.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_80"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Announcement Event:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	(i) The public announcement by any entity of any transaction or event that, if completed, would
	constitute a Merger Event or Tender Offer, or (ii) any subsequent public announcement by any entity of a change to a transaction
	that is the subject of an announcement of the type described in clause (i) of this sentence (including, without limitation, a new
	announcement, whether or not by the same party, relating to such a transaction or the announcement of a withdrawal from, or the
	abandonment or discontinuation of, such a transaction), as determined by the Calculation Agent. For the avoidance of doubt, the
	occurrence of an Announcement Event with respect to any transaction shall not preclude the occurrence of a later Announcement Event
	with respect to such transaction. For purposes of this definition of &ldquo;Announcement Event,&rdquo; (A) &ldquo;Merger Event&rdquo;
	shall mean such term as defined under Section 12.1(b) of the Equity Definitions (but, for the avoidance of doubt, the remainder
	of the definition of &ldquo;Merger Event&rdquo; in Section 12.1(b) of the Equity Definitions following the definition of &ldquo;Reverse
	Merger&rdquo; therein shall be disregarded) and (B) &ldquo;Tender Offer&rdquo; shall mean such term as defined under Section 12.1(d)
	of the Equity Definitions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 2.5IN">
	Nationalization, Insolvency or Delisting:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cancellation and Payment (Calculation Agent Determination);
<I>
	provided
</I>
	that, in addition to
	the provisions of Section 12.6(a)(iii) of the Equity Definitions, it will also constitute a Delisting if the Exchange is located
	in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange,
	The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors); if the Shares are immediately re-listed,
	re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their
	respective successors), such exchange or quotation system shall thereafter be deemed to be the Exchange.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_81"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	Additional
	Disruption Events:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -2.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.25IN">
	Change in Law:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable;
<I>
	provided
</I>
	that Section 12.9(a)(ii) of the Equity Definitions is hereby amended
	by (i)&nbsp;replacing the word &ldquo;Shares&rdquo; with the phrase &ldquo;Hedge Positions&rdquo; in clause (X) thereof; (ii)&nbsp;inserting
	the parenthetical &ldquo;(including, for the avoidance of doubt and without limitation, adoption or promulgation of new regulations
	authorized or mandated by existing statute)&rdquo; at the end of clause (A) thereof; (iii) replacing the phrase &ldquo;the interpretation&rdquo;
	in the third line thereof with the phrase &ldquo;or announcement of the formal or informal interpretation&rdquo;; and (iv) immediately
	following the word &ldquo;Transaction&rdquo; in clause (X) thereof, adding the phrase &ldquo;in the manner contemplated by the
	Hedging Party on the Trade Date&rdquo;.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.25IN">
	Failure to Deliver:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.25IN">
	Insolvency Filing:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.25IN">
	Hedging Disruption:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable;
<I>
	provided
</I>
	that:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3.25IN">
</TD>
<TD STYLE="WIDTH: 0.4IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 12.9(a)(v) of the Equity Definitions is hereby amended by (a)&nbsp;inserting the following
	words at the end of clause (A) thereof: &ldquo;in the manner contemplated by the Hedging Party on the Trade Date&rdquo; and (b)&nbsp;inserting
	the following language at the end of such Section:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3.25IN">
</TD>
<TD STYLE="WIDTH: 0.4IN">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;,
<I>
	provided
</I>
	that any such inability that occurs solely due to the deterioration of
	the creditworthiness of the Hedging Party shall not be deemed a Hedging Disruption. For the avoidance of doubt, the term &ldquo;equity
	price risk&rdquo; shall be deemed to include, but shall not be limited to, stock price and volatility risk. And, for the further
	avoidance of doubt, any such transactions or assets referred to in phrases (A) or (B) above must be available on commercially reasonable
	pricing terms.&rdquo;; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3.25IN">
</TD>
<TD STYLE="WIDTH: 0.4IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 12.9(b)(iii) of the Equity Definitions is hereby amended by inserting in the third line
	thereof, after the words &ldquo;to terminate the Transaction&rdquo;, the words &ldquo;or a portion of the Transaction affected
	by such Hedging Disruption&rdquo;.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_82"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 2.25IN">
	Hedging Party:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For all applicable Additional Disruption Events, Dealer;
<I>
	provided
</I>
	that all calculations
	and determinations by the Hedging Party shall be made in good faith and in a commercially reasonable manner;
<I>
	provided further
</I>
	that nothing herein shall limit or alter, or be deemed to limit or alter, the ability of Dealer (whether acting as Dealer, the
	Hedging Party, the Determining Party or the Calculation Agent) to hedge its obligations under the Transaction in a manner it deems
	appropriate, as determined by Dealer in its sole discretion. The parties agree that they will comply with the provisions set forth
	in the second paragraph under &ldquo;Calculation Agent&rdquo; below.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_83"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 2.75IN">
	Determining Party:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For all applicable Extraordinary Events, Dealer;
<I>
	provided
</I>
	that all calculations and determinations
	by the Determining Party shall be made in good faith and in a commercially reasonable manner. The parties agree that they will
	comply with the provisions set forth in the second paragraph under &ldquo;Calculation Agent&rdquo; below.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 2.75IN">
	Non-Reliance:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT">
	Agreements and Acknowledgments&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 2.75IN; TEXT-ALIGN: LEFT">
	Regarding Hedging Activities:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 2.75IN; TEXT-ALIGN: LEFT">
	Additional Acknowledgments:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Applicable
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_84"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
<B>
	4.
</B>
</TD>
<TD STYLE="WIDTH: 2.75IN; PADDING-BOTTOM: 10PT; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
<B>
<U>
	Calculation Agent.
</U>
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
	Dealer;
<I>
	provided
</I>
	that, following the occurrence and during the continuance of an Event of Default of the type described in Section 5(a)(vii) of the Agreement with respect to which Dealer is the sole Defaulting Party, Counterparty shall have the right to designate a nationally recognized independent equity derivatives dealer to replace Dealer as the Calculation Agent, and the parties shall work in good faith to execute any appropriate documentation required by such replacement Calculation Agent. All calculations, adjustments, specifications, choices and determinations by the Calculation Agent shall be made in good faith and in a commercially reasonable manner. The parties agree that they will comply with the provisions set forth in the immediately following paragraph.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -3.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -3.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In the case
	of any calculation, adjustment or determination by the Determining Party or the Calculation Agent, as the case may be, following
	any written request from Counterparty, the Determining Party or the Calculation Agent, as the case may be, shall promptly provide
	to Counterparty a written explanation describing in reasonable detail the basis for such calculation, adjustment or determination
	(including any quotation, market data or information from internal or external sources used in making such calculation, adjustment
	or determination), but without disclosing any proprietary or confidential models used by it for such calculation, adjustment or
	determination or any information that is subject to an obligation not to disclose such information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<B>
	5.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Account Details
</U>
	.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Account for payments to Counterparty:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Bank:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	ABA#:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Acct No.:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Acct Name:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	For final credit
<BR>
	to account:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Account for delivery
	of Shares to Counterparty:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	To be advised.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Account for payments to Dealer:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Bank:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	SWIFT:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Bank Routing:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Acct No:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Acct Name:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Account for delivery of Shares from Dealer:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	To be advised.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<B>
	6.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Offices
</U>
	.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	The Office of Counterparty for the Transaction is: Inapplicable, Counterparty is not a Multibranch
	Party.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	The Office of Dealer for the Transaction is: New York
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Morgan Stanley
	&amp; Co. LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1585 Broadway,
	5th Floor
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	New York, NY 10036
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<B>
	7.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Notices
</U>
	.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Address for notices or communications to Counterparty:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Novavax, Inc.
<BR>
	20 Firstfield Road
<BR>
	Gaithersburg, Maryland 20878
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_85"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2IN">
	Attention:
</TD>
<TD>
	Chief Financial Officer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Telephone No.:
</TD>
<TD>
	(240) 268-2030
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Facsimile No.:
</TD>
<TD>
	(240) 268-2100
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Email:
</TD>
<TD>
	bphillips@Novavax.com
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	With a copy to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Ropes &amp; Gray LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Attention: Isabel Dische, Esq. and Thomas Holden, Esq.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Telephone No: (212) 596-9000
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Facsimile No: (212) 596-9090
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	Email: isabel.dische@ropesgray.com; thomas.holden@ropesgray.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Address for notices or communications to Dealer:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2IN">
	To:
</TD>
<TD>
	Morgan Stanley &amp; Co. LLC
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	1585 Broadway, 4th Floor
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	New York, NY 10036
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2IN">
	Attention:
</TD>
<TD>
	David Oakes
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Telephone:
</TD>
<TD>
	(212) 761-5319
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Facsimile:
</TD>
<TD>
	(212) 404-9480
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Email:
</TD>
<TD>
	David.Oakes@morganstanley.com
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2IN">
	With a copy to:
</TD>
<TD>
	Morgan Stanley &amp; Co. LLC
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<A NAME="FIS_UNIDENTIFIED_TABLE_86"></A>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	1221 Avenue of the Americas, 34th Floor
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	New York, NY 10020
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Attention:
</TD>
<TD>
	Anthony Cicia
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Telephone:
</TD>
<TD>
	(212) 762-4828
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Facsimile:
</TD>
<TD>
	(212) 507-4338
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Email:
</TD>
<TD>
	Anthony.Cicia@morganstanley.com
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	8.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Representations and Warranties of Counterparty
</U>
	.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35PT; TEXT-ALIGN: JUSTIFY">
	Each of the representations and
	warranties of Counterparty set forth in Section 1 of the Purchase Agreement (the &ldquo;
<B>
	Purchase
</B>
<B>
	Agreement
</B>
	&rdquo;)
	dated as of January 25, 2016, among Counterparty, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives
	of the Initial Purchasers party thereto (the &ldquo;
<B>
	Initial Purchasers
</B>
	&rdquo;), are true and correct and are hereby deemed
	to be repeated to Dealer as if set forth herein, except to the extent that such representations and warranties, if not true or
	correct, would not have a material adverse effect on the power or ability of Company to execute and deliver this Confirmation or
	to perform its obligations hereunder. Counterparty hereby further represents and warrants to Dealer on the date hereof and on and
	as of the Premium Payment Date that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty has all necessary corporate power and authority to execute, deliver and perform its
	obligations in respect of the Transaction; such execution, delivery and performance have been duly authorized by all necessary
	corporate action on Counterparty&rsquo;s part; and this Confirmation has been duly and validly executed and delivered by Counterparty
	and constitutes its valid and binding obligation, enforceable against Counterparty in accordance with its terms, subject to applicable
	bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors&rsquo; rights and
	remedies generally, and subject, as to enforceability, to general principles of equity, including principles of commercial reasonableness,
	good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity) and except that rights
	to indemnification and contribution hereunder may be limited by federal or state securities laws or public policy relating thereto.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Neither the execution and delivery of this Confirmation nor the incurrence or performance of obligations
	of Counterparty hereunder will conflict with or result in a breach of (i) the Certificate of Incorporation or the Amended and Restated
	By-Laws of Counterparty (or any equivalent documents), (ii) any applicable law or regulation, or any order, writ, injunction or
	decree of any court or governmental authority or agency, or (iii) any agreement or instrument filed as an exhibit to Company&rsquo;s
	Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (as updated by any subsequent filings) to which Counterparty
	or any of its subsidiaries is a party or by which Counterparty or any of its subsidiaries is bound or to which Counterparty or
	any of its subsidiaries is subject, or constitute a default under, or result in the creation of any lien under, any such agreement
	or instrument except, in the case of clause (iii) above, for any such conflict, breach, default or lien that would not, individually
	or in the aggregate, have a material adverse effect on (x) Counterparty and its subsidiaries, taken as a whole, (y) Dealer&rsquo;s
	rights or obligations relating to the Transaction, or (z) the power or ability of Counterparty to execute and deliver this Confirmation
	or perform its obligations hereunder.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No consent, approval, authorization, or order of, or filing with, any governmental agency or body
	or any court is required in connection with the execution, delivery or performance by Counterparty of this Confirmation, except
	such as have been obtained or made and such as may be required under the Securities Act or state securities laws.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty is not and, after consummation of the transactions contemplated hereby, will not be
	required to register as an &ldquo;investment company&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty is an &ldquo;eligible contract participant&rdquo; (as such term is defined in Section
	1a(18) of the Commodity Exchange Act, as amended, other than a person that is an eligible contract participant under Section 1a(18)(C)
	of the Commodity Exchange Act).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Each of it and its affiliates is not, on the date hereof, in possession of any material non-public
	information with respect to Counterparty or the Shares.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The documents incorporated by reference in the Offering Memorandum, when they were filed with the
	U.S. Securities Exchange Commission (the &ldquo;
<B>
	Commission
</B>
	&rdquo;) conformed in all material respects to the requirements
	of the Exchange Act, and the Offering Memorandum does not contain any untrue statement of a material fact or omit to state a material
	fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(h)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	To Counterparty&rsquo;s knowledge, no state or local (including any non-U.S. jurisdiction&rsquo;s)
	law, rule, regulation or regulatory order applicable to the Shares would give rise to any reporting, consent, registration or other
	requirement (including without limitation a requirement to obtain prior approval from any person or entity) by Dealer as a result
	of Dealer owning or holding (however defined) Shares except for the reporting requirements of the Exchange Act and the rules promulgated
	thereunder;
<I>
	provided
</I>
	that Counterparty makes no representation or warranty regarding any such requirement that is applicable
	generally to the ownership of equity securities by Dealer solely as a result of it being a financial institution or broker-dealer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty understands that no obligations of Dealer to it hereunder will be entitled to the
	benefit of deposit insurance and that such obligations as of the date hereof are not guaranteed by any Affiliate of Dealer or any
	governmental agency.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(j)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	COUNTERPARTY UNDERSTANDS THAT THE TRANSACTION IS SUBJECT TO COMPLEX RISKS THAT MAY ARISE WITHOUT
	WARNING AND MAY AT TIMES BE VOLATILE AND THAT LOSSES MAY OCCUR QUICKLY AND IN UNANTICIPATED MAGNITUDE AND IS WILLING TO ACCEPT
	SUCH TERMS AND CONDITIONS AND ASSUME (FINANCIALLY AND OTHERWISE) SUCH RISKS.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(k)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty (A) is capable of evaluating investment risks independently, both in general and with
	regard to all transactions and investment strategies involving a security or securities; (B) will exercise independent judgment
	in evaluating the recommendations of any broker-dealer or its associated persons, unless it has otherwise notified the broker-dealer
	in writing; and (C) has total assets of at least USD 50 million.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(l)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty is not as of the Trade Date, and Counterparty shall not be after giving effect to
	the transactions contemplated hereby, &ldquo;insolvent&rdquo; (as such term is defined in Section 101(32) of the U.S. Bankruptcy
	Code (Title 11 of the United States Code) (the &ldquo;
<B>
	Bankruptcy Code
</B>
	&rdquo;)) and Counterparty would be able to purchase
	1,468,213 Shares in compliance with the laws of the jurisdiction of Counterparty&rsquo;s incorporation or organization.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(m)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty understands, agrees and acknowledges that Dealer has no obligation or intention to
	register the Transaction under the Securities Act, any state securities law or other applicable federal securities law.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(n)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Without limiting the generality of Section 3(a)(iii) of the Agreement, the Transaction will not
	violate Rule 13e-1 or Rule 13e-4 under the Exchange Act.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Other Provisions
</U>
	.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	[
<I>
	Reserved
</I>
	.]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Repurchase Notices
</U>
</I>
	. Counterparty shall, on any day on which Counterparty effects
	any repurchase of Shares, promptly give Dealer a written notice of such repurchase (a &ldquo;
<B>
	Repurchase Notice
</B>
	&rdquo;) on
	such day if following such repurchase, the number of outstanding Shares as determined on such day is (i) less than 257.9 million
	(in the case of the first such notice) or (ii) thereafter more than 11.0 million less than the number of Shares included in the
	immediately preceding Repurchase Notice. Counterparty agrees to indemnify and hold harmless Dealer and its affiliates and their
	respective officers, directors, employees, affiliates, advisors, agents and controlling persons (each, an &ldquo;
<B>
	Indemnified
	Person
</B>
	&rdquo;) from and against any and all direct losses (including losses relating to Dealer&rsquo;s commercially reasonable
	hedging activities as a consequence of becoming, or of the risk of becoming, a Section 16 &ldquo;insider&rdquo;, including without
	limitation, any forbearance from commercially reasonable hedging activities or cessation of commercially reasonable hedging activities
	and any losses in connection therewith with respect to the Transaction), claims, damages, judgments, liabilities and reasonable
	expenses (including commercially reasonable attorney&rsquo;s fees of one outside counsel in each relevant jurisdiction), joint
	or several, which an Indemnified Person may become subject to, as a result of Counterparty&rsquo;s failure to provide Dealer with
	a Repurchase Notice on the day and in the manner specified in this paragraph, and to reimburse, within 30 days, upon written request,
	each of such Indemnified Persons for any reasonable legal or other expenses incurred in connection with investigating, preparing
	for, providing testimony or other evidence in connection with or defending any of the foregoing. If any suit, action, proceeding
	(including any governmental or regulatory investigation), claim or demand shall be brought or asserted against the Indemnified
	Person as a result of Counterparty&rsquo;s failure to provide Dealer with a Repurchase Notice in accordance with this paragraph,
	such Indemnified Person shall promptly notify Counterparty in writing, and Counterparty, upon request of the Indemnified Person,
	shall retain counsel reasonably satisfactory to the Indemnified Person to represent the Indemnified Person and any others Counterparty
	may designate in such proceeding and shall pay the commercially reasonable fees and expenses of such counsel related to such proceeding.
	Counterparty shall not be liable for any settlement of any proceeding contemplated by this paragraph that is effected without its
	written consent, but if settled with such consent or if there be a final judgment for the plaintiff, Counterparty agrees to indemnify
	any Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Counterparty shall not,
	without the prior written consent of the Indemnified Person (such consent not to be unreasonably withheld, conditioned or delayed),
	effect any settlement of any pending or threatened proceeding contemplated by this paragraph that is in respect of which any Indemnified
	Person is a party and indemnity could have been sought hereunder by such Indemnified Person, unless such settlement includes an
	unconditional release of such Indemnified Person from all liability on claims that are the subject matter of such proceeding on
	terms reasonably satisfactory to such Indemnified Person. If the indemnification provided for in this paragraph is unavailable
	to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then Counterparty
	hereunder, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified
	Person as a result of such losses, claims, damages or liabilities. The remedies provided for in this paragraph &lrm;(b) are not
	exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.
	The indemnity and contribution agreements contained in this paragraph shall remain operative and in full force and effect regardless
	of the termination of the Transaction.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Regulation M
</U>
</I>
	. Counterparty is not on the Trade Date engaged in a distribution, as
	such term is used in Regulation M under the Securities Exchange Act of 1934, as amended (the &ldquo;
<B>
	Exchange Act
</B>
	&rdquo;),
	of any securities of Counterparty, other than a distribution meeting the requirements of the exception set forth in Rules 101(b)(10)
	and 102(b)(7) of Regulation M. Counterparty shall not, until the second Scheduled Trading Day immediately following the Effective
	Date, engage in any such distribution.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	No Manipulation
</U>
</I>
	. Counterparty is not entering into the Transaction to create actual
	or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress
	or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares) or otherwise
	in violation of the Exchange Act.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(e)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Transfer or Assignment
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall have the right to transfer or assign any of its rights or obligations hereunder
	with respect to all, but not less than all, of the Options hereunder (such Options, the &ldquo;
<B>
	Transfer Options
</B>
	&rdquo;);
<I>
	provided that
</I>
	such transfer or assignment shall be subject to reasonable conditions that Dealer may impose, including but
	not limited, to the following conditions:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(A)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	With respect to any Transfer Options, Counterparty shall not be released from its notice and indemnification
	obligations pursuant to Section &lrm;9(b) or any obligations under Section &lrm;9(n) or &lrm;9(s) of this Confirmation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(B)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such transfer or assignment shall be effected on terms, including any reasonable undertakings by
	such third party (including, but not limited to, an undertaking with respect to compliance with applicable securities laws in a
	manner that, in the reasonable judgment of Dealer, will not expose Dealer to material risks under applicable securities laws) and
	execution of any reasonable documentation and delivery of legal opinions with respect to securities laws and other matters by such
	third party and Counterparty, as are reasonably requested and reasonably satisfactory to Dealer;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(C)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dealer will not, as a result of such transfer and assignment, be required to pay the transferee
	on any payment date an amount under Section 2(d)(i)(4) of the Agreement greater than an amount that Dealer would have been required
	to pay to Counterparty in the absence of such transfer and assignment;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(D)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	An Event of Default, Potential Event of Default or Termination Event will not occur as a result
	of such transfer and assignment;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(E)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall cause the transferee to make such Payee Tax Representations and to provide such
	tax documentation as may be reasonably requested by Dealer to permit Dealer to determine that results described in clauses (C)
	and (D) will not occur upon or after such transfer and assignment; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(F)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall be responsible for all reasonable costs and expenses, including reasonable counsel
	fees, incurred by Dealer in connection with such transfer or assignment.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Dealer may transfer or assign all or any part of its rights or obligations under the Transaction
	(A) without Counterparty&rsquo;s consent to any affiliate of Dealer (1) that has a long-term issuer rating or a rating for its
	long term, unsecured and unsubordinated indebtedness, in either case, that is equal to or better than Dealer&rsquo;s credit rating
	at the time of such transfer or assignment, or (2) whose obligations hereunder will be guaranteed, pursuant to the terms of a customary
	guarantee in a form used by Dealer generally for similar transactions, by Dealer or Dealer&rsquo;s ultimate parent, or (B) with
	Counterparty&rsquo;s consent (such consent not to be unreasonably withheld or delayed) to any other third party with a long-term
	issuer rating or a rating for its long term, unsecured and unsubordinated indebtedness, as the case may be, equal to or better
	than the lesser of (1) the credit rating of Dealer at the time of such transfer or assignment and (2) A- by Standard and Poor&rsquo;s
	Rating Group, Inc. or its successor (&ldquo;
<B>
	S&amp;P
</B>
	&rdquo;), or A3 by Moody&rsquo;s Investor Service, Inc. (&ldquo;
<B>
	Moody&rsquo;s
</B>
	&rdquo;)
	or, if either S&amp;P or Moody&rsquo;s ceases to rate such debt, at least an equivalent rating or better by a substitute rating
	agency mutually agreed by Counterparty and Dealer;
<I>
	provided
</I>
	that any transfer or assignment described in clause (A) or (B)
	above shall not result in a deemed exchange by Counterparty within the meaning of Section 1001 of the Code;
<I>
	provided further
</I>
	that (x) Counterparty will not be required, as a result of such transfer or assignment, to pay the transferee or assignee on any
	payment date an amount under Section 2(d)(i)(4) of the Agreement greater than the amount, if any, that Counterparty would have
	been required to pay Dealer in the absence of such transfer or assignment and (y) Dealer shall cause the transferee or assignee
	to make such Payee Tax Representations and to provide such tax documentation as may be reasonably requested by Counterparty to
	permit Counterparty to determine that the results described in clause (x) of this proviso will not occur upon or after such transfer
	and assignment. If at any time at which (A) the Section 16 Percentage exceeds 8.5%, (B) the Option Equity Percentage exceeds 14.5%,
	or (C) the Share Amount exceeds the Applicable Share Limit (if any applies) (any such condition described in clauses (A), (B) or
	(C), an &ldquo;
<B>
	Excess Ownership Position
</B>
	&rdquo;), Dealer is unable after using its commercially reasonable efforts to effect
	a transfer or assignment of Options to a third party on pricing terms reasonably acceptable to Dealer and within a time period
	reasonably acceptable to Dealer such that no Excess Ownership Position exists, then Dealer may designate any Exchange Business
	Day as an Early Termination Date with respect to a portion of the Transaction (the &ldquo;
<B>
	Terminated Portion
</B>
	&rdquo;), such
	that following such partial termination no Excess Ownership Position exists. In the event that Dealer so designates an Early Termination
	Date with respect to a portion of the Transaction, a payment shall be made pursuant to Section 6 of the Agreement as if (1) an
	Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and a Number of
	Options equal to the number of Options underlying the Terminated Portion, (2) Counterparty were the sole Affected Party with respect
	to such partial termination and (3) the Terminated Portion were the sole Affected Transaction (and, for the avoidance of doubt,
	the provisions of Section &lrm;9(l) shall apply to any amount that is payable by Dealer to Counterparty pursuant to this sentence
	as if Counterparty was not the Affected Party). Dealer shall notify Counterparty of an Excess Ownership Position with respect to
	which it intends to seek a transfer or assignment as soon as reasonably practicable after becoming aware of such an Excess Ownership
	Position. The &ldquo;
<B>
	Section 16 Percentage
</B>
	&rdquo; as of any day is the fraction, expressed as a percentage, (A) the numerator
	of which is the number of Shares that Dealer and any of its affiliates or any other person subject to aggregation with Dealer for
	purposes of the &ldquo;beneficial ownership&rdquo; test under Section 13 of the Exchange Act, or any &ldquo;group&rdquo; (within
	the meaning of Section 13 of the Exchange Act) of which Dealer is or may be deemed to be a part beneficially owns (within the meaning
	of Section 13 of the Exchange Act), without duplication, on such day (or, to the extent that for any reason the equivalent calculation
	under Section 16 of the Exchange Act and the rules and regulations thereunder results in a higher number, such higher number) and
	(B) the denominator of which is the number of Shares outstanding on such day. The &ldquo;
<B>
	Option Equity Percentage
</B>
	&rdquo;
	as of any day is the fraction, expressed as a percentage, (A) the numerator of which is the sum of (1) the product of the Number
	of Options and the Option Entitlement and (2) the aggregate number of Shares underlying any other call option transaction sold
	by Dealer to Counterparty, and (B) the denominator of which is the number of Shares outstanding. The &ldquo;
<B>
	Share Amount
</B>
	&rdquo;
	as of any day is the number of Shares that Dealer and any person whose ownership position would be aggregated with that of Dealer
	(Dealer or any such person, a &ldquo;
<B>
	Dealer Person
</B>
	&rdquo;) under any law, rule, regulation, regulatory order or organizational
	documents or contracts of Counterparty that are, in each case, applicable to ownership of Shares (&ldquo;
<B>
	Applicable Restrictions
</B>
	&rdquo;),
	owns, beneficially owns, constructively owns, controls, holds the power to vote or otherwise meets a relevant definition of ownership
	under any Applicable Restriction, as determined by Dealer in its reasonable discretion. The &ldquo;
<B>
	Applicable Share Limit
</B>
	&rdquo;
	means a number of Shares equal to (A) the minimum number of Shares that would give rise to reporting or registration obligations
	(except for any filings of Form 13F, Schedule 13D or Schedule 13G under the Exchange Act) or other requirements (including obtaining
	prior approval from any person or entity) of a Dealer Person, or is reasonably likely to result in an adverse effect on a Dealer
	Person, under any Applicable Restriction, as determined by Dealer in its reasonable discretion,
<I>
	minus
</I>
	(B) 1% of the number
	of Shares outstanding.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding any other provision in this Confirmation to the contrary requiring or allowing
	Dealer to purchase, sell, receive or deliver any Shares or other securities, or make or receive any payment in cash, to or from
	Counterparty, Dealer may designate any of its affiliates to purchase, sell, receive or deliver such Shares or other securities,
	or to make or receive such payment in cash, and otherwise to perform Dealer&rsquo;s obligations in respect of the Transaction and
	any such designee may assume such obligations; provided that Counterparty shall have recourse to Dealer in the event of failure
	by such assignee to perform any of such obligations hereunder. Dealer shall be discharged of its obligations to Counterparty to
	the extent of any such performance to Counterparty by such affiliate of Dealer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(f)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Staggered Settlement
</U>
</I>
	. If upon advice of counsel with respect to applicable legal
	and regulatory requirements, including any requirements relating to Dealer&rsquo;s hedging activities hereunder, Dealer reasonably
	determines that it would not be practicable or advisable to deliver, or to acquire Shares to deliver, any or all of the Shares
	to be delivered by Dealer on any Settlement Date for the Transaction, Dealer may, by notice to Counterparty on or prior to any
	Settlement Date (a &ldquo;
<B>
	Nominal Settlement Date
</B>
	&rdquo;), elect to deliver the Shares on two or more dates (each, a &ldquo;
<B>
	Staggered
	Settlement Date
</B>
	&rdquo;) only to the extent reasonably necessary, as reasonably determined by Dealer in good faith, to avoid
	an Excess Ownership Position as follows:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	in such notice, Dealer will specify to Counterparty the related Staggered Settlement Dates (each
	of which will be on or prior to such Nominal Settlement Date) and the number of Shares that it will deliver on each Staggered Settlement
	Date;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the aggregate number of Shares that Dealer will deliver to Counterparty hereunder on all such Staggered
	Settlement Dates will equal the number of Shares that Dealer would otherwise be required to deliver on such Nominal Settlement
	Date; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the Net Share Settlement terms will apply on each Staggered Settlement Date, except that the Net
	Shares will be allocated among such Staggered Settlement Dates as specified by Dealer in the notice referred to in clause (i) above.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(g)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	[
<I>
	Reserved
</I>
	.]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(h)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	[
<I>
	Reserved
</I>
	.]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Additional Termination Events
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in this Confirmation, upon any Early Conversion in respect
	of which a &ldquo;Notice of Conversion&rdquo; (as such term is defined in the Indenture) that is effective as to Counterparty has
	been delivered by the relevant converting &ldquo;Holder&rdquo; (as such term is defined in the Indenture):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(A)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Counterparty shall, within five Scheduled Trading Days of the Conversion Date for such Early Conversion,
	provide written notice (an &ldquo;
<B>
	Early Conversion Notice
</B>
	&rdquo;) to Dealer specifying the number of Convertible Notes surrendered
	for conversion on such Conversion Date (such Convertible Notes, the &ldquo;
<B>
	Affected Convertible Notes
</B>
	&rdquo;)
<FONT STYLE="FONT-WEIGHT: NORMAL">
	,
	and the giving of such Early Conversion Notice
</FONT>
<B>
</B>
	shall constitute an Additional Termination Event as provided in this
	clause &lrm;(i);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(B)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	upon receipt of any such Early Conversion Notice, Dealer shall designate an Exchange Business Day
	as an Early Termination Date (which Exchange Business Day shall be on or as promptly as reasonably practicable after the related
	settlement date for such Affected Convertible Notes) with respect to the portion of the Transaction corresponding to a number of
	Options (the &ldquo;
<B>
	Affected Number of Options
</B>
	&rdquo;) equal to the lesser of (x) the number of Affected Convertible Notes
<I>
	minus
</I>
	the &ldquo;Affected Number of Options&rdquo; (as defined in the Base Call Option Confirmation), if any, that relate
	to such Affected Convertible Notes and (y) the Number of Options as of the Conversion Date for such Early Conversion;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage145"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(C)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any payment hereunder with respect to such termination shall be calculated pursuant to Section
	6 of the Agreement as if (x) an Early Termination Date had been designated in respect of a Transaction having terms identical to
	the Transaction and a Number of Options equal to the Affected Number of Options, (y) Counterparty were the sole Affected Party
	with respect to such Additional Termination Event and (z) the terminated portion of the Transaction were the sole Affected Transaction
	(and, for the avoidance of doubt, the provisions of Section &lrm;9(l) shall apply to any amount that is payable by Dealer to Counterparty
	pursuant to this Section &lrm;9(i)(i) as if Counterparty were not the Affected Party) (and, in determining the amount payable pursuant
	to Section 6 of the Agreement, the Calculation Agent shall not take into account any adjustments to the Conversion Rate pursuant
	to any Excluded Provision);
<I>
	provided
</I>
	that the amount payable with respect to such termination shall not be greater than
	(1) the Applicable Percentage,
<I>
	multiplied by
</I>
	(2) the Affected Number of Options,
<I>
	multiplied by
</I>
	(3) the excess of
	(I) the Conversion Rate (after taking into account any applicable adjustments to the Conversion Rate pursuant to Section 14.03
	of the Indenture),
<I>
	multiplied by
</I>
	the Applicable Limit Price on the settlement date for the Shares to be delivered pursuant
	to the Indenture in respect of the Affected Convertible Note,
<I>
	minus
</I>
	(II) USD 1,000;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(D)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	for the avoidance of doubt, in determining the amount payable
	in respect of such Affected Transaction pursuant to Section 6 of the Agreement, the Calculation Agent shall assume that (x) the
	relevant Early Conversion and any conversions, adjustments, agreements, payments, deliveries or acquisitions by or on behalf of
	Counterparty leading thereto had not occurred, (y) no adjustments to the Conversion Rate have occurred pursuant to any Excluded
	Provision and (z) the corresponding Convertible Notes remain outstanding; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(E)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the Transaction shall remain in full force and effect, except that, as of the Conversion Date for
	such Early Conversion, the Number of Options shall be reduced by the Affected Number of Options
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in this Confirmation if an event of default with respect
	to Counterparty occurs under the terms of the Convertible Notes as set forth in Section 6.01 of the Indenture, and such event of
	default results in the Convertible Notes becoming or being declared due and payable pursuant to the Indenture, then such event
	of default shall constitute an Additional Termination Event applicable to the Transaction and, with respect to such Additional
	Termination Event, (A) Counterparty shall be deemed to be the sole Affected Party, (B) the Transaction shall be the sole Affected
	Transaction and (C) Dealer shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement
	(which Early Termination Date shall be on or as promptly as reasonably practicable after Dealer becomes aware of the occurrence
	of such acceleration).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage146"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(iii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Promptly (but in any event within five Scheduled Trading Days) following any Repurchase Event (as
	defined below), Counterparty may notify Dealer of such Repurchase Event and the aggregate principal amount of Convertible Notes
	subject to such Repurchase Event (any such notice, a &ldquo;
<B>
	Convertible Notes Repurchase Notice
</B>
	&rdquo;);
<I>
	provided
</I>
	that any such Convertible Notes Repurchase Notice shall contain an acknowledgment by Counterparty of its responsibilities under
	applicable securities laws, and in particular Section 9 and Section 10(b) of the Exchange Act and the rules and regulations thereunder,
	in respect of such Repurchase Event and the delivery of such Convertible Notes Repurchase Notice. The receipt by Dealer from Counterparty
	of any Convertible Notes Repurchase Notice shall constitute an Additional Termination Event as provided in this Section &lrm;9(i)(iii).
	Upon receipt of any such Convertible Notes Repurchase Notice, Dealer shall designate an Exchange Business Day following receipt
	of such Convertible Notes Repurchase Notice (which Exchange Business Day shall be on or as promptly as reasonably practicable after
	the related settlement date for the relevant Repurchase Event) as an Early Termination Date with respect to the portion of the
	Transaction corresponding to a number of Options (the &ldquo;
<B>
	Repurchase Options
</B>
	&rdquo;) equal to the lesser of (A) (x) the
	aggregate principal amount of such Convertible Notes specified in such Convertible Notes Repurchase Notice,
<I>
	divided by
</I>
	USD
	1,000,
<I>
	minus
</I>
	(y) the number of Repurchase Options (as defined in the Base Call Option Confirmation), if any, that relate
	to such Convertible Notes, and (B) the Number of Options as of the date Dealer designates such Early Termination Date and, as of
	such date, the Number of Options shall be reduced by the number of Repurchase Options. Any payment hereunder with respect to such
	termination (the &ldquo;
<B>
	Repurchase Unwind Payment
</B>
	&rdquo;) shall be calculated pursuant to Section 6 of the Agreement as
	if (1) an Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and
	a Number of Options equal to the number of Repurchase Options, (2) Counterparty were the sole Affected Party with respect to such
	Additional Termination Event and (3) the terminated portion of the Transaction were the sole Affected Transaction (and, for the
	avoidance of doubt, the provisions of Section &lrm;9(l) shall apply to any amount that is payable by Dealer to Counterparty pursuant
	to this Section &lrm;9(i)(iii) as if Counterparty was not the Affected Party). &ldquo;
<B>
	Repurchase Event
</B>
	&rdquo; means that
	(i) any Convertible Notes are repurchased (whether pursuant to Section 15.02 of the Indenture or otherwise) by Counterparty or
	any of its subsidiaries, (ii) any Convertible Notes are delivered to Counterparty in exchange for delivery of any property or assets
	of Counterparty or any of its subsidiaries (howsoever described), (iii) any principal of any of the Convertible Notes is repaid
	prior to the final maturity date of the Convertible Notes (other than upon acceleration of the Convertible Notes described in Section
	&lrm;9(i)(ii)), or (iv) any Convertible Notes are exchanged by or for the benefit of the Holders (as defined in the Indenture)
	thereof for any other securities of Counterparty or any of its Affiliates (or any other property, or any combination thereof) pursuant
	to any exchange offer or similar transaction;
<I>
	provided
</I>
	that neither (i) any conversion of Convertible Notes pursuant to
	the terms of the Indenture, nor (ii) any exchange of Convertible Notes pursuant to Section 15.06 of the Indenture, shall in either
	case constitute a Repurchase Event.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(j)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Amendments to Equity Definitions
</U>
</I>
	.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 11.2(e)(vii) of the Equity Definitions is hereby amended by (x) inserting the words &ldquo;similar
	corporate&rdquo; immediately prior to the word &ldquo;event&rdquo; and (y) deleting the words &ldquo;diluting or concentrative&rdquo;
	and replacing them with the word &ldquo;material&rdquo;; and adding the phrase &ldquo;or the Options&rdquo; at the end of the sentence.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Section 12.9(b)(i) of the Equity Definitions is hereby amended by replacing &ldquo;either party
	may elect&rdquo; with &ldquo;Dealer may elect or, if Counterparty represents that it and its officers and directors are not aware
	of any material nonpublic information with respect to Counterparty or the Shares, Counterparty may elect,&rdquo;.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(k)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	No Collateral or Setoff
</U>
</I>
	. Neither party shall have the right to set off any obligation
	that it may have to the other party under the Transaction against any obligation such other party may have to it, whether arising
	under the Agreement, this Confirmation or any other agreement between the parties hereto, by operation of law or otherwise.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage147"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(l)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Alternative Calculations and Payment on Early Termination and on Certain Extraordinary Events
</U>
</I>
	.
	If (a) an Early Termination Date (whether as a result of an Event of Default or a Termination Event) occurs or is designated with
	respect to the Transaction or (b) the Transaction is cancelled or terminated upon the occurrence of an Extraordinary Event (except
	as a result of (i) a Nationalization, Insolvency or Merger Event in which the consideration to be paid to holders of Shares consists
	solely of cash, (ii) a Merger Event that is within Counterparty&rsquo;s control, or (iii) an Event of Default in which Counterparty
	is the Defaulting Party or a Termination Event in which Counterparty is the Affected Party other than an Event of Default of the
	type described in Section 5(a)(iii), (v), (vi), (vii) or (viii) of the Agreement or a Termination Event of the type described in
	Section 5(b) of the Agreement, in each case that resulted from an event or events outside Counterparty&rsquo;s control), and if
	Dealer would owe any amount to Counterparty pursuant to Section 6(d)(ii) and 6(e) of the Agreement or any Cancellation Amount pursuant
	to Article 12 of the Equity Definitions (any such amount, a &ldquo;
<B>
	Payment Obligation
</B>
	&rdquo;), then Dealer shall satisfy
	the Payment Obligation by the Share Termination Alternative (as defined below), unless (a)&nbsp;Counterparty gives irrevocable
	telephonic notice to Dealer, confirmed in writing within one Scheduled Trading Day, no later than 12:00 p.m. (New York City time)
	on the Merger Date, Announcement Date (in the case of a Nationalization, Insolvency or Delisting), Early Termination Date or date
	of cancellation, as applicable, of its election that the Share Termination Alternative shall not apply, (b) Counterparty remakes
	the representation set forth in Section &lrm;8(f) as of the date of such election and (c) Dealer agrees, in its commercially reasonable
	discretion, to such election, in which case the provisions of Section 12.7 or Section 12.9 of the Equity Definitions, or the provisions
	of Section 6(d)(ii) and 6(e) of the Agreement, as the case may be, shall apply.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_87"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2.75IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Share Termination Alternative:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If applicable, Dealer shall deliver to Counterparty the Share Termination Delivery Property on, or within a commercially reasonable period of time after, the date when the relevant Payment Obligation would otherwise be due pursuant to Section 12.7 or 12.9 of the Equity Definitions or Section 6(d)(ii) and 6(e) of the Agreement, as applicable, in satisfaction of such Payment Obligation in the manner reasonably requested by Counterparty free of payment.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Share Termination Delivery Property:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A number of Share Termination Delivery Units, as calculated by the Calculation Agent, equal to the Payment Obligation divided by the Share Termination Unit Price. The Calculation Agent shall adjust the Share Termination Delivery Property by replacing any fractional portion of a security therein with an amount of cash equal to the value of such fractional security based on the values used to calculate the Share Termination Unit Price.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Share Termination Unit Price:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The value to Dealer of property contained in one Share Termination Delivery Unit, as determined by the Calculation Agent in good faith and by commercially reasonable means and notified by the Calculation Agent to Dealer at the time of notification of the Payment Obligation. For the avoidance of doubt, the parties agree that in determining the Share Termination Delivery Unit Price the Calculation Agent may consider the purchase price paid in connection with the purchase of Share Termination Delivery Property.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Share Termination Delivery Unit:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	One
	Share or, if the Shares have changed into cash or any other property or the right to receive cash or any other property as
	the result of a Nationalization, Insolvency or Merger Event (any such cash or other property, the &ldquo;
<B>
	Exchange Property
</B>
	&rdquo;),
	a unit consisting of the type and amount of such Exchange Property received by a holder of one Share (without consideration
	of any requirement to pay cash or other consideration in lieu of fractional amounts of any securities) in such Nationalization,
	Insolvency or Merger Event, as determined by the Calculation Agent.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Failure to Deliver:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Applicable
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage148"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_88"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2.75IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other applicable provisions:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If Share Termination Alternative is applicable, the provisions of Sections 9.8, 9.9 and 9.11 (as modified above) of the Equity Definitions and the provisions set forth opposite the caption &ldquo;Representation and Agreement&rdquo; in Section &lrm;2 will be applicable, except that all references in such provisions to &ldquo;Physically-settled&rdquo; shall be read as references to &ldquo;Share Termination Settled&rdquo; and all references to &ldquo;Shares&rdquo; shall be read as references to &ldquo;Share Termination Delivery Units&rdquo;. &ldquo;Share Termination Settled&rdquo; in relation to the Transaction means that the Share Termination Alternative is applicable to the Transaction.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(m)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Waiver of Jury Trial
</U>
</I>
	. Each party waives, to the fullest extent permitted by applicable
	law, any right it may have to a trial by jury in respect of any suit, action or proceeding relating to the Transaction. Each party
	(i) certifies that no representative, agent or attorney of either party has represented, expressly or otherwise, that such other
	party would not, in the event of such a suit, action or proceeding, seek to enforce the foregoing waiver and (ii) acknowledges
	that it and the other party have been induced to enter into the Transaction, as applicable, by, among other things, the mutual
	waivers and certifications provided herein.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(n)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Registration
</U>
</I>
	. Counterparty hereby agrees that if, in the good faith reasonable judgment
	of Dealer based on the advice of counsel, the Shares (&ldquo;
<B>
	Hedge Shares
</B>
	&rdquo;) acquired by Dealer for the purpose of
	hedging its obligations pursuant to the Transaction cannot be sold in the public market by Dealer without registration under the
	Securities Act, Counterparty shall, at its election, either (i) in order to allow Dealer to sell the Hedge Shares in a registered
	offering, make available to Dealer an effective registration statement under the Securities Act and enter into an agreement, in
	form and substance reasonably satisfactory to Dealer, substantially in the form of an underwriting agreement for a registered secondary
	offering of a similar size;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that if Dealer, in its sole reasonable discretion, is not satisfied
	with access to due diligence materials, the results of its due diligence investigation, or the procedures and documentation for
	the registered offering referred to above, then clause (ii) or clause (iii) of this paragraph shall apply at the election of Counterparty,
	(ii) in order to allow Dealer to sell the Hedge Shares in a private placement, enter into a private placement agreement substantially
	similar to private placement purchase agreements customary for private placements of equity securities of similar size, in form
	and substance reasonably satisfactory to Dealer (in which case, the Calculation Agent shall make any adjustments to the terms of
	the Transaction that are necessary, in its commercially reasonable judgment, to account for any commercially reasonable discount
	from the public market price of the Shares incurred on the sale of Hedge Shares in a private placement), or (iii) purchase the
	Hedge Shares from Dealer at the Relevant Price on such Exchange Business Days, and in the amounts, requested by Dealer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(o)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Tax Disclosure
</U>
</I>
	. Effective from the date of commencement of discussions concerning
	the Transaction, Counterparty and each of its employees, representatives, or other agents may disclose to any and all persons,
	without limitation of any kind, the tax treatment and tax structure of the Transaction and all materials of any kind (including
	opinions or other tax analyses) that are provided to Counterparty relating to such tax treatment and tax structure.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(p)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Right to Extend
</U>
</I>
	. Dealer may postpone or add, in whole or in part, any Valid Day or
	Valid Days during the Settlement Averaging Period or any other date of valuation, payment or delivery by Dealer, with respect to
	some or all of the Options hereunder, if Dealer reasonably determines, in its commercially reasonable judgment and, in respect
	of clause (ii) below, based on the advice of counsel, that such action is reasonably necessary or advisable (i) to preserve Dealer&rsquo;s
	hedging or hedge unwind activity hereunder in light of existing liquidity conditions (but only if there is a material decrease
	in liquidity relative to Dealer&rsquo;s expectations on the Trade Date) or (ii) to enable Dealer to effect transactions in Shares
	in connection with its hedging, hedge unwind or settlement activity hereunder in a manner that would, if Dealer were Issuer or
	an affiliated purchaser of Issuer, be in compliance with applicable legal or regulatory requirements, requirements of self-regulatory
	organizations with jurisdiction over Dealer or its affiliates, or related policies and procedures adopted in good faith by Dealer
	(so long as such policies and procedures would generally be applicable to counterparties similar to Counterparty and transactions
	similar to the Transaction);
<I>
	provided
</I>
	that no such Valid Day or other date of valuation, payment or delivery may be postponed
	or added more than 50 Valid Days after the original Valid Day or other date of valuation, payment or delivery, as the case may
	be.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage149"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(q)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Status of Claims in Bankruptcy
</U>
</I>
	.
<I>
</I>
	Dealer acknowledges and agrees that this
	Confirmation is not intended to convey to Dealer rights against Counterparty with respect to the Transaction that are senior to
	the claims of common stockholders of Counterparty in any United States bankruptcy proceedings of Counterparty;
<I>
	provided
</I>
	that nothing herein shall limit or shall be deemed to limit Dealer&rsquo;s right to pursue remedies in the event of a breach by
	Counterparty of its obligations and agreements with respect to the Transaction;
<I>
	provided
</I>
	,
<I>
	further
</I>
	, that nothing herein
	shall limit or shall be deemed to limit Dealer&rsquo;s rights in respect of any transactions other than the Transaction.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(r)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Securities Contract; Swap Agreement
</U>
</I>
	. The parties hereto intend for (i) the Transaction
	to be a &ldquo;securities contract&rdquo; and a &ldquo;swap agreement&rdquo; as defined in the Bankruptcy Code, and the parties
	hereto to be entitled to the protections afforded by, among other Sections, Sections 362(b)(6), 362(b)(17), 546(e), 546(g), 555
	and 560 of the Bankruptcy Code, (ii) a party&rsquo;s right to liquidate the Transaction and to exercise any other remedies upon
	the occurrence of any Event of Default under the Agreement with respect to the other party to constitute a &ldquo;contractual right&rdquo;
	as described in the Bankruptcy Code, and (iii) each payment and delivery of cash, securities or other property hereunder to constitute
	a &ldquo;margin payment&rdquo; or &ldquo;settlement payment&rdquo; and a &ldquo;transfer&rdquo; as defined in the Bankruptcy Code.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(s)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Notice of Certain Other Events
</U>
</I>
	. Counterparty covenants and agrees that:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	promptly following the public announcement of the results of any election by the holders of Shares
	with respect to the consideration due upon consummation of any Merger Event, Counterparty shall give Dealer written notice of (x)
	the weighted average of the types and amounts of consideration that holders of Shares have elected to receive upon consummation
	of such Merger Event or (y) if no holders of Shares affirmatively make such election, the types and amounts of consideration actually
	received by holders of Shares (the date of such notification, the &ldquo;
<B>
	Consideration Notification Date
</B>
	&rdquo;);
<I>
	provided
</I>
	that in no event shall the Consideration Notification Date be later than the date on which such Merger Event is consummated; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(ii)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	promptly following any adjustment to the Convertible Notes in connection with any Potential Adjustment
	Event, Merger Event or Tender Offer, Counterparty shall give Dealer written notice of the details of such adjustment.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(t)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Wall Street Transparency and Accountability Act
</U>
</I>
	. In connection with Section 739 of
	the Wall Street Transparency and Accountability Act of 2010 (&ldquo;
<B>
	WSTAA
</B>
	&rdquo;), the parties hereby agree that neither
	the enactment of WSTAA or any regulation under the WSTAA, nor any requirement under WSTAA or an amendment made by WSTAA, shall
	limit or otherwise impair either party&rsquo;s otherwise applicable rights to terminate, renegotiate, modify, amend or supplement
	this Confirmation or the Agreement, as applicable, arising from a termination event, force majeure, illegality, increased costs,
	regulatory change or similar event under this Confirmation, the Equity Definitions incorporated herein, or the Agreement (including,
	but not limited to, rights arising from Change in Law, Hedging Disruption, an Excess Ownership Position, or Illegality (as defined
	in the Agreement)).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(u)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Agreements and Acknowledgements Regarding Hedging
</U>
</I>
	. Counterparty understands, acknowledges
	and agrees that: (A) at any time on and prior to the Expiration Date, Dealer and its affiliates may buy or sell Shares or other
	securities or buy or sell options or futures contracts or enter into swaps or other derivative securities in order to adjust its
	hedge position with respect to the Transaction; (B) Dealer and its affiliates also may be active in the market for Shares other
	than in connection with hedging activities in relation to the Transaction; (C) Dealer shall make its own determination as to whether,
	when or in what manner any hedging or market activities in securities of Issuer shall be conducted and shall do so in a manner
	that it deems appropriate to hedge its price and market risk with respect to the Relevant Prices; and (D) any market activities
	of Dealer and its affiliates with respect to Shares may affect the market price and volatility of Shares, as well as the Relevant
	Prices, each in a manner that may be adverse to Counterparty.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage150"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(v)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Early Unwind
</U>
	.
</I>
	In the event the sale of the &ldquo;Option Securities&rdquo; (as defined
	in the Purchase Agreement) is not consummated with the Initial Purchasers for any reason by 5:00 p.m. (New York City time) on the
	Premium Payment Date, or such later date as agreed upon by the parties (the Premium Payment Date or such later date, the &ldquo;
<B>
	Early
	Unwind Date
</B>
	&rdquo;),
<B>
</B>
	the Transaction shall automatically terminate (the &ldquo;
<B>
	Early Unwind
</B>
	&rdquo;)
<B>
</B>
	on
	the Early Unwind Date and (i) the Transaction and all of the respective rights and obligations of Dealer and Counterparty under
	the Transaction shall be cancelled and terminated and (ii) each party shall be released and discharged by the other party from
	and agrees not to make any claim against the other party with respect to any obligations or liabilities of the other party arising
	out of and to be performed in connection with the Transaction either prior to or after the Early Unwind Date. Each of Dealer and
	Counterparty represents and acknowledges to the other that, upon an Early Unwind, all obligations with respect to the Transaction
	shall be deemed fully and finally discharged.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(w)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Payment by Counterparty
</U>
</I>
	. In the event that, following payment of the Premium, (i)
	an Early Termination Date occurs or is designated with respect to the Transaction as a result of a Termination Event or an Event
	of Default (other than an Event of Default arising under Section 5(a)(ii) or 5(a)(iv) of the Agreement) and, as a result, Counterparty
	owes to Dealer an amount calculated under Section 6(e) of the Agreement, or (ii) Counterparty owes to Dealer, pursuant to Section
	12.7 or Section 12.9 of the Equity Definitions, an amount calculated under Section 12.8 of the Equity Definitions, such amount
	shall be deemed to be zero.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(x)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Other Adjustments Pursuant to the Equity Definitions
</U>
	.
</I>
	Notwithstanding anything to
	the contrary in this Confirmation, solely for purposes of this Section &lrm;9(x), the terms &ldquo;Potential Adjustment Event,&rdquo;
	&ldquo;Merger Event,&rdquo; and &ldquo;Tender Offer&rdquo; shall each have the meanings assigned to such term in the Equity Definitions
	(as amended by Section &lrm;9(j)(i)), and upon the occurrence of a Merger Date, the occurrence of a Tender Offer Date, or the declaration
	by Counterparty of the terms of any Potential Adjustment Event, respectively, as such terms are defined in the Equity Definitions,
	the Calculation Agent may, in its sole discretion, adjust the Cap Price to preserve the fair value of the Options to Dealer;
<I>
	provided
</I>
	that in no event shall the Cap Price be less than the Strike Price;
<I>
	provided further
</I>
	that any adjustment to the Cap Price
	made pursuant to this Section &lrm;9(x) shall be made without duplication of any other adjustment or determination hereunder (including,
	for the avoidance of doubt, adjustments or determinations made in accordance with &ldquo;Method of Adjustment,&rdquo; &ldquo;Consequences
	of Merger Events / Tender Offers&rdquo; and &ldquo;Consequences of Announcement Events&rdquo; in Section &lrm;3 above).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(y)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Tax Forms
</U>
</I>
	. Counterparty shall provide to Dealer a valid U.S. Internal Revenue Service
	(&ldquo;
<B>
	IRS
</B>
	&rdquo;) Form W-9 on or before the date of execution of this Confirmation and will promptly tender an updated
	IRS Form W-9 or applicable IRS Form W-8 if the previously tendered IRS Form W-9 becomes incorrect as a result of a change in facts.
	Dealer shall provide Counterparty a valid IRS Form W-9 or applicable IRS Form W-8 on or before the date of execution of this Confirmation
	and will promptly tender an updated IRS Form W-9 or applicable IRS Form W-8 if the previously tendered IRS Form W-9 or applicable
	IRS Form W-8 becomes incorrect as a result of a change in facts.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage151"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(z)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
<U>
	Certain Withholding Taxes
</U>
</I>
	. &ldquo;Indemnifiable Tax&rdquo; as defined in Section
	14 of the Agreement shall not include any tax imposed or collected pursuant to Section 871(m) of the Code or Sections 1471 through
	1474 of the Code, any current or future regulations or official interpretations thereof, any agreement entered into pursuant to
	Section 1471(b) of the Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental
	agreement entered into in connection with the implementation of such Sections of the Code (a &ldquo;
<B>
	FATCA Withholding Tax
</B>
	&rdquo;).
	For the avoidance of doubt, a FATCA Withholding Tax is a Tax the deduction or withholding of which is required by applicable law
	for the purposes of Section 2(d) of the Agreement.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage152"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Please
<FONT STYLE="FONT-SIZE: 10PT">
	confirm
	that the foregoing correctly sets forth the terms of our agreement by executing this Confirmation and returning it to Dealer
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	Very truly yours,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 3IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="PADDING-BOTTOM: 24PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	MORGAN STANLEY &amp; CO. LLC
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Scott McDavid
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	Authorized Signatory
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Scott McDavid
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Managing Director
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 44%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Accepted and confirmed
<BR>
	as of the Trade Date:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="PADDING-BOTTOM: 24PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NOVAVAX, INC.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 32%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Stanley C. Erck
</FONT>
</TD>
<TD STYLE="WIDTH: 65%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="PADDING-LEFT: 37.5PT; TEXT-INDENT: -37.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Authorized Signatory
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="PADDING-LEFT: 37.5PT; TEXT-INDENT: -37.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President and CEO
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage153"></A>
<A NAME="V431853_EX21_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 21
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	LIST OF SUBSIDIARIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following is a list of subsidiaries of the Company as of
	December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 52%; TEXT-DECORATION: UNDERLINE; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Name of Subsidiary
</U>
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 47%; TEXT-DECORATION: UNDERLINE; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Jurisdiction of Incorporation or Organization
</U>
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Novavax AB
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Sweden
</FONT>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<BR>
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage154"></A>
<A NAME="V431853_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 23.1
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	Consent of Independent Registered Public
	Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We consent to the incorporation by reference in the following
	Registration Statements:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(1)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-206354) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(2)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-198121) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(3)
</TD>
<TD>
	Registration Statement (Form S-3 No. 333-193549) pertaining to Novavax Inc. common stock,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(4)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-190600) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(5)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-190599) pertaining to the Novavax Inc. 2013 employee stock purchase plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(6)
</TD>
<TD>
	Registration Statement (Form S-3 No. 333-187267) pertaining to Novavax Inc. common stock,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(7)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-183113) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(8)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-145298) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(9)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-130990) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(10)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-110401) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(11)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-97931) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(12)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-46000) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(13)
</TD>
<TD>
	Registration Statement (Form S-8 No. 333-77611) pertaining to the Novavax Inc. stock incentive plan,
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(14)
</TD>
<TD>
	Registration Statement (Form S-8 No. 33-80279) pertaining to the Novavax Inc. stock incentive plan, and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 31.5PT">
	(15)
</TD>
<TD>
	Registration Statement (Form S-8 No. 33-80277) pertaining to Novavax Inc. stock incentive plan
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	of our reports dated February 29, 2016, with respect to the
	consolidated financial statements of Novavax Inc., and the effectiveness of internal control over financial reporting of Novavax,
	Inc., included in this Annual Report (Form 10-K) of Novavax Inc. for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ Ernst &amp; Young LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Baltimore, MD
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	February&nbsp;29, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage155"></A>
<A NAME="V431853_EX23-2_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23_2"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 23.2
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have issued our report dated March 12,
	2014 with respect to the consolidated financial statements for the year ended December 31, 2013 included in the Annual Report of
	Novavax, Inc. on Form 10-K for the year ended December 31, 2015. We hereby consent to the incorporation by reference of said report
	in the Registration Statements of Novavax, Inc. on Forms S-3 (No. 333-193549 and No. 333-187267) and on Forms S-8 (No. 333-206354,
	No. 333-198121, No. 333-190600, No. 333-190599, No. 333-183113, No. 333-145298, No. 333-130990, No. 333-110401, No. 333-97931,
	No. 333-46000, No. 333-77611, No. 33-80279, and No. 33-80277).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ Grant Thornton LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	McLean, Virginia
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	February 29, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage156"></A>
<A NAME="V431853_EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
<B>
	Exhibit 31.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	I, Stanley C. Erck, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report
	on Form 10-K of Novavax, Inc.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report
	does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
	in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
	report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial
	statements, and other financial information included in this report, fairly present in all material respects the financial condition,
	results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying
	officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
	and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
	registrant and we have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0.5IN">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0.5IN">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0.5IN">
	c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0.5IN">
	d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying
	officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
	auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0.5IN">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0.5IN">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Date: February 29, 2016
</TD>
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	By:
<U>
	/s/ Stanley C. Erck&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	President and Chief Executive Officer
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage157"></A>
<A NAME="V431853_EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 31.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF PRINCIPAL FINANCIAL
	AND ACCOUNTING OFFICER
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	I, Barclay A. Phillips, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report
	on Form 10-K of Novavax, Inc.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report
	does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
	in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
	report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial
	statements, and other financial information included in this report, fairly present in all material respects the financial condition,
	results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying
	officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
	and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
	registrant and we have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such disclosure
	controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
	material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
	those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such internal
	control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
	to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
	external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evaluated the effectiveness
	of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
	of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosed in this report
	any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most
	recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying
	officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
	auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all significant deficiencies
	and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
	adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any fraud, whether or not
	material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
	financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Date: February 29, 2016
</TD>
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	By:
<U>
	/s/ Barclay A. Phillips&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	Senior Vice President, Chief Financial
<BR>
	Officer and Treasurer
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage158"></A>
<A NAME="V431853_EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 32.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
	PURSUANT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	TO 18 UNITED STATES C. &sect;1350
</B>
<BR>
<B>
	(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	the Annual Report of Novavax, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal period ended December 31, 2015 as filed
	with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Stanley C. Erck, President and Chief
	Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section&nbsp;906 of
	the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	2)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of
	operations of the Company for the dates and periods covered by this Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	Date: February 29, 2016
</TD>
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	By:
<U>
	/s/ Stanley C. Erck&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
	President and Chief Executive Officer
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage159"></A>
<A NAME="V431853_EX32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 32.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF PRINCIPAL FINANCIAL
	AND ACCOUNTING OFFICER
<BR>
	PURSUANT TO 18 UNITED STATES C. &sect;1350
</B>
<BR>
<B>
	(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	the Annual Report of Novavax, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal period ended December 31, 2015 as filed
	with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Barclay A. Phillips, Senior Vice
	President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section&nbsp;906
	of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies
	with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained
	in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the
	dates and periods covered by this Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	Date: February 29, 2016
</TD>
<TD STYLE="WIDTH: 50%; PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	By:
<U>
	/s/ Barclay A. Phillips&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
</TD>
<TD STYLE="PADDING: 0; FONT-SIZE: 10PT; TEXT-INDENT: 0">
	Senior Vice President, Chief Financial
<BR>
	Officer and Treasurer
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
